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Abstract 
Introduction: Cardiac-surgery associated-acute kidney injury (CSA-AKI) is associated 
with increased morbidity and mortality. Furthermore, patients who develop CSA-AKI 
have higher incidences of progression to chronic renal impairment and reduced long-
term mortality. The mechanism for this association is not fully understood. We 
hypothesized that increased cellular senescence and biological age might be linked 
to both the development of CSA-AKI and future reduced mortality. 
Objectives: To investigate the relationship between markers of cellular senescence 
and aging and the development of CSA-AKI. 
Methods: DNA was extracted from peripheral leukocytes pre-operatively. Telomere 
length was measured with quantitative polymerase chain reaction (qPCR) and DNA 
methylation-based models of biological age and senescence were developed using 
targeted sequencing.  
Results: Between January 2016 and April 2017, 254 patients were recruited. Of these 
54 (21.3%) developed AKI. No association was found between mean Telomere length 
(mTL) and CSA-AKI on univariate analysis (p=0.304), or on propensity matching 
(p=0.833). However, a subgroup analysis of South Asian patients showed a significant 
association between reduced mTL and CSA-AKI on both univariate (p =0.025) and 
multivariate analysis (p = 0.036). Predicted methylation age (pMA) was significantly 
associated with CSA-AKI (p=0.013) whereas chronological age was not (p=.0.106). 
ROC curve analysis also demonstrated that pMA was a better predictor of CSA-AKI 
than chronological age (p=0.012 vs p=0.047). In subgroup analysis, South Asian 
patients again demonstrated a stronger association with CSA-AKI than other 
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ethnicities. On propensity matched analysis of the total population, the difference 
between chronological age and pMA (Delta age) was reduced in the AKI cohort, 
although this failed to reach statistical significance (p=0.07).  
Conclusion: pMA was significantly associated with CSA-AKI with a predictive ability 
superior to that of chronological age. mTL was found to be significantly associated 
with CSA-AKI in the South Asian population but not in the study population as a 
whole. 
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CHAPTER 1: General Introduction 
1.1 Cardiac surgery associated Acute Kidney Injury 
Cardiac surgery associated acute kidney injury (CSA-AKI) is an acute decline in kidney 
function that occurs following a cardiac surgical procedure. The incidence of CSA-AKI 
is approximately 0.3% to 30% depending on the definition of acute kidney injury (AKI) 
(1). Its underlying cause is thought to be multifactorial including the patient’s pre-
morbid condition, and the insults that they sustained intra-operatively and in the 
early post-operative period. CSA-AKI is clinically significant as it has been found to be 
associated with increased morbidity and reduced short and long term-mortality. 
 
1.1.1 Definition of CSA-AKI 
The study of AKI was initially complicated by a lack of consensus as to how to define 
this clinical entity. In 2004, the Acute Dialysis Quality Initiative Group introduced the 
Risk-Injury-Failure-Loss-End-Stage (RIFLE) classification; a consensus definition by 
which to grade AKI (2). The criteria that they developed is shown in Table 1 and can 
be met by changes in either serum creatinine (sCr) or glomerular filtration rate (GFR) 
or by changes in urine output. The RIFLE criteria measures changes from baseline 
over a seven-day period and has been validated in the setting of cardiac surgery (3).  
 
In 2007, the Adult Kidney Injury Network (AKIN) modified the RIFLE criteria in 
response to findings that even minimal changes in sCr were associated with adverse 
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outcomes after cardiac surgery (4, 5). The AKIN criteria differ from the RIFLE criteria 
in 5 ways; 
1. Risk, injury, and failure categories were replaced with stages 1,2, and 3. Loss 
and ESRF were lost as categories. 
2. An absolute increase in creatinine of 0.3mg/dl (>26.4 µmol/l) or more was 
added to stage 1. 
3. The use of eGFR was abandoned 
4. All patients with Renal Replacement Therapy (RRT) classified as stage 3 
5. Changes in serum Creatinine or urine output are measured over any 48-hour 
period within the first 7 days post-operatively rather than as a change from 
baseline within a 7-day period. 
 
The change in time periods between AKIN and RIFLE has the advantage of eliminating 
the need for a baseline creatinine. However, the AKIN criteria have been criticised 
for the over-diagnosis of AKI if the patient’s serum creatinine is not corrected for fluid 
status. This is because an initial drop in sCr due to fluid overload in the first 24 hours 
post-operatively can lower the threshold for stage 1 AKI for any subsequent rise in 
creatinine. Engelberger et al argue that this effect leads to the over-diagnosis of CSA-
AKI due to a state of fluid overload following cardiac surgery (6). However, several 
other studies suggest no significant difference in peri-operative predictive power of 
RIFLE and AKIN (7, 8), whilst Bastin et al found that the AKIN criteria correlate better 
with mortality post-cardiac surgery (9).  
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A third attempt was made to standardise the definition of AKI with the Kidney 
Disease: Improving Global Outcomes (KDIGO) classification (10). This classification 
effectively combines the RIFLE and AKIN by classifying AKI as either an increase in sCr 
of >26.4 µmol/l over 48 hours or an increase of 1.5 times baseline over a rolling 7-
day period (Table 1). The definition of AKI by urine output classified in the RIFLE 
criteria is common to all three classification systems. However, whilst the KDIGO 
classification has been validated in cardiac surgery, it has not been found to be 
superior to the AKIN criteria for the prediction of AKI (9) or mortality (11). As such, in 
this thesis the more established AKIN criteria will be used for the definition of CSA-
AKI. 
 
RIFLE 
Stages 
Definition 
(over 7 days) 
AKIN 
stages 
Definition 
(over 48hrs) 
KDIGO 
stages 
Definition 
Risk sCr>1.5 x 
baseline/ reduced 
GFR>25%  
Stage 1 sCr>1.5 x baseline/ 
>0.3mg/dl (>26.4 
µmol/l) increase 
Stage 1 sCr > 1.5 x baseline over 
7 days or >0.3mg/dl 
(>26.4 µmol/l) increase 
over 48 hours 
Injury sCr>2 x baseline/ 
reduced 
GFR>50% 
Stage 2 sCr>2 x baseline Stage 2 
 
sCr > 2 x baseline 
Failure sCr>3 x baseline/ 
reduced GFR 
>75% 
Stage 3 sCr>3 x baseline or 
increased to 4.0 
mg/dl [≥ 354 µmol/l] 
with an acute 
increase 
of at least 0.5 mg/dl 
[44 µmol/l]) 
Stage 3 sCr > 3 x baseline or 
increase to 4mg/dl or 
any RRT 
Loss Persistent AKI 
with complete 
loss of function > 
4 weeks 
    
End 
stage 
RRT for > 
3months 
    
 
Table 1: Comparison of the RIFLE, AKIN and KDIGO classification criteria for defining 
AKI.  
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1.1.2 Pathophysiology of CSA-AKI 
The pathogenesis of CSA-AKI is not fully understood but is thought to be 
multifactorial. Multiple processes including ischaemia-reperfusion injury (IRI), 
nephrotoxic agents, venous congestion, systemic inflammation, microembolisation, 
neurohormonal activation, oxidative stress, and haemodynamic factors may all 
contribute to the development of AKI in a synergistic manner (12). Cardiopulmonary 
bypass (CPB) has been cited as the cause for several of these mechanisms. Due to 
their high metabolic activity, the kidneys are susceptible to ischemia-reperfusion 
injury associated with CPB. A reduced cardiac output state activates the renin-
angiotensin system, the sympathetic nervous system and the release of vasopressin 
(13). This results in vasoconstriction with reduced renal blood flow and glomerular 
filtration. The renal medulla has a PaO2 of approximately 10-20mmHg and is highly 
metabolically active (14). As such it is susceptible to regional hypoxia. Sgouralis et al 
recently developed a mathematical model of renal blood flow and oxygen transport 
in rats during CPB. They conclude that the rewarming phase of CPB is when the 
kidney is most likely to suffer hypoxic injury due to the combination of low medullary 
blood flow and high medullary oxygen consumption (15).  
 
Renal micro-emboli released at the time of cardiac surgery are thought to contribute 
to the development of CSA-AKI. Blauth et al demonstrated renal atheroembolic 
disease in 10.4% of patients undergoing CPB for coronary revascularisation or valve 
disease (16). Furthermore, CPB is itself known to be a source of micro-emboli (17). 
However, no studies have demonstrated a direct association between embolic load 
and CSA-AKI.  
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The use of CPB has been associated with an increased systemic inflammatory 
response and induction of oxidative stress. CPB has been shown to result in elevated 
levels of pro-inflammatory cytokines and complement activation (18, 19) due to the 
interface between the blood and the artificial membrane of the bypass circuit. It is 
associated with increased haemolysis and the release of intravascular free 
haemoglobin (Hb), resulting in increased renal tubular cell exposure to free iron 
which may result in renal injury (20).    
 
It is important to consider that the above mechanisms of renal injury are not confined 
to cardiopulmonary bypass. Renal ischaemia, micro-emboli, systemic inflammation 
and oxidative stress are also thought to be factors in cardiac surgery without 
cardiopulmonary bypass (‘off pump surgery’) but to a lesser degree. However, 
objective comparative evidence between the two techniques is lacking and clinical 
studies comparing renal outcomes in cardiac surgery with and without the use of 
cardiopulmonary bypass have failed to consistently demonstrate a benefit to 
performing surgery ‘off-pump’. A 2010 meta-analysis of 22 randomised controlled 
trials comparing the incidence of AKI in on-pump and off-pump cardiac surgery found 
a significant reduction in AKI in the off-pump group but no significant difference in 
the rate of RRT (21). It should be noted that this trial is limited by the lack of 
consensus definition for AKI used in the included studies. In two more recent 
randomised controlled trials (RCTs), AKIN criteria were used to define AKI. Reents et 
al (22) found no significant difference in AKI between on-pump and off-pump in 1612 
elderly coronary artery bypass graft (CABG) patients. However, the CORONARY trial 
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(23) randomised patients between on and off-pump CABG and found a significant 
reduction in CSA-AKI at 30 days in the off-pump group. These mixed findings suggest 
that additional factors may play more of a role in the development of CSA-AKI than 
the use of cardiopulmonary bypass. Such factors include nephrotoxic agents, blood 
transfusion and pre-operative predispositions (e.g. genetic variation) 
.  
1.1.3 Risk factors for CSA-AKI 
Numerous studies have investigated associations and risk factors of CSA-AKI. In a 
recent meta-analysis of 14 case control studies, pre-operative, intra-operative and 
post-operative risk factors for AKI were studied (24). All studies defined AKI using the 
RIFLE criteria. Age, NYHA class III/IV, hypertension, preoperative creatinine, 
peripheral vascular disease, respiratory system disease, diabetes mellitus, and 
cerebrovascular disease were identified as pre-operative factors associated with AKI. 
Intra-operative factors were cardiopulmonary bypass time, aortic clamping time, use 
of intra-aortic balloon pump, and type of surgery, whilst postoperative factors were 
infection, need for re-sternotomy, and low cardiac output. All of these factors are 
non-modifiable and are therefore clinically useful only in terms of early identification 
of at-risk patients. Several studies that have focused on modifiable risk factors of 
CSA-AKI identified the use of nephrotoxic agents, pre-operative anaemia and 
intra/post-operative transfusion.  
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Nephrotoxic Agents 
Potential nephrotoxic agents associated with CSA-AKI include Angiotensin 
Converting Enzyme (ACE) Inhibitors, Angiotensin receptor blockers (ARBs), Non-
steroidal anti-inflammatory drugs (NSAIDs), diuretics, metformin and intravenous 
contrast from pre-operative angiography. However, evidence to date is mostly 
limited to the pre-operative use of Renin inhibitors, ACE Inhibitors and ARB’s. Coca 
et al (25) demonstrated a graded increase in CSA-AKI across three levels of pre-
operative ACE Inhibitor use (none, held, and continued), whilst a meta-analysis of 
predominantly non-randomised retrospective trials found pre-operative ACE 
Inhibitor use to be associated with both increased rates of AKI and mortality 
following cardiac surgery (26). A significant number of patients undergo angiography 
with contrast in the pre-operative period. A limited number of single center, 
retrospective studies have evaluated the time period between angiogram and 
cardiac surgery as a risk factor for CSA-AKI with conflicting results. Ranucci et al (27) 
and Medallion et al (28) both found angiography to be independently associated with 
CSA-AKI if performed within 24 hours of surgery. The latter study also demonstrated 
an association with angiography up to 5 days from surgery if high contrast doses were 
used. However, Ozkaynak et al (29) demonstrated no such association in 573 
consecutive patients. As such, a common practice is to delay surgery until at least 5 
days from angiogram if the patient’s condition is stable enough to allow such a wait.  
 
Pre-operative anaemia and blood transfusion 
Pre-operative anaemia, major post-operative bleeding and the need for allogenic 
blood transfusion are interdependent in terms of their effect on outcomes after 
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cardiac surgery. Many studies have demonstrated that pre-operative anaemia is 
associated with poor outcomes and AKI post cardiac surgery. Loor et al (30) 
demonstrated that pre-operative anaemia and blood transfusion had a combined 
effect on post-operative eGFR with an incremental decline in renal function across 
the groups:  - anaemia/ - transfusion; + anaemia/ - transfusion; - anaemia/ + 
transfusion; and + anaemia/ + transfusion. This study suggests that transfusion plays 
a greater role in CSA-AKI than pre-operative anaemia. This finding is supported by 
Goldberg et al (31), who investigated nadir haematocrit and transfusion during CPB 
and concluded that transfusion has a more profound effect on post-operative 
outcomes than anaemia. Rannucci et al (32) , showed that major bleeding was also 
an independent risk factor of CSA-AKI and, together with pre-operative anaemia and 
transfusion, had a cumulatively detrimental effect on in-hospital death, stroke and 
AKI. Interestingly, a recent study that corrected for the detrimental effects of 
perioperative bleeding and transfusion as well as patient co-morbidity, found no 
relationship between pre-operative anaemia and rates of CSA-AKI (33). As such a 
balance must be found between correcting anaemia and avoiding blood transfusion.  
 
1.1.4 Genetic pre-disposition for CSA-AKI 
The current evidence for a genetic predisposition to CSA-AKI is sparse and has 
focused on demonstrating the associations with various single nucleotide 
polymorphisms (SNP’s). In 2003, Gaudino et al (34) quantified the -174G/C 
polymorphism of the promotor region of the Interleukin (IL) -6 gene in 111 patients 
undergoing cardiac surgery and found that G homozygotes had worse post-operative 
renal and pulmonary function. A single-center study of 130 coronary artery bypass 
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patients found a relationship between Apolipoprotein E (APOE) status and CSA-AKI 
with patients who lack the APOE E4 allele being at increased risk (35). APOE is a 
mediator of cholesterol metabolism. Stafford-Smith et al (36) performed pre-
operative genetic testing of 12 candidate polymorphisms in 1671 patients 
undergoing cardiac surgery. When combined with clinical risk factors certain 
polymorphisms improved the predictability of CSA-AKI 4-fold in Caucasians and 2-
fold in African-Americans. Most of the polymorphisms were associated with 
increased renal inflammatory or vasoconstrictor responses. Similar work by Isbir et 
al (37) confirmed the association of the ACE I/D and APOE gene polymorphisms with 
the development of CSA-AKI.  
 
More recently, Jouan et al (38) failed to find any such association with CSA-AKI and 
single nucleotide polymorphisms (SNP’s) of APOE (Cys112Arg, Arg158Cys), Tumour 
necrosis factor (TNF-308G>A), or Lymphotoxin-α (Cys13Arg, +252 A>G), but did find 
that IL6-572G>C and IL10-592C polymorphisms predicted the combined clinical 
endpoint of death, myocardial infarction, stroke, low cardiac output state, AKI, and 
sepsis. In 2015, a genome wide association study (GWAS) of CSA-AKI was performed 
to identify predisposing genetic loci (39). 9 SNP’s were found to meet significance in 
the discovery set, with 2 replicated with significance in the validation set; rs13317787 
at 3p21.6 and rs10262995 at 7p14.3. For both SNP’s, AKI incidence increased with 
each copy of the minor allele. The 3p21.6 locus is an intergenic region bounded by 
GRM7 (glutamate receptor, metabotropic 7) and LMCD1 (LIM and cysteine rich 
domains protein 1, dyxin) genes. No direct functional roles are currently attributed 
to this region. The 7p14.3 locus involves a region in the BBS9 gene, named for its 
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association with Bardet-Biedl syndrome (BBS). Kidney disease is a key feature and 
major source of early mortality with BBS and a BBS9 translocation is associated with 
Wilm’s Tumour.  
 
The limited number of studies done to date demonstrate that there does appear to 
be a genetic predisposition to CSA-AKI, primarily through the mediation of the post-
operative inflammatory response (34). The majority of studies conclude that the 
addition of genetic polymorphisms significantly improves predictive risk compared 
to models based solely on clinical parameters. However, to date, such tests have not 
been routinely implemented in clinical practice. Moreover, receiver operative 
characteristic (ROC) curve analysis has not been performed to assess additional 
incremental predictive value of these genetic variations over clinical parameters. 
 
1.1.5 Existing models for predicting CSA-AKI 
Several risk stratification models have been developed to predict the risk of a patient 
developing AKI following cardiac surgery (40). Early models primarily focused on AKI 
requiring post-operative renal replacement therapy (RRT) but more recent models 
have also been developed for milder forms of AKI. To date, only the RRT scoring 
systems have been externally validated. In 1997, Chertow et al (41) first published a 
risk stratification algorithm for predicting AKI following cardiac surgery in the 
Continuous Improvement in Cardiac Surgery Study (CICSS). AKI was defined as a 
patient requiring RRT within 30 days of their index operation. In their prospectively 
collected data of 42,773 patients, 1.1% were defined as having AKI. The Area under 
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Curve (AUC) was 0.76 for the multivariate analysis of 10 variables. The score was 
internally validated in a smaller cohort of 3795 patients. In several external validation 
studies, the AUC was only modest (42-44). This is thought to be due to the CICSS 
population not being representative of the normal cohort of cardiac surgical patients 
as it included a very high proportion of males 99.1%, and excluded patients with pre-
existing renal failure. Several other scoring systems have since been developed to 
predict CSA-AKI requiring RRT (45-47). Thakar et al (47), developed the Cleveland 
Clinic Score to predict post-operative RRT in a retrospective analysis of 33,217 
patients. It has been extensively validated externally and has also been tested in less 
severe forms of CSA-AKI not requiring RRT. Wong et al (48) found that the Cleveland 
Clinic Score was a good predictor of more severe degrees of CSA-AKI (AUC of 0.78 for 
AKIN stage 3) but less so for the milder degrees of AKI (AKIN 1 and 2). Mehta et al 
(45) developed a bed-side tool scoring system for post-op AKI requiring RRT using 
data from the Society of Thoracic Surgeons (STS) database. The STS database has 
subsequently been used to develop an online scoring calculator to predict a range of 
post-operative morbidities of which one is renal failure as defined by the RIFLE 
criteria.  Wijeysundera et al (46) developed a simple 8-point scoring system, which 
predicted post-op RRT with similar accuracy compared to the more complex systems 
developed by Thakar and Mehta.  An external comparison of the predictive powers 
of these three main scoring systems found that whilst all three tended to 
underestimate the true risk of RRT post cardiac surgery, the Cleveland Clinic score 
performed best with an AUC of 0.82 (49). 
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More recent studies have tried to apply scoring tools to less severe forms of CSA-AKI. 
Palomba et al (50) derived the Acute Kidney Injury in Cardiac Surgery (AKICS) Score 
in ARF defined as Cr >2mg/dl or a rise of >50% above baseline (corresponding to AKIN 
1 or RIFLE R). The AKICS score was based on 8 variables with 5 categories developed 
to predict risk and differs from previous scores in that it includes intra-operative 
variables such as cardiopulmonary bypass time and central venous pressure. It 
demonstrated good discrimination in both the development and validation cohorts 
with AUC values of 0.843 and 0.847 respectively. Brown et al (51) developed the 
Northern New England Cardiovascular Disease Study Group (NNECDSG) score 
prospectively on 8363 patients with an endpoint of severe renal failure (Defined as 
an eGFR of <30) or RRT. Pre-operative patients with moderate (eGFR<60) or severe 
renal insufficiency (eGFR<30) were excluded from analysis. The NNECDSG score 
included 11 peri-operative variables and performed reasonably well in the derivation 
cohort with an AUC of 0.72. However, no further external validation has been 
performed of this scoring system.  
 
1.1.6 Predictive risk calculators for mortality following cardiac surgery 
Predictive risk calculators are routinely used in cardiac surgery to estimate patient 
mortality risk prior to undertaking a procedure. The two most widely used scoring 
systems currently in practice are the Society of Thoracic Surgeons (STS) online 
calculator (52) and the European System for Cardiac Operative Risk Evaluation 
(EuroSCORE) (53). Of the two, the STS score is more in depth containing 65 fields 
compared to 17 in the EuroSCORE. The EuroSCORE also only provides a prediction on 
in-hospital mortality whilst the STS score also provides risk scores for Renal failure, 
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stroke, prolonged ventilation, deep sternal wound infection, reoperation, and long 
length of stay. Despite these differences, a comparison between the two scores by 
Ad et al (54) showed gross equivalence between the two in terms of predicting in-
hospital mortality following cardiac surgery. As EuroSCORE is the primary risk score 
used in Europe and is the score used for risk adjusted mortality in the UK, it will be 
used in the current study to provide an indicator of the risk of specific patient groups 
 
1.1.7 Clinical significance of CSA-AKI 
1.1.7.1 Association with long-term mortality 
CSA-AKI is more prevalent in patients with high levels of co-morbidity. As such, it is 
not surprising that the development of AKI post-cardiac surgery is associated with 
increased in-hospital mortality (55). Several studies have also demonstrated an 
association between post-operative AKI and reduced long-term survival (56). 
Interestingly, this association persists even when the degree of kidney injury is mild 
(57), and where there is complete resolution of the injury prior to discharge (58). 
Gallagher et al (59) demonstrated that CSA-AKI was an independent predictor of 
mortality at a median follow-up of 5.6 years in a propensity matched analysis of 1124 
patients undergoing first time CABG. Previous studies have also demonstrated a link 
with CSA-AKI and increased long-term rates of cardiovascular events including 
myocardial infarction, heart failure and stroke. Hansen et al (60) studied 4752 
patients undergoing cardiac surgery of which 1457 (30.7%) developed AKI within 30 
days. Of those with AKI, the weighted hazard ratio (HR) was 1.37 (95% CI: 1.05-1.80) 
for all-cause mortality and 1.41 (95% CI: 1.11-1.80) for the 5-year risk of the 
composite cardiovascular endpoint of heart failure, myocardial infarction and stroke. 
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However, the mechanism by which CSA-AKI is related to increased long-term 
mortality is not currently understood.  
 
1.1.7.2 Association with long-term renal dysfunction 
Recent studies have shown that AKI post cardiac surgery is also associated with an 
increased rate of developing subsequent Chronic Kidney Disease (CKD) (61-63). 
Ryden et al (62) demonstrated a hazard ratio for end-stage renal disease of 2.92 (95% 
CI, 1.87–4.55) for mild kidney injury (AKIN stage 1) and 3.81 (95% CI, 2.14–6.79) for 
moderate kidney injury (AKIN stage 2 to 3). As with the effect of AKI on long-term 
mortality, Xu et al (61) demonstrated that the relationship between AKI and 
subsequent CKD persisted even if complete resolution of AKI occurred prior to 
discharge.  
 
1.2 Developing the hypothesis – linking CSA-AKI with decreased long-term 
mortality and risk of CKD 
The underlying mechanism by which CSA-AKI predisposes to reduced long-term 
mortality and renal function has not yet been elicited. Animal studies have 
demonstrated that episodes of severe ischaemic renal injury result in morphological 
changes at the renal tubule level that predispose to reduced long term renal function 
(64). There is also evidence that ischaemic renal injury in rats results in persistent 
alterations in gene expression (65). These results suggest that episodes of AKI result 
in physical changes in the kidney that predispose to a decline in long-term function. 
With this in mind it is interesting to note the results of a sub-group analysis of the 
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CORONARY trial (66) that looked at the development of post-operative AKI in 
patients randomised to coronary artery bypass grafting with (on-pump) or without 
(off-pump) cardiopulmonary bypass. On-pump surgery has been shown to be 
associated with increased rates of AKI in comparison to off-pump cardiac surgery 
(21). This is thought to be due to renal ischaemic injury and an increased systemic 
inflammatory response associated with cardiopulmonary bypass. As such we would 
expect that off-pump surgery results in less CSA-AKI and subsequently reduced rates 
of long-term renal dysfunction. However, although the CORONARY trial did show that 
off-pump coronary surgery reduced the risk of CSA-AKI by 17%, there was no 
difference between the two groups in terms of loss of kidney function at 1 year 
(expressed as patients with a new requirement for RRT). Nor was there any 
difference seen in mortality at one year between the groups. If AKI was acting as a 
direct causal factor for further renal decline then the difference between the two 
groups would be expected to continue beyond a year. Also, a mortality difference 
might also be expected as the development of CSA-AKI has consistently been 
demonstrated as being associated with increased long-term mortality. Possible 
explanations for the lack of such findings are; 
1. The follow up period of 1 year was too short to detect a change in 
development of CKD/mortality. 
2. The number of patients with AKI was too low to affect the overall outcome of 
long-term CKD/mortality. 
3. The development of CSA-AKI is not a direct causal link to the subsequent 
development of CKD/mortality. 
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We suggest that patients who develop AKI post-cardiac surgery are already at an 
increased risk of CKD and increased long-term mortality due to some underlying 
predisposition. In ‘on-pump’ surgery this predisposition is more likely to result in AKI 
due to the larger associated inflammatory response, without altering the progression 
to long-term CKD and death. We hypothesise that this predisposition lies in a 
patient’s capacity for cellular regeneration, with those patients with increased 
senescence being more susceptible to ischaemia induced AKI, the long-term 
development of CKD, and reduced long-term survival.  
 
1.3 Cell senescence 
Cell senescence is defined as the process whereby normal diploid cells cease to 
divide. As cells continue to divide the risk of them accumulating oncogenic mutations 
increases. Mechanisms of inducing cellular senescence exist to limit the number of 
cell divisions that can occur physiologically and prevent damaged cells from taking 
part in further replication.  As such senescence has an anti-oncogenic effect. It should 
be noted that senescence does not in itself cause aging. Rather it is the failure to 
clear senescent cells and the reduced capacity of progenitor cells to replace them 
that decreases tissue regeneration and produces an aged phenotype (67). Increased 
senescence may contribute to aging by changes in the secretome profile of senescent 
cells to favour proinflammatory cytokines and matrix metalloproteinases (68).  
 
Cell senescence appears to be triggered as a response to DNA damage. It has been 
postulated that these DNA damage response (DDR) signals can be generated either 
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by progressive telomere shortening and dysfunction (the telomere theory of 
senescence), or by mitochondrial induced reactive oxidative species causing damage 
to DNA (the mitochondrial theory of senescence) (69). 
  
1.3.1 Markers of cellular senescence 
Several markers have been used in attempts to develop a signature of cellular 
senescence and aging. Telomere biology has been extensively used as a marker of 
cellular senescence and biological aging. Studies have primarily focused on Telomere 
length (TL) as a marker of senescence. Different markers of telomere induced 
senescence include mean telomere length, measurement of the shortest telomere 
length in a cell, and the rate of telomere attrition.  
 
Several other markers have been commonly used to measure senescence. Levels of 
proteins such as Senescence-associated β–galactosidase (SAβG) are associated with 
senescence but have been found not to trigger it (70). Other markers used to 
measure senescence such as senescence-associated heterochromatin foci (SAHF), 
phosphorylated H2AX histone (γH2AX), p16, p53, and Promyelocytic leukemia 
nuclear bodies (PML-NBs) are all involved in the senescence inducing pathways 
resulting from DNA damage or telomere shortening (71).  
 
Numerous microarray studies have demonstrated altered gene expression in aging 
with a 2009 meta-analysis identifying 56 genes that are consistently overexpressed 
with increasing age and 17 that are consistently under-expressed (72). Evidence for 
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altered gene expression in cell senescence is less well studied but evidence exists of 
genes that are candidate markers of senescence (73).  
 
Finally, it has been proposed that epigenetic modifications play a role in aging and 
cell senescence by acting as molecular switches, switching off or activating 
senescence related genes (the gene-silencing theory of aging) (74). In particular, DNA 
methylation of gene promotor regions has been found to be well associated with 
chronological age (75)and more recently DNA methylation signatures for both aging 
and cellular senescence have been developed (76, 77).  
 
In this thesis we will focus on genetic and epigenetic markers of cell senescence by 
studying Telomere biology and DNA methylation status and their association with 
CSA-AKI. 
 
1.4 The role of Telomeres and Telomerase in Cell Senescence 
1.4.1 The structure and function of Telomeres 
Telomeres are repetitive, non-coding DNA sequences located at the end of 
chromosomes that control when a dividing cell undergoes senescence (78). Their 
primary function is to provide a protective cap to the chromosome so that coding 
genetic material is not lost during cell division. During cell division, the replicating 
DNA polymerase is not able to completely copy the lagging strand of DNA all the way 
to its end, resulting in the loss of a portion of DNA at the 5’ end with each division. 
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This has been termed the ‘end replication problem’ (79). The presence of the 
telomere cap ensures that it is telomeric DNA and not coding DNA that is lost during 
DNA replication, maintaining the integrity of the genome. With each subsequent cell 
division, the telomere length is progressively shortened until a critical length is 
reached at which point the cell is no longer able to divide and is rendered senescent, 
undergoing apoptosis (80). As such, telomere length has been postulated as a 
biomarker for biological age.  
 
Telomeres not only protect genomic material during DNA replication, their structure 
also prevents free DNA ends from degradation by DNA repair mechanisms.  These 
mechanisms are designed to recognise single stranded DNA at chromosomal breaks 
and trigger either degradation by nucleases or end-joining reactions that fuse two 
free DNA ends. Mammalian telomeres are comprised of double stranded tandem 
TTAGGG hexameric repeats followed by 3’ G-rich single stranded overhangs (78) 
(Figure 1). This 3’ single stranded free end folds back on itself and binds to the double 
stranded telomeric DNA forming a ‘t-loop’. At the point where this binding occurs, 
the duplex DNA is displaced forming a triple stranded structure (d-loop) that is 
stabilised by telomere binding proteins (81). Telomeres are coated with a complex of 
6 binding proteins collectively termed the Shelterin proteins (82). It is this T-loop-
Shelterin protein complex that prevents the free DNA end from degradation. 
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Figure 1: Schematic representation of the structure of the mammalian telomere 
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1.4.2 The structure and function of telomerase 
The process by which telomere length (TL) changes with each cell division is non-
linear. Several processes are involved in telomere homeostasis, principally the action 
of the enzyme complex telomerase. The primary function of telomerase is to 
maintain telomere length by adding TTAGGG repeats to the 3’ end of the 
chromosome (83). It is a ribonuclear protein consisting of two main subunits; 
Telomerase RNA Component (TERC) and Telomerase reverse transcriptase (TERT). 
TERC contains an 11-bp sequence complimentary to the telomeric overhang which 
TERT, a DNA polymerase, uses as a template to synthesise telomeric DNA to the ends 
of chromosomes (Figure 2). Telomerase thereby acts to counter the Telomere 
attrition that occurs during cell replication. As such, telomerase activity is tissue 
dependent with higher levels seen in tissues with increased cell replication such as 
germ cells, stem cells, haematopoietic cells, and activated lymphocytes. Most 
cancerous cells also show increased telomerase activity, allowing prolonged cell 
division. In contrast, terminally differentiated somatic cells usually express low or 
absent levels of telomerase activity. 
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Figure 2: Schematic representation of telomere elongation by telomerase. Image 
created by Fatma Uzbas and reproduced without change under the Creative 
Commons Attribution-Share Alike 3.0 Unported license.  
https://commons.wikimedia.org/wiki/File:Working_principle_of_telomerase.png#fil
elinks 
 
Transcriptional regulation of TERT is the main influencing factor on Telomerase 
activity (84). Whilst TERC is constitutively expressed in all tissue cells, TERT 
expression in somatic cells decreases as cells differentiate (85).  After the discovery 
of the Telomerase enzyme complex, TERT was thought only to be expressed in 
germline cells, stem cells or cancer. However, TERT expression has subsequently 
been demonstrated in cells of the cardiovascular system (86) as well as circulating 
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leukocytes. Janic et al, (87) demonstrated that TERT expression was upregulated in 
circulating leukocytes of patients treated with low dose statin therapy and that this 
upregulation correlated with an improvement of endothelial function and a decrease 
of inflammation/oxidative stress.  
 
TERT expression and subsequently Telomerase activity can be modulated in response 
to certain stimuli in both health and disease. Gizard et al (88) demonstrated that TERT 
expression was inducible by certain inflammatory stimuli resulting in high levels of 
TERT expression in macrophages of human atherosclerotic lesions. Furthermore, 
Cheng et al (89) demonstrated that TERT knock out (KO) mice show telomere 
shortening and reduced regenerative capacity following renal ischaemic injury. 
Similar murine models were found to cause progressive cardiac myocyte death and 
hypertrophy suggesting that telomere shortening may contribute to age related 
heart failure in humans (90). Conversely, when heart failure was induced 
mechanically, telomerase activity was upregulated as part of a compensatory 
mechanism to promote cell regeneration. The increased telomerase activity was 
found to co-localise with the proliferation marker Ki67 in the nuclei of dividing 
myocytes, and was associated with prolonged telomere length (TL) (91). Richardson 
et al (92) demonstrated a 6.45-fold increase in cells expressing TERT in response to 
myocardial cryoinjury. As well as upregulation in response to pathological stimuli, 
increased physical activity via voluntary wheel running in mice is found to upregulate 
telomerase activity with subsequent reduction in vascular apoptosis regulators (93). 
A similar finding is found in humans where significant changes in lifestyle are 
associated with increased telomerase activity and telomere length (94). Aberrant 
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expression of human TERT can effectively immortalise cells by maintaining TL and 
thus preventing triggering of cell senescence. 
 
1.4.3 How does TL induce senescence? 
There appear to be two mechanisms that can induce cell senescence. The first, 
termed Mortality stage 1 (M1) senescence is triggered by critical telomere shortening 
and is irreversible in the sense that it cannot be overcome by physiological 
mechanisms. It represents replicative exhaustion on the part of the dividing cell and 
has thus been termed replicative senescence.  However, mutations in the cell cycle 
inhibitors p53, p16 /Retinoblastoma (Rb) protein can allow cells to bypass M1 
senescence and continue to divide with further telomere attrition. This process 
eventually results in crisis where non-telomere dependent mechanisms trigger a 
truly irreversible cell cycle arrest (termed M2 senescence) (95). Despite their inability 
to proliferate both M1 and M2 senescent cells remain viable.  
 
Direct evidence that telomere shortening results in cell senescence can be 
demonstrated by inducing TERT expression in Telomerase negative cells. Such cells 
aberrantly expressing transfected TERT demonstrate increased Telomere length and 
are able to divide indefinitely (96). Furthermore, inducing a transient expression of 
telomerase increases a cell’s lifespan in accordance with its increased telomere 
length rather than for the duration of telomerase expression (97). This indicates that 
it is telomere length that directly controls senescence rather than telomerase 
activity.  
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Although there is a considerable body of evidence suggesting that it is telomere 
shortening that is responsible for triggering M1 senescence, the exact mechanism 
behind this trigger is not fully understood. Current mechanisms proposed include 
DNA damage induced by short telomeres, telomere position effects and the loss of 
3′ G-rich telomere single-strand overhangs. 
 
The preferred theory of telomere induced cell senescence proposes that shortened, 
dysfunctional telomeres trigger events that are usually triggered by DNA double 
strand breaks (DSBs). Cells react to DSBs by triggering the DNA damage checkpoint 
response (DDR) which halts cell proliferation until the damaged DNA has been 
removed. Telomeres function to protect chromosomal ends and stop them being 
recognized as double strand DNA breaks. However, progressive shortening leads to 
loss of the protective functions of the telomere associated proteins Telomeric repeat 
binding factor 2 (TRF-2) and Protection-of-Telomeres – 1 (POT-1), allowing critically 
short telomeres to be recognized as DNA breaks and trigger a DDR (98).  If this DDR 
response is prolonged, cells are triggered to enter M1 senescence. D’Adda et al (99) 
showed that senescent human fibroblasts express phosphorylated H2AX (γH2AX), a 
robust marker of cellular DSBs. Using Chromatin Immunoprecipitation (ChIP) the 
authors demonstrated that these γH2AX foci localized to a sub-telomeric region on 
specific chromosomes of senescent cells known to have short telomeres. H2AX foci 
signal through ataxia-telangiectasia mutated serine/threonine kinase (ATM) to p53, 
resulting in the upregulation of p21 and G2 phase growth arrest (100). For any given 
cell, it is only one or two of the shortest telomeres that produce such γH2AX repair 
foci. This suggests that the proportion of critically short telomeres may be a more 
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relevant marker of cell senescence than average telomere length. This theory is 
supported by the findings of Hemann et al (101) who crossed mTR-/- G6 mice that 
have short telomeres with mice heterozygous for telomerase (mTR+/-) that have long 
telomeres. The resulting offspring had an equal mix of short and long-telomeres but 
their phenotype mimicked that of the mTR -/- mice. Further analysis showed that it 
was these shortened telomeres that were associated with telomere dysfunction.  
 
Telomere position effects (TPE) refers to the reversible inactivation of genes near a 
telomere by mechanisms that depend both on the length of the telomere and its 
distance to the gene. Initial experiments on the chromosomal end of yeast S. 
Cerevisiae demonstrated that genes placed immediately adjacent to the telomeric 
repeats were repressed in terms of both phenotype and mRNA analysis (102). The 
frequency of gene silencing is decreased by increasing the distance between the gene 
promoter and the telomere (103). Baur et al (104) demonstrated that this silencing 
of peri-telomeric genes also occurs in Mammalian cells and that it is potentiated by 
increasing telomere length. This suggests that the expression of genes near telomeric 
DNA may alter as the telomere shortens, providing a potential mechanism as to how 
cell senescence may be triggered by telomere attrition. However, to date, no culprit 
genes have been identified to support this theory. 
 
A final proposed mechanism for telomere induced senescence is the erosion of 3’G 
rich single stranded overhangs. Whereas telomere length decreases progressively 
with population doubling, the 3’G rich single stranded overhang remains relatively 
conserved until declining rapidly as the cell approaches senescence (105). Further 
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evidence that cell senescence is governed by mechanisms other than critically short 
telomere length is the finding that upregulation of certain telomere binding proteins 
(such as TRF) can delay the onset of senescence by lowering the TL setpoint at which 
senescence is induced (106).  
 
1.4.4 Non-telomere dependent mechanisms of cell senescence 
In addition to replicative senescence induced by telomere attrition, it is accepted that 
senescence can also be triggered by non-telomeric pathways. Processes that cause 
DNA damage or activate proliferative pathways can also induce senescence by 
triggering a DDR. Such induction of senescence acts as a tumour suppressor 
mechanism. Oncogene activation is a hallmark of cancer but in normal cells, 
oncogene activation triggers cell senescence (107). As with replicative senescence, 
oncogene induced senescence is triggered via the formation of a DDR. However, the 
mechanisms by which this occurs are not yet understood.   
 
1.5 The role of DNA methylation in cell senescence  
1.5.1 Introduction to DNA methylation 
DNA methylation (DNAm) is one of several epigenetic phenomena. Epigenetics refers 
to functional modifications to the genetic code that do not alter the base nucleotide 
sequence. Such modifications can switch genes on or off and thus determine which 
proteins are transcribed and include DNA methylation, histone modification, non-
coding RNA and RNA splicing variants. DNAm is a post-translational process in which 
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a methyl group is covalently added to fifth position of the cytosine pyrimidine ring 
within DNA. In mammalian cells, DNAm almost exclusively occurs in the context of 
CG dinucleotides, referred to as CpG sites (i.e. where a cytosine is followed by a 
guanine). CpG sites are concentrated in large clusters, termed CpG islands, and are 
often found in gene promoter regions (108). Whilst the majority of CpG sites in non-
promotor regions are methylated, CpG islands are usually hypomethylated (109).  
 
1.5.2 DNA methylation, gene expression and disease 
The effect of DNA methylation is to inhibit transcription either directly via methyl 
groups projecting into the major groove of the DNA helix or indirectly by the 
recruitment of DNA binding proteins (110, 111).Changes in DNA methylation have 
been shown to alter gene expression by several mechanisms. Hypermethylation at 
CpG island promotor sites may result in gene silencing. This mechanism has been well 
documented in the setting of carcinogenesis due to the silencing of tumour-
suppressor genes, allelic loss or genetic mutation (112). The role of DNA methylation 
at non-CpG island promotors is less well understood, with methylation still able to 
alter gene expression even in genes without CpG islands in their promotor region 
(113). Global hypomethylation at non-gene promoter sites can result in the loss of 
transcriptional inhibition, resulting in the aberrant and potentially harmful 
expression of normally silenced genes. As such, methylation status has the potential 
to alter gene expression independently of the underlying genetic code.  
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Several processes can influence DNA methylation including environmental factors. 
Fraga et al (114) studied monozygotic twins with identical genotypes and found that 
although they are epigenetically indistinguishable when young, as they aged, they 
displayed increasing variability in their epigenetic signatures both in terms of DNAm 
and histone acetylation.  Methylation driven alterations in gene expression as a result 
of environmental stimuli provide a possible explanation for the link between 
genotype and phenotype. Furthermore, if such alterations occur within the germline 
then they have the potential to be passed directly onto the subsequent generations. 
As such, epigenetic modifications such as DNA methylation provide a potential 
mechanism for environmental risk factors to alter gene expressions and contribute 
to the pathogenesis of disease. Disease processes that are triggered by such 
mechanisms include cancer and cardiovascular disease (115, 116). DNA methylation 
is also thought to play a role in the aging process and the development of cellular 
senescence.  
 
1.5.3 DNA methylation and cellular senescence  
DNAm is heavily implicated in cellular senescence (117). Studies have identified 
patterns of methylation that correlate with cell senescence. Koch et al (77) 
demonstrated 6 specific CpG sites that correlated closely with cellular senescence in 
regard to the number of passages, population doublings, or days of in-vitro culture. 
Whilst these epigenetic patterns for senescence correlate well with those of aging, 
they are not identical (118). This suggests that cell senescence is not just a hallmark 
of the aging process but that it can be altered by underlying molecular processes, 
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including DNA methylation. In this thesis, the DNA methylation status of patients 
undergoing cardiac surgery in the context of both cardiovascular disease and renal 
ischaemic injury will be investigated.   
 
1.6 Cell senescence, aging and disease  
Since the turn of the century, cardiovascular disease (CVD) has topped the World 
Health Organisation list as the single biggest cause of death in the world. A number 
of established risk factors exist for the development of CVD. These are traditionally 
classified as modifiable such as hypertension, hypercholesterolaemia, smoking, 
diabetes and obesity, or non-modifiable such as age, sex and ethnicity. However, the 
high prevalence of CVD cannot always be attributed to these risk factors. As a result, 
the search for novel predictors of cardiovascular disease is ongoing. As CVD is an age-
related condition, mechanisms of aging and cell senescence have been postulated as 
having key roles in its pathogenesis. 
 
1.6.1 Telomere biology and cardiovascular disease 
Ever since 1990 when Harley et al proposed that reduced telomere length is related 
to the aging process, telomere shortening has been linked to age related disease 
processes (119). Cawthon et al (120) showed that overall mortality was associated 
with short telomere lengths in people over the age of 60 and there is a growing body 
of evidence linking telomere attrition with cardiovascular disease, 
neurodegenerative disease, and cancer (121),(122),(123). Since telomerase functions 
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to maintain telomere length, reduced telomerase activity is also thought to be 
implicated in the development of age-related diseases. In this thesis, we will focus on 
the role of cellular senescence and Telomere biology in cardiovascular disease, and 
CSA-AKI. 
 
Telomere biology has been associated with several age related cardiovascular 
disease processes including atherosclerosis (124),  ventricular diastolic dysfunction 
(125), coronary artery calcification (126), calcific aortic stenosis (127) and prognosis 
following acute coronary syndrome (128). Several theories have been postulated for 
mechanisms underlying these associations. The ‘Telomere hypothesis’ states that 
short telomeres are the primary abnormality responsible for the subsequent 
development of disease. This hypothesis is supported by the findings of Brouilette el 
al (129) that the offspring of patients with coronary artery disease have shorter 
telomeres than matched controls prior to the onset of any disease. This theory states 
that genetically determined short telomere length (TL) predisposes to the 
development of atherosclerosis and such an association has been found in several 
studies (124). This theory is further supported by the finding of reduced TL in vascular 
smooth muscle cells taken from atherosclerotic plaques of patients with coronary 
artery disease (CAD) (130). However, there is conflicting evidence as to the causal 
role of short telomeres in CAD with de Meyer et al (131) demonstrating no 
association between TL and pre-clinical atherosclerosis in carotid and femoral 
vessels. Furthermore, in a second study De Meyer et al (132) found no association 
between TL and the development of atherosclerosis in a repeat of Brouilette’s 
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experiment. These findings cast doubts over the validity of the telomere hypothesis 
of cardiovascular disease. 
 
An alternative ‘modulating effects’ hypothesis suggests that rather than inherited TL 
predisposing to cardiovascular disease it is the effect of modulating environmental 
factors on telomere attrition that is responsible (133). Several cardiovascular risk 
factors have been found to be associated with short TL including smoking, diabetes, 
hypercholesterolaemia, hypertension, physical inactivity and obesity (134-137). TL is 
thought to be associated with these risk factors due to increased inflammation, 
oxidative stress, and factors that modulate the activity of telomerase. Inflammation 
is associated with increased cell proliferation and hence increased telomere attrition 
in somatic cells due to their low telomerase activity. Oxidative stress results in the 
formation of single stranded breaks, preferentially at the telomeres, causing 
accelerated telomere attrition at the next cell division (134, 138).  
 
A competing hypothesis for a telomeric predisposition for cardiovascular disease is 
the immunosenesence theory. This theory states that in patients with either 
inherited reduced TL or environmentally accelerated telomere attrition, critical 
telomere shortening causes haematopoietic progenitors to become senescent. Early 
senescence of endothelial progenitor cells (EPC’s) results in reduced vascular 
endothelial repair mechanisms and increased atherosclerosis (133). Hammadah et al 
(139) sort to test this hypothesis by measuring the effect of TL and number of 
circulating progenitor cells (CD34+ cells) on outcomes in patients with coronary 
artery disease. They found both TL and CD34+ cell number to be independent and 
56 
 
additive risk factors for cardiovascular events. The same mechanism of increased 
haematopoietic senescence has been attributed to the association of anaemia with 
short telomeres in setting of chronic heart failure (140). 
 
In summary, no single theory has yet been able to fully explain all aspects of the 
associations so far demonstrated between telomere length and the development of 
cardiovascular disease. Whilst there may be a predisposition to cardiovascular 
disease due to inherited short telomere length, this mechanism does not appear to 
be via the development of atherosclerosis. There is convincing evidence that 
environmental factors modulating the rate of telomere shortening play a crucial role 
in disease, and a growing body of evidence that the early senescence of 
haematopoietic and endothelial progenitor cells might also have an important role 
to play. 
 
1.6.3 Telomere biology and AKI 
Westhoff et al (141) performed a detailed analysis of the potential mechanisms by 
which increased cell senescence might cause renal impairment in mice. Using a TERC 
knock out mice model the authors simulate the short telomere lengths seen in the 
aging kidney due to the loss of functional telomerase activity. They demonstrated 
that critical telomere shortening is associated with reduced structural and functional 
integrity of the kidney in response to ischaemia reperfusion injury (IRI). TERC 
negative mice developed more marked reduction in Creatinine Clearance, increased 
interstitial fibrosis at 30 days and a lack of compensatory hypertrophy of the non-
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injured kidney. In addition, they identify several markers of cell senescence that are 
upregulated in response to critically short telomeres and IRI including p21, p53 and 
p16 with downregulation of the proliferation marker Ki67. Cheng et al (89) 
demonstrated similar findings in both TERC and TERT knock out mice, demonstrating 
that the knock outs displayed delayed recovery following IRI compared to wild type 
mice.  They also showed a similar upregulation of P16 and delayed expression of Ki67 
in response to IRI.  
 
To date, no clinical studies have examined telomere biology and the development of 
AKI in humans. The animal studies outlined above are based on ischaemic models of 
AKI.  
 
1.6.4 DNA Methylation and cardiovascular disease 
The role of DNA methylation in the pathophysiology of cardiovascular disease (CVD) 
is not yet well understood. Altered DNA methylation in CVD could be due to changes 
in methylation associated with the classical cardiovascular risk factors such as age, 
sex, smoking and diabetes or with the underlying disease mechanisms such as 
atherosclerosis. Zhang et al (116) reviewed the topic in 2016 and concluded that the 
relationship between DNAm, cardiovascular disease and its associated risk factors is 
complicated with different studies reporting conflicting results. For example, the 
development of atherosclerosis, the underlying pathology in the majority of CVD, has 
been shown to be associated with both global hypo- and hypermethylation. Early 
studies demonstrated global DNA hypomethylation associated with atheroma 
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formation in APOE -/- mice both in PBMC and aortic tissue prior to the onset of 
atheroma (142). Similar findings of global DNA hypomethylation were described by 
Hiltunen et al (143) both in advanced human atherosclerotic lesions and in APOE -/- 
mice. They also described genomic hypomethylation in rabbits following intimal 
hyperplasia induced by balloon denudation of the aorta. Global hypomethylation was 
also demonstrated in a rabbit model of atherosclerotic aortas (144) as well as in 
peripheral leukocytes in patients with vascular disease compared to normal controls 
(145). However, more recent papers by Stenvinkel et al (146) and Kim et al (147) have 
demonstrated that global DNA hypermethylation in peripheral blood leukocytes is 
associated with the development of CVD. Even Lund’s earlier work, although 
reporting global DNA hypomethylation in APOE -/- mice, demonstrated 
hypermethylation of the human monocytic-macrophage cell line in response to 
Atherogenic lipoprotein profiles. Such cells were found to be present in the aorta 
prior to the onset of atherosclerosis suggesting that changes in DNA methylation may 
be a causal factor in the development of atheroma.  
 
Zhang et al (116) suggest that a potential cause of these conflicting results lies in the 
fact that the studies measured different markers of global methylation status and did 
so using a variety of techniques. Furthermore, analyses were performed in different 
tissues. An alternative explanation is that the effect of DNA methylation may be 
variable overtime and a state of global hypomethylation does not preclude the later 
development of hypermethylation in CVD.  
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In addition to atherosclerosis, differential DNAm has been demonstrated in diabetes, 
hyperlipidemia, homocysteinuria, female gender, BMI, and smoking. For example, 
Tsaprounis et al (148) demonstrated lower DNA methylation levels in smokers 
compared to non-smokers, which may contribute to their predisposition to CVD. 
Interestingly, this effect was partially reversible on cessation of smoking for 3months 
or more. 
 
1.6.5 DNA Methylation studies and AKI 
Several studies have demonstrated that DNA methylation status can be altered in 
response to AKI. In 2006, Pratt et al (149) reported altered DNAm status in rats 
following ischaemia/reperfusion injury (I/RP injury). However, it should be noted that 
this study only investigated methylation status at a single CpG site within the 
promoter region of the C3 gene, and the degree of I/RP injury was severe with 24 
hours of cold ischaemia followed by 2 hours reperfusion in an ex-vivo circuit. 
Subsequently, both hypo- and hypermethylation of several promoter site CpG’s have 
been proposed as biomarkers of AKI. Endo et al (150) report an association between 
increased levels of unmethylated DNA in the promoter region of Slc22a12, a urate 
transporter in proximal tubule cells, and acute kidney cortical necrosis.  Furthermore, 
Huang et al (151) showed that there was a global reduction in DNA 
hydroxymethylation in the kidneys of mice with I/RP injury. Conversely, 
hypermethylation of CpG’s of the promotor region of Kallikrien (KLK1) was seen in 
patients with established AKI versus healthy controls (152).  
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Whilst the above studies demonstrate that DNA methylation is altered in response 
to AKI or renal I/RP injury, they tell us little about the nature or mechanism of the 
association and further study is needed. Furthermore, whilst such changes may be 
useful in the early detection of AKI once the insult has occurred it does not allow us 
to predict a person’s susceptibility to AKI prior to its onset. The current study aims to 
establish whether DNA methylation changes indicative of increased biological age 
and cellular senescence can predict the onset of CSA-AKI.  
 
1.7 Summary of Hypothesis 
We propose that patients with increased cellular senescence and a reduced ability 
for tissue regeneration are more susceptible to ischaemia-induced AKI and 
predisposed to reduced long-term survival.  To test this hypothesis, we will study 
telomere biology and DNA methylation in patients undergoing cardiac surgery and 
compare those who develop AKI with those who do not. This population will also be 
followed up for the development of the primary endpoints of CKD and death.   
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CHAPTER 2: Aims 
2.1 Aims of Mean Telomere Length analysis experiment 
1. To determine if mean telomere length is associated with the development of 
cardiac surgery associated-acute kidney injury (CSA-AKI) 
2.2 Aims of STELA experiment 
The aims of this pilot study were 2-fold; 
1. To determine if an alternative method of telomere length measurement was associated 
with the development of CSA-AKI. 
2. To investigate the correlation in mean Telomere length measurement between STELA and 
qPCR performed on the same samples.  
 
2.3 Aims of DNA methylation experiment 
1. To correlate predetermined methylation signatures for aging and cellular 
senescence with the development of CSA-AKI.  
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CHAPTER 3: Methods: Clinical study 
3.1 Study Overview 
A single-center prospective cohort study was performed at Barts Heart Centre, 
London. Pre-operative blood tests were taken and processed to acquire DNA and 
RNA for subsequent analysis. Pre-operative baseline plasma, serum and urine were 
also collected. In a subset of patients, serum and urine samples were collected on 
the first post-operative day to allow for testing of novel renal biomarkers and 
markers of inflammation. 
 
3.2 Study Objectives 
The primary objective of this study was to investigate whether pre-operative markers 
of cell senescence could be used to predict the development of CSA-AKI.  
 
3.3 Sample size  
We aimed to recruit 50 cases of CSA-AKI for the primary analysis. From a review of 
the literature, the prevalence of AKI following cardiac surgery was estimated to be 
approximately 10-20%. As such it was estimated that 250 and 500 patients would 
need to be recruited to provide the required number of 50 in the AKI cohort. As the 
protocol requires minimal patient intervention/participation, a high drop-out rate 
was not envisaged. Accordingly, no correction in study numbers has been made for 
this.  
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3.4 Study duration 
It was expected that the study would take between 12 and 18 months to recruit. In reality 
254 patients (55 AKI cohort) were recruited between 27/1/16 and 28/9/16. Unfortunately, 
due to a sample processing error, 35 samples were found to have insufficient DNA for 
downstream processing. In 8 of these cases, DNA was successfully obtained after re-
extraction. However, between 30/1/17 and 7/4/17 a further 27 patients had to be recruited 
to replace the inadequate samples.  
3.5 Patient Recruitment 
The study aimed to enroll the majority of patients undergoing cardiac surgery at Barts 
Health. As such the exclusion criteria were minimal. This was to allow the recruitment 
of a large number of patients and improve our ability to find trends in a heterogenous 
population of patients and surgical procedures. 
3.5.1 Inclusion criteria: 
• Patients undergoing cardiac surgery at Barts Heart Centre 
3.5.2 Exclusion criteria 
• Patients with renal transplant 
• Patients on renal dialysis 
• Patients unable to give informed consent. 
• Patients already recruited into other trials 
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3.5.3 Timing of Recruitment 
Elective patients were recruited on the evening prior to their surgery. If patients were 
to be operated in the afternoon they were sometimes consented on the day of 
surgery if there was sufficient time to allow the patient to consider their 
participation. We set this time period at no less than 2 hours. Potentially suitable 
patients were identified by review of the operating theatre schedule.  
 
Urgent and emergency patients were recruited either on the evening prior to surgery 
or the morning of their surgery. However, all patients were given a minimum of 2 
hours to consider their participation. 
 
3.6 Informed Consent 
All patients recruited to the study were given a typed Patient Information Sheet (PIS) 
outlining what their participation involved and the potential risks and the benefits. 
The PIS and consent form are shown in Appendix A. A patient’s capacity to give 
informed consent was based on the clinical team’s judgement when consenting the 
patient for surgery. If a patient was deemed to have capacity to consent for their 
cardiac surgical procedure, they were also assumed to have capacity to give informed 
consent for trial participation.  
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3.7 Criteria for discontinuation 
A patient’s involvement in the current study ended if either of the following criteria 
were met; 
1. At 7 days post- operatively. 
2. The patient was discharged from the hospital during the study period 
3. The patient died 
4. The patient withdrew consent for further participation 
3.8 Data Collection 
3.8.1 Protocol for data collection 
The protocol for data collection is show in Figure 3.  
 
 
Figure 3: Flow chart demonstrating the procedure for study data collection 
 
 
Participant Written Informed Consent 
Pre-operative demographic data collected 
Pre-operative blood and urine sample collected 
 
Participant undergoes surgery 
Intra-operative data collected 
 
 
 
 
 
Post-operative blood collected at Day 1 and Day 3 or 4 
Post-operative urine collected at Day 1 
Post-operative data collected 
66 
 
• Pre-operatively: Venous blood and urine sample were taken for baseline values 
of renal biomarkers and markers of inflammation. Pre-operative demographic and 
clinical data was recorded. The included fields were: Admission date; Recruitment 
date; Procedure Date; Age; Gender; Ethnicity; Height; Weight; Pre-operative 
angina status; Number of previous MI; Previous PCI; Previous cardiac surgery; 
History of malignancy; Diabetes; Hypertension; Hypercholesterolaemia; Smoking 
history; Renal disease; Pulmonary disease; Neurological impairment; Extracardiac 
arteriopathy; Pre-operative heart rhythm; extent of coronary artery disease; Left 
main stem disease; Pre-operative Angiotensin Converting Enzyme (ACE) inhibitor 
use; Pre-operative statin use; Pre-operative Diuretic use; Left ventricular function. 
Pre-operative white blood cell count (WCC); Preoperative Haemoglobin; Pre-
operative International normalised ratio (INR); Activated Partial Thromboplastin 
Time (APTT) 
 
• Intra-operatively: Routine intra-operative clinical data was recorded. The 
included fields were: Operative urgency; Operation type; Procedure Date; 
Cardiopulmonary bypass time; Aortic cross-clamp time 
  
• Post-operatively: Blood and urine samples were collated on day 1 post-
operatively. This blood was taken at 0900 hours regardless of the patient’s time 
of surgery. This means that this day 1 sample is taken at approximately 15 – 20 
hours post-operatively depending on whether the patient was operated in the 
morning or afternoon. However, it was decided that morning blood sampling 
represents real world practice and a useful biomarker would need to be able to 
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distinguish between risk of AKI and no risk of AKI for samples taken anywhere 
from 12-24 hours post-operatively. Further blood samples were taken on day 3 
or 4 post-operatively for renal function. If any additional bloods were performed 
by the clinical team in the first 7 days, the renal function results were also noted. 
Post-operatively, clinical data was recorded including; Extubation date; 
Vasopressor discontinued date; Inotropes discontinued date; 1st haemoglobin in 
intensive care unit (ITU); Urine output in 1st 12 hours; Reoperation; Blood 
transfusion in ITU; Clotting products given; New Atrial Fibrillation (AF); Day of 
onset of AF; Pharmocology for treatment of AF; AF resolved prior to discharge; 
Post-operative Ileus; Respiratory tract infection; Sternal wound infection; Harvest 
site wound infection; Neurological dysfunction; New Stroke; Myocardial 
Ischaemia; repeat revascularisation; Date of discharge; length of stay; CRP on 
post-operative days 1, 2, and 3; Mortality at discharge; Mortality at 1 year follow 
up.  
 
3.9 Specimen Sample Collection 
3.9.1 Blood sampling 
A total of 14.5 millilitres (mls) of blood was taken from the patient pre-operatively. 
This was stored as; 
• 2x Full blood count = 8 mls 
• 1x Serum-separating tube (SST) = 4 mls 
• 1x PAXgene RNA tubes = 2.5 mls 
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A further SST was taken on the first post-operative day. The results were documented 
of all renal function tests taken in the early post-operative period (1-7 days) as part 
of the patient’s routine post-operative care. These were done at a minimum 
frequency of every 2 days and processed by the hospital laboratory.  
3.9.2 Urine sampling 
8mls of urine were taken from each patient pre-operatively via a mid-stream urine 
sample or directly from the catheter port at time of catheter insertion in surgery. A 
further 8mls were taken on the first post-operative day directly from the catheter 
bag. No urine was sampled from the urine collection bag.  
 
3.10 Ethical Approval and Trial Registration 
The study was sponsored by Queen Mary University of London (QMUL). Final 
Research and Development (R&D) approval was provided by the Joint Research 
Management Office of QMUL and Barts Health NHS Trust (Reference: 010706). 
Research Ethics Committee (REC) board approval was granted by London-Queen 
Square Research Ethics Committee. (REC Number: 15/LO/1741). The trial was 
registered with clinicaltrials.gov (Registration number: NCT02692833). The relevant 
documentation for sponsorship and R&D and ethical approvals is listed in Appendix 
A. 
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3.11 Study Populations and Statistical Analyses 
The current studies were performed as case control studies with cases being defined 
by the outcome of CSA-AKI or mortality. As such associated risk factors were defined 
with Odd’s ratio’s and 95% confidence intervals generated by binary logistical 
regression. Univariate and multivariate analyses were performed with binary 
logistical regression with mTL and DNA methylation age as independent variables and 
development of AKI as the binary dependent variable. Further analyses were 
performed in which mTL and DNA methylation age were treated as an interval, non-
normally distributed dependent variables and clinical parameters used as 
independent variables. For continuous independent variables Spearman’s rho 
correlation was used. For categorical independent variables, the Mann-Whitney U 
test was used for variables with 2 levels and the Kruskal-Wallis test for variables with 
more than 2 levels. 
 
A propensity score analysis was performed to match cases and controls for all 
significant determinants of AKI other than mTL. The propensity matching was 
performed by Dr Gabriella Captur (Cardiology Registrar, St Bartholomew’s Hospital; 
using ‘R’ statistical software). Multiple logistical regression with 1:1 nearest 
neighbour matching was used to develop the propensity score with the development 
of CSA-AKI as the dependent variable. Factors entered into the model were based on 
well documented predictors of AKI from the literature and included age, gender, 
ethnicity, BMI, type of operation, diabetes; pre-op LV function, Pre-operative AF, Pre-
op creatinine; Bypass time and Logistic EuroSCORE. 
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All continuous variables were tested for normality with the Shapiro-Wilks test. P-
values of <0.05 were considered as significant. Analyses were performed using SPSS 
Version 22 and R version 3.0.1 for propensity matching.  
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CHAPTER 4: Methods: Laboratory 
4.1 Rationale of chosen methodology for Telomere length measurement 
4.1.1 Introduction  
Telomere length (TL) can be measured by several different methods. The suitability 
of any one method is dependent on a number of factors including the raw material 
available, the accuracy of the measurements required, and the resources available 
(153). Different methods that have been utilised to measure TL include terminal 
restriction fragment (TRF) length analysis, polymerase chain reaction (PCR) based 
techniques, and fluorescent in-situ hybridisation (FISH) techniques.  
 
4.1.2 Terminal restriction fragment (TRF) analysis 
The first method used to quantify TL was TRF analysis by Southern blotting. As such, 
it has been used to validate subsequent methods of TL measurement that have been 
developed and is therefore considered the gold standard technique. In brief, the 
technique uses restriction enzymes to digest genomic DNA in a way that excludes the 
telomeric sequences, resulting in short fragments of genomic DNA and the longer 
uncut telomeres. The digestion products are then visualised using Southern blotting 
or by in-gel hybridisation using a probe specific for telomeric DNA (154). The resulting 
DNA is seen as a smear due to the variable telomere lengths between chromosomes 
and between different cells of the same individual. The length of this smear as well 
as the signal intensity are used to calculate an average telomere length for the 
sample.  The advantages of this technique are that it has good reliability and provides 
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an absolute rather than a relative measure of TL. Despite this, comparisons of TL 
measured by TRF analysis are not necessarily comparable across different studies due 
to differences in restriction enzymes used. Different restriction enzymes differ in the 
average distance from the last available restriction site to the start of the true 
telomeric repeats. This means that both the length of the telomeric region and a 
variable portion of the sub-telomeric region are included in the measure for mean TL 
(mTL). The degree of variation cannot be measured and is an inherent source of error 
in measuring TL length by TRF analysis. Other drawbacks of the TRF technique is that 
it requires large amounts of input DNA and is relatively expensive and time 
consuming to perform in comparison to other techniques such as qPCR.  
 
4.1.3 Quantitative polymerase chain reaction (qPCR) 
Q-PCR involves labelling the target DNA of interest with a fluorescent probe and then 
amplifying it by PCR. A standard curve generated by serial dilution of a standard of 
known concentration is run in the same reaction allowing for quantification of the 
unknown samples (Figure 4). Initial attempts to measure TL by qPCR using 
oligonucleotide primers designed to hybridise to the TTAGGG and CCCTTA repeats 
failed due to the formation of only primer dimer products. In 2002, Cawthon et al’s 
(155) landmark paper described a method of measuring relative mean telomere 
length using a primer pair that anneal to both the 3’ and 5’ ends of the Telomere but 
have mismatches along their length preventing primer-dimer formation. This method 
determines relative mean telomere length by calculating the factor by with each 
experimental DNA sample differs from a reference DNA sample in its ratio of 
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telomere repeat copy number to single copy gene (SCG) copy number. This ratio, 
termed the Telomere/SCG (T/S) ratio, should be proportional to the mean telomere 
length of the experimental samples. This original 2002 protocol is the method most 
frequently used by investigators to measure mTL. The reasons for this are that it 
allows high throughput of samples as PCR cyclers commonly measure 96 samples or 
384 samples in a single run. It is also relatively cheap to run but does require 
expensive PCR cycling equipment. However, qPCR is limited in terms of its tendency 
to produce variation between ‘batches’ of samples and therefore experimenters 
must ensure that appropriate measures are taken to account for inter-and intra-
assay variability. Similar to TRF analysis, qPCR is limited in that it only measures mean 
TL and gives no information about individual short telomeres or chromosomal ends 
lacking a telomere (156). One of the main sources of variation in Cawthon’s original 
2002 protocol was variation due to pipetting errors in loading the reactions in 
separate Telomere (T) and Standards (S) wells/tubes. Cawthon later modified his own 
technique to allow both the telomere and SCG reactions to be run in the same 
reaction tube, thus eliminating this particular source of error. This technique is 
termed monochrome multiplex quantitative PCR reaction (MMqPCR)(157). 
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Figure 4: PCR output showing successful quantification of a 5-point standard curve 
for the Telomere Reaction run in duplicate. 
 
 
A further modification to the qPCR method of Telomere length analysis was 
developed by O’Callaghan et al (158) aimed at allowing absolute rather than relative 
quantification of TL. To do this the original qPCR TL protocol was modified to use 
reference samples of known lengths. These lengths were 84 base pairs for the 
telomere reaction and 75 base pairs for the single copy gene with the telomere 
standard comprising 14 copies of the TTAGGG repeat.  
4.1.4 Short Telomere Length Analysis (STELA) 
A common limitation of both TRF analysis and qPCR is that they are only able to 
provide a measure of mean telomere length and provide no information of the length 
of the shortest telomeres, a factor that is thought to be central to the induction of 
senescence (101). To address this problem, Baird et al (159) modified the qPCR 
singleplex protocol to allow single telomere length analysis (STELA) from a subset of 
chromosomes. The technique relies on annealing a 6-base-pair ‘telorette’ (TTAGGG) 
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with a 20-nucleotide non-complementary tail to the G-rich 3′ overhang. In a second 
step, the telorette is ligated to the 5′ end of the complementary C-rich strand of the 
chromosome, which effectively tags the end of the telomere with the non-
complementary telorette tail. PCR is then performed with a primer that matches this 
tail together with a chromosome specific upstream primer located in the sub-
telomeric region. The main problem with this method is that not all chromosomes 
have sub-telomeric sequences suitable for primer design. As such, traditional STELA 
is limited to a small number of chromosomes only and STELA is primarily performed 
on the XpYp telomere (160). Following PCR, the reaction products are serially diluted 
and resolved by Southern blotting to determine individual telomere lengths (Figure 
5).  
 
Figure 5: XpYp STELA. Following telomere specific PCR, the products are separated by 
Southern Blotting. On serial dilution, the TRF-like smear resolves to individual 
Telomeres from which the shortest telomere length can be derived. 
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Finally, a novel method termed universal-STELA (U-STELA) was developed by Bendix 
et al (161) and allows the length of individual telomeres to be measured regardless 
of position. This is achieved using restriction enzymes to cleave the DNA into short 
genomic fragments and intact telomeres as in TRF analysis. PCR is then performed 
using specialised oligonucleotides that are annealed to either end of both the 
genomic fragments and the telomeric DNA. In brief, the oligonucleotides annealed 
to the genomic fragments are designed in such a way as to bind to themselves once 
the double stranded fragments dissociate at the start of PCR. Meanwhile the 
oligonucleotide sequences annealed to either end of the telomeric DNA are designed 
to promote the binding of telomere specific primers and facilitate amplification. 
Therefore, the individual telomeres are selectively amplified. Finally, the PCR 
products are visualised by Southern blotting. The disadvantages of STELA are that it 
is highly labour intensive and technically challenging to perform and is less able to 
measure long telomere lengths. 
 
4.1.5 Quantitative fluorescence in-situ hybridisation (Q-FISH) 
Q-FISH for TL measurement was first described by Landorp et al (162) in 1996, and 
visualises telomeres by hybridisation using a probe for the telomeric repeat sequence 
(CCCTAA)3. It therefore allows an estimation of the size of all 92 telomeres within the 
genome, unlike TRF or qPCR analysis. It is also able to identify telomere free 
chromosome ends. A crucial difference between Q-FISH and the methods of TL 
measurement outlined above is that it requires intact cells rather than DNA for the 
substrate of the reaction, in order to visualise the chromosomes in metaphase. A 
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limitation of the technique is that it cannot be used to measure TL in cells that are no 
longer dividing. This limits its use in large clinical studies where such cells are rarely 
available. It is also time consuming, labour intensive, and requires specialist 
equipment and knowledge of chromosomal banding patterns (156). 
 
Flow-FISH is an adaptation of q-FISH which combines flow-cytometry with the 
hybridisation of telomere binding probes in solution. The use of flow cytometry 
allows for high throughput analysis and can also allow specific subpopulations of cells 
to be identified. As such it is particularly useful in measuring TL in hemopoietic cells 
(153). However, there are several disadvantages associated with its use. Non-fixed 
cells are difficult to work with due to issues such as fragility and clumping, and the 
technique is sensitive to reagents used to preserve cells. Also, as with qPCR and TRF 
analysis, only a measure of mean TL is produced with no data provided on individual 
telomere lengths. 
 
4.1.6 Rationale for selecting qPCR as the primary method of TL measurement 
In the current study, we elected to perform TL measurement by singleplex qPCR. As 
the substrate for our experiments is stored frozen DNA we are unable to perform 
FISH, which requires intact dividing cells. Whilst the TRF method is often considered 
the gold-standard for TL measurement, the numbers of patients in the current study 
(~250) would have made using this technique extremely time consuming. There is 
also the issue that the TRF method may lack precision as it measures an undefined 
portion of the sub-telomeric region in addition to the telomeric DNA. As such, qPCR 
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was chosen as the method of TL measurement as it is relatively cheap, easier to 
perform on large numbers of samples, and well established in the literature. 
Cawthon’s original singleplex protocol was chosen over MMqPCR as it as felt that the 
additional complexity of this technique did not merit the improved precision 
reported with the singleplex and multiplex qPCR showing strong correlation in the 
measurement of mean TL (163). However, several modifications were made to this 
original protocol to optimise the results to our specific samples and laboratory 
equipment (See section 4.4.6). 
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4.2 Measuring DNA methylation signatures of aging and cellular senescence 
Alternations in DNA methylation have been implicated in both aging and cellular 
senescence. Several studies have developed epigenetic clocks to predict 
chronological age based on the methylation status of age-linked CpG probes (76, 
164). Furthermore, deviation of this predicted methylation age (pMA) away from the 
true chronological age has been used as a measure of ‘biological age’ to predict all-
cause mortality (165). The first study to attempt to develop an epigenetic signature 
for aging was published by Koch et al in 2011 (166). This model was based on just 5 
CpG sites and achieved a correlation between predicted and chronological age of 
0.64 with an average precision of +/- 12.7 years. 
 
In 2013, both Horvath and Hannum published their epigenetic clocks. Horvath (164) 
obtained DNA methylation data from several publicly available databases. This model 
was based on methylation at 353 CpG sites and was highly accurate across a range of 
tissues. Correlation with predicted age was 0.96 across all tissues with a mean 
absolute error (MAE) of 3.6 years when tested against a validation subset. In the 
same year, Hannum et al (76) published their genetic clock based on 71 CpG sites. 
This signature was developed from a derivation population of 656 individuals based 
on DNA derived from peripheral blood. This signature predicated chronological age 
in a validation cohort of 174 subjects with an R value of 0.91 and root mean squared 
error (RMSE) of 4.9 years. Interestingly, only 5 CpG sites overlapped between the 
epigenetic clocks of Horvath and Hannum.  
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In 2016, Weidner et al (167) produced an alternative epigenetic clock based on just 
3 CpG sites. 102 age-associated CpG sites were identified from pooled DNA 
methylation data from 4 studies which used the Human-Methylation27 BeadChip 
platform (Illumina, San Diego, CA, USA). An epigenetic clock based on all 102 sites 
predicted chronological age with an R value of 0.98 and an RMSE of 4.26 years.  When 
just the top 3 CpG sites were measured in a second independent population of 82 
blood samples, chronological age was predicted with an RMSE of 7.3 years.  
 
Finally, in 2018, Levine et al (168) published the PhenoAge clock. This clock combined 
DNA methylation data from 513 individuals together with clinical data to generate a 
measure of ‘phenotypic age’. DNA PhenoAge was then correlated with chronological 
age (R = 0.71) and a range of clinical outcomes. PhenoAge was able to predict the 
onset of several age-related disease processes including all‐cause mortality, cancers, 
health span, physical functioning, and Alzheimer's disease.  
 
Of the 5 epigenetic clocks described above, Horvath’s and Hannum’s are the most 
accurate. Hannum’s also has the advantage of being derived solely from DNA 
harvested from peripheral blood and from only 71 CpG sites rather than 353. As such, 
Hannum et al’s 71 CpG epigenetic clock was chosen as a marker of in the current 
experiment. 
 
Koch et al (77) demonstrated an epigenetic signature for cellular senescence based 
on alterations in methylation at 6 CpG sites. This signature was derived from 51 
samples of known passage number using the Human-Methylation27 BeadChip. These 
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51 samples were derived from a range of tissues. Combination of the 6 CpG sites 
enabled reliable estimations of passage numbers in fibroblasts and mesenchymal 
stem cells (MSC) (R2 = 0.90; MAE = 3). 
 
This thesis aims to correlate the methylation signature for aging described by 
Hannum and the methylation signature for senescence described by Koch, with 
outcomes after cardiac surgery. The primary outcome is the development of CSA-
AKI, and secondary outcomes are in-hospital and 1-year mortality.  
 
4.3 Sample processing 
4.3.1 Immediate sample processing 
All blood samples were processed at 30 minutes from time of collection. The 
PAXgene tubes were mixed by inversion and then frozen at -20 ˚C for long term 
storage. The technical information provided with the PAXgene system quotes that 
samples can be stored for 8 years in this state (169). The remaining samples were 
centrifuged at 4000 revolutions per minute (rpm) for 10 minutes and aliquoted into 
plasma, buffy coat and serum. These aliquots were then stored at -80˚C for 
subsequent analysis. Urine samples were aliquoted into 2ml cryovials and stored at -
80˚C. 
4.3.2 Sample storage 
PAXgene RNA tubes were stored in -20 ̊ C freezers in the department of Translational 
Medicine at the William Harvey Research Institute (WHRI). The aliquoted samples of 
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urine, plasma, serum, and buffy coat were stored in -80 ˚C freezers at the Heart 
Centre, WHRI.  
4.3.3 DNA extraction 
DNA was extracted from frozen buffy coat using the EZ1 DNA blood 350µl kit and the 
Biorobot EZ1 containing a buffy coat card (Qiagen, Germany). The Biorobot is able to 
process 6 samples per run over a 20-minute time period. The automated process 
extracts DNA using magnetic particle technology. Cells are lysed allowing DNA to bind 
to the silica surface of magnetic particles. The particles are then separated from the 
lysates using a magnet, and finally the DNA is washed off the surface of the beads 
and eluted in a volume of 200µl. In brief, frozen buffy coat was thawed and mixed by 
retro-pipetting several times. For each sample, 300 µl of buffy coat was placed in a 
1.5ml reaction tube and placed in the Biorobot together with a cartridge from the 
EZ1 DNA kit, a specialised pipette tip and holder, and a 1.5ml elution tube. The final 
eluted volume of 200ml was aliquoted into 1x120µl and 4x20µl aliquots and stored 
at -20 ˚C for subsequent analysis. Prior to aliquoting, a magnet was applied to the 
tube to draw residual magnetic beads from the extraction process to the bottom of 
the sample. The 120µl aliquot was stored at 4 ˚C until the purity and quantity of the 
DNA had been measured by Spectrophotometry (within 48 hours of extraction).  
 
4.3.4 DNA Quantification and Quality Control 
DNA concentration was measured on a Nanodrop 2000 Spectrophotometer 
(Thermofischer Scientific, Germany) using 1µl of non-diluted eluted DNA. The 
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nanodrop was blanked with nuclease free, PCR-grade water as per the EZ1 handbook 
instructions (170). The Nanodrop spectrophotometer measures DNA concentrations 
by measuring the absorbance of light at a wavelength of 260nm, using a modification 
of the Beer-Lambert equation. Whilst Thermofischer quote a working detection 
range of 0.4 – 15000 ng/µl, expert opinion is that readings of less than 10ng/µl may 
be unreliable. As such, any samples with a concentration of <10ng/µl were not 
deemed suitable for downstream processing and were earmarked for DNA re-
extraction.  
 
DNA Purity was indicated using the ratio of absorbance at 260nm and 280nm (the 
260/280 ratio). Pure DNA has a 260/280 ratio of approximately 1.8. Any sample with 
a ratio of <1.7 or > 2 was re-extracted. The 260/230 ratio is a secondary measure of 
DNA purity, and if low can represent the presence of contamination products 
absorbing at 230nm. Automated DNA extraction processes using magnetic bead 
separation are known to produce low 260/230 ratios due to the presence of residual 
magnetic beads in the eluted samples (171). However, this has not been found to 
interfere with downstream PCR experiments. Anslinger et al tested DNA extracted 
using the EZ1 Biorobot from a range of initial samples including blood, hair, sperm, 
teeth, and saliva. In downstream PCR experiments they found no evidence of any 
PCR inhibition (172). As such, we used the 260/280 ratio as the sole determinant of 
DNA purity. 
 
Finally, DNA integrity was measured using gel electrophoresis. High DNA integrity is 
important for successful DNA methylation status experiments. In initial experiments 
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80ug of genomic DNA was found to produce a visible band on a 2% Agarose gel run 
at 70mV for 90 minutes. I subsequently found that adding 2µl of the undiluted DNA 
sample was universally sufficient to produce a visible band. An example gel 
electrophoresis result for DNA integrity is shown in Figure 6. 
 
 
Figure 6: Gel electrophoresis for DNA integrity. 2% Agarose gel run for 90 minutes. 
Single band seen on gel at high molecular weight and no smear indicating good DNA 
integrity 
 
 
4.3.5 RNA extraction 
RNA extraction was performed manually using the PAXgene blood RNA system 
(Qiagen, Manchester, UK) consisting of a blood collection tube (PAXgene Blood RNA 
Tube) and a nucleic acid purification kit (PAXgene Blood RNA Kit) as per the 
manufacturer’s instructions.  In brief, 2.5mls of blood was collected in a PAXgene 
bottle and stored at -80 ̊ C for subsequent analysis. Once defrosted samples were left 
to stand upright at room temperature for 2 hours to allow for full lysis of cells. The 
PAXgene tubes were centrifuged at 4000rpm for 10 minutes and the pellet washed 
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with RNase free water before repeat centrifuging. The washed pellet was suspended 
in ethanol before being lysed with a kit binding buffer and Protease K whilst shaking 
at 700 rpm for 10 minutes at 55 ̊ C. The resulting lysate was then placed in a PAXgene 
shredder spin column and centrifuged to remove debris before undergoing a series 
of washes using PAXgene RNA spin columns. Next, the spin columns were incubated 
with a DNase incubation mix to remove genomic DNA contamination. After 3 further 
washing steps, RNA was eluted from the spin column membrane with a total of 80µl 
of elution buffer. Finally, the eluate was incubated for 5 minutes at 65 ̊ C before being 
stored in aliquots at -20 ˚C.  
4.3.6 RNA quantification and Quality Control 
RNA was quantified using the same methodology as for DNA (see section 4.3.4). RNA 
purity was again indicated by the 260/280 ratio with pure RNA known to have a ratio 
of approximately 2.  
 
4.4 Telomere Length Analysis by Quantitative PCR 
4.4.1 DNA Thawing 
All DNA samples were prepared as previously described in section 4.3. At the time of 
analysis, DNA samples were removed from storage at -20 ˚C and defrosted slowly on 
ice. After briefly centrifuging for 2-3 seconds to collect all the sample in the bottom 
of the reaction tubes, samples were mixed gently by retro-pipetting. 
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Spectrophotometry was then performed to ensure that the defrosted samples 
demonstrated similar traces, concentrations and ratios to their pre-frozen levels.  
4.4.2 Thermocycling equipment 
Real time PCR was performed with the Corbett Research Rotorgene 6000 
Thermocycler (Qiagen, Manchester, UK). In the early optimisation stages of assay 
development individual reaction tubes were used in a 72 well carousel. For the study 
analysis, a 100 well, heat sealed rota-disc was used. 
4.4.3 Principals of PCR set-up 
PCR must be performed under strict conditions to prevent cross-contamination 
between samples and controls. All steps of the PCR set up were performed on a 
separate work-bench that was pre-treated with ethanol and RNAse Away 
decontamination reagent (Fischer scientific, Loughborough, UK). All pipettes and 
reaction tubes were treated with Ultra-violet (UV) cross-linkage (Spectrolinker XL-
1000, Spectroline,) which prevents PCR contamination by forming pyrimidine dimers 
in contaminant DNA which function as termination sites (173). All pre-amplification 
steps were performed using sterile, filter-pipette tips. All components of the PCR mix 
were stored in aliquots and used in a single PCR reaction only.  
4.4.4 Final PCR protocol 
The protocol for the TL analysis was based on that by Brouilette et al in the West of 
Scotland Primary Prevention Study (WOSCOPS) (174). In this study, the authors 
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measured TL in over 1500 patients, by a method modified from Cawthon’s original 
2002 protocol (155). This method was chosen over Cawthon’s original protocol as it 
uses smaller reaction volumes of 20µl instead of 50uL and thus allows the use of a 
100 well rotor-disc (15-25 µl reaction volumes).  
 
The primers used were as described in the WOSCOPS protocol and are listed in  
Table 2. The reference gene 36b4 was used to provide a ratio for telomere repeat 
sequence copy number to single-copy gene copy number. All primers were ordered 
from Sigma Aldrich Co LLC (Poole UK). The desalted oligonucleotide primers were 
reconstituted with sterile nuclease free water (NFW) and stored in 20µl aliquots of 
100µM concentrations at -20˚C. At the time of use, aliquots were defrosted and 
mixed with 180µl of NFW to produce a working solution of 10µM concentration. 
 
Primer  Sequence 
Tel 1 (Forward) 5’CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT3’ 
Tel 2 (Reverse) 5’GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT3’ 
36b4 Forward 5’CAGCAAGTGGGAAGGTGTAATCC3’ 
36b4 Reverse 5’CCCATTCTATCATCAACGGGTACAA3’ 
 
Table 2: Primer sequence for the Telomere reaction (Tel1/Tel2) and the single copy 
gene (36b4). 
 
The components of the PCR Mastermixes are shown  
Table 3. Two different master mixes were produced with a final volume of 15µl, one 
for the Telomere reaction and the other for the SCG. 5µl of sample DNA 
(concentration 1ng/µl) were added to the Mastermix to produce a final reaction 
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volume of 20µl.  For each 100 well rotor disc both the Telomere and the SCG reactions 
for a single sample were run in parallel in the same PCR run. This was to minimise 
any difference in T/S ratio due to slight variations in individual run conditions. For 
each rotor disc, 50 wells were dedicated to Telomere reactions and 50 to the 
corresponding 36b4 SCG reactions. Each 50 wells included 19 samples, a 5-point 
standard curve and a negative control, all run in duplicate. The standard curve was 
produced from serial dilutions (5ng-0.156ng DNA; 2-fold dilution, 5 points) of stock 
human mixed genomic DNA (Promega, UK). The negative control was nuclease free 
water. After loading each well of the Rotor disc by manually pipetting, the disc was 
sealed with Rotor-disc heat sealer as per the manufacturer’s instructions. Conditions 
were as described in the WOSCOPS protocol. The specificity of all amplifications was 
confirmed with melt curve analysis. The cycling conditions and settings of the melt 
curve analysis are given in Table 4. 
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Component Concentration Volume 
Telomere run 
KiCqStart SYBR Green qPCR Readymix - 10µl 
Tel 1 Primer 300nmol/L 0.6µl 
Tel 2 Primer 300nmol/L 0.6µl 
Nuclease free water - 3.8µl 
Final Volume 15µl 
Single copy gene run 
KiCqStart SYBR Green qPCR Readymix - 10µl 
36b4 F 300nmol/L 0.6µl 
36b4 R 500nmol/L 1µl 
Nuclease free water - 3.4µl 
Final Volume 15µl 
 
Table 3: Components of PCR Mastermixes for TL measurement. 
 
PCR Cycle Settings 
Annealing 95˚C for 10 minutes 
Amplification 35 cycles of 
95˚C for 15 seconds 
58˚C for 60 seconds 
Melt Ramp from 50 ̊ C to 95 ̊ C rising by 1 ̊ C with each step 
Wait 90 seconds of pre-melt conditioning on first step 
Wait 5 seconds for each step afterwards 
Optimise gain before melt on all tubes 
The gain giving the highest fluorescence less than 90 
will be selected 
 
Table 4: PCR cycling conditions for TL measurement. 
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4.4.5 Calculation of T/S ratio 
Standard curves were included in each run allowing concentrations to be measured 
for the samples for both the Telomere reaction (T) and the SCG reaction (S). The 
‘Automated Threshold’ function was used to generate best fit standard curves. The 
duplicate runs produced two concentrations per sample which were then averaged 
to produce a mean concentration for both T and S. The mean relative telomere length 
was then calculated as a ratio of T/S.  
 
4.4.6 Optimisation and rationale of chosen protocol  
The following features characterise a well optimised PCR experiment; 
 
1. A high R2 value: The R2 value, otherwise termed the coefficient of determination, 
is a measure of how well the standard curve fits with the data points that form it. 
Optimal PCR amplifications should have an R2 value of >0.99. As such, this value was 
set as the minimum acceptable value for a PCR to be considered successful in this 
experiment. 
 
2. A reaction efficiency close to 100% (or 1): The reaction efficiency is a measure of 
how much the DNA target is amplified in each PCR cycle. In a 100% efficient reaction, 
the amount of amplification product doubles with each PCR cycle. Whilst is not 
theoretically possible for a single amplification product to amplify at >100% 
efficiency, a PCR amplification can yield an overall efficiency of >100% if the efficiency 
is measured from a standard curve gradient or if non-specific amplification occurs. It 
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is thought that PCR efficiencies should lie within the range of 0.90 and 1.10 (or 90 to 
110%). efficiencies  
  
3. Demonstration of reproducibility: both between duplicate samples in the same 
run (intra-assay variability) and across different runs (inter-assay variability). In PCR 
experiments the Coefficient of Variation (CV) is usually used as a measure of variation 
between repeat results. The CV is calculated as; 
CV       =         Standard deviation of series 
                                                                                 Mean of series 
 
In this study, both the mean intra-assay and inter-assay variability were measured 
for both the validation and study cohorts (see section 5.1).   
 
4. A single peak on melt-curve analysis: This implies that a single PCR product has 
been amplified. 
 
As previously mentioned, the WOSCOPS protocol was chosen due to its smaller 
reaction volume allowing the use of the 100 well rotor-disc. Accordingly, the primers 
and PCR amplification conditions used were taken from same protocol. However, 
during our initial experiments to ensure the applicability of this protocol to our 
laboratory and thermocycling equipment we encountered several difficulties that 
required changes to be made to the standard protocol. These difficulties included; 
1. Over efficiency of PCR amplification  
2. Differences in reaction efficiencies between the telomere and SCG runs 
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3. Inconsistencies in the PCR runs with some runs demonstrating poor R2 values 
and efficiencies despite no apparent changes in set-up.  
 
In initial optimisation experiments, the WOSCOPS protocol was used without 
modification. However, increased reaction efficiencies of 1.15-1.6. were consistently 
demonstrated. As such, different amplification temperatures were used (54˚C, 58˚C, 
62˚C) to try to optimise the PCR efficiency to closer to 1. However, these changes did 
not affect the reactions. To minimise for the presence of PCR inhibitors, a more dilute 
serial dilution was performed with the concentration of the top standard reduced 
from 20mg/µl to 5ng/µl. This change had the effect of improving the reaction 
efficiency to 1.08 and 1.09 for the telomere and SCG runs respectively. Therefore, a 
5-point, 2-fold dilution series ranging from 5ng-0.156ng of DNA was used for all 
subsequent runs. As a consequence of the change in the standard curve from that of 
the WOSCOPS protocol, the amount of input DNA was reduced to 5ng per reaction 
to ensure that the samples remained clustered around the middle of the standard 
curve.  
 
The above changes to the protocol were performed using individual wells held in a 
72 well carousel. For the validation and study runs, the 100 well rotor-disc was used. 
The PCR was found to run equally well in this format. In a further modification to the 
original protocol it was decided to run both the telomere and SCG reactions in 
adjacent wells of the same run to minimise errors resulting from slight differences in 
conditions between runs. To do this the telomere run was extended from 25 to 35 
cycles.  
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The second two issues listed above were nullified by the method chosen for 
determining relative quantitation of telomere length. This will be described further 
in the following section. 
 
4.4.7 Standard curve method Vs delta-delta CT method for relative quantitation of 
TL 
In relative quantitation PCR, the amplification of the gene of interest is normalised 
to that of an endogenous reference or housekeeper gene that is ubiquitously 
expressed. Relative quantitation can be performed by one of two main methods; the 
standard curve method or the delta-delta cycle threshold (delta-delta CT) method. 
The first method involves running a standard curve comprised of serial dilutions of 
stock DNA of known concentration. The standard curve is produced by plotting 
concentration against cycle threshold (CT) level. The CT value of a sample is the 
amplification cycle at which the samples fluorescence signal exceeds an arbitrary 
threshold value above baseline and within the exponential amplification phase of the 
PCR. With the fluorescence threshold set for both the standards and samples within 
a run, the concentrations of the unknown samples can be measured by plotting their 
position on the standard curve according to their CT value. Separate standard curves 
are used to quantify expression of the gene of interest (X) and SCGs (Y) within the 
unknown samples and the relative gene expression recorded as a ratio of X/Y. 
 
In contrast, the delta-delta CT method does not rely on standard curves and uses a 
single calibrator sample present in all runs to ensure comparison across runs. For 
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each sample, the CT value is normalised against that of the reference gene and then 
further normalised against that of a calibrator sample present in all runs 
 
The standard curve method was chosen for this thesis as it has two main advantages 
over the delta-delta CT method. Firstly, the delta-delta CT method requires that the 
reaction efficiencies for the gene of interest (GOI) and the single copy reference gene 
be approximately the same. This is because raw CT data is compared directly with no 
correction made for differing reaction efficiencies. The standard curve method can 
correct for differences in reaction efficiency between the GOI and reference genes, 
as relative quantification is calculated separately using different standard curves. 
Secondly, running standard curves in each run provides an in-built form of quality 
control that ensures that the PCR has amplified effectively (i.e. a value for R2 and a 
reaction efficiency is given for each run). The only disadvantage of the standard curve 
method is that it is more time consuming as the need for a set of standards in each 
run reduces the number of samples that can be processed within that run.  
 
4.4.8 Confirmation of valid PCR for Telomere length 
A typical appearance of the amplification plots and standard curves generated for 
both the Telomere and SCG runs are shown in Figure 7. Extending the telomere run 
from 25 to 35 cycles has the effect of producing a late amplification in the negative 
control. This is likely due to trace DNA contamination being amplified due to the 
ubiquitous expression of telomere DNA. However, the CT values of these negative 
controls were approximately 10 cycles more than those of the samples/standards 
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representing a DNA concentrations 1000-fold less than the most dilute standard. 
Such trace contamination will not affect the final results. When the Telomere run is 
run for 25 cycles, this amplification in the negative control is not seen. In addition, 
melt curve analysis of telomere amplification run over 25 cycles demonstrates no 
product formation in the negative controls (Figure 8).  
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Figure 7: Typical amplification plots and standard curves for Telomere run (A, C) and SCG run (B, D). A: Amplification plot for Telomere run (CT value for 
negative controls > 10 cycles higher than samples/standards). B: Amplification plot for SCG run (Negative control does not reach threshold). C: Standard 
curve for telomere run. D: Standard curve for SCG. All samples (Red) lie within the points of the standard curve (Blue) for both telomere and SCG runs.  
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Figure 8: Melt curve analysis for Telomere run (A) and SCG run (B). A single peak is 
seen in each curve confirming the presence of a single amplification product. The 
negative controls are seen as flat lines at the bottom of each melt curve.  
A 
B 
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4.5 Measurement of Single Telomere Length Analysis (STELA) 
As part of the main study analysis propensity matching was performed between 
patients with and without CSA-AKI. This resulted in 51 matched pairs (see section 
5.5). Of these, 12 pairs were selected; 6 with AKIN stage 1 AKI patients and 6 with 
AKIN stage 2 AKI patients. In each case, the 6 pairs with the closest matched 
propensity scores were selected for analysis.  
 
DNA was extracted as previously described in section 4.3.3. For STELA analysis at the 
XpYp telomere we used the single telomere length analysis (STELA) assay previously 
described (159). This analysis was performed for us by Professor Duncan Baird who 
first described the technique (Division of Cancer and Genetics, Cardiff University). 
Briefly, genomic DNA was solubilised by dilution in 10mM Tric-HCl (pH 7.5), 
quantified by Hoechst 33258 fluorometry (BioRad, Hercules, USA) and diluted to 
10ng/µl in 10mM Tris-HCl (pH 7.5). 10ng of DNA was further diluted to 250 pg/µl in 
a volume of 40µl containing 1µM Telorette2 linker and 1 mM Tris-HCl pH 7.5. 
Multiple PCRs (typically 6 reactions per sample) were carried out for each test DNA 
in 10µl volumes 250pg of DNA, 0.5µM of the telomere-adjacent and Teltail primers, 
75mM Tris-HCl pH8.8, 20mM (NH4)2SO4, 0.01% Tween-20, 1.5mM MgCl2, and 0.05 
U of a 10:1 mixture of Taq (ABGene, Epsom, UK) and Pwo polymerase (Roche 
Molecular Biochemicals, Lewes, UK). The reactions were cycled with a Tetrad2 
thermocycler (BioRad, USA) under the following conditions: 22 cycles of 94°C for 15 
seconds, 65°C for 30 seconds and 68°C for 8mins. The DNA fragments were resolved 
by 0.5% TAE agarose gel electrophoresis, and detected by Southern hybridisations 
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with a random-primed α-33P labelled (Ready-To-Go DNA Labeling Beads, GE 
Healthcare) TTAGGG repeat probe, together with a probe to detect the 1 Kb 
(Stratagene, La Jolla, USA) and 2.5 kb (BioRad) molecular weight marker. The 
hybridised fragments were detected by phosphorimaging with a Typhoon 
phosphorimager (GE Healthcare, USA). The molecular weights of the DNA fragments 
were calculated using the Phoretix 1D quantifier (Nonlinear Dynamics, Newcastle-
upon-Tyne, UK). 
 
The Wilconxon rank log test was used for comparison of mTL and 25th centile 
Telomere length between the matched groups 
 
  
4.6 DNA Methylation Methods  
DNA was extracted and quality control performed as detailed in sections 4.3. In 
addition, sample concentration was determined by Fluorometric quantification 
(Qubit). The DNA then underwent bisulphite conversion. This process converts 
unmethylated cytosine (C) to thymine (T) whilst leaving methylated cytosine (Cm) 
unconverted. Sequencing of the bisulphite converted DNA can therefore determine 
the methylation status of every individual cytosine residue (175, 176).  
 
A list of the desired CpG sites for study were sent to a third party (Dr Robert Lowe, 
Blizzard Institute, QMUL) for assistance with Primer Design. Unfortunately, only 44 
out of 77 passed the design tests, meaning that the algorithms used in primer design 
were not able to find a pair of primers that would amplify the desired portion of the 
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genome within a prespecified range of stringency. By reducing the design stringency, 
we were able design primers for all the CpG sites but had to accept that in doing so 
we increased the likelihood that a proportion of the PCR reactions might fail. Primer 
pairs usually amplified portions of DNA containing multiple CpG sites. By overlapping 
the PCR products of the primer pairs, we were able to deduce the methylation status 
at individual sites.  
 
Region specific PCR was performed with the Fluidigm 48:48 Access Array (Fluidigm, 
San Francisco, US), which allows target enrichment of 48 samples at one time. A 
detailed description of this methodology is given in Appendix B. This work was 
performed by Dr Charles Mein’s team (the Genome Center, QMUL). In brief, the 
primer inlets of the Access Array were loaded with pooled primer pairs (forward and 
reverse) diluted to a final concentration of 1µM per primer. Fluidigm CS1 and CS2 
custom sequences were added to the 5’ end of each primer (CS1 is added to the 
forward, and CS2 is added to the reverse), allowing for the later addition of unique 
barcodes to each sample. Each of the 48 Sample inlets were loaded with 4µL of 
bisulphite converted DNA and mastermix solution. Once prepared, the Access Array 
was placed in the primed Pre-PCR IFC Controller AX for the samples and primers to 
be automatically combined (1.5 hours duration). The Array was then transferred to 
the Fluidigm FC1TM Cycler for target amplification by PCR. Following amplification, the 
PCR products were harvested. Quality control was performed on a random selection 
of the harvested PCR products using an Aligent 2200 TapeStation System and D1000 
ScreenTape (Aligent technologies) to determine the quantity and integrity of the PCR 
product.  
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The PCR products were then barcoded using a second PCR reaction. The function of 
this step was to label all amplicons from a given sample with a common sequence to 
allow subsequent identification once all of the PCR products had been pooled for 
sequencing. In addition, the barcode contains an Illumina sequencing adaptor (p5 or 
p7) that allows the final library of PCR products to bind to the oligo lawn of the 
Illumina Flow cell. Once the PCR products had been successfully barcoded they were 
pooled for sequencing using the Illumina MiSeq platform (Illumina, California, USA). 
 
The sequencing process generates millions of reads in total representing all of the 
DNA fragments. Sequences within the pooled DNA library are separated into 
individual samples based on the unique sample specific barcodes attached to each 
fragment during preparation of the library. Within fragments from the sample, reads 
with similar base sequences are clustered and grouped by forward and reverse reads. 
Any discrepancies are resolved by comparison within these grouped reads. Finally, 
the percentage of methylated cytosine residues is calculated for each CpG site for all 
fragments generated from a single sample. 
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CHAPTER 5: Mean Telomere Length and Cardiac Surgery 
Associated -Acute Kidney Injury 
5.1 Results of Validation experiments 
Prior to performing the study runs, a validation experiment was performed to 
confirm the reproducibility of the telomere length assay. Three separate runs were 
performed on the first 19 samples in the cohort. Sample 10 was excluded as it had a 
low concentration of DNA to conserve it for the main study runs.  
5.1.1 Intra-assay variability 
All samples were run in duplicate. Intra-assay variability, defined as the coefficient of 
variability (CV) of duplicates, was calculated by averaging the CV values across all 
three runs separately for the Telomere and single copy gene (SCG) amplifications. 
This method gave an intra-assay variability of 4.99 and 2.85 for the Telomere and SCG 
amplifications respectively.  However, a handful of samples showed a large variation 
in CV value which skewed the results and was thought to arise from pipetting loading 
variation. When duplicate samples with a CV value of greater than 10 were excluded 
from the analysis (7 out of 114 samples, 6.1%) the respective average CV values 
improved to 2.50 (Telomere) and 2.44 (SCG).  As such, in our main cohort any 
duplicates with CV of greater than 10 were repeated. 
5.1.2 Inter-assay variability 
Inter-assay variability was measured as the average CV of the Telomere/SCG (T/S) 
ratio of all 19 samples across the 3 runs. A graphical representation of the variation 
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across the three runs is shown in Figure 9. The average CV for all samples was 8.03. 
This improved to 6.43 when the samples with large intra-assay variability were 
excluded from the analysis. 
 
 
Figure 9: Results of validation experiment. Three separate runs were performed on 19 
patient samples.   
 
5.2 The study population 
The current study is a prospective case control study. Cases were defined as patients 
who developed Cardiac Surgery Associated- Acute Kidney Injury (CSA-AKI) in 
accordance with AKIN criteria and controls were defined as patients with no AKI. The 
final number of patients tested for mean telomere length (mTL) was 254.  
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Figure 10 shows a graphical representation of the recruitment process. Of the 281 
patients recruited 254 had valid DNA samples processed. Of the remaining 27, 5 had 
no blood collected. 1 patient withdrew consent prior to blood sampling, 3 patients 
had their operation cancelled and were rescheduled at times that precluded 
sampling and 1 patient was cancelled and was never rescheduled. The remaining 22 
patients had blood samples taken but incorrectly processed for buffy coat resulting 
in DNA yields that were too low for downstream processing. Of the 254 patients who 
had valid DNA samples for mean telomere length analysis 54 developed CSA-AKI 
(cases) and 200 did not (controls). A sample log of the 254 patients tested for mTL is 
given in Appendix C. A summary of the raw data for mTL measurement is given in 
Appendix D together with a summary of the inter-assay variability between the 
standards measured in each PCR run (Coefficient of variation of standards = 2.9%)  
 
5.3 Tests of Normality 
Each continuous variable was tested for normality using the Shapiro Wilks test. P-
values of less than 0.05 were regarded as differing significantly from a normal 
distribution. A summary of these normality tests is shown in Appendix E. These tests 
were used to determine which statistical tests were appropriate to run for each 
variable; e.g. Students t test for normally distributed continuous variables and Mann-
Whitney U test for non-normally distributed continuous variables. 
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Figure 10: Schematic outlining patient recruitment and sampling. Of the 281 patients 
recruited, 254 patients had valid DNA samples processed. Of these, 54 experienced 
post-operative AKI.  
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5.4 Univariate associations of Telomere Length with main outcomes.  
Binary logistic regression was used to determine associations between Telomere 
length and the primary outcome of development of CSA-AKI as well as the secondary 
endpoints of in-hospital mortality, 1-year mortality, and a composite outcome 
combining stroke, new AF, reoperation, and CSA-AKI. 
 
No significant association was seen between mTL and the primary outcome of 
development of CSA-AKI as defined by the AKIN criteria (Table 5). Neither were any 
significant associations seen between the secondary endpoints of in-hospital 
mortality or 1-year mortality. To increase the number of events, a composite 
endpoint was created combining the following outcomes; New AF, Stroke, AKI, and 
return to theatre. However, no association was found between mTL and the presence 
of this composite endpoint. Box plots for mTL and AKI and mTL and composite 
endpoint are shown in Figure 11 and Figure 12. 
 
To further investigate the relationship between Telomere length and our primary and 
secondary outcomes, the study population was divided into quintiles of mean 
Telomere length. Differences in outcomes between patients in the top and bottom 
quintiles of mTL were then investigated. The rationale for doing this was to attempt 
to unmask any subtle associations between mTL and the outcome measures. 
Comparison of the rates of each of the endpoints between the top and bottom 
quintiles was performed using Fischer’s exact test. Again, no significant associations 
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were found between Telomere length and any of the previous outcome measures; 
AKI, in-hospital mortality, 1-year mortality or composite outcome (Table 6).  
 
Outcome 
measure 
N Mean T/S 
Ratio 
SD OR 95% CI p-value 
AKI 
No 
Yes 
 
200 
54 
 
0.760 
0.735 
 
0.162 
0.163 
 
0.375 
 
0.058-2.436 
 
0.304 
In-hospital 
mortality 
No 
Yes 
 
 
249 
5 
 
 
0.755 
0.754 
 
 
0.162 
0.184 
 
 
0.985 
 
 
0.004-
232.624 
 
 
0.996 
1-year 
mortality 
No 
Yes 
 
 
205 
16 
 
 
0.755 
0.726 
 
 
0.162 
0.162 
 
 
0.315 
 
 
0.013-7.787 
 
0.481 
Composite 
outcome* 
No 
Yes 
 
 
133 
121 
 
 
0.766 
0.742 
 
 
0.161 
0.164 
 
 
0.409 
 
 
0.089-1.886 
 
 
0.252 
 
Table 5: Association between TL and the main study outcomes. *Composite outcome 
includes New AF, Stroke, Reoperation, and AKI. 
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Figure 11: Box plots for mTL (black line) in the AKI and No-AKI groups: p=0.304. Black 
horizontal line represents median value, box represents interquartile range and 
vertical line indicates range.  
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Figure 12: Box plots for mTL (black line) and development of the Composite 
outcome.p=0.252. Black horizontal line represents median value, box represents 
interquartile range and vertical line indicates range.   
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Association Top Quintile TL  
n= 50 
Bottom Quintile TL  
n = 51 
p-value 
AKI 
   Yes 
   No 
 
8 (16.0%) 
42 (84.0%) 
 
11 (21.6%) 
40 (78.4%) 
0.323 
In-hospital mortality 
   Yes 
   No 
 
1 (2%) 
49 (98%) 
 
1 (2%) 
50 (98%) 
0.748 
1-year mortality 
   Yes 
   No 
 
1 (2.4%) 
40 (97.6%) 
 
3 (7.3%) 
38 (92.7%) 
0.308 
Composite outcome 
   Yes 
   No 
 
21 (42.0%) 
29 (58.0%) 
 
27 (52.9%) 
24 (47.1%) 
0.184 
 
Table 6: Association of rates of AKI, In-hospital mortality, 1-year mortality, and 
composite outcome in patients in the top and bottom quintiles of mTL.  
 
5.5 Propensity matched analysis of mTL and CSA-AKI 
51 matched pairs were obtained from a possible maximum of 54. Details of the 
matched populations are given in Appendix F. Shapiro-Wilk’s test of normality run on 
the matched cohort showed that mTL was normally distributed for both cases and 
controls. As such, comparison of mTL in the matched populations was performed 
using a Student t-test. No significant association was observed in mTL between cases 
and controls in the matched populations (Table 7). A boxplot of median mTL in the 
propensity matched groups is shown in Figure 13. 
 
 Mean of differences CI of difference p- value 
TS/ ratio No – T/S ratio 
Yes 
0.00617 -0.0523 – 0.0646 0.833 
 
Table 7: Comparison of mTL in Cases Vs Controls in 51 propensity matched patient 
pairings. 
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Figure 13: Boxplot of mTL in Cases Vs Controls in 51 propensity matched patient 
pairings. 
 
5.6 Whole population associations with mean Telomere Length 
The raw data for the measurement of mTL for all 254 study patients is given in 
Appendix D. A summary of the associations between mTL and all continuous 
independent pre-operative and intra-operative variables is shown in Table 8. A 
similar summary for categorical independent variables is shown in Table 9. Significant 
associations were seen between mTL and age, use of post-operative vasopressors, 
operation type (CABG Vs No CABG), and hypercholesterolaemia. A graphical 
representation of the variation of mTL with age is shown in Figure 14.  
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T/S ratio with Correlation Coefficient p-value 
Age -0.213 0.001 
Length of Stay -0.008 0.903 
BMI -0.079 0.208 
Vasopressor duration 0.159 0.011 
Inotropic duration -0.059 0.355 
Ventilation duration -0.008 0.903 
First Hb in ITU 0.05 0.446 
UO in first 12 hours 0.101 0.125 
CPB time 0.057 0.375 
X-clamp time 0.000 0.994 
Pre WCC -0.032 0.611 
Pre INR -0.037 0.558 
Pre-APTT -0.005 0.936 
Pre-CRP 0.155 0.245 
Pre-Hb 0.043 0.491 
Pre-op Cr 0.005 0.938 
Pre-op eGFR 0.046 0.502 
Day 3 CRP -0.035 0.635 
Day 1 Hb 0.094 0.139 
Hb Diff -0.12 0.851 
 
Table 8: Summary table of Spearman correlations between mTL and all continuous 
independent variables. P-values <0.05 shown in bold. 
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 N Mean T/S 
Ratio 
SD Median p-value 
Gender 
Male 
Female 
 
183 
71 
 
0.754 
0.756 
 
0.163 
0.162 
 
0.757 
0.775 
 
0.817 
Ethnicity 
White 
South Asian 
Black 
Mixed 
Asian 
Middle Eastern 
Other 
 
182 
49 
12 
2 
3 
2 
4 
 
0.751 
0.737 
0.855 
0.829 
0.853 
0.646 
0.773 
 
0.163 
0.145 
0.193 
0.226 
0.206 
0.286 
0.116 
 
0.767 
0.753 
0.924 
0.829 
0.924 
0.647 
0.773 
0.245 
 
 
CABG 
No 
Yes 
 
104 
150 
 
0.783 
0.735 
 
0.171 
0.154 
 
0.821 
0.751 
 
0.02 
Angina Status 
CCS0 
CCS1 
CCS2 
CCS3 
CCS4 
 
54 
43 
116 
26 
11 
 
0.787 
0.787 
0.739 
0.703 
0.758 
 
0.166 
0.175 
0.156 
0.153 
0.144 
 
0.782 
0.834 
0.755 
0.671 
0.783 
 
0.106 
Dyspnoea 
NYHA 1 
NYHA 2 
NYHA 3 
NYHA 4 
 
42 
130 
68 
9 
 
0.753 
0.747 
0.773 
0.747 
 
0.150 
0.172 
0.154 
0.133 
 
0.753 
0.753 
0.800 
0.775 
 
0.654 
Previous Cardiac 
Surgery 
No 
Yes 
 
237 
17 
 
0.751 
0.805 
 
0.162 
0.161 
 
0.759 
0.778 
 
0.126 
History of Malignancy 
No 
Yes 
 
236 
18 
 
0.755 
0.755 
 
0.162 
0.170 
 
0.759 
0.778 
 
0.947 
Diabetes 
No 
Diet 
Oral 
Insulin 
 
189 
4 
50 
11 
 
0.765 
0.777 
0.710 
0.770 
 
0.164 
0.112 
0.156 
0.164 
 
0.792 
0.817 
0.679 
0.758 
 
0.190 
Diabetes 
No 
Yes 
 
189 
65 
 
0.765 
0.724 
 
0.164 
0.156 
 
0.792 
0.727 
 
0.076 
Hypertension 
No 
Yes 
 
64 
190 
 
0.781 
0.746 
 
0.178 
0.156 
 
0.835 
0.755 
 
0.162 
Hypercholesterolaemia 
No 
 
132 
 
0.774 
 
0.168 
 
0.821 
 
0.042 
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Yes 122 0.734 0.154 0.746 
Smoker 
Non-smoker 
Ex-smoker 
Current smoker 
 
 
114 
115 
25 
 
 
0.743 
0.768 
0.745 
 
0.174 
0.156 
0.133 
 
0.743 
0.777 
0.760 
 
0.524 
Pre-op Renal Disease 
No 
Yes 
 
209 
45 
 
0.757 
0.743 
 
0.162 
0.163 
 
0.760 
0.767 
 
0.633 
Pulmonary Disease 
No 
COPD 
Asthma 
 
225 
17 
12 
 
0.757 
0.738 
0.734 
 
0.160 
0.197 
0.164 
 
0.768 
0.647 
0.656 
 
0.936 
Neurological disease 
No 
TIA/RIND 
CVA 
 
226 
16 
12 
 
0.756 
0.767 
0.717 
 
0.163 
0.145 
0.185 
 
0.768 
0.756 
0.647 
 
0.693 
PVD 
No 
Yes 
 
241 
13 
 
0.758 
0.689 
 
0.163 
0.137 
 
0.769 
0.644 
 
0.130 
Previous PCI 
No 
Yes 
 
216 
38 
 
0.754 
0.760 
 
0.164 
0.157 
 
0.767 
0.758 
 
0.979 
Previous MI 
No 
Yes 
 
188 
66 
 
0.757 
0.749 
 
0.168 
0.146 
 
0.769 
0.757 
 
0.647 
Previous ACE 
No 
Yes 
 
151 
103 
 
0.763 
0.742 
 
0.164 
0.159 
 
0.775 
0.753 
 
0.322 
Previous Statin 
No 
Yes 
 
93 
161 
 
0.779 
0.741 
 
0.168 
0.158 
 
0.820 
0.748 
 
0.088 
Pre-op diuretic 
Yes 
No 
 
223 
31 
 
0.756 
0.746 
 
0.162 
0.171 
 
0.758 
0.768 
 
0.704 
LV Ejection Fraction 
Good 
Fair 
Poor 
 
198 
47 
9 
 
0.748 
0.783 
0.745 
 
0.166 
0.147 
0.168 
 
0.759 
0.777 
0.758 
 
0.339 
Operative Urgency 
Elective 
Urgent 
Emergency 
 
217 
35 
2 
 
0.760 
0.725 
0.720 
 
0.166 
0.142 
0.018 
 
0.769 
0.727 
0.720 
 
0.382 
Reoperation 
No 
Yes 
 
241 
13 
 
0.754 
0.759 
 
0.160 
0.204 
 
0.763 
0.707 
 
0.788 
Transfused in ITU      
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No 
Yes 
160 
94 
0.758 
0.748 
0.164 
0.161 
0.759 
0.768 
0.501 
Clotting products in ITU 
No 
Yes 
 
200 
54 
 
0.759 
0.740 
 
0.162 
0.166 
 
0.775 
0.753 
 
0.333 
New AF 
No 
Yes 
 
181 
73 
 
0.754 
0.756 
 
0.163 
0.163 
 
0.758 
0.772 
 
0.914 
Post-op LRTI 
No 
Yes 
 
197 
57 
 
0.756 
0.751 
 
0.162 
0.163 
 
0.769 
0.753 
0.967 
 
Table 9: Summary of associations of mTL with independent categorical variables. P-
values <0.05 shown in bold. 
 
 
 
Figure 14: Relationship between age and mTL. The strength of the linear correlation 
is given by the R2 value of 0.061 (p=0.001). 
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5.7 Analysis of significant predictors of CSA-AKI 
5.7.1: Univariate analysis 
A separate analysis to determine the significant predictors of CSA-AKI was performed 
using a range of pre-operative and intra-operative variables and AKI as a categorical 
dependant variable. Post-operative variables were excluded from analysis because 
although they may associate with AKI, they are not predictors of its development. 
The first haemoglobin measured in the intensive care unit (1st Hb in ITU) was included 
as a predictor as it is a measure of intra-operative blood loss/transfusion which is a 
known risk factor for CSA-AKI.  Univariate analysis was performed using binary 
logistic regression with odds ratio’s (OR) and 95% confidence intervals quoted (Table 
10). Factors that were significant on univariate analysis were entered into a 
multivariate model to determine independent predictors of CSA-AKI. Significant 
factors (p<0.05) on univariate analysis are summarised in Table 11 and listed in order 
of strength of association. 
 
A separate univariate analysis using AKI as the independent variable is given in Table 
12. This table shows the differences in baseline demographics between those 
patients who developed CSA-AKI and those who did not.  
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Predictor OR 95% CI p-value 
Age 1.019 0.995-1.044 0.118 
Female Gender 1.11 0.573-2.151 0.757 
Ethnicity (compared to 
white) 
South Asian 
Black 
Mixed 
Asian 
Middle Eastern 
Other 
 
 
1.622 
1.352 
0.000 
0.000 
0.000 
1.352 
 
 
0.790-3.330 
0.348-5.249 
NA 
NA 
NA 
0.137-13.381 
 
 
0.187 
0.663 
0.999 
0.999 
0.999 
0.797 
 
BMI 1.041 0.979-1.106 0.199 
Cardiac Procedure 
(compared to CABG) 
CABG + valve 
CABG + valve +other 
CABG + other 
Valve alone 
Valve + other 
Other 
 
 
 
1.168 
4.087 
1.362 
1.202 
0.876 
1.277 
 
 
 
0.423-3.223 
0.246-67.82 
0.135-13.71 
0.577-2.505 
0.232-3.304 
0.424-3.848 
 
 
 
0.765 
0.326 
0.793 
0.623 
0.845 
0.664 
CABG (Yes Vs No) 0.917 0.499-1.686 0.781 
Pre-op Angina 
(compared to stage 0) 
CCS 1 
CCS 2 
CCS 3 
CCS 4 
 
 
1.742 
1.744 
1.725 
1.278 
 
 
0.621-4.889 
0.734-4.145 
0.529-5.622 
0.232-7.038 
 
 
0.291 
0.208 
0.366 
0.778 
Pre-op NYHA stage 
NYHA 2 
NYHA 3 
NYHA 4 
 
1.250 
1.538 
4.000 
 
0.499-3.131 
0.574-4.124 
0.853-18.75 
 
0.634 
0.392 
0.079 
Previous Cardiac 
Surgery  
1.599 0.538-4.753 0.399 
Previous Malignancy 1.958 0.699-5.485 0.201 
Diabetes Yes/No 2.026 1.064-3.859 0.032 
Hypertension 1.230 0.601-2.514 0.571 
Hypercholesterolaemia 2.164 1.165-4.018 0.015 
Previous Smoking 
Ex-smoker 
Current 
 
1.442 
1.828 
 
 
0.755-2.755 
0.674-4.956 
 
0.268 
0.236 
Pre-op renal 
dysfunction (eGFR<60) 
1.665 0.803-3.452 0.171 
Pre op COPD 1.266 0.394-4.070 0.692 
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Pre-op Asthma 4.114 1.266-13.368 0.019 
Pre-op Neuro disease 
TIA or RIND 
CVA 
 
0.503 
0.704 
 
0.111-2.287 
0.149-3.318 
 
0.374 
0.657 
Previous PVD 1.698 0.502-5.741 0.394 
Pre-op ACEI 0.899 0.489-1.652 0.731 
Pre-op Statin 0.977 0.524-1.822 0.942 
Pre-op LV Function 
Fair 
Poor 
 
1.730 
0.510 
 
0.845-3.541 
0.062-4.196 
 
0.134 
0.531 
Pre-op Urgency 
Urgent 
Emergency 
 
0.442 
3.429 
 
0.149-1.314 
0.211-55.82 
 
0.142 
0.387 
1st Hb in ITU 0.981 0.964-0.999 0.036 
Pre-op WCC 1.063 0.939-1.205 0.335 
Pre-op INR 3.873 0.378-39.61 0.254 
Pre-op APTT 1.039 0.968-1.115 0.287 
Pre-op CRP 1.007 0.988-1.026 0.480 
Pre-op Hb 0.776 0.649-0.928 0.005 
Pre-op Cr 1.009 0.997-1.022 0.123 
Pre-eGFR 0.992 0.979-1.005 0.234 
Bypass time 1.013 1.006-1.020 <0.001 
X-Clamp time 1.012 1.004-1.021 0.003 
Logistic EuroSCORE 0.513 0.101-2.608 0.421 
T/S Ratio 0.375 0.058-2.436 0.304 
 
Table 10: Univariate analysis of the association of all pre-operative and intra-
operative variables with the development of CSA-AKI. 
 
 
Variable OR p-value 
Bypass time 1.013 <0.001 
X-Clamp time 1.012 0.003 
Pre-op Hb 0.776 0.005 
Hypercholesterolaemia 2.164 0.0145 
Pre-op Asthma 4.114 0.019 
Diabetes Yes/No 2.026 0.032 
1st Hb in ITU 0.981 0.036 
 
Table 11: Summary of predictors of CSA-AKI on univariate analysis listed by strength 
of association. 
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 Non-AKI (n=200) AKI (n=54) p-value 
 
Age (median + IQR) 65 (20) 68 (16.8) 0.065 
Male Gender 145 (72.5%) 38 (70.4%) 0.439 
BMI 27.1 (6.4) 30.0 (6.3) 0.103 
Ethnicity 
White 
South Asian 
Black/Mixed 
Other 
 
146 (73%) 
35 (17.5%) 
11 (5.5%) 
8 (4%) 
 
36 (66.7%) 
14 (25.9%) 
3 (5.6%) 
1 (1.9%) 
 
0.502 
 
Operation 
CABG 
Valve 
CABG + Valve 
Other 
 
97 (48.5%) 
65 (32.5%) 
22 (11%) 
16 (8%) 
 
24 (44.4%) 
18 (33.3%) 
7 (13%) 
5 (9.3%) 
 
0.944 
 
NYHA IV 5 (2.6%) 4 (7.5%) 0.290 
CCS IV 9 (4.6%) 2 (3.8%) 0.765 
Diabetes 45 (22.5%) 20 (37.0%) 0.025 
Hypertension 148 (74%) 42 (77.8%) 0.354 
Hypercholesterolaemia 88 (44%) 34 (63%) 0.010 
Smoking History 
Non-smoker 
Ex-smoker 
Current Smoker 
 
94 (47%) 
88 (44%) 
18 (9%) 
 
20 (37%) 
27 (50%) 
7 (13%) 
 
0.376 
Pre-op eGFR <60 32 (16%) 13 (24.1%) 0.121 
Previous COPD/Asthma 19 (9.5%) 10 (18.5%) 0.059 
Previous TIA/CVA 24 (12%) 4 (7.4%) 0.245 
LV Function 
Good (>50%) 
Fair (39-49%) 
Poor (<39%) 
 
159 (79.5%) 
33 (16.5%) 
8 (4%) 
 
39 (72.2%) 
14 (25.9%) 
1 (1.9%) 
 
0.236 
Operative Urgency 
Elective 
Urgent 
Emergency 
 
168 (84%) 
31 (15.5%) 
1 (0.5%) 
 
49 (90.7%) 
4 (7.4%) 
1 (1.9%) 
 
0.199 
Pre-op Haemoglobin 13.7 (2.3) 13.1 (1.9) 0.007 
Pre-op Creatinine 82 (29) 86 (31) 0.083 
Cross-Clamp Time 64 (43) 77 (59) 0.003 
Cardiopulmonary Bypass 
Time 
95 (39) 103 (65) 0.004 
 
 
Table 12: Differences in pre-operative and intra-operative variables between patients 
who developed CSA-AKI and those who did not. Significant associations (p-value < 
0.05) are shown in bold.  IQR = interquartile range.  
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5.7.2: Multivariate analysis 
5.7.2.1 Variable selection 
There is no universally accepted method of variable selection in multivariate analysis 
and different studies use different methodology. A widely used practice in medical 
research is to perform variable selection by only including significant predictors on 
univariate analysis in a multivariate model. However, this method can risk masking 
of significant associations that are not significant on univariate analysis but that 
become significant once confounding factors are controlled for. Heinze et al (177) 
argue that non-significant variables should not be excluded from the multivariate 
model, particularly if they are the variable of interest. Furthermore, they argue that 
the most valid method of performing multivariate analysis is to include all variables 
without any selection. This however, is impractical for all but the largest of studies 
due to the problem of over-fitting the model.  
 
Overfitting occurs when too many independent variables are applied to the 
multivariate model. The ‘rule of 10 events’ is a statistical standard that states that for 
logistic and Cox regression, models should be built with a minimum of 10 outcome 
events per predictor variable (EPV). Applying this rule means that we can only really 
correct for 5 variables for AKI and 2 variables for 1-year mortality. As such some 
method of variable selection is required. In the analysis below we have included all 
predictors with a significance level of p<0.05 together with age and mTL in a 
multivariate model to find which were independent predictors for the development 
of CSA-AKI. Cross-clamp time was not included as it was not thought to be sufficiently 
independent from cardiopulmonary bypass time. The two variables are directly 
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related as bypass time incorporates cross-clamp time within it. Similarly, Pre-
operative Haemolobin (Pre-op Hb) and 1st Hb in ITU are also inter-dependant and so 
only the most significant variable, Pre-op Hb, was used. Results of this analysis are 
shown in Table 13.  
 
This model improves the accuracy of predicting AKI from 78.7% to 81.2% (Nagelkerke 
R square value = 0.234). Increasing cardiopulmonary bypass time, pre-operative 
history of asthma, hypercholesterolaemia, and pre-operative haemoglobin level 
were found to be significant independent predictors of CSA-AKI. Neither mTL nor age 
were significant independent predictors of CSA-AKI. 
 
 
 
 
Variable Odds Ratio 95% CI p-value 
T/S Ratio 0.627 0.071-5.508 0.674 
Age 1.008 0.980-1.037` 0.563 
Hypercholesterolaemia 2.170 1.041-4.524 0.039 
Hx of COPD 0.986 0.251-3.868 0.984 
Hx of Asthma 6.240 1.584-24.584 0.009 
Bypass Time 1.016 1.008-1.024 <0.001 
Diabetes Yes/No 1.696 0.783-3.673 0.180 
Pre-op Hb 0.771 0.625-0.953 0.016 
 
Table 13: Multivariate model of independent predictors of CSA-AKI. Significant p-
values <0.05 shown in bold. 
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5.8 Analysis of mTL as a predictor of 1-year mortality 
The above analysis of section 5.7 was repeated to identify independent predictors of 1-year 
mortality following cardiac surgery. In this analysis post-operative factors that might be 
predictors of 1-year mortality were included in the analysis. Results of the univariate analyses 
are shown in Table 14, with significant predictors summarised by strength of association in 
Table 15.  
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Variable OR 95% CI p-value 
LOS (increasing LOS a/w AKI) 1.04 1.014 - 1.075 0.004 
Age 1.022 0.978 – 1.067 0.329 
Female Gender 1.15 0.350 – 3.317 0.801 
Ethnicity (compared to white) 
South Asian 
Black 
Mixed 
Asian 
Middle Eastern 
Other 
 
 
1.007 
0 
0 
0 
0 
4.139 
 
 
0.270-3.751 
NA 
NA 
NA 
NA 
0.399-42.90 
 
 
0.992 
0.999 
0.999 
0.999 
0.999 
0.234 
BMI 0.975 0.874-1.088 0.652 
Cardiac Procedure (compared 
to CABG) 
CABG + valve 
CABG + valve +other 
CABG + other 
Valve alone 
Valve + other 
Other 
 
 
0.591 
0.000 
4.333 
1.204 
0.929 
0.684 
 
 
0.069-5.055 
NA 
0.397-47.30 
0.364-3.980 
0.106-8.129 
0.079-5.890 
 
 
0.631 
0.993 
0.229 
0.761 
0.947 
0.730 
CABG (Yes Vs No) 0.948 0.340-2.644 0.919 
Pre-op Angina (compared to 
stage 0) 
CCS 1 
CCS 2 
CCS 3 
CCS 4 
 
 
1.667 
1.348 
0.625 
0.000 
 
 
0.350-7.930 
0.341-5.330 
0.062-6.339 
NA 
 
 
0.521 
0.670 
0.691 
0.999 
Pre-op NYHA stage 
NYHA 2 
NYHA 3 
NYHA 4 
 
2.846 
2.741 
22.20 
 
0.344-25.533 
0.294-25.51 
1.919-256.82 
 
0.332 
0.376 
0.013 
Previous Cardiac Surgery  0.910 0.112-7.396 0.929 
Previous Malignancy 2.786 0.556-13.97 0.213 
Pre-op Diabetes 
Diet 
Oral 
Insulin 
 
0.000 
2.600 
0.000 
 
NA 
0.887-7.618 
NA 
 
0.995 
0.082 
0.991 
Diabetes Yes/No 1.910 0.661-5.523 0.232 
Hypertension 0.807 0.268-2.427 0.702 
Hypercholesterolaemia 0.350 0.109-1.121 0.077 
Smoking History 
Ex-smoker 
Current 
 
2.480 
3.638 
 
0.738-8.339 
0.755-17.53 
 
0.142 
0.107 
Pre-op renal dysfunction 
(eGFR<60) 
2.652 0.860-8.174 0.09 
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Pre-op COPD 1.846 0.381-8.951 0.446 
Pre-op Asthma 0.000 NA 0.999 
Pre-op Neuro disease 
TIA 
CVA 
 
4.650 
1.722 
 
1.128-19.16 
0.201-14.74 
 
0.033 
0.620 
Previous PVD 1.176 0.142-9.731 0.881 
Pre-op ACEI 2.041 0.636-6.546 0.230 
Pre-op Statin 0.241 0.081-0.720 0.011 
Pre-op LV Function 
Fair 
Poor 
 
0.571 
1.714 
 
0.087-2.175 
0.088-10.74 
 
0.473 
0.626 
Pre-op Urgency 
Urgent 
Emergency 
 
1.639 
14.75 
 
0.434-6.187 
0.868-250.6 
 
0.466 
0.063 
Extubation Date 1.610 1.149-2.256 0.006 
Vasopressor Date 1.098 1.005-1.200 0.039 
No. of Inotrope days 1.072 0.985-1.167 0.108 
1st Hb in ITU 0.998 0.968-1.028 0.871 
UO 1st 12 hours 0.999 0.998-1.000 0.165 
Reoperation  12.79 3.492-46.86 <0.001 
Pt transfused in ITU 4.243 1.418-12.69 0.010 
Clotting products 2.475 0.849-7.212 0.097 
Post-op AF 0.787 0.244-2.537 0.688 
Pre-op WCC 1.166 0.960-1.416 0.12 
Pre-op INR 11.58 0.655-204.7 0.095 
Pre-op APTT 1.036 0.866-1.239 0.699 
Pre-op CRP 1.102 1.023-1.187 0.011 
Pre-op Hb 0.555 0.404-0.762 <0.001 
Pre-op Cr 1.031 1.012-1.051 0.002 
Pre-eGFR 0.958 0.928-0.989 0.009 
Bypass time 1.009 1.001-1.018 0.036 
X-Clamp time 1.009 0.997-1.022 0.142 
Logistic EuroSCORE 0.819 0.240-2.790 0.749 
T/S Ratio 0.315 0.013-7.787 0.481 
 
Table 14: Univariate analysis of the association of all pre-operative and intra-
operative variables with 1-year mortality. 
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Variable OR p-value 
Reoperation  12.79 <0.001 
Pre-op Hb 0.555 <0.001 
Pre-op Cr 0.974 0.002 
LOS (increasing LOS 
a/w AKI) 
1.04 0.004 
Extubation Date 1.610 0.005 
Pre-eGFR 0.958 0.009 
Pt transfused in ITU 4.243 0.010 
Pre-op CRP 1.102 0.011 
Pre-op Statin 0.241 0.011 
NYHA 4 22.20 0.013 
TIA/RIND 4.65 0.033 
Bypass time 1.009 0.036 
Vasopressor Date 1.098 0.039 
 
Table 15: Summary of predictors of 1-year mortality on univariate analysis listed by 
strength of association 
 
Again, all of the factors in Table 15 were entered into a multivariate logistic 
regression together with mTL and age, to find which were independent predictors 
for 1-year mortality (Table 16). Pre-CRP was excluded as more than 80% of cases 
were missing. The estimated GFR was also excluded. This was because the exact 
value for eGFR was not reported if more than 90. In such cases the results were 
reported as ‘>90’ and therefore skewed the subsequent analyses. This model 
improves the accuracy of predicting 1-year mortality from 93.5% to 97% (Nagelkerke 
R square value = 0.760). Pre-operative history of stoke and pre-operative 
haemoglobin level were found to be significant predictors of 1-year mortality.  
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Mean TL was not found to be associated with 1-year mortality on multivariate 
modelling.  
 
 
Variable Adjusted Odds 
Ratio 
95% CI p-value 
T/S Ratio 0.000 0.000-8.397 0.108 
Age 1.015 0.909-1.133 0.793 
LOS 0.933 0.788-1.104 0.418 
NYHA 1 
NYHA 2 
NYHA 3 
0.000 
2.210 
9.660 
0.000-NA 
0.016-307.07 
0.052-1779.8 
 
0.997 
0.753 
0.394 
TIA 
CVA 
95.48 
76.71 
1.550-5881.9 
1.173-5014.9 
0.030 
0.042 
Pre-op Statin 0.455 0.041-5.056 0.522 
Extubation days 2.120 0.518-8.671 0.296 
Vasopressor days 1.131 0.963-1.329 0.133 
Reoperation 6.462 0.006-6841.0 0.600 
Blood Transfusion 
in ITU 
14.62 0.525-406.5 0.114 
Pre-op Hb 0.183 0.048-0.693 0.012 
Pre-op Cr 1.030 0.995-1.065 0.092 
Bypass Time 1.013 0.979-1.048 1.048 
 
Table 16: Multivariate model of independent predictors of 1-year mortality. 
Significant p-values <0.05 shown in bold. 
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5.9 Potential over-fitting of multivariate model 
As previously outlined in section 5.7.2.1, there is a potential problem of overfitting in 
the two multivariate analyses reported above due to relatively few outcome events; 
54 in the case of AKI, and just 16 for 1-year mortality. Applying the ‘rule-of-10’ means 
that we can only really correct for 5 variables for AKI and 2 variables for 1-year 
mortality. The multivariate analysis for both CSA-AKI and 1-year mortality were 
repeated with the number of included variables limited to 5 and 2 respectively. For 
CSA-AKI, mTL and age were combined with the 3 most significant predictors on 
univariate analysis. For 1-year mortality mTL and pre-operative Hb were included in 
the model, as this variable was consistently strongly associated both on univariate 
and full multivariate analysis. The results of the multivariate analyses are shown in 
Table 17 and Table 18. Again, mTL was neither associated with the development of 
CSA- AKI nor 1-year mortality. Both of these revised models had lower accuracy for 
predicting AKI and 1-year mortality than those including all significant predictors 
from the univariate analyses. In fact, Vittinghoff et al report that the rule-of-10-
events can be relaxed, particularly for analyses undertaken to show adequate control 
of confounding (178).  
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Variable Adjusted Odds 
Ratio 
95% CI p-value 
T/S Ratio 0.567 0.068-
4.712 
0.599 
Age 1.008 0.981-
1.036 
0.564 
Bypass time 1.015 1.008-
1.022 
<0.001 
Pre-op Hb 0.758 0.619-
0.927 
0.007 
Hypercholesterolaemia 2.355 1.161-
4.779 
0.018 
 
Table 17: Multivariate model of independent predictors of CSA-AKI limited to 5 
predictors. Significant p-values <0.05 shown in bold 
 
 
Variable Adjusted Odds 
Ratio 
95% CI p-value 
T/S Ratio 0..395 0.058-2.689 0.342 
Pre-op Hb 0.778 0.650-0.930 0.006 
 
Table 18: Multivariate model of independent predictors of 1-year mortality limited to 
2 predictors. Significant p-values <0.05 shown in bold. 
 
5.10 Receiver Operating Characteristic curve analyses 
Receiver operating characteristic (ROC) curve analysis was performed for mTL against 
the development of CSA-AKI.  This graphical plot determines the diagnostic ability of 
a variable to predict a binary outcome (e.g. AKI Vs No-AKI). Using every value of the 
variable as a cut-off point, the sensitivity (true positive rate) of a variable is plotted 
against the corresponding 1-specificity (false positive rate). The greater the area 
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under the resulting curve, the more useful the test is at predicting the outcome. An 
area under the curve (AUC) of 1 represents a test that perfectly predicts the correct 
outcome 100% of the time whist an AUC of 0.5 indicates that the measurement of 
interest cannot distinguish between the two groups.  An AUC significantly below 0.5 
indicates that the test predicts a negative test outcome (e.g. if a patient does not 
have a disease). For our analysis, a p-value of <0.05 was used to indicate that the AUC 
was significantly different from 0.5.  
 
ROC curves were calculated for mTL, age and Logistic EuroSCORE. The combined ROC 
curves for these three variables are shown in Figure 15 with the accompanying AUC 
values, 95% confidence intervals and significance values shown in Table 19. 
 
Whilst none of the variables are significant predictors of CSA-AKI, Age is the best 
predictor of the three with the highest AUC value. The AUC of 0.459 for mTL indicates 
that it is unable to predict CSA-AKI. The fact that this value is slightly less than 0.5 is 
consistent with the fact that a higher value of mTL would be expected to be 
associated with a lower biological age and thus a reduced risk of AKI; i.e. mTL would 
be expected to predict a negative disease state.  
 
The same analyses were run for 1-year mortality as an outcome. The combined ROC 
curves for 1-year mortality for the same three variables are shown Figure 16 with the 
accompanying Area under curve (AUC) values, 95% confidence intervals and 
significance values shown in Table 20. mTL was again not able to predict 1-year 
mortality with an AUC of 0.459. Age just missed significance (AUC 0.629, p = 0.095) 
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and EuroSCORE was seen to be able to predict 1-year mortality with an AUC of 0.741 
(p=0.002).  
 
 
Figure 15: Combined ROC curve of mTL (T/S Ratio), age and Logistic EuroSCORE for 
predicting CSA-AKI 
 
 
 
 AUC 95% CI p-value Cut-off Sensitivity Specificity 
T/S ratio 0.459 0.373-
0.545 
0.357 0.618 0.759 0.305 
Age 0.574 0.486-
0.661 
0.099 61.15 0.741 0.397 
EuroSCORE 0.562 0.479-
0.646 
0.165 0.025 
(2.5%) 
0.717 0.419 
 
Table 19: Diagnostic ability of mTL (T/S Ratio), age, and Logistic EuroSCORE for 
predicting CSA-AKI with cut-off points shown. None of the three variables are 
significant predictors of CSA-AKI.  
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Figure 16: Combined ROC curve of mTL (T/S Ratio), age and Logistic EuroSCORE for 
predicting 1-year mortality 
 
 
 
 AUC 95% CI p-value Cut-off Sensitivity Specificity 
T/S ratio 0.459 0.320-
0.597 
0.581 0.634 0.75 0.332 
Age 0.629 0.466-
0.793 
0.095 68.35 0.733 0.62 
EuroSCORE 0.741 0.647-
0.834 
0.002 0.040 
(4%) 
0.733 0.635 
 
Table 20: Diagnostic ability of mTL (T/S Ratio), age, and Logistic EuroSCORE for 
predicting 1-year mortality with cut-off points shown. P-values for statistically 
significant predictors are shown in bold. 
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5.11. Additional Analyses on Mean Telomere Length and CSA-AKI 
5.11.1 Analysis of effects of fall in serum creatinine level 
Studies have shown that the effect of an acute fall in serum creatinine is also 
associated with poor outcome similar to AKI (4). As such we identified all patients 
with an acute fall in serum creatinine >26 µmol/l in keeping with the equivalent rise 
in creatinine defined as AKI in the AKIN criteria (Table 1). Only patients with a fall in 
the first 48 hours were identified to avoid classifying patients with recovery of 
previously elevated creatinine. Nine such patients were identified. Of note, 1 of the 
9 patients was already classified as AKI due to a subsequent rise in serum creatinine 
after an initial fall. These nine patients were excluded from the data set completely 
and the analysis of mTL and AKI repeated. However, no significant association was 
found between mTL and the development of CSA-AKI (Table 21, Figure 17). The 
analysis was also repeated with the 9 patients added to the AKI group with no 
significant change in the association between mTL and CSA-AKI (results not shown).   
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Outcome 
measure 
N Mean T/S 
Ratio 
SD OR 95% CI p-value 
AKI 
No 
Yes 
 
192 
53 
 
0.761 
0.734 
 
0.163 
0.164 
 
0.363 
 
0.055-2.400 
 
0.293 
 
Table 21: Association between mTL and development of CSA-AKI in the whole 
population excluding patients whose serum Cr fell by >26 µmol/l. 
 
 
 
 
 
 
Figure 17: Boxplots for mTL and the development of CSA-AKI in the whole population 
excluding patients whose serum Cr fell by >26 µmol/l. Black bars represent median. 
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5.11.2 mTL and CSA-AKI: Investigating the effect of removing patients of South 
Asian Origin 
 
The effect of ethnicity on Telomere length was investigated. We hypothesised that 
unreliability in the recorded birth dates of the South Asian immigrant population in 
East London might have affected our results. To test this theory, all patients of South 
Asian descent were excluded from the population and the association between mTL 
and CSA-AKI was rerun. The results are shown in Table 22 and Figure 18 and show 
that the trend towards shorter telomeres in the patients who developed CSA-AKI has 
been lost completely. As a result, we looked closer at just the South Asian population 
and found that in this population reduced mTL in patients was significantly associated 
with the development of  CSA-AKI (p=0.028) ( Table 23, Figure 19).  
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Outcome 
measure 
N Mean T/S 
Ratio 
SD OR 95% CI p-value 
AKI 
No 
Yes 
 
165 
40 
 
0.759 
0.761 
 
0.167 
0.167 
 
1.083 
 
0.135-8.697 
 
0.940 
 
Table 22: Association between mTL and development of CSA-AKI in the whole 
population excluding patients of South Asian descent. 
 
 
 
 
 
 
 
Figure 18: Boxplots for mTL and the development of CSA-AKI in the whole population 
excluding patients of South Asian descent. Black bars represent Median values. 
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Outcome 
measure 
N Mean T/S 
Ratio 
SD OR 95% CI p-value 
AKI 
No 
Yes 
 
35 
14 
 
0.767 
0.660 
 
0.142 
0.127 
 
0.003 
 
0.000-0.489 
 
0.025 
 
Table 23: Association between mTL and development of CSA-AKI in patients of South 
Asian descent 
 
 
 
 
 
 
Figure 19: Boxplots for mTL and the development of CSA-AKI in patients of South Asian 
descent. Black bars represent median. 
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5.11.2.1: Univariate analysis of mTL and CSA-AKI in South Asians 
A repeat of the univariate and multivariate analyses outlined in sections 5.7.1 and 
5.7.2 were performed but limited to the South Asian population. Results of the 
Univariate analysis are shown in Table 24. Some categories are listed as Non-
applicable (N/A) as the reduced sample size removed any events from one of the 
coding categories. Significant associations (p<0.1) on univariate analysis are 
summarised in Table 25. 
 
5.11.2.2. Multivariate analysis of mTL and CSA-AKI in South Asians 
Of the significant predictors of CSA-AKI given in Table 25, Pre-op Hb and Pre-op eGFR 
were excluded for reasons described previously. The remaining two variables were 
run as a multivariate analysis thus avoiding the problem of overfitting with just 14 
outcomes in the AKI group. The result shows that mTL remains an independent 
predictor of CSA-AKI (Table 26).  Even when age was added to the model, mTL 
remained as a significant independent predictor of CSA-AKI in the South Asian 
population (Table 27).  
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Predictor OR 95% CI p-value 
Age 1.042 0.976-1.112 0.218 
Female Gender 0.682 0.156-2.972 0.610 
BMI 0.997 0.881-1.136 0.997 
CABG (Yes Vs No) 1.500 0.271-8.300 0.642 
Pre-op Angina 
CCS 1 
CCS 2 
CCS 3 
CCS 4 
 
0.000 
0.857 
1.667 
1.000 
 
n/a 
0..55-13.479 
0.152-18.217 
0.041-24.547 
 
0.999 
0.913 
0.675 
1.000 
Pre-op NYHA stage 
NYHA 2 
NYHA 3 
NYHA 4 
 
1.000 
0.947 
0.400 
 
0.053-18.915 
0.076-11.870 
0.023-6.848 
 
1.000 
0.967 
0.527 
Previous Cardiac Surgery 2.615 0.152-44.968 0.508 
Previous Malignancy N/A   
Diabetes Yes/No 2.969 0.780-11.301 0.111 
Hypertension 1.000 0.170-5.878 1.000 
Hypercholesterolaemia 3.088 0.732-13.025 0.125 
Previous Smoking N/A   
Pre-op renal dysfunction 
(eGFR<60) 
0.788 0.179-3.477 0.753 
Pre op COPD N/A   
Pre-op Asthma N/A   
Pre-op Neuro disease N/A   
Previous PVD 1.698 0.502-5.741 0.394 
Pre-op ACEI 1.000 0.286-3.499 1.000 
Pre-op Statin 3.852 0.435-34.130 0.226 
Pre-op LV Function N/A   
Pre-op Urgency 1.500 0.271-8.300 0.642 
1st Hb in ITU 0.947 0.894-1.002 0.059 
Pre-op WCC 1.192 0.872-1.629 0.271 
Pre-op INR 17.792 0.198-1600.967 0.210 
Pre-op APTT 1.141 0.915-1.423 0.241 
Pre-op CRP 1.018 0.882-1.176 0.805 
Pre-op Hb 0.674 0.437-1.041 0.075 
Pre-op Cr 1.012 0.989-1.036 0.295 
Pre-eGFR 0.969 0.940-0.999 0.045 
Bypass time 1.007 0.982-1.032 0.576 
X-Clamp time 0.995 0.967-1.023 0.703 
Logistic EuroSCORE 0.147 0.000-46.472 0.514 
T/S Ratio 0.003 0.000-0.489 0.025 
 
Table 24: Univariate analysis of the association of all pre-operative and intra-
operative variables with CSA-AKI for the South Asian population.  
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Predictor OR 95% CI p-value 
T/S Ratio 0.003 0.000-0.489 0.025 
Pre-eGFR 0.969 0.940-0.999 0.045 
1st Hb in ITU 0.947 0.894-1.002 0.059 
Pre-op Hb 0.674 0.437-1.041 0.075 
 
Table 25: Summary of univariate analysis of predictors of CSA-AKI in the South Asian 
population listed by strength of association. 
 
 
 
 
Predictor OR 95% CI p-value 
T/S Ratio 0.002 0.000-0.521 0.028 
Ist Hb in ITU 0.941 0.882-1.003 0.061 
 
Table 26: Results of a Multivariate analysis of mTL and CSA-AKI in the South Asian 
population 
 
 
 
 
Predictor OR 95% CI p-value 
T/S Ratio 0.002 0.000-0.665 0.036 
Age 1.019 0.945-1.098 0.627 
Ist Hb in ITU 0.940 0.882-1.002 0.058 
 
Table 27: Results of the multivariate analysis when age is added as a variable in the 
model. mTL remained an independent predictor of CSA-AKI in the South Asian 
population.  
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5.11.3 Analysis of mTL as a predictor of 1-year mortality in South Asian population 
The analysis of mTL as a predictor of 1-year mortality was repeated for the South Asian 
population. The results are shown in Table 28 and graphically in Figure 20. Of the 40 
patients with complete 1-year mortality data, only 3 had died within 12 months of their index 
operation. (7.5%). Whilst these patients did have reduced telomere length the trend did not 
reach statistical significance (p=0.118). However, 1-year mortality was also associated with 
a trend towards increased age (p=0.085). When the association between mTL and age was 
corrected for age its significance was reduced (p=0.236).  
 
Outcome 
measure 
N Mean T/S 
Ratio 
SD OR 95% CI p-value 
Alive at 1 year 
Yes 
No 
 
37 
3 
 
0.751 
0.611 
 
0.132 
0.197 
0.000 0.000-7581 0.118 
 
Table 28: Association between mTL and 1-year mortality in patients of South Asian 
descent 
 
 
Figure 20: Boxplots for mTL and 1-year mortality in patients of South Asian descent. 
Black bars represent median   
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5.12 Results of STELA Experiment 
The STELA gels of the 24 samples showing the telomere length distribution are shown 
in Figure 21 Due to one sample in the control population (sample 103) having a 
borderline DNA concentration an additional sample was run (sample 175) as an 
alternative match. Sample 103 was successfully run, negating the need for sample 
175 in subsequent analysis. Unfortunately sample 244 (AKI cohort) failed. STELA 
analysis was repeated for this sample using an increased amount of input DNA but 
again failed. As such this sample and its matched control had to be excluded from 
subsequent analysis. 
 
The raw data listing all telomere lengths for each sample is given in Appendix G. 
Figure 22 is the graphical representation of this data and shows the distribution of 
the individual XpYp telomere lengths from each sample. From a visual inspection 
there does not appear to be an obvious trend in mean telomere length between the 
AKI cohort and their controls with many of the 95% CI’s overlapping. Table 29 shows 
a summary of the data for each sample including mean, median, and 25th percentiles 
of TL. No significant differences were found between the matched AKI and Non-AKI 
groups for either mTL (5.037 Vs 5.346; p = 0.657), median TL (4.920 Vs 5.134; p = 
0.859) or 25th percentile TL (3.725 Vs 3.698; p = 0.790) using a related samples 
Wilcoxon signed rank test.  
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Figure 21: STELA Gels of the 12 matched AKI-control pairs. Red samples = AKI 
cohort. Note, no fragments seen for sample 244.   
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Figure 22: Scatter plot showing the distribution of telomere lengths for each sample. 
Red bars show the mean and 95% confidence intervals. Light blue and white bands 
indicate paired samples (11 total). Within each pair the first sample is the control, and 
the second from the AKI cohort.  
 
 
Pair  25th Percentile Mean Median 
AKI Non-AKI AKI Non-AKI AKI Non-AKI 
1 3.151 3.586 3.605 6.62 3.539 6.421 
2 4.048 3.126 5.303 4.899 5.89 4.687 
3 5.123 3.761 6.311 4.959 6.594 4.858 
4 3.371 3.679 4.644 5.445 4.284 5.341 
5 3.174 5.011 4.701 6.497 4.408 6.402 
6 3.517 3.409 5.075 5.247 5.104 4.811 
7 3.696 3.198 4.555 4.734 4.429 4.421 
8 2.864 4.208 3.693 5.808 3.538 5.595 
9 3.707 3.733 5.708 5.037 5.207 4.664 
10 3.800 3.767 5.837 4.975 5.220 4.902 
11 4.529 3.205 6.375 4.589 5.902 4.370 
       
Mean 3.725 3.698 5.073 5.346 4.920 5.134 
p=value  0.790 0.657 0.859 
 
Table 29: Comparison of mean TL, median TL and 25th percentile TL between the 11 
propensity matched sample pairs. Mean values for the combined AKI/Non-AKI 
cohorts are shown in dark grey.   
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5.13 Correlation between qPCR and STELA measurements of mean TL  
23 samples were successfully analysed for mean TL by both qPCR and STELA. For 
these samples, the result of mTL obtained by each method were compared using 
Spearman’s Correlation. The correlation is shown in Figure 23. The Spearman 
Correlation Coefficient between the two variables was 0.199 (p= 0.374).  
 
  
 
 
Figure 23: Correlation between Mean TL as measured by STELA and T/S Ratio 
measured by qPCR. Green dots = AKI cohort. Blue dots = Non-AKI cohort.  
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5.14 Discussion of mTL Telomere Length and CSA-AKI 
5.14.1 Discussion of main findings 
 
Primary outcome 
This study attempts to determine if a well-recognised and studied marker of 
senescence such as Telomere length can predict the development of CSA-AKI. The 
main finding of this study is that, in our overall population, Telomere length is not 
associated with the development of CSA-AKI [OR 0.375 (0.058-2.436); p=0.304]. The 
trend of the non-significant association is in the expected direction with the OR<1 
signifying a negative correlation between Telomere length and AKI; i.e. as mTL 
decreases the risk of developing AKI increases. ROC curve analysis showed that mTL 
is a worse predictor of CSA-AKI and 1-year mortality than a patient’s age.  
 
The fact that mTL was not significantly associated with CSA-AKI in >250 patients 
means that it is unlikely to ever play a significant role in the risk stratification of 
patients undergoing cardiac surgery. It also implies that even if patients with reduced 
telomere length have higher levels of cellular senescence, this does not confer 
significantly increased risk of developing AKI when compared to the already 
recognised risk factors such as length of cardiopulmonary bypass and pre-operative 
anaemia. 
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Secondary endpoints 
No significant association was found between mTL and any of the secondary 
outcomes of in-hospital mortality, 1-year mortality and the composite outcome. Due 
to the low numbers of endpoints in In-hospital mortality (n=5) and 1-year mortality 
(n-16), this is not surprising. The study is underpowered to detect all but the largest 
of effect sizes with these low number of endpoints. To try to address this, a 
composite outcome was created consisting of CSA-AKI, new AF, stroke, and 
reoperation. This endpoint was created to provide a measure of post-operative 
morbidity. The more commonly used composite outcome in studies of patients post-
cardiac surgery is ‘Major Adverse Cardiac and Cerebrovascular Events’ (MACCE) 
(179). This endpoint encompasses 30-day mortality together with, stroke, myocardial 
infarction, and need for repeat revascularisation. This measure was not used in the 
current study due to the absence of patients with post-operative MI or repeat 
revascularisation. As such the use of MACCE would only have yielded 9 endpoints (5 
deaths; 4 stoke). 
 
Other significant findings 
 
Mean Telomere length was found to be significantly associated with several other 
variables. The strongest association that we see is the correlation with age 
(Spearman correlation coefficient of -0.213; p=0.001). The spread of the values of 
mTL (T/S Ratio) are similar to that published by Qiagen in a validation experiment 
performed on the same PCR platform as used in the present study (Corbett Research 
Rotorgene 6000, Qiagen, Manchester, UK). (180). The abstract of this experiment is 
shown in Appendix H with the relationship between mTL and age shown in figure 6. 
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Qiagen’s experiment serves as a measure of validation that the results that we have 
obtained for mTL in the current studies are accurate. However, it is also notable that 
the association found between mTL and age is not as strong in the current study as 
that found by Qiagen. This may be a result of the population being studied and reflect 
the fact that these are patients rather than healthy controls. Support for this can be 
found in the results of a large study of the West of Scotland Primary Prevention Study 
(WOSCOPS) cohort (174). Brouilette et al found that whist the matched control 
population showed a significant correlation with age (n=1058; R=0.01; p<0.001) the 
cases with coronary artery disease did not (n=464; R =0.06; p=0.190)(Figure 24). The 
authors performed telomere length measurement in >1500 patients using broadly 
the same methodology for Telomere measurement as that used in the current study. 
In comparison, our study results show a stronger correlation between T/S ratio and 
age over a reduced number of similar patients (n=254; R=0.247; p=0.001).  
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Figure 24: Telomere length as a function of age in controls and cases. Controls are 
shown as blue circles (n=1058), cases as red squares (n=484). Telomere length is 
plotted as log T/S ratio. R values were 0.01 (p=0.001) for controls and 0.06 (p = 
0.1902) for cases. Reprinted from The Lancet, Vol 369, Telomere length, risk of 
coronary heart disease, and statin treatment in the West of Scotland Primary 
Prevention Study: a nested case-control study, Pages No 109, Copyright (2007), with 
permission from Elsevier. 
 
The other significant associations that were found with Telomere length include 
duration of vasopressor therapy, history of hypercholesterolaemia and type of 
cardiac surgery (CABG Vs Non-CABG). Mean Telomere length was found to have a 
significant positive association with duration of post-operative vasopressor therapy 
(OR 0.159; p=0.011). The reason for this association is not clear and is the reverse of 
the relationship that we would have expected to observe. If we assume that more 
elderly or frail individuals are more likely to need blood pressure support following 
surgery, we would have expected a negative relationship between telomere length 
and vasopressor duration. However, this assumption may be incorrect. There is 
149 
 
evidence to suggest that the inflammatory response to cardiac surgery is reduced in 
elderly patients. Dieleman et al performed a retrospective analysis of 28,513 patients 
and investigated the link between age and the development of Systemic 
Inflammatory Response Syndrome (SIRS) following cardiac surgery (181). They found 
that increased patient age was strongly associated with reduced postoperative SIRS 
prevalence in the first 24 hours post-operatively with a relative risk value of 1.38 in 
patients aged less than 43 years compared to patients aged 72-83. As such, younger 
patients might on average be expected to require a greater duration of vasopressor 
support and would also be expected to have increased telomere length in 
comparison to older patients, although this hypothesis is purely speculative. If this 
were the case, we would expect to see a correlation between age and vasopressor 
support also. Our results do show a negative correlation between age and duration 
of vasopressor therapy but this does not reach statistical significance (Spearman 
correlation – 0.063; p= 0.318). 
 
Mean Telomere length was found to have a statistically significant association with 
patients undergoing coronary artery bypass grafting (CABG) compared to those 
having other types of cardiac surgery (Non-CABG). The average mTL in the CABG 
group was 0.735 compared to 0.783 in the non-CABG group (p=0.02). This finding is 
in line with previous studies that report associations between telomere length, 
atherosclerosis and coronary artery calcification. Samini et al were the first to 
discover the association between reduced telomere length and CAD in a pilot study 
of 30 patients (124). The 10 patients with CAD had mean terminal restriction 
fragment (TRF) lengths of 303 (SD 90) base pairs shorter than those of the 20 control 
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patients (p=0·002). Weischer et al performed a large population study that measured 
mTL by PCR in >19000 patients who were followed up for the endpoints of MI, IHD 
and death over a 19-year period. Reduced mTL was found to be associated with 
increased risk of all three primary endpoints [adjusted HR= 1.10 (95% CI 1.01–1.19) 
for MI, 1.06 (1.00–1.11) for IHD, and 1.09 (1.05–1.13) for early death per 1000–base 
pair decrease in telomere length]. 
 
The potential underlying mechanisms for this well-established association has been 
previously discussed in section 1.6.1. The Telomere hypothesis states that it is the 
attrition of telomeres that is directly responsible for the development of subsequent 
disease. Alternatively, the modulating hypothesis states that it is the association of 
short telomere length with atherosclerotic risk factors such as smoking, diabetes, 
hypercholesterolaemia, hypertension, physical inactivity and obesity that is 
responsible for the observed association between mTL and CAD. If this second 
hypothesis is correct then mTL would be expected to be associated with the 
traditional atherosclerotic risk factors in this cohort. This is in line with our own 
observations. Hypercholesterolaemia was associated with a significant reduction in 
mTL with an average mTL of 0.734 and 0.744 in patients with and without 
hypercholesterolaemia respectively (p=0.042). A similar trend was seen in patients 
taking statin therapy although this did not reach statistical significance (0.081). This 
may reflect previous findings that statin therapy attenuates the risk of premature 
telomere shortening (174). In terms of other recognized atherosclerotic risk factors, 
we found trends towards reduced mTL in diabetes (p=0.07), hypertension (p=0.162) 
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and increased BMI (p=0.2), although none of these trends reached statistical 
significance. 
 
5.14.2 Comparison of results with previous studies 
The main outcome of this study is the lack of an association between mTL and CSA-
AKI. This specific area has not been studied before and as such there is no body of 
evidence for direct comparison. To date, this study remains the sole study of the 
association between mTL and AKI in humans, with the animal models of AKI produced 
by Westhoff et al previously discussed in section 1.6.3. However, there are a few 
previous studies into Telomere length and outcomes after cardiac surgery. 
 
Brault et al studied the relationship between Telomere length and frailty in elderly 
patients undergoing cardiac surgery (182). In 59 patients over the age of 70 there 
was an unexpected positive association between mTL and increasing number of 
clinical frailty criteria. Although the authors mention that one of the primary 
outcomes of the study was renal failure, the relationship between mTL and this 
outcome is not described. Since the study only included 59 patients, there were likely 
too few patients with post-operative renal failure to draw meaningful conclusions. 
 
D’Amario et al studied the relationship between the growth properties of cardiac 
stem cells (CSCs) and several markers of cardiac function following cardiac surgery 
including ventricular wall thickness, chamber diameter and volume, ventricular mass 
and ejection fraction (183). In 55 patients, telomere length of CSC’s harvested from 
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right atrial tissue was included as one of the studied growth properties. Statistically 
significant positive associations were described between mTL and ventricular wall 
thickness, ventricular mass, ventricular mass/chamber volume ratio, and post-
operative ejection fraction, whilst a significant negative association was found with 
end-diastolic and end-systolic volumes. However, how these findings of reduced mTL 
and markers of reduced cardiac function related to clinical endpoints was not 
investigated.  
 
Roberts et al investigated the relationship between mean peripheral leukocytes 
telomere length (LTL) and right atrial telomere length (ATL) with the incidence of 
post-operative AF in 35 patients undergoing cardiac surgery (184). The authors found 
no association between either LTL or ATL and the development of AF. They also 
demonstrated consistently higher LTL than ATL within patients, with a consistent 
relationship across both the AF and Non-AF cohort. Limitations of this study include 
its small patient numbers and the fact that patients with new onset of AF post-op 
were not differentiated from patients with a history of chronic or paroxysmal AF, two 
very distinct conditions in terms of pathophysiology, In the current study, no 
association was found with mTL and the incidence of new post-operative AF (OR 
1.045; p=0.959) which is consistent with Roberts et al’s findings. The current study 
remains one of the few of telomere length and clinical outcomes following cardiac 
surgery, and the largest to date.  
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5.14.3 Discussion of additional analysis of mTL in CSA-AKI.  
Additional analyses showed that excluding patients with acute falls in serum 
creatinine did not alter the finding of a lack of association between mTL and CSA-AKI. 
However, a subgroup analysis based on ethnicity revealed an interesting finding of a 
significant association between mTL and CSA-AKI only in South Asian patients. The 
population as a whole are primarily either white (n=182) or South Asian (n=49) with 
just 14 black/mixed race patients and 9 patients with other ethnicities. When 
comparing the South Asian population with the rest of the cohort, there was no 
significant difference in mean TL (0.737 Vs 0.759; p = 0.473), incidence of AKI (28.6% 
Vs 19.5%; p = 0.164), or 1-year mortality (7.5% Vs 7.2%; p = 0.944). However, within 
the South Asian population, reduced mTL was significantly associated with the 
subsequent development of CSA-AKI on both univariate (OR = 0.003; p = 0.025) and 
multivariate analysis (OR 0.002; p = 0.036). At present the reason for the finding of 
reduced mTL in CSA-AKI for South Asians only is not clear and cannot be elicited 
further from the current findings. It may be that a second factor is predisposing South 
Asian patients with short Telomere’s and increased cell senescence to CSA-AKI as 
part of a two-hit phenomenon. As a clinically based outcome study, the aim of the 
present study was to identify whether or not an association between mTL and the 
development of CSA-AKI existed, not to determine the mechanism underlying it. This 
will now form the focus of future investigation.  
 
In this cohort, there was a trend towards reduced mTL in patients who were 
deceased at 1 year compared with those who were alive (0.611 Vs 0.751) but this 
failed to reach statistical significance (p=0.118). This was likely due to the extremely 
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low number of endpoints, with just 3 deaths at 1 year out of the 40 patients for which 
1-year mortality data was available (7.5%). This makes the analysis underpowered 
and limits the validity of drawing any conclusions based on this small population. In 
addition, it is worth noting that at least part of the cause of this association was 
increased age in the deceased patients. When we corrected for age the strength of 
the association between mTL and 1-year mortality was reduced (p=0.236). It may be 
that with further follow up out to 5 years the number of endpoints increases 
sufficiently to allow any true association between long term survival and mTL to 
become apparent, both in the South Asian subgroup and in the study population as 
a whole.  
 
5.14.4 Discussion of STELA Pilot experiment 
The aims of this pilot study were to investigate whether an alternative method of TL 
measurement would reveal an association with CSA-AKI and to determine the 
correlation between TL measurements made by different methods in the same 
samples. The first finding of this pilot study was that, as with the main study, there 
was no significant difference between mTL between the AKI cohort and their 
matched controls. The STELA method measures the range of lengths of the XpYp 
telomeres within a sample. Lin et al (185)and Williams et al (186) have used STELA 
derived telomere length to determine prognosis in Chronic Lymphocytic Leukaemia 
(CLL), Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS). Lin et 
al determined the fusogenic threshold of the XpYp chromosomes in CLL, defined as 
the value of mean TL in a sample below which telomere end-to-end fusion events 
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were seen to occur. For the XpYp telomere this fusogenic threshold was a mean TL 
of <3.81KBp. Williams et al found that using this same fusogenic threshold provided 
high prognostic resolution in MDS [HR = 5.0, P < 0.0001] but not AML [HR = 0.68, P = 
0.2]. Unfortunately, this method of stratifying patients could not be used in this pilot 
study as only 2 of the 22 paired samples demonstrated a mTL level below this 
fusogenic threshold of 3.81. Interestingly both of these samples formed part of the 
AKI cohort. As such, mean TL, median TL and 25th Percentile TL were used to compare 
the two cohorts with none of these measures showing any significant difference 
between the matched cohorts (Table 29).   
 
The second aim of this pilot study was to determine the intra-sample correlation 
between mTL measured by qPCR and STELA. Baird et al (187) demonstrated excellent 
correlation between mTL measured with XpYp STELA and with TRF analysis (r=0.91, 
P<0.001; n=10), suggesting that XpYp telomere length reflects genome-wide 
telomere length. In our analysis of 23 samples we found little correlation in mTL 
measurement between the two methods. This finding calls in to doubt the reliability 
of telomere length measurement on an individual level. The fact that the findings of 
our main study closely echo findings from previous studies such as correlation with 
age suggests that the distribution of telomere lengths within the population as a 
whole is accurate. However, there may be inter-individual differences in XpYp mTL 
and qPCR genome wide mTL that have resulted in our findings of poor mTL 
correlation within this relatively small subgroup. 
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In summary, the use of an alternative method of measurement did not alter the 
finding that mTL was not significantly associated with the development of CSA-AKI. 
 
5.14.5 Strengths and limitations of mTL experiments 
There are several strengths to the current study. Firstly, it is prospective in nature 
and therefore does not suffer from collection bias associated with retrospective 
studies. Secondly, the current study includes a larger population than the studies 
described previously that have investigated telomere length in the setting of cardiac 
surgery. A further strength of the current study is its ambition. It attempts what many 
studies into telomere length have not, which is to investigate if telomere length 
correlates with a disease process before the onset of that process. Several studies 
have associated reduced mTL with various disease states and have therefore 
suggested that, due to the link between telomere shortening and reduced cellular 
regeneration, mTL might act as a biomarker of age-related degenerative disease 
(188). In practice, this hypothesis is difficult to test as such a study would involve a 
long latency between mTL measurement and the development of the disease 
process. We have attempted to simulate this situation in a more acute setting with 
the use of an inducible disease process in the form of CSA-AKI. Mean telomere length 
was measured before the onset of the disease process (the ischaemic insult of cardiac 
surgery), and correlated with outcome (the development of CSA-AKI).  
 
There are, however, limitations to the current study. The most obvious limitation is 
that the population’s size may still be too small to detect weak associations between 
telomere length and surgical outcomes. As such, it may be that telomere length is a 
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contributing factor in the development of CSA-AKI but that the size of the effect is 
too small to be seen in a sample of 254 patients; i.e. the current study might be 
underpowered to detect a weak association between mTL and CSA-AKI. This primarily 
results from the fact that the outcomes studied are relatively infrequent in terms of 
the total population studied. In this cohort, the incidence of AKI, in-hospital mortality 
and 1-year mortality were 21%, 2%, and 7% respectively. As such, large numbers of 
patients need to be tested in order to generate sufficient endpoints to detect even 
moderate associations. However, the primary aim of this study was not to determine 
if a weak association exists between mTL and CSA-AKI. The aim was to determine 
whether a measure of biological age such Telomere length could predict CSA-AKI, 
and other post-operative outcomes, better than the patients chronological age or 
other recognised risk factors for AKI. As previously discussed in Chapter 1, the 
aetiology of CSA-AKI is multifactorial and numerous factors have been shown to be 
associated with its development previously. Hence, merely adding another factor to 
the list that is weakly associated with its development may not be clinically beneficial. 
From the results of our univariate analysis we identified several factors associated 
with the development of CSA-AKI in our cohort, such as cardiopulmonary bypass 
time, pre-operative haemoglobin, and hypercholesterolaemia. This suggests that the 
traditional risk factors are better predictors of CSA-AKI. Although age was also not 
significantly associated with CSA-AKI [OR 1.019 (0.995-1.044; p = 0.118), on ROC 
curve analysis it was a better predictor of AKI than mTL with an AUC of 0.574 
compared to 0.479 for mTL. Hence, this study can conclude that, for the population 
as a whole, TL is not a clinically useful parameter in terms of predicting CSA-AKI.  
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A second potential limitation of the study is the possibility that the measured mean 
leukocyte telomere length is not representative of the mean telomere length in renal 
tissue. This could result in cellular senescence at a renal level being different to that 
measured in peripheral blood and masking any relationship between reduced 
telomere length and CSA-AKI. As it is not ethically or practically viable to perform a 
renal biopsy on every patient undergoing cardiac surgery in order to obtain renal 
tissue, peripheral blood was chosen as an alternative. There is conflicting evidence 
as to whether telomere length remains constant across different tissues within an 
individual. Dlouha et al (189) examined the relationship between mTL in leukocytes 
compared with mTL from 11 different body tissues including the kidney, liver, brain, 
muscle, skin, spleen, heart and fat. They found no significant correlations between 
mTL in leukocytes and any other tissue with the exception of skeletal smooth muscle. 
However, their analysis only included samples from 12 patients. This paper also 
highlighted that relative TL can be markedly affected by DNA degradation. As all of 
our samples were tested for integrity on gel electrophoresis prior to their analysis, 
this should not have introduced error into this study. In studies with larger sample 
sizes, mTL was seen to be more consistent across tissue types. Takubo et al (190) 
measured mTL across 5 different tissues (heart, liver, kidney, brain and spleen) and 
found that TL was relatively consistent across tissues of the same individual. 
Furthermore, they demonstrated that mTL in renal cortex showed a significant 
negative correlation with age.  Friedrich et al (191) measured telomere length by 
Southern Blot in three tissues of different proliferation rates (peripheral blood 
leukocytes, skin, and synovial tissue). Although the authors found significantly 
shorter mTL in leukocytes than skin or synovial fluid, mTL was highly correlated 
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between all tissue types of the same individuals regardless of age. This led the 
authors to conclude that telomere length measurement in easily accessible tissues 
such as blood could serve as a surrogate parameter for the relative mTL in other 
tissues. As such, the majority of the studies into telomere length and associated 
disease have use peripheral leukocytes telomere length. Furthermore, for a test to 
be clinically useful it must be possible to obtain samples from patients in a way that 
is acceptable to them. With the above in mind, the decision to focus our area of study 
on leukocyte telomere length from peripheral blood seems justified. 
  
A final limitation of the current study is that mTL may not be a true indicator of 
telomere induced cellular senescence. Despite the considerable body of work that 
has repeatably demonstrated the relationship between mTL and age-related disease, 
Hemann et al (101) present evidence that it is the length of the shortest telomere 
within a cell rather than the mean length that triggers the cell to enter senescence. 
To address this potential issue, we performed STELA of the XpYp telomere in a subset 
of the study patients. However, as previously discussed this analysis was not able to 
address the issue of a single chromosome with short telomeres being able to trigger 
senescence of a whole cell because STELA is only able to be performed on a limited 
to number of chromosomes (160). Although a single research group has reported 
their experience of Universal-STELA (U-STELA) which allows the length of individual 
telomeres to be measured regardless of position (161), this technique is not well 
established nor widely reported. As we have not been able to measure the burden 
of short telomere lengths for each sample, we have not been able to test Hemann et 
al’s hypothesis in this study. Rather we have assumed that given the large number of 
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peripheral leukocytes within each sample, the mTL across all chromosomes will 
correlate with the burden of short chromosomes capable of triggering senescence. 
This seems a fair assumption to make given that many previous studies have 
established the validity of mTL as a biomarker of senescence. However, it remains a 
potential source of error in our study findings.  
 
5.14.6 Conclusion 
The main finding of this experiment is that mTL is not a clinically useful predictor of 
the development of AKI for the majority of patients who undergo cardiac surgery. It 
is inferior in this respect to an individual’s age or to the already recognized risk factors 
such as duration of cardiopulmonary bypass or pre-operative anaemia. However, 
more in-depth analysis has revealed an interesting finding that patients of South 
Asian descent do exhibit a significant association between reduced mTL and CSA-AKI. 
The underlying mechanism for this is not clear and its determination should form the 
basis of future investigation.  
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CHAPTER 6: DNA Methylation Aging Signatures and Cardiac 
Surgery Associated- Acute Kidney Injury.   
6.1 Building a Methylation signature for aging.  
The source data from the DNA methylation experiments was in the form of Beta 
values which give a percentage methylation for each CpG site. Therefore, for each 
sample up to 77 Beta values were generated (71 for the aging array and 6 for 
senescence). In order to study the associations of these values with clinical outcomes 
it was necessary to build a model that would combine the 71 aging associated beta 
values into a single measure of methylation predicted age. This model and the 
resulting values of predicted methylation age (pMA) was generated by Dr Robert 
Lowe (Blizzard Institute, QMUL)  
 
To define an aging methylation signature a similar approach was used to that of both 
Hannum et al. [1] and Horvath [2]. The source data from the aging and senescence 
methylation CpG’s generated a total of 526 CpG’s. This is because our primers 
amplified fragments containing CpG’s clustered around the target CpG. Analysis was 
restricted to those CpGs which were covered by more than 100 reads to reduce the 
effect of highly noisy methylation values, leaving a total of 316 CpGs. The initial aim 
was to build a model from the data provided by using 27 “healthy” control samples 
with known ages that were run in the same sequencing run as the study cohort. These 
healthy control samples were provided by Dr Vasantha Muthuppalaniappan and 
obtained from healthy kidney donors. Three samples were removed due to low 
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amount of sequencing leaving 24 samples to build a model on. Ages in years were 
transformed using the following function as suggested by Horvath [2]. 
 
f(A) = {
log(A + 1) − log⁡(A + 1), A ≤ 20
A − 20
A + 1
, A > 20
 
 
Where A is the age of a sample in years. The rationale for this transformation is that 
it is; 
a) continuous 
b) logarithmic up till 20 years old and then linear from that point onwards, 
c) defined for prenatal samples e.g. A can be -1.  
 
Following this conversion, an elastic net regression model was used to regress the 
316 CpGs and then a prediction based on the methylation levels of each of these 316 
CpGs can be made. As part of the elastic net regression a single hyper-parameter was 
fitted using a 5-fold cross validation. To test the model, a leave one out cross 
validation was used. Specifically, a single sample was removed and the model trained 
as above and then the age of the missing sample predicted. This was done for each 
sample and the root mean squared error (RMSE) of the prediction calculated. This 
initial analysis resulted in a RMSE of 11.59 years.  
 
To see if this prediction could be improved, the existing Illumina 450K data provided 
by Hannum et al. was used [1] (n=656). First, the 316 CpGs were overlapped with 
probes contained on the array leaving a total of 48 CpGs in common between the 
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two experiments. The CpG ID of these is provided in the Appendix I. Following the 
same approach as above an elastic net regression model was used to regress the 48 
CpGs. The hyper-parameter was fitted using a 10-fold cross validation (due to the 
larger number of samples available) and the model was trained on the Hannum et al 
data and tested on the 24 “healthy” control samples. This resulted in a reduced RMSE 
of 6.89 years and a spearman correlation of 0.75 (Figure 25). The same model was 
then run on the remaining samples to predict the ages of each sample. These 
predicted ages were used in subsequent analyses for association with outcome after 
cardiac surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Predicted age in years based on methylation status against actual age in 
years for the training group of 24 healthy controls. The central dark grey dashed line 
represents a perfect prediction. Light grey dashed lines are +/- 5 years. Figure 
provided by Dr Robert Lowe. 
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6.2 Measures of aging in DNA methylation study 
As a result of the aging model that we constructed built on the Hannum aging 
signature, each study participant had a single measure of predicted age. Previous 
papers have used varying methodologies to relate this predicted age with clinical 
outcomes. Hannum et al describe a measure of aging rate termed the Apparent 
Methylomic Aging Rate (AMAR) which is the ratio of the methylome derived 
predicted age to the true chronological age. Therefore, a higher value of AMAR 
means a higher predicted age (76). Other studies use the difference between the 
chronological age and the predicted methylation age (Delta age) as a biomarker for 
aging and used this measure in subsequent analyses (164). For completeness, 
analyses have been run using the raw values of pMA together with both AMAR and 
Delta age to see if any significant associations exist with any of the measured 
outcomes.  
  
6.3 The study population 
Of the 254 patients that were sequenced (see section 5.2), 14 failed the sequencing 
process. The reason for this was thought to be a loss of DNA integrity. Sequencing of 
DNA methylation status requires DNA of high structural integrity as outlined 
previously in section 4.3.4. Although all DNA samples were tested for integrity using 
gel electrophoresis, after extraction it is possible that the storage of the DNA at -20°C 
and subsequent thawing may have led to degradation of a small proportion of the 
samples. Of the 240 samples successfully sequenced 50 developed cardiac surgery 
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associated-acute kidney injury (CSA-AKI) (20.8%; 50/240). This is a similar proportion 
as in the original study population (21.2%; 54/254).  
 
Repeats of the normality tests for this reduced population were the same as those 
shown in Appendix E. Additional normality tests were performed for the 4 measures 
of aging and are also shown in Appendix E. 
 
6.4 Univariate associations of methylation aging with main outcomes.  
Univariate associations between the 4 markers of age (Age, pMA, AMAR, and Delta 
age) and the primary outcome of CSA-AKI is shown in Table 30, together with the 
secondary outcomes of in-hospital mortality, 1-year mortality, and composite 
endpoint (New AF, Stroke, Reoperation, and AKI). Of the 4 markers of age, only pMA 
was significantly associated with the development of CSA-AKI with a mean pMA of 
65.62 in the AKI group and 59.7 in the non-AKI group (p=0.013).  
 
No significant differences were seen for any of the other outcomes apart from the 
composite outcome of new AF, stroke, reoperation or AKI. Both Age and pMA were 
significantly increased in the patients reaching one of these endpoints; 66.19 years 
Vs 62.36 years for Age (p=0.034) and 63.47 years Vs 58.74 years for pMA (p= 0.014). 
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 AKI In-hospital 
mortality 
1-year 
mortality 
Composite 
outcome 
Yes 
n = 
50 
No 
n= 
190 
Yes 
n = 5 
No 
n 
=235 
Yes 
n = 
16 
No 
n 
=192 
Yes 
n 
=113 
No 
n 
=127 
Age Mean 66.99 63.41 65.18 64.13 66.62 63.54 66.19 62.36 
OR  
(95% CI) 
1.021  
(0.996-1.046) 
1.006 
(0.941-1.075) 
1.018  
(0.977-1.061) 
1.021 
(1.002-1.041) 
p-value 0.106 0.868 0.385 0.034 
Predicted 
age 
Mean 65.62 59.74 64.67 60.89 64.99 60.57 63.47 58.74 
OR  
(95% CI) 
1.030 
(1.006 -
1.053) 
1.018 
(0.957-1.084) 
1.022 
(0.986-1.060) 
1.023 
(1.005-1.042) 
p-value 0.013 0.567 0.239 0.014 
AMAR Mean 0.994 0.949 0.959 0.958 0.988 0.962 0.969 0.948 
OR  
(95% CI) 
5.404 
(0.812-
35.969) 
1.045  
(0.004-
254.80) 
2.611  
(0.126-54.185 
2.209  
(0.453-10.78) 
p-value 0.081 0.988 0.535 0.327 
Delta Age Mean 1.38 3.67 0.51 3.25 1.63 2.97 2.71 3.61 
OR  
(95% CI) 
0.977 
(0.946-1.008) 
0.973 
(0.891-1.063) 
0.987 
(0.937-1.038) 
0.991 
(0.966-1.017) 
p-value 0.148 0.541 0.604 0.488 
 
Table 30: Association between Age, Predicted methylation age, AMAR and Delta age 
with the main study outcomes.  
 
As in our previous analysis of mTL, the cohort was divided into quintiles for Age, pMA, 
AMAR and Delta age. Patients in the top and bottom quintiles were then compared 
for rates of the primary and secondary endpoints using cross tabulation with 
significance values derived by Fischer’s exact test. The results are shown in Table 31, 
and demonstrate the same relationships as those derived from analysis of the whole 
cohort. Again, only pMA was significantly associated with rates of CSA-AKI whilst both 
Age and pMA were associated with development of the composite outcome. No new 
relationships were unmasked by this methodology.  
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 AKI In-hospital 
mortality 
1-year mortality Composite 
outcome 
Yes No Yes No Yes No Yes No 
Age Top 
Quintile 
14 
(29.2%) 
34 
(70.8%) 
2 
(4.2%) 
46 
(95.8%) 
5 
(13.2%) 
33 
(86.8%) 
33 
(68.8%) 
15 
(31.3%) 
Bottom 
Quintile 
9 
(18.8%) 
39 
(81.3%) 
1 
(2.1%) 
47 
(97.9%) 
3 
(7.1%) 
39 
(92.9%) 
21 
(43.8%) 
27 
(64.3%) 
p-value 0.339 1.00 0.467 0.023 
pMA Top 
Quintile 
17 
(35.4%) 
31 
(64.6%) 
2 
(4.2) 
46 
(95.8%) 
5 
(12.2%) 
36 
(87.8%) 
32 
(66.7%) 
16 
(33.3%) 
Bottom 
Quintile 
6 
(12.5%) 
42 
(87.5%) 
1 
(2.1%) 
47 
(97.9%) 
3 
(7.5%) 
37 
(92.5%) 
18 
(37.5%) 
30 
(62.5%) 
p-value 0.016 1.00 0.712 0.008 
AMAR Top 
Quintile 
13 
(27.1%) 
35 
(72.9%) 
2 
(4.2%) 
46 
(95.8%) 
5 
(11.6%) 
38 
(88.4%) 
23 
(47.9%) 
25 
(52.1%) 
Bottom 
Quintile 
8 
(16.7%) 
40 
(83.3%) 
2 
(4.2%) 
46 
(95.8%) 
5 
(13.5%) 
32 
(86.5%) 
19 
(39.6%) 
29 
(60.4%) 
p-value 0.324 1 1 0.537 
Delta 
Age 
Top 
Quintile 
8 
(16.7%) 
40 
(83.3%) 
2 
(4.2%) 
46 
(95.8%) 
5 
(13.5%) 
32 
(86.5%) 
19 
(39.6%) 
29 
(60.4%) 
Bottom 
Quintile 
13 
(27.1%) 
35 
(72.9%) 
2 
(4.2%) 
46 
(95.8%) 
5 
(11.6%) 
38 
(88.4%) 
23 
(47.9%) 
25 
(52.1%) 
p-value 0.324 1.00 1.00 0.537 
 
Table 31: Association of rates of AKI, In-hospital mortality, 1-year mortality, and 
composite outcome in patients in the top and bottom quintiles of Age, pMA, AMAR, 
and Delta Age. 
 
6.5 Propensity matched analysis of methylation aging and CSA-AKI 
A propensity matched analysis was performed for the 4 markers of aging and the 
development of CSA-AKI, using the same methodology as previously described in 
section 5.5. Due to the loss of a proportion of the samples in the sequencing process 
we were only able to achieve 43 matched pairings. Shapiro-Wilk’s test of normality 
run on the matched cohort showed that pMA was normally distributed for both cases 
and controls, but that Age, AMAR, and Delta Age were not. As such, the Wilcoxon 
Signed Rank test was used as a non-parametric alternative to the Students T-test for 
paired samples. In this analysis none of the 4 measures of age differed significantly 
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between the paired populations (Table 32). Delta age showed the greatest difference 
with a value of 1.89 in the AKI cohort compared to 6.12 in the non-AKI cohort 
(p=0.07).  
 
 AKI Non AKI 
Age  Mean +/- SD 66.97+/- 14.31 67.16 +/- 13.6 
p-value 0.975 
Predicted Age Mean +/- SD 65.09 +/- 14.70 61.04 +/- 12.19 
p-value 0.241 
AMAR Mean +/- SD 0.986+/- 0.154 0.934 +/- 0.154 
p-value 0.144 
Delta Age Mean +/- SD 1.89 +/- 9.51 6.12 +/- 11.05 
p-value 0.074 
 
Table 32: Comparison of Age, pMA, AMAR, and Delta Age in Cases Vs Controls in 43 
propensity patched patient pairings.  
 
 
6.6 Whole population Associations with chronological age, predicted 
methylation age, AMAR, and Delta age. 
The same statistical methodology as previously outlined in section 5.6 was employed 
to determine whole population associations with pMA, AMAR, and Delta age. A 
summary of the associations between aging measures and all continuous 
independent pre-operative and intra-operative variables is shown in Table 33. A 
similar summary for categorical independent variables is shown in Table 34.  
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Variable Age  pMA AMAR Delta Age 
Corr 
Coeff 
p-
value 
Corr 
Coeff 
p-
value 
Corr 
Coeff 
p-
value 
Corr 
Coeff 
p-
value 
Length of 
post-op stay 
0.129 0.047 0.168 0.01 0.112 0.084 -0.097 0.135 
Age - - 0.701 0.000 -0.197 0.002 0.277 0.000 
BMI -0.026 0.690 0.007 0.910 0.024 0.717 -0.020 0.759 
Extubation 
day 
0.286 0.000 0.237 0.000 0.020 0.757 0.011 0.872 
Vasopressor 
day 
-0.092 0.156 -0.100 0.125 -0.026 0.687 0.005 0.935 
Inotrope 
day 
0.056 0.390 0.010 0.876 -0.093 0.154 0.070 0.280 
1st Hb in ITU -0.247 0.000 -0.171 0.011 0.089 0.191 -0.139 0.039 
Urine 
output 1st 
12 hours 
-0.193 0.004 -0.116 0.088 0.048 0.482 -0.071 0.300 
Pre WCC -0.076 0.243 -0.003 0.964 0.110 0.089 -0.101 0.119 
Pre INR 0.076 0.245 0.018 0.785 -0.091 0.164 0.092 0.161 
Pre APTT 0.018 0.786 0.050 0.450 0.048 0.465 -0.050 0.449 
Pre CRP -0.097 0.475 -0.182 0.181 -0.053 0.696 0.070 0.611 
Pre Hb -0.310 0.000 -0.254 0.000 -0.051 0.427 -0.007 0.909 
D1 Hb -0.155 0.017 -0.094 0.148 -0.030 0.648 -0.020 0.760 
Hb Diff -0.118 0.071 -0.152 0.019 -0.049 0.449 0.047 0.475 
Bypass time 0.065 0.331 0.051 0.445 0.107 0.109 -0.077 0.249 
Xclamp 
time 
0.081 0.228 0.034 0.606 0.046 0.488 -0.014 0.829 
Log 
EuroSCORE 
0.555 0.000 0.371 0.000 -0.090 0.168 0.109 0.094 
T/S ratio -0.237 0.000 -0.227 0.000 -0.073 0.259 0.063 0.329 
 
Table 33: Summary table of Spearman correlations between Age, Predicted age, AMAR, 
and Delta age and all continuous independent variables. p-values <0.05 shown in bold. 
Corr Coeff = Spearman correlation coefficient. 
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 N Mean Age +/- 
SD 
p-value pMA +/- SD p-
value 
Mean AMAR +/- 
SD 
p-value Delta age +/- SD p-value 
Gender 
Male 
Female 
 
171 
69 
 
63.78 +/- 13.4 
65.13 +/- 14.9 
 
0.215 
 
61.22 +/- 14.80 
60.35 +/- 14.37 
 
0.890 
 
 
0.966 +/- 0.167 
0.938 +/- 0.144 
 
0.247 
(MWU) 
 
2.55 +/- 10.35 
4.78 +/- 8.81 
 
0.165 
Ethnicity 
White 
South Asian 
Black 
Mixed 
Asian 
Middle Eastern 
Other 
 
174 
43 
12 
2 
3 
2 
4 
 
65.29 +/- 13.9 
64.28 +/- 10.3 
54.03 +/- 15.7 
50.50 +/- 34.6 
65.47 +/- 5.53 
59.00 +/- 16.97 
52.50 +/- 20.27 
 
0.150 
 
 
61.75 +/- 14.67 
62.44 +/- 12.67 
50.73 +/- 16.22 
53.44 +/- 27.71 
53.36 +/- 6.83 
57.78 +/- 5.96 
52.94 +/- 22.72 
 
0.183 
 
0.954 +/- 0.163 
0.976 +/- 0.151 
0.947 +/- 0.178 
1.138 +/- 0.232 
0.814 +/- 0.037 
1.006 +/- 0.189 
1.000 +/- 0.137 
 
0.201 
(KW) 
 
3.55 +/- 10.22 
1.84 +/- 9.27 
3.31 +/- 10.77 
-2.94 +/-  6.94 
12.00 +/- 1.29 
1.22 +/-  11.01 
-0.44 +/- 6.37 
 
0.184 
CABG 
No 
Yes 
 
98 
142 
 
60.14 +/- 16.69 
66.93 +/- 10.68 
 
0.004 
 
57.34 +/- 16.60 
63.47 +/- 12.61 
 
0.007 
 
0.962 +/- 0.160 
0.956 +/- 0.162 
 
0.974 
 
2.80 +/- 8.83 
3.47 +/- 10.70 
 
0.751 
Angina Status 
CCS0 
CCS1 
CCS2 
CCS3 
CCS4 
 
53 
38 
111 
23 
11 
 
60.00 +/- 15.23 
61.06 +/- 16.61 
66.77 +/- 12.00 
66.77 +/- 9.12 
65.26 +/- 12.32 
 
0.089 
 
57.06 +/- 14.30 
56.68 +/- 17.81 
63.84 +/- 13.18 
62.93 +/- 12.20 
65.65 +/- 11.44 
 
0.015 
 
0.967 +/- 0.167 
0.927 +/- 0.146 
0.964 +/- 0.148 
0.950 +/- 0.185 
1.030 +/- 0.232 
 
0.607 
 
2.94 +/- 9.53 
4.38 +/- 7.89 
2.94 +/- 9.92 
3.83 +/- 11.90 
-0.38 +/- 14.09 
 
0.797 
Dyspnoea 
NYHA 1 
NYHA 2 
NYHA 3 
NYHA 4 
 
38 
126 
63 
8 
 
60.30 +/- 15.30 
64.24 +/- 13.42 
66.51 +/- 12.62 
65.45 +/- 15.30 
 
0.227 
 
56.66 +/- 15.42 
62.01 +/- 14.65 
61.84 +/- 13.23 
60.19 +/- 9.57 
 
0.256 
 
0.948 +/- 0.180 
0.970 +/- 0.148 
0.942 +/- 0.156 
0.958 +/- 0.245 
 
0.625 
 
3.64 +/- 10.90 
2.23 +/- 9.15 
4.67 +/- 9.92 
5.26 +/- 12.90 
 
0.453 
Previous Cardiac Surgery 
No 
Yes 
 
224 
16 
 
65.12 +/-12.84 
50.80 +/- 19.93 
 
0.004 
 
61.79 +/- 13.61 
49.51 +/- 22.75 
 
0.031 
 
0.958 +/- 0.158 
0.956 +/- 0.210 
 
0.701 
 
3.33 +/- 10.04 
1.29 +/- 8.91 
 
0.488 
171 
 
Hx of Malignancy 
No 
Yes 
 
223 
17 
 
63.84 +/- 13.82 
68.39 +/- 13.85 
 
0.132 
 
60.66 +/- 14.59 
64.99 +/- 15.30 
 
0.336 
 
0.958 +/- 0.162 
0.958 +/- 0.154 
 
0.872 
 
3.18 +/- 10.04 
1.29 +/- 8.91 
 
0.768 
Diabetes 
No 
Diet 
Oral 
Insulin 
 
181 
4 
45 
10 
 
62.99 +/- 14.53 
74.50 +/- 7.51 
67.97 +/- 10.26 
64.16 +/- 13.41 
 
0.102 
 
59.90 +/- 15.20 
65.67 +/- 5.89 
64.06 +/- 13.37 
64.49 +/- 10.15 
 
0.203 
 
0.958 +/- 0.155 
0.887 +/- 0.102 
0.951 +/- 0.194 
1.020 +/- 0.155 
 
0.166 
(KW) 
 
3.08 +/- 9.38 
8.83 +/- 8.49 
3.91 +/- 12.62 
-0.33 +/- 6.45 
 
0.273 
Diabetes 
No 
Yes 
 
181 
59 
 
62.99 +/- 14.53 
67.77 +/- 10.78 
 
0.046 
 
55.09 +/- 16.77 
63.02 +/- 13.30 
 
0.036 
 
0.958 +/- 0.155 
0.958 +/- 0.179 
 
0.927 
(MWU) 
 
3.08 +/- 9.38 
3.53 +/- 11.65 
 
0.646 
Hypertension 
No 
Yes 
 
62 
178 
 
57.76 +/- 17.62 
66.39 +/- 11.50 
 
0.002 
 
58.72 +/- 16.77 
63.02 +/- 13.30 
 
0.003 
 
0.970 +/- 0.188 
0.954 +/- 0.151 
 
0.819 
 
2.66 +/- 9.57 
3.38 +/- 10.12 
 
0.990 
High cholesterol 
No 
Yes 
 
127 
113 
 
61.39 +/- 16.01 
67.27 +/- 10.10 
 
0.009 
 
58.72 +/- 16.56 
63.50 +/- 11.73 
 
0.019 
 
0.966 +/- 0.173 
0.950 +/- 0.147 
 
0.868 
 
2.68 +/- 10.16 
3.77 +/- 9.75 
 
0.620 
Smoker 
Non-smoker 
Ex-smoker 
Smoker 
Ex Vs Current 
Non Vs Current 
 
106 
111 
23 
 
62.16 +/- 16.10 
67.15 +/- 10.84 
58.97 +/- 12.80 
0.007 
0.152 
 
0.007 
 
58.61 +/- 16.54 
63.21 +/- 12.70 
60.98 +/- 13.02 
p = 0.784 
p = 0.588 
 
0.348 
 
0.948 +/- 0.155 
0.948 +/- 0.151 
1.053 +/- 0.207 
 
0.053 
 
 
P=0.022 
P=0.02 
 
3.55 +/- 9.08 
3.93 +/- 10.21 
-2.00 +/- 11.50 
 
0.068 
 
 
p=0.022 
p=0.035 
Renal Disease 
No 
Yes 
 
197 
43 
 
62.59 +/- 14.04 
71.35 +/- 10.29 
 
0.000 
 
59.56 +/- 14.92 
67.41 +/- 11.47 
 
0.001 
 
0.960 +/- 0.169 
0.950 +/- 0.121 
 
0.791 
 
3.03 +/- 10.28 
3.93 +/- 8.41 
 
0.542 
Pulmonary Disease 
No 
COPD 
Asthma 
 
216 
14 
10 
 
63.71 +/- 14.17 
69.06 +/- 10.40 
67.00 +/- 9.15 
 
0.396 
 
60.21 +/- 14.21 
69.99 +/- 16.66 
64.71 +/- 17.88 
 
0.066 
 
0.955 +/- 0.158 
1.016 +/- 0.209 
0.951 +/- 0.159 
 
0.349 
 
3.50 +/- 9.62 
-0.93 +/- 14.01 
2.29 +/- 10.53 
 
0.128 
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Neuro disease 
No 
TIA/RIND 
CVA 
 
213 
16 
11 
 
63.33 +/- 14.05 
70.20 +/- 10.97 
71.56 +/- 8.89 
 
0.022 
 
60.45 +/- 14.49 
66.39 +/- 13.66 
63.07 +/- 18.54 
 
0.216 
 
0.963 +/- 0.155 
0.944 +/- 0.115 
0.895 +/- 0.295 
 
0.334 
 
2.87 +/- 9.34 
3.81 +/- 8.41 
8.48 +/- 19.52 
 
0.340 
PVD 
No 
Yes 
 
227 
13 
 
63.97 +/- 14.02 
67.54 +/- 9.91 
 
0.475 
 
60.85 +/- 14.82 
63.08 +/- 11.55 
 
0.545 
 
0.959 +/- 0.161 
0.947 +/- 0.177 
 
0.775 
 
3.12 +/- 9.78 
4.46 +/- 13.16 
 
0.823 
Previous PCI 
No 
Yes 
 
203 
36 
 
63.52 +/- 14.25 
67.28 +/- 10.73 
 
0.226 
 
60.16 +/- 15.14 
65.09 +/- 10.80 
 
0.057 
 
0.954 +/- 0.161 
0.979 +/- 0.167 
 
0.503 
 
3.36 +/- 9.95 
2.20 +/- 10.27 
 
0.724 
Previous MI 
No 
Yes 
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62 
 
63.41 +/- 14.97 
65.91 +/- 10.18 
 
0.489 
 
60.05 +/-15.76 
63.38 +/- 11.15 
 
0.157 
 
0.954 +/- 0.160 
0.973 +/- 0.169 
 
0.553 
 
3.36 +/- 9.73 
2.53 +/- 10.82 
 
0.770 
Previous ACE 
No 
Yes 
 
144 
96 
 
64.24 +/- 14.61 
64.05 +/- 12.67 
 
0.622 
 
61.20 +/- 15.39 
60.62 +/- 13.55 
 
0.459 
 
0.960 +/- 0.158 
0.955 +/- 0.167 
 
0.627 
 
3.04 +/- 9.57 
3.42 +/- 10.57 
 
0.593 
Previous Statin 
No 
Yes 
 
90 
150 
 
58.98 +/- 17.10 
67.27 +/- 10.33 
 
0.000 
 
57.09 +/- 17.65 
63.30 +/-11.99 
 
0.006 
 
0.976 +/- 1.172 
0.948 +/- 0.154 
 
0.406 
 
1.89 +/- 9.57 
3.98 +/- 10.14 
 
0.158 
LV function 
Good 
Fair 
Poor 
Good Vs fair 
Fair Vs Poor 
 
185 
46 
9 
 
64.00 +/- 14.18 
64.42 +/- 12.94 
66.16 +/- 12.31 
0.878 
0.641 
 
0.900 
 
61.42 +/- 15.49 
58.85 +/- 11.47 
62.58 +/- 11.10 
0.348 
0.467 
 
0.619 
 
0.966 +/- 0.164  
0.927 +/- 0.148 
0.959 +/- 0.150 
 
0.090 
 
 
0.090 
0.400 
 
2.58 +/- 10.21 
5.57 +/- 8.57 
3.64 +/- 10.55 
 
0.180 
 
 
0.065 
0.439 
Urgency 
Elective 
Urgent 
Emergency 
 
 
204 
34 
2 
 
64.52 +/- 14.22 
61.76 +/- 11.62 
68.50 +/- 4.95 
 
0.286 
 
60.96 +/- 15.27 
60.91 +/- 10.81 
62.88 +/- 12.68 
 
0.893 
 
0.952 +/- 0.160 
0.999 +/- 0.169 
0.914 +/- 0.119 
 
0.396 
 
 
 
3.55 +/- 10.08 
0.85 +/- 9.21 
5.62 +/- 7.73 
 
0.443 
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Reoperation 
No 
Yes 
 
229 
10 
 
64.37 +/- 13.49 
63.30 +/- 17.24 
 
0.926 
 
61.09 +/- 14.47 
60.87 +/- 17.74 
 
0.993 
 
0.956 +/- 0.158 
0.972 +/- 0.199 
 
0.768 
 
3.28 +/- 10.00 
2.43 +/- 9.00 
 
0.955 
Transfused ITU 
No 
Yes 
 
153 
87 
 
62.74 +/- 13.94 
66.66 +/- 13.38 
 
0.029 
 
59.96 +/- 15.07 
62.75 +/- 13.80 
 
0.155 
 
0.963 +/- 0.170 
0.950 +/- 0.146 
 
0.623 
 
2.78 +/- 10.48 
3.91 +/- 8.98 
 
0.379 
Clotting products in ITU 
No 
Yes 
 
192 
48 
 
63.49 +/- 13.95 
66.86 +/- 13.18 
 
0.082 
 
60.41 +/- 14.47 
63.19 +/- 15.33 
 
0.362 
 
0.960 +/- 0.162 
0.952 +/- 0.161 
 
0.639 
 
3.07 +/- 10.03 
3.67 +/- 9.79 
 
0.617 
New AF 
No 
Yes 
 
170 
70 
 
61.94 +/- 14.02 
69.55 +/- 11.86 
 
0.000 
 
59.11 +/- 15.06 
65.47 +/- 12.61 
 
0.000 
 
0.962 +/- 0.168 
0.949 +/- 0.143 
 
0.801 
 
2.83 +/- 10.35 
4.07 +/- 8.95 
 
0.417 
 
Table 34: Summary of associations of Age, Predicted age, AMAR, and Delta age with independent categorical variables. p-values <0.05 shown 
in bold.
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In our study cohort, pMA showed good correlation with chronological age 
(Spearman correlation coefficient of 0.7; Figure 26). Furthermore, pMA and 
chronological age showed the same patterns of correlation across all pre-operative 
and intra-operative variables, although the degree of associations varied. However, 
pMA showed a stronger correlation with length of post-operative stay than 
chronological age (Spearman correlation coefficient of 0.168 Vs 0.129). The 
relationship between pMA and length of post-operative stay is shown in Figure 27. 
Both pMA and chronological age were significantly correlated with mTL (p<0.001; 
Table 33).  
 
By comparing the four different aging markers, Age, pMA, AMAR, and Delta age, it 
is possible to see the individual effects of the independent variables on predicted 
methylation age in relation to chronological age. Smoking history alone altered the 
trend in pMA away from that of chronological age. This is demonstrated in Figure 
28. Current smokers have higher mean predicted methylation ages than their 
chronological age, whereas the trend is reversed for non-and ex-smokers. This is 
reflected in a significant difference in both AMAR (predicted age/actual age) and 
Delta age (Actual age – predicted age) in current smokers. Current smokers had a 
significantly increased mean AMAR compared to ex-smokers (1.053 Vs 0.948; p= 
0.02) and non-smokers (1.053 Vs 0.948; p= 0.022). The same relationships are seen 
in Delta age; mean Delta age of -2.0 in smokers compared to 3.93 in ex-smokers (p= 
0.035), and 3.55 in non-smokers (p=0.022). The increase in mean AMAR and 
reduction in mean Delta age seen in smokers is the result of higher pMA. As such, 
smoking appears to be associated with an accelerated methylation aging rate.  
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Figure 26: Correlation of Predicated methylation age with chronological age for all 
subjects (AKI and non-AKI). R2 value of 0.573; Spearman Correlation Coefficient = 
0.7. p<0.001 
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Figure 27: Correlation between predicted methylation age and length of post-
operative stay. R2 = 0.031. Spearman Correlation coefficient = 0.168. p= 0.01 
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Figure 28: Relationship between smoking history and mean chronological age (blue 
bars) and predicted age (green bars). Current smokers have a higher mean predicted 
methylation age than their chronological age, where as in non-smokers and ex-
smokers the relationship is reversed.  
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6.7 Analysis of methylation aging as a predictor of CSA-AKI 
6.7.1 Univariate analysis 
Due to 14 of the samples failing the sequencing process the final population for 
analysis of methylation age was reduced from 254 to 240. This necessitated 
repeating the full analysis for predictors of CSA-AKI using the same methodology as 
in section 5.7.1. In addition, pMA, AMAR and Delta age were added as independent 
variables. Results of the univariate binary logistic regression analyses are shown in 
Table 35 with the statistically significant predictors summarised in Table 36. Of the 
4 measures of aging tested, only pMA was significantly associated with the 
development of CSA-AKI (OR 1.030 (1.006-1.053; p = 0.013). As such, it was the only 
aging marker used in subsequent multivariate analysis. 
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 OR 95% CI p-value 
Age 1.021 0.996 – 1.046 0.106 
Predicted Age 1.030 1.006 - 1.053 0.013 
AMAR 5.404 0.812 - 35.97 0.081 
Delta Age 0.977 0.946 – 1.008 0.148 
Female Gender 1.21 0.620 - 2.386 0.569 
Ethnicity (compared to 
white) 
South Asian 
Black 
Mixed 
Asian 
Middle Eastern 
Other 
 
 
1.594 
1.373 
0.000 
0.000 
0.000 
1.352 
 
 
0.742-3.424 
0.353-5.344 
NA 
NA 
NA 
0.069-1.091 
 
 
0.232 
0.648 
0.999 
0.999 
0.999 
0.787 
 
BMI 1.049 0.985-1.117 0.136 
Cardiac Procedure 
(compared to CABG) 
CABG + valve 
CABG + valve +other 
CABG + other 
Valve alone 
Valve + other 
Other 
 
 
 
1.350 
4.500 
1.500 
1.340 
1.038 
1.406 
 
 
 
0.481-3.793 
0.270-75.03 
0.148-15.18 
0.621-2.891 
0.270-3.988 
0.461-4.288 
 
 
 
0.569 
0.295 
0.731 
0.455 
0.956 
0.549 
CABG (Yes Vs No) 0.848 0.452-1.592 0.609 
Pre-op Angina 
(compared to stage 0) 
CCS 1 
CCS 2 
CCS 3 
CCS 4 
 
 
1.500 
1.635 
1.985 
1.250 
 
 
0.508-4.432 
0.682-3.919 
0.600-6.569 
0.227-6.889 
 
 
0.463 
0.270 
0.261 
0.798 
Pre-op NYHA stage 
NYHA 2 
NYHA 3 
NYHA 4 
 
1.320 
1.524 
5.333 
 
 
0.521-3.348 
0.591-4.355 
0.819-19.30 
 
0.577 
0.434 
0.045 
Previous Cardiac 
Surgery (yes Vs No) 
1.808 0.598-5.467 0.294 
Previous Malignancy 1.648 0.552-4.918 0.370 
Diabetes Yes/No 1.430 1.021-2.002 0.037 
Hypertension 1.301 0.619-2.732 0.487 
Hypercholesterolaemia 2.149 1.134-4.072 0.019 
PreviousSmoking 
Ex-smoker 
Current 
 
1.495 
1.725 
 
 
0.765-2.925 
0.598-4.980 
 
0.240 
0.313 
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Pre-op renal 
dysfunction (eGFR<60) 
1.620 0.762-3.444 0.210 
Pre op COPD 1.657 0.495-5.543 0.412 
Pre-op Asthma 2.762 0.746-10.228 0.128 
Pre-op Neuro disease 
TIA 
CVA 
 
0.519 
0.807 
 
0.114-2.364 
0.168-3.864 
 
0.396 
0.788 
Previous PVD 1.749 0.516-5.932 0.370 
Pre-op ACEI 1.232 0.656-2.312 0.517 
Pre-op Statin 0.973 0.512-1.850 0.935 
Pre-op LV Function 
Fair 
Poor 
 
1.875 
0.536 
 
0.906-3.883 
0.065-4.424 
 
0.091 
0.562 
Pre-op Urgency 
Urgent 
Emergency 
 
0.471 
3.533 
 
0.158-1.408 
0.217-57.61 
 
0.178 
0.375 
1st Hb in ITU 0.982 0.964-1.000 0.050 
Pre-op WCC 1.049 0.922-1.193 0.468 
Pre-op INR 5.307 0.503-56.03 0.165 
Pre-op APTT 1.039 0.967-1.117 0.296 
Pre-op CRP 1.007 0.988-1.026 0.495 
Pre-op Hb 0.763 0.632-0.922 0.005 
Pre-op Cr 1.008 0.996-1.021 0.194 
Pre-eGFR 0.993 0.979-1.007 0.323 
Bypass time 1.015 1.007-1.022 <0.0001 
X-Clamp time 1.015 1.006-1.023 0.001 
Logistic EuroSCORE 0.586` 0.152-2.258 0.437 
T/S Ratio 0.428 0.062-2.943 0.388 
 
Table 35: Univariate analysis of the association of all pre-operative and intra-
operative variables with the development of CSA-AKI in the DNA methylation 
population.  
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Variable OR p-value 
Bypass time 1.015 <0.001 
X-Clamp time 1.015 0.001 
Pre-op Hb 0.763 0.005 
Predicted Age 1.030 0.013 
Hypercholesterolaemia 2.149 0.019 
Diabetes Yes/No 1.430 0.037 
Pre-op NYHA stage 
NYHA 2 
NYHA 3 
NYHA 4 
 
1.320 
1.524 
5.333 
 
0.577 
0.434 
0.045 
1st Hb in ITU 0.982 0.050 
 
Table 36: Summary of predictors of CSA-AKI on univariate analysis listed by strength 
of association. 
 
6.7.2 Multivariate analysis 
Predictors that were significantly associated with CSA-AKI on univariate analysis 
were entered into a multivariate model. Cross-clamp time was excluded from the 
model as it is closely associated with cardiopulmonary bypass time. Similarly, ‘1st Hb 
in ITU’ was excluded as it is strongly correlated with ‘Pre-op Hb’ (Spearman 
Correlation co-efficient of 0.527; p-0.000). Adjusted Odds ratios for the multivariate 
analysis are shown in Table 37.. Cardiopulmonary bypass time and pre-operative 
hypercholesterolaemia were found to be independent predictor of CSA-AKI. After 
adjustment, predicted methylation age was no longer independently associated 
with the development of CSA-AKI (p=0.077). 
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Variable Adjusted Odds 
Ratio 
95% CI p-value 
Predicted age 1.026 0.997-1.056 0.077 
Bypass Time 1.017 1.009-1.026 <0.001 
Pre-op Hb 0.806 0.641-1.012 0.064 
Hypercholesterolaemia 2.173 1.023-4.615 0.043 
Diabetes Yes/No  1.232 0.814-1.865 0.325 
NYHA 4 4.274 0.527-34.655 0.174 
 
Table 37: Multivariate model of independent predictors of CSA-AKI. Significant p-
values <0.05 shown in bold. Nagelkaerke R square = 0.241. Block 0 predictive value 
= 78.8%, Block 1 predictive value = 80.2% 
 
 
6.8 Analysis of methylation age as a predictor of 1-year mortality 
A repeat of the analysis of section 5.8. was performed for the secondary outcome 
of 1-year mortality. Results of the univariate binary logistic regression analyses are 
shown in Table 38 with the statistically significant predictors summarised in Table 
39.  
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 OR 95% CI p-value 
LOS (increasing LOS 
a/w AKI) 
1.043 1.013-1.074 0.005 
Age 1.018 0.977-1.061 0.385 
Predicted age 1.022 0.986-1.060 0.239 
AMAR 2.611 0.126-54.185 0.535 
Delta Age 0.987 0.937-1.038 0.604 
Female Gender 1.104 0.367-3.323 0.860 
Ethnicity (compared to 
white) 
South Asian 
Black 
Mixed 
Asian 
Middle Eastern 
Other 
 
 
1.102 
0 
0 
0 
0 
3.917 
 
 
0.294-4.132 
NA 
NA 
NA 
NA 
0.378-40.605 
 
 
0.886 
0.999 
0.999 
0.999 
0.999 
0.253 
BMI 0.977 0.877-1.090 0.680 
Cardiac Procedure 
(compared to CABG) 
CABG + valve 
CABG + valve +other 
CABG + other 
Valve alone 
Valve + other 
Other 
 
 
0.578 
0 
4.048 
1.239 
0.934 
0.639 
 
 
0.067-4.959 
NA 
0.371-44.209 
0.373-4.115 
0.106-8.222 
0.074-5.506 
 
 
0.617 
0.999 
0.252 
0.726 
0.951 
0.684 
CABG (Yes Vs No) 0.938 0.335-2.624 0.903 
Pre-op Angina 
(compared to stage 0) 
CCS 1 
CCS 2 
CCS 3 
CCS 4 
 
 
1.892 
1.380 
0.698 
0 
 
 
0.395-9.059 
0.349-5.465 
0.068-7.122 
NA 
 
 
0.425 
0.646 
0.762 
0.999 
Pre-op NYHA stage 
NYHA 2 
NYHA 3 
NYHA 4 
 
2.640 
2.640 
24.750 
 
0.318-21.901 
0.282-24.674 
2.053-298.43 
 
0.368 
0.368 
0.012 
Previous Cardiac 
Surgery (Yes Vs No) 
0.918 0.112-7.504 0.936 
Previous Malignancy 2.600 0.518-13.04 0.245 
Diabetes Yes/No 1.421 0.833-2.422 0.197 
Hypertension 0.839 0.278-2.529 0.755 
Hypercholesterolaemia 0.362 0.113-1.163 0.088 
 
Ex-smoker 
Current 
 
2.411 
3.750 
 
0.715-8.123 
0.772-18.21 
 
0.156 
0.101 
Pre-op renal 
dysfunction (eGFR<60) 
2.662 0.860-8.246 0.090 
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Pre op COPD 2.247 0.453-11.15 0.322 
Pre-op Asthma 0 NA 0.999 
Pre-op Neuro disease 
TIA or RIND 
CVA 
 
1.805 
0.074 
 
0.798-4.079 
NA 
 
0.156 
0.000 
Previous PVD 1.097 0.132-9.082 0.932 
Pre-op ACEI 1.966 0.611-6.320 0.257 
Pre-op Statin 0.249 0.083-0.747 0.013 
Pre-op LV Function 
Fair 
Poor 
 
0.540 
1.582 
 
0.117-2.492 
0.181-13.870 
 
0.430 
0.679 
Pre-op Urgency 
Urgent 
Emergency 
 
1.587 
13.75 
 
0.419-6.005 
0.809-233.72 
 
0.497 
0.070 
Extubation Date 1.596 1.142-2.232 0.006 
Vasopressor Date 1.096 1.003-1.197 0.042 
No. of Inotrope days 1.069 0.982-1.163 0.124 
1st Hb in ITU 0.998 0.968-1.027 0.870 
UO 1st 12 hours 0.999 0.998-1.000 0.190 
Reoperation  21.25 4.992-90.46 <0.001 
Pt transfused in ITU 4.400 1.466-13.20 0.008 
Clotting products 0.372 0.127-1.090 0.071 
Post-op AF 0.770 0.238-2.488 0.662 
Pre-op WCC 1.158 0.954-1.407 0.139 
Pre-op INR 10.637 0.601-188.17 0.107 
Pre-op APTT 1.045 0.871-1.253 0.635 
Pre-op CRP 1.108 1.026-1.195 0.009 
Pre-op Hb 0.539 0.386-0.752 <0.001 
Pre-op Cr 1.032 1.012-1.052 0.002 
Pre-eGFR 0.959 0.929-0.990 0.011 
Bypass time 1.009 1.001-1.018 0.033 
X-Clamp time 1.010 0.998-1.023 0.108 
Logistic EuroSCORE 0.823 0.253-2.677 0.746 
T/S Ratio 0.326 0.013-8.035 0.493 
 
Table 38: Univariate analysis of the association of all pre-operative and intra-
operative variables with the development of 1-year mortality in the DNA 
methylation population. 
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Variable OR p-value 
Pre-op Hb 0.539 <0.001 
Reoperation  21.25 <0.001 
Pre-op Cr 1.032 0.002 
Extubation Date 1.596 0.006 
Pt transfused in ITU 4.400 0.008 
Pre-op CRP 1.108 0.009 
LOS (increasing LOS 
a/w AKI) 
1.043 0.005 
Pre-eGFR 0.959 0.011 
Pre-op NYHA stage 
NYHA 2 
NYHA 3 
NYHA 4 
 
2.640 
2.640 
24.750 
 
 
0.368 
0.368 
0.012 
Pre-op Statin 0.249 0.013 
Cardiopulmonary 
Bypass time 
1.009 0.033 
Vasopressor Date 1.096 0.042 
 
Table 39: Summary of predictors of 1-year mortality on univariate analysis listed by 
strength of association. 
 
 
None of the measures of aging were significant predictors of 1-year mortality. As 
the measure of aging closest to reaching significance, pMA was used in the 
subsequent multivariate analysis together with the significant predictors listed in 
Table 39. Again, ‘patient transfused in ITU’ was excluded due to its close relationship 
with pre-operative haemoglobin level. Pre-operative CRP was also excluded due to 
184/240 patients having no pre-operative CRP value recorded, thus potentially 
biasing the data. Estimated eGFR was excluded as it was neither a linear nor a 
categorical variable due to the fact that any patient with an eGFR of above 90 has a 
value of ‘>90’return by the laboratory. The adjusted odd’s ratios of the remaining 
predictors in the multivariate model are shown in Table 40. Only pre-operative 
haemoglobin level was found to be an independent predictor of 1-year mortality 
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with reduced haemoglobin level associated with increased risk of death (OR 0.356; 
p = 0.006). 
 
 
Variable Adjusted Odds 
Ratio 
95% CI p-value 
Predicted Age 1.020 0.938-1.109 0.638 
LOS 0.977 0.872-1.094 0.682 
NYHA 4 NA NA 0.997 
Pre-op Statin 0.643 0.085-4.881 0.643 
Extubation date 1.637 0.632-4.240 0.310 
Vasopressor Date 1.147 0.976-1.348 0.097 
Reoperation 0.384 0.000-781.037 0.806 
Pre-op Hb 0.356 0.171-0.742 0.006 
Pre-op Cr 1.029 1.000-1.059 0.052 
Bypass Time 1.020 0.994-1.046 0.135 
 
Table 40: Multivariate model of independent predictors of 1-year mortality. 
Significant p-values <0.05 shown in bold. Model Nagelkaerke R square = 0.648. Block 
0 predictive value = 93%, Block 1 predictive value = 96.8% 
 
 6.9 Adjustment for over fitting 
As previously described in section 5.9, there is a potential for overfitting in both of 
the above multivariate analyses due to the limited number of the primary endpoint 
(AKI, n- 50). As such, the analysis was repeated with just pMA and the 4 most 
significantly associated predictors on univariate analysis (Table 41). The result of 
this was that pre-operative Hb also became a significant predictor of CSA-AKI in 
addition to cardiopulmonary bypass time and hypercholesterolaemia. 
 
 
 
 
 
 
 
187  
Variable Adjusted Odds 
Ratio 
95% CI p-value 
Predicted age 1.025 0.996-1.054 0.087 
Bypass Time 1.017 1.009-1.025 <0.001 
Pre-op Hb 0.779 0.625-0.971 0.026 
Hypercholesterolaemia 2.202 1.042-4.653 0.039 
Diabetes Yes/No  1.292 0.863-1.933 0.213 
 
Table 41: Multivariate model of independent predictors of CSA-AKI limited to 5 
predictors. Significant p-values <0.05 shown in bold. Model Nagelkaerke R square = 
0.233. Block 0 predictive value = 79.2%, Block 1 predictive value = 81.0.% 
 
With only 16 endpoints for 1-year mortality, the model for predicting this endpoint 
was adjusted to include just 2 predictors; pMA and Pre-operative Hb. As expected, 
the finding that pre-operative Hb but not pMA predicted 1-year mortality was 
unchanged (Table 42). 
 
 
Variable Adjusted Odds 
Ratio 
95% CI p-value 
Predicted age 1.015 0.973-1.058 0.500 
Pre-op Hb 0.544 0.389-0.761 <0.001 
 
Table 42: Multivariate model of independent predictors of 1-year mortality limited 
to 2 predictors. Significant p-values <0.05 shown in bold. Model Nagelkaerke R 
square = 0.0168. Block 0 predictive value = 92.3%, Block 1 predictive value = 92.8% 
 
 
6.10 Receiver Operating Characteristic curve analyses of DNA methylation 
aging measures 
6.10.1. Predictors of AKI 
The ROC curves for each of the 4 measures of aging are shown in Figure 29 with the 
corresponding AUC values and significance levels in Table 43. Increasing values of 
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age, pMA and AMAR were statistically significant predictors of CSA-AKI. Of the 
three, pMA was the most significantly associated (AUC = 0.615; p= 0,012). The AUC 
of <0.5 for Delta age indicates that the risk of AKI increases as Delta age falls. As 
Delta age is a measure of chronological age minus pMA this finding confirms that 
the risk of AKI increases as pMA increases.  
 
 
 
Figure 29: Receiver Operator characteristic (ROC) Curve demonstrating the 
diagnostic ability for the 4 measured aging measures in predicting CSA-AKI; Age 
(blue line), predicted methylation age (green line), AMAR (red line), and Delta Age 
(purple line). 
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Test Result 
Variable  
Area 
Under 
Curve 
Std Error P-value 95% Confidence intervals 
Lower 
Bound 
Upper 
Bound 
Age 0.591 0.047 0.047 0.500 0.683 
Predicted 
Age 
0.615 0.045 0.012 0.526 0.705 
AMAR 0.597 0.044 0.034 0.511 0.684 
Delta-AGE 0.418 0.045 0.075 0.330 0.507 
 
Table 43: Diagnostic ability of age, predicted methylation age, AMAR, and Delta age 
for predicting cardiac surgery associated AKI. P-values for statistically significant 
predictors are shown in bold. 
 
6.10.2 Predictors of 1-year mortality 
The same 4 aging measures were correlated with 1-year survival. Logistic 
EuroSCORE was not included in this analysis as it had previously been run as part of 
the Telomere Length analysis (see section 5.12). The ROC curves are seen in Figure 
30 with the corresponding AUC and significance values given in Table 44. Our results 
show that none of the four measures of aging were significant predictors of 1-year 
mortality. 
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Figure 30: Receiver Operator characteristic (ROC) Curve demonstrating the 
diagnostic ability for the 4 measured aging measures in predicting 1-year mortality; 
Age (blue line), predicted methylation age (green line), AMAR (red line), and Delta 
Age (purple line).  
 
 
 
Test Result 
Variable  
Area 
Under 
Curve 
Std Error P-value 95% Confidence intervals 
Lower 
Bound 
Upper 
Bound 
Age 0.609 0.080 0.149 0.452 0.766 
Predicted 
Age 
0.582 0.085 0.278 0.416 0.748 
AMAR 0.539 0.086 0.601 0.370 0.709 
Delta-AGE 0.452 0.087 0.522 0.282 0.622 
 
Table 44: Diagnostic ability of age, predicted methylation age, AMAR, and Delta 
age for predicting 1-year mortality. 
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6.11 Additional Analyses of DNA methylation aging 
6.11.1 Analysis of effects of fall in serum creatinine level 
As previously described in section 5.11.1, analyses were done in which patients with 
acute falls in serum creatinine post-op (>26mmol/L in 48 hours) were excluded from 
the ‘No AKI’ patient group. As a result, 9 patients were excluded from the analysis. 
The results of the 4 measures of aging against the development of CSA-AKI in this 
population are shown in Table 45. As for telomere length, the analysis was also 
repeated with the 9 patients added to the AKI group with the overall effect of mildly 
reducing the strength of associations between the 4 measures of aging and CSA-AKI 
(results not shown).  
 
 
 AKI 
Yes 
n = 49 
No 
n= 182 
Age Mean 67.07 63.60 
OR (95% CI) 1.020 (0.995-1.045) 
p-value 0.122 
Predicted 
age 
Mean 65.66 59.93 
OR (95% CI) 1.029 (1.006 -1.053) 
p-value 0.016 
AMAR Mean 0.994 0.950 
OR (95% CI) 5.220 (0.765-35.637) 
p-value 0.092 
Delta Age Mean 1.41 3.66 
OR (95% CI) 0.977 (0.947-1.009) 
p-value 0.163 
 
Table 45:  Association between the 4 measures of aging and development of CSA-
AKI in the whole population excluding patients whose serum Cr fell by >26 µmol/l  
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6.11.2 Investigating the effect of removing patients of South Asian Origin 
As previously described for mTL in section 5.11.2, a subgroup analysis was 
performed on patients of South Asian origin. When these patients were excluded 
from the population the effect sizes of the aging measures on CSA-AKI were reduced 
as shown in Table 46. There was no longer any significant association between pMA 
and CSA-AKI (Figure 31). When the South Asian population was analysed in isolation, 
pMA was significantly associated with CSA-AKI despite the reduced sample size 
(Table 47 and Figure 32).  
 
 
 AKI 
Yes 
n = 38 
No 
n= 159 
Age Mean 66.73 63.52 
OR (95% CI) 1.017 (0.990-1.044) 
p-value 0.221 
Predicted 
age 
Mean 64.31 59.77 
OR (95% CI) 1.021 (0.996-1.047) 
p-value 0.097 
AMAR Mean 0.980 0.949 
OR (95% CI) 3.099 (0.376-25.539) 
p-value 0.293 
Delta Age Mean 2.42 3.74 
OR (95% CI) 0.987 (0.953-1.022) 
p-value 0.469 
 
Table 46: Association between the 4 measures of aging and development of CSA-AKI 
in the whole population excluding patients of South Asian descent. 
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Figure 31: Boxplot of pMA and development of CSA-AKI in the whole population 
excluding patients of South Asian descent. Black bars represent median values.   
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 AKI 
Yes 
n = 12 
No 
n= 31 
Age Mean 67.82 62.91 
OR (95% CI) 1.050 (0.980-1.124) 
p-value 0.165 
Predicted 
age 
Mean 69.76 59.61 
OR (95% CI) 1.076 (1.008-1.148) 
p-value 0.028 
AMAR Mean 1.039 0.951 
OR (95% CI) 81.026 (0.451-14544.908) 
p-value 0.097 
Delta Age Mean -1.939 3.300 
OR (95% CI) 0.931 (0.855-1.015) 
p-value 0.105 
 
Table 47: Association between the 4 measures of aging and development of CSA-AKI 
in the patients of South Asian descent. Significant values (p<0.05) are shown in bold. 
 
 
Figure 32: Boxplot of pMA and development of CSA-AKI in the patients of South 
Asian descent. Black bars represent median values. 
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6.11.2.1: Univariate analysis of pMA and CSA-AKI in South Asians 
A repeat of the univariate analyses outlined in sections 6.7.1 was performed 
including all the same variables but limited to the South Asian population. Whilst 
CSA-AKI is significantly associated with pMA in this population (p = 0.028, Table 47) 
none of the other variables tested were significantly associated at a p-value of <0.05 
(results not shown). As such, no multivariate analysis was performed.  
 
6.11.3 Analysis of DNA methylation aging as a predictor of 1-year mortality in the 
South Asian population 
The analysis of the 4 measures of aging as predictors of 1-year mortality was 
repeated separately for the Non-South Asian populations and the South Asian 
population. The results are shown in Table 48 and Table 49 respectively. Of note, 
the number of endpoints in this analysis are much reduced. Of the 35 patients with 
complete 1-year mortality data, only 3 had died within 12 months of their index 
operation. (8.6%). No measures of aging were significantly associated with 1-year 
mortality in either group.   
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 1 year mortality 
Yes 
n = 13 
No 
n= 160 
Age Mean 64.77 63.72 
OR (95% CI) 1.005 (0.965-1.047) 
p-value 0.799 
Predicted 
age 
Mean 62.31 60.55 
OR (95% CI) 1.008 (0.970-1.048) 
p-value 0.678 
AMAR Mean 0.980 0.960 
OR (95% CI) 2.095 (0.072-60.835) 
p-value 0.667 
Delta Age Mean 2.45 3.17 
OR (95% CI) 0.993 (0.938-1.051) 
p-value 0.803 
 
Table 48: Association between the 4 measures of aging and 1-year mortality in the 
whole population excluding patients of South Asian descent. 
 
 1-year mortality 
Yes 
n = 3 
No 
n= 32 
Age Mean 74.63 62.63 
OR (95% CI) 1.176 (0.976-1.417) 
p-value 0.087 
Predicted 
age 
Mean 76.58 60.64 
OR (95% CI) 1.101 (0.994-1.219) 
p-value 0.066 
AMAR Mean 1.026 0.974 
OR (95% CI) 7.113 (0.004-11814.412) 
p-value 0.604 
Delta Age Mean -1.954 1.986 
OR (95% CI) 0.958 (0.842-1.090) 
p-value 0.514 
 
Table 49: Association between the 4 measures of aging and 1-year mortality in 
patients of South Asian descent.  
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6.12 DNA methylation markers of senescence and outcomes after cardiac 
surgery 
 
6.12.1 DNA Methylation senescence markers: Methodology 
In addition to the 71 CpG site Aging array, the methylation status of the 6 CpG sites 
described by Koch et al (77) as correlating with cellular senescence were 
determined. The 6 CpG sites and their genomic sequences are shown in Table 50.  
 
Of the 6 CpG sites assayed, 2 failed. One of these (GRM7) failed due to a failure of 
sequence amplification. The other failed site (PRAMEF-2) did produce reads but 
these mapped to an incorrect position in the Genome implying that the primer had 
not correctly amplified the target CpG. That left a total of 4 CpG sites as potential 
markers of cellular senescence. 
 
CpG site Genomic Sequence 
GRM7 GTGCTGGAGGTGCTCCTGTGCGCGCTGGCGGCGGCGGCGCGC 
CASR TGGCTGCAGCCAGGAAGGACCGCACGCCCTTTCGCGCAGGAG 
PRAMEF2 AGAAGGTGGTGACTTACCAGCGCTGGACTCACTTTGCAGAGT 
SELP ACATAAAACTCCATGGCTATCGCTGTTCCTCACTTTCTGAAC 
CASP14 CTCTTCTACCTAGGAGATGACGGGCTGGGGAAGCCATCTCAA 
KRTAP13-3 TGACTATGCATGTTGGGTCTCGGGGTTTTGGATCCAATAGCT 
 
Table 50: The 6 CpG sites in the senescence panel and their corresponding genetic 
sequences.  
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Developing a measure of cellular senescence in our study population was 
challenging as there is no direct measure of senescence available on which to base 
a model. In the aging model of DNA methylation outlined above, a separate 
population of healthy volunteers of known ages was available which were run on 
the same array against which a model could be built. In the case of cellular 
senescence, although the same control group was available, their level of 
senescence was not known. As the blood samples in this study came from live 
patients at a single time point it was not possible to know the passage number or 
population doubling time of the leukocytes from which DNA was extracted. As such, 
we have utilised the data published from Koch’s original paper that described the 
methylation senescence signature (77). This paper developed models for predicting 
senescence based on plots of percentage Methylation of the CpG sites against 
passage number for linear regression analysis. The original plots from Koch et al are 
shown in Figure 33. We used these same plots to determine cut off methylation 
percentages for senescence based on passage numbers. Using the CpG site for SELP 
as an example, because SELP negatively correlates with passage number, if we 
define a passage number of 5 as indicating senescence, any sample with a % 
methylation of less than 71% (see red line, Figure 33) can be assumed to have a 
passage number of greater than 5 and thus be deemed to be senescent. In our 
routine laboratory work we find that cell lines usually senescence after a passage 
number of 5. For each of the 4 CpG targets successfully sequenced, this method was 
used to convert the methylation status to a binary measure of senescence 
(senescent/non-senescent) and strength of association was measured using the Chi-
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squared test. For completeness, further analyses were performed using passage 
numbers of 10 and 15 as a cut off for defining senescence.  
 
In addition to the above method simple logistic regression analyses were performed 
for each of the 4 CpG sites with the Beta-values for methylation run against the 
outcome of CSA-AKI.  
 
 
 
Figure 33: Methylation level of the 6 CpG sites plotted against passage number. The 
various colours denote the tissue type sampled. The red line demonstrates the 
determined senescence cut off for SELP. Reprinted from Aging Cell, Vol 11 (2), Koch 
et al, Monitoring of cellular senescence by DNA-methylation at specific CpG sites, 
Page 368, Copyright (2011), with permission from John Wiley and Sons  
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6.12.2 DNA Methylation senescence markers: Results 
Simple logistical regression analysis of methylation beta values against CSA-AKI 
showed no significant associations for any of the 4 CpG sites (Table 51). Neither 
were there any significant relationships with either of the 4 sites and CSA-AKI in a 
multiple logistical regression analysis. The raw data for the Methylation senescence 
arrays together with the data coded into a binary senescent/non-senescent variable 
is shown in Appendix J. The results of the coded analysis are shown in Table 52. 
 
CpG Site B-value OR 95% CI p-value 
SELP -0.016 0.985 0.965-1.004 0.128 
CASP14 0.000 1 0.985-1.015 0.990 
CASR -0.001 0.999 0.970-1.038 0.936 
KRTAP13-3 -0.016 0.984 0.965-1.003 0.105 
 
Table 51: Results of Binary logistical regression for each of the CpG sites with 
development of CSA-AKI. None of the relationships reached statistical significance.  
 
CPG Site Passage No. 
(Senescent/No
n-senescent) 
% Senescent 
AKI 
% Non- 
Senescent AKI 
p-value 
SELP 5 (154/100) 23.4 18.0 0.306 
10 (107/147) 24.3 19.0 0.312 
15 (57/197) 21.1 21.3 0.965 
CASP14 5 (26/228) 19.2 21.5 0.790 
10 (19/235) 21.1 21.3 0.982 
15 (13/241) 23.1 21.2 0.869 
CASR 5 (181/73) 22.1 19.2 0.607 
10 (106/148) 19.8 22.3 0.633 
15 (49/205) 22.4 21.0 0.821 
KRTAP13-
3 
5 (77/177) 29.9 17.5 0.027 
10 (31/223) 29.0 20.2 0.259 
15 (13/241) 30.8 20.7 0.390 
   
Table 52: Analysis of CpG sites coded into senescent/Non-senescent based on cut-
off values of % methylation approximating to passage numbers of 5, 10 and 15. 
Statistically significant associations are shown in bold (p<0.05)  
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The coded senescence variable for KRTAP13-3 (KRTAP133-Senescent at 5%) was 
entered into a multiple logistical regression together with the other significant 
predictors of AKI previously demonstrated in this cohort (See section 5.7.2.1;Table 
13). The results of this are shown in Table 53 and demonstrate that KRTAP13-3 
continues to be an independent predictor of CSA-AKI (p=0.041) together with the 
previously demonstrate significant predictors which were cardiopulmonary bypass 
time (p<0.001), hypercholesterolaemia (0.021), pre-operative asthma (p= 0.015), 
and pre-operative haemoglobin (0.005). 
 
The above analyses, including binary logistical regression, multiple logistical 
regression and Chi-squared testing of the coded methylation Beta-values were 
repeated using 1-year mortality as the outcome variable in place of CSA-AKI. No 
significant associations were found between any of the CpG sites and 1-year 
mortality across any of these analyses (results not shown).  
 
 
Variable Odds Ratio 95% CI p-value 
KRTAP133-Senescent at 5% 2.141 1.031-4.447 0.041 
Bypass time 1.016 1.009-1.024 <0.001 
Pre-op Hb 0.737 0.596-0.912 0.005 
Hypercholesterolaemia 2.374 1.141-4.939 0.021 
Diabetes (yes/no) 1.619 0.736-3.566 0.231 
Hx of asthma 5.602 1.405-22.335 0.015 
 
Table 53: Multivariate model of independent predictors of CSA-AKI including 
KRTAP133-Sen. Significant p-values <0.05 shown in bold 
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6.13 Logistical regression analysis of individual CpG sites and CSA-AKI 
Finally, to determine whether any of the 526 CpG sites were individually associated 
with CSA-AKI we performed logistical regression analysis for each individual CpG 
with CSA-AKI as a binary outcome. This statistical analysis was performed by Dr Erini 
Marouli (Lecturer in Computational Biology, WHRI). Out of 526 CpG’s, 37 were 
associated with the development of CSA-AKI at a p-value of <0.05 (results for the 
top 40 associated CpG’s are shown in Appendix K). However, with this number of 
variables being tested the likelihood of observing ‘significant’ associations 
increases. The Bonferroni correction is a commonly used method for countering this 
effect. It alters the p-value to a more stringent value so the chance of introducing a 
Type 1 error is reduced (i.e. rejecting the null hypothesis when there is not sufficient 
evidence to). However, it increases the risk of Type 2 error (failing to reject the null 
hypothesis when you should).  
 
Applying the Bonferroni correction to this dataset produces a corrected significance 
level of p<9.5e-5. Using this value none of the tested CpG’s were significantly 
associated with CSA-AKI. Adjusting the analyses to correct for differences in gender 
and age did not significantly alter the associations between CpG methylation and 
CSA-AKI.  
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6.14 General Discussion of DNA methylation data 
6.14.1 Discussion of significant findings in aging model of DNA Methylation 
 
Primary outcome 
For the 4 measures of age analysed, only the predicted DNA methylation age (pMA) 
was a significant predictor of the development of CSA-AKI on univariate analysis (OR 
1.030 p=0.013). The mean pMA in patients who developed AKI was 65.62 years 
compared to 59.74 in those who did not, a difference of 5.9 years. In comparison 
the chronological age of patients who developed AKI was 66.99 years compared to 
63.41 in those who did not, a difference of 3.6 years. This finding is consistent with 
our original hypothesis that a patient’s ‘biological age’ may be more important in 
determining their outcome after cardiac surgery than their chronological age. In this 
study we have used a previously validated group of 71 CpG sites that have been 
shown to be highly predictive of age, and built a model of methylation age based on 
a population of healthy controls. In applying this model to predict the ages of the 
study population we generated values of predicted methylation (pMA) that varied 
from the true chronological age. In doing so we have used pMA as a surrogate 
marker of biological age.  
 
Previous studies into methylation signatures of aging have used measures that 
incorporate the individual’s chronological age either as a ratio (AMAR) or as a 
difference (Delta age). In the case of our hypothesis that the biological age may be 
a more accurate predictor of CSA-AKI than chronological age, to use either of these 
methods seems counter intuitive as the incorporation of the chronological age 
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might mask any clinically significant associations that exist when the predicted 
methylation age is considered in isolation. This was found to be the case in the 
prediction of CSA-AKI with neither AMAR nor Delta age demonstrating a statistically 
significant association. By running all four markers of aging against all clinical 
variables it was possible to detect the effects of variables on methylation status that 
would not have been apparent had only chronological age and pMA been analysed. 
One example of this is the effect of smoking which is discussed below.  
 
On multivariate analysis, pMA was no longer significantly associated with the 
development of CSA-AKI. Nearly all of the variables found to be significant 
predictors of CSA-AKI and included in the multivariate model are themselves 
affected by chronological age. As such their inclusion in the model reduces the 
likelihood of aging markers being shown to be independent predictors.  
 
In the propensity score analysis undertaken in this cohort, the propensity score 
model included chronological age as a variable i.e. cases and controls were age-
matched. This had to be the case to ensure that any differences in pMA seen were 
not simply due to differences in chronological age between the cohorts. As such, 
the ages of the cases and controls were very well matched (66.97 in AKI group Vs 
67.17 in the Non-AKI group; p = 0.975). Mean pMA was higher in the AKI group 
compared to the Non-AKI group (65.09 Vs 61.04), although this did not reach 
statistical significance (p= 0.241). A comparison of Delta-age between the two 
groups failed to reach statistical significance (p=0.07) using an alpha of <0.05. 
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However, this result means that the likelihood of accepting the null hypothesis that 
there is no difference in Delta age between the two groups, is less than 1 in 10.  
 
In the ROC curve analysis, chronological age, pMA and AMAR all demonstrated p-
values of <0.05, meaning that the area under the curve (AUC) was significantly 
different from 0.5 and therefore that these measures were able to distinguish 
between AKI and non-AKI patients to varying degrees. Of the three measures it was 
pMA that again showed the strongest association (AUC = 0.615; p=0.012). As a result 
of all of the analyses performed, we conclude that increasing pMA is significantly 
associated with the development of post-operative AKI and that its predictive ability 
is superior to that of chronological age. 
 
Unlike genetic variations, epigenetic associations with disease can be consequential 
as well as causal. Distinguishing between the two is not always easy and a key step 
is determining whether or not the variation was present prior to the onset of the 
disease process (192). As the blood samples were drawn prior to the onset of CSA-
AKI, it seems obvious to conclude that the observed increases in pMA in the AKI 
group are causal. However, if the higher rates of CSA-AKI are a byproduct of higher 
cellular age or senescence in the AKI group then the observed methylation changes 
could also be consequential. Whether the observed association is causal or 
consequential is not of primary import. If the clinical application is to identify 
patients at higher risk of post-operative complications, the association alone is 
sufficient. Unfortunately, as the strength of the association between pMA and CSA-
AKI is not strong (AUC of 0.61), the current epigenetic signature for predicting 
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methylation age is unlikely to be useful in terms of risk stratification for individual 
patients developing CSA-AKI. As such, the value of this exploratory study is to 
provide preliminary proof-of-concept validation that targeted methylation 
signatures are associated with post-operative complications, specifically the 
development of CSA-AKI. However, by demonstrating that pMA was more closely 
associated with CSA-AKI than chronological age we provide evidence that epigenetic 
aging signatures are interesting targets for future studies into the optimisation of 
cardiovascular risk modification at an individual level.  
 
Secondary outcome 
The secondary endpoints for this study included in-hospital mortality and 1-year 
mortality. Neither pMA, chronological age, AMAR or Delta age were significantly 
associated with either of these outcomes. Further analysis was not performed for 
in-hospital mortality due to the low number of cases that died in this period (n=5). 
However, analyses were run on predictors of 1-year mortality. pMA was not found 
to be associated with 1-year mortality on either univariate or multivariate analysis. 
Again, these analyses were limited by the low number of patients reaching this 
endpoint (n= 16). The study was designed to recruit sufficient numbers for outcome 
of the primary end-point of CSA-AKI and as such analyses of these secondary 
endpoints appear underpowered. 
 
As previously described in chapter 5, a composite outcome was created to increase 
the number of endpoints. This composite outcome was designed as a measure of 
post-operative morbidity and combined the endpoints of new CSA-AKI, new AF, 
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stroke and reoperation. We found that predicted methylation age was associated 
with composite outcome whereas chronological age was not (OR 1.023; p=0.014). 
However, this trend seems primarily due to the association of pMA with CSA-AKI. If 
we remove AKI from the composite endpoint (leaving, new AF, stroke and, 
reoperation) the relationship with predicted age no longer reaches significance (0R 
= 0.988; p=0.189). In summary, of all of the outcome measures, only CSA-AKI shows 
a significant association with predicted methylation age on univariate analysis only.  
 
 
Other significant findings 
 
All 4 measures of age were run against a range of pre-operative, intra-operative and 
post-operative variables (Table 33 and Table 34). The strength of correlation of pMA 
with chronological age was seen to be similar in the study subjects (R=0.7) as that 
seen in the model of healthy controls from which the predicted ages were derived 
(R=0.75) (Figure 25 and Figure 26). This suggests that the model was applicable to 
the study subjects. However, the pMA of the study subjects tended to 
underestimate the chronological age in comparison with the heathy controls. This 
can be seen in the comparative tables of Age, pMA, AMAR and Delta age shown in 
Appendix L. The average Delta age of the 24 healthy controls was 1.59 compared to 
-3.8 in the study population, indicating that pMA underestimated age in the study 
population. This is surprising as we had expected the study patients to have 
increased pMA in comparison to healthy controls, due to their significant cardiac 
disease. There are two possible interpretations for this finding. Firstly, that the 
observation represents a real reduction in pMA in the study patients over the 
disease state. It is difficult to hypothesise why this might be the case. However, it 
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might be a result of the patients in the study group having commenced on 
treatment to correct their underlying disease state such as antihypertensives, lipid 
lowering medications and smoking cessation. DNA methylation is a dynamic process 
and changes in risk exposure can be quickly reflected in reversal of methylation 
changes (148). As such methylation status may represent current risk exposure 
rather than cumulative lifetime risk exposure. As such, it could be argued that 
commencement of such therapies may artificially reduce the pMA in the study 
subjects if DNA methylation is measured at a point at which they have commenced 
treatment. 
 
The second explanation, is that the population from which the model of pMA was 
derived differed in some way from the study population so that the model under-
predicted methylation age when applied to the study population but not when 
applied to the healthy control population. We tested whether the ages of the model 
derivation (model) cohort and the study (test) cohort were well matched and found 
that they were, both in terms of average age and age range, with the model cohort 
actually showing a greater age range (Figure 34).  
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Figure 34: Box plots for age for the study cohort (Test) and the Model derivation 
cohort (Model). Solid black lines represent mean age with Interquartile range boxes 
and range (dotted line). Figure provided by Dr Robert Lowe.  
 
An alternative explanation is that the observed reduction in pMA in the study 
subjects is due to the different tissue handling of the study population to that of the 
healthy controls which the model for pMA was trained on. The healthy controls 
from which the model of pMA was derived were provided from a different study 
with different protocols for tissue storage and DNA extraction. As DNA methylation 
is highly dependent of the integrity of the extracted DNA it might be that these 
differences in sample preparation have resulted in slight variations in the predictive 
model that causes it to underestimate pMA in the study cohort but not in the 
healthy controls. However, as we are only looking at the relationship of pMA with 
outcomes within our study population and not across studies, it is the difference in 
pMA between the two groups rather than the actual values that are of primary 
interest. The fact that, as a group, the predicted methylation ages of the study 
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subjects are less than their chronological ages does not invalidate the finding that 
pMA was significantly greater in the AKI group.  
 
As a result of the close correlation between chronological age and pMA it is not 
surprising that pMA largely followed chronological age in terms of its associations 
with pre-operative and intra-operative factors (see tables 33 and 34). Factors which 
associated strongly with age were also found to associate strongly with pMA. For 
example, length of post-operative stay, pre-op diabetes, hypertension and 
hypercholesterolaemia were all positively associated with increased age/pMA 
whilst pre-operative haemoglobin was negatively associated. The only exception to 
this correlation between age and pMA was seen in smoking status. Whilst a 
significant difference was seen between the age of ex-smokers and current smokers 
(67.15 years Vs 58.97 years; p= 0.007), this trend was not seen in pMA (63.21 years 
Vs 60.98 years; p= 0.784). The significant difference seen in Delta age between these 
two groups (+3.93 years Vs -2.00 years; p=0.022) reveals the effect of smoking on 
methylation age with current smokers showing a marked elevation in pMA when 
compared with ex-smokers. The same effect is seen when current smokers are 
compared with lifelong non-smokers (p=0.035) but no difference is seen in Delta 
Age between non-smokers and ex-smokers (3.55 Years Vs 3.93 years; p= NS) 
indicating that once a patient has stopped smoking, their predicted methylation age 
returned to that of non-smokers. This finding demonstrates the dynamic changes in 
methylation status that can occur in response to altered environmental stimuli. 
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6.14.2 Discussion of significant findings in senescence models of DNA 
Methylation. 
Of the 4 successfully assayed CpG sites, none showed any significant correlation 
with AKI when the % methylation level of the individual samples were run against 
CSA-AKI using logistical regression. However, when the % methylation values were 
converted to binary values of senescent or non-senescent, KRTAP13-3 was 
significantly associated with the development of CSA-AKI. 29.9% of senescent 
samples developed CSA-AKI compared with 17.5% of non-senescent samples, 
meaning that rates of senescence were 42.6% in the AKI group compared with 27% 
in the non-AKI group (p=0.027). Similar trends were seen if senescence was defined 
using passage numbers of 10 or 15, but these analyses did not reach statistical 
significance due to the reduced proportion of cells coded as senescent with these 
passage numbers. Multivariate analysis was performed in which the above analysis 
for KRTAP13-3 at a passage number of 5 was combined with the other factors 
previously found to be significantly associated with the development of CSA-AKI on 
univariate analysis (see Table 53). In this analysis KRTAP13-3 defined senescence 
remained as an independent predictor of CSA-AKI (p=0.041) together with the 
previously demonstrate significant predictors which were cardiopulmonary bypass 
time (p<0.001), hypercholesterolaemia (0.021), pre-operative asthma (p= 0.015), 
and pre-operative haemoglobin (0.005). 
 
In the development of the original 6 CpG methylation signature for senescence 
performed by Koch et al, no consideration was given to the functional relevance of 
the genes corresponding to the 6 markers. Instead the CpG sites were picked solely 
on their predictive values as epigenetic markers (77). The in-vivo function of 
212  
KRTAP13-3 has not been fully elicited but it is thought to code for a Keratin associate 
protein (KRTAP) within the hair cortex. These proteins form a matrix within which 
hair keratin intermediate filaments are embedded. They are essential for the 
formation of a rigid and resistant hair shaft through their extensive disulfide bond 
cross-linking with abundant cysteine residues of hair keratins 
(https://www.uniprot.org/uniprot/Q3SY46). KRTAP13-3 has not been found to be 
involved directly in renal function or play a role in cell senescence.  
 
6.14.3 Comparison of results with previous studies 
No previous studies have been performed into associations between methylation 
status and outcome following cardiac surgery. However, several studies have linked 
methylation status with some of the pre-operative factors investigated in the 
current study. Firstly, we will look at the association of pMA with chronological age. 
The various studies outlining epigenetic clocks and their ability to predict 
chronological age have already been discussed in section 4.2. Hannum et al first 
described the signature of 71 CpG probes associated with aging that we have used 
for the current study. This model was applied to a validation cohort of 174 samples 
processed in exactly the same manner as the training set, and achieved a correlation 
between pMA and age of 0.91 with an RMSE of 4.9 years. It is not stated whether 
these 174 patients were healthy controls nor is their mean age or age range given, 
preventing normalisation of the RMSE for direct comparison with the current study. 
Our aging model was similarly applied to a validation cohort of 24 healthy controls 
achieving a correlation between pMA and age of 0.75 with an RMSE of 6.89. We 
have already seen that Horvath’s methylation aging signature predicts chronological 
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age with a mean absolute error (MAE) of 3.6 years and an R correlation of 0.96. This 
compares with a MAE of 5.5 years in our validation cohort. However, in a further 
study by Koch et al, pMA was determined using an epigenetic-aging signature based 
on just 5 CpG sites (166). This model achieved a correlation between predicted and 
chronological age of 0.64 with an average precision of +/- 12.7 years. As such, we 
feel that our model achieved a good degree of age prediction in the healthy control 
group given the limited number of CpG’s mapped in the current study.  
 
DNA methylation aging and gender. Hannum et al found that the methylation aging 
rate, defined by the authors as AMAR, was 4% quicker in males than in females. We 
found a similar trend in the current study with AMAR being 3% greater in males than 
females although this result did not meet statistical significance (p=0.247). The non-
significant result is likely representative of the study being underpowered to detect 
a true difference of this size.  
 
DNA methylation aging and smoking. One of the main findings of this study was a 
significant reduction in Delta age in smokers compared to non-smokers or ex-
smokers. Several studies have previously demonstrated changes in methylation 
status associated with smoking. The study by Tsaprouni et al has already been 
discussed, in which an EWAS was performed on 464 individuals (22 smokers, 263 
ex-smokers and 179 non-smokers). They found 53 probes that associated with 
smoking and were able to replicate 30 of these in an independent cohort of 356 
twins (41 current, 104 ex-smokers and 211 non-smokers). All 30 probes were found 
to exceed the genome wide threshold of significance. All but 1 of these probes 
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showed a clear trend that smokers have lower methylation levels than non-
smokers, and for all 30, methylation levels were at least partially restored in ex-
smokers. From this the authors conclude that methylation changes in smoking are 
at least partially reversible upon cessation.  
 
It should be noted that all of the studies outlined above investigated a direct link 
between smoking and changes to the methylome. This is different from the current 
study in which smoking has been found to associate with changes in a predictive 
model for aging built on 48 methylation probes. One possible explanation is that 
smoking induces generalised hypomethylation of multiple CpG’s and as such results 
in accelerated aging rates in our model of pMA. This theory is supported by previous 
studies that haves shown that heavy chronic smoking itself has nominally significant 
effects on methylation status at nearly one quarter of the CpG loci in the genome 
(193). Beach et al (194) investigated the effect of smoking status on aging rate using 
the same 71 probe epigenetic clock proposed by Hannum et al (76). However, as 
this study was solely based on new analysis of data in publicly available databases, 
smoking status was defined by demethylation at cg05575921 rather than by 
determining the smoking status of individuals. Demethylation at cg05575921 has 
previously been shown to be strongly associated with daily cigarette use (193). 
Aging rate was determined from an index of the discrepancy between biological and 
chronological age created by regressing chronological age on biological age and 
using the residual as the dependent variable. Smoking status was found to be 
associated with accelerated aging at all levels of smoking exposure. The results of 
the current study echo these results. In addition, we have demonstrated that the 
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effect of smoking on aging rate appears to be lost in ex-smokers, supporting the 
finding of Tsaprouni that smoking related methylation changes are reversible on 
cessation. This finding is also supported by the findings of a pilot study by Lei et al, 
which demonstrated reduced aging rate in 22 patients following smoking cessation 
(195). Again, this study utilised the differentially methylated residue (DMR) to 
determine smoking status.  
 
6.14.4 Discussion of additional analysis of pMA in CSA-AKI 
As with the mTL analysis performed in chapter 5, exclusion of patients with acute 
falls in serum creatinine within the first 48 hours post-operatively did not alter the 
associations between the 4 measures of aging and CSA-AKI.  
 
In a subgroup analysis of South Asian patients compared with the rest of the 
population, we found that exclusion of South Asian patients reduced the strength 
of the association between pMA and CSA-AKI compared with the total population. 
(OR 1.021; p = 0.097 Vs OR 1.030; p = 0.013). When patients of South Asian descent 
were analysed in isolation, the association between pMA and CSA-AKI was 
increased and remained statistically significant (OR 1.076, p = 0.028), despite the 
reduced sample size. Within this subgroup, pMA was the only significant predictive 
factor for CSA-AKI ahead of current recognised risk factors such as bypass time 
(p=0.508), Diabetes (p=0.286), pre-operative renal disease (p=0.411) and pre-
operative haemoglobin (p=0.195). Unlike the analysis of mTL and CSA-AKI, exclusion 
of the South Asian population does not appear to eliminate the association between 
pMA and CSA-AKI in the rest of the population. There is still a trend of increased 
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pMA in the AKI cohort although this fails to reach statistical significance. Part of the 
reduction in p-value can be attributed to a reduction in sample size from 240 (total 
population) to 197 (Non-South Asian population). Furthermore, the association 
between pMA and AKI remains stronger than that of chronological age supporting 
our previous conclusion that methylation-based measures of age are interesting 
targets for future studies into the optimisation of cardiovascular risk stratification. 
However, we can also conclude that, as with mTL, pMA is much more closely 
correlated with CSA-AKI in South Asian patients than other ethnicities and further 
studies are needed to elicit the potential mechanisms underlying this finding.  
 
Analysis of the association of the 4 measures of aging and 1-year mortality was 
limited due to the small number of endpoints in the mortality group (n=3). 
Interpretation is also complicated by the fact that the patients who died had 
increased chronological age. However, If we look at the chronological-age-corrected 
measures of AMAR and Delta age there are trends towards increased aging rates in 
the non-survivors (Table 49) As such, further follow up is awaited to see if an 
increased number of endpoints reveals any significant associations.  
 
6.14.5 Strengths and limitations DNA methylation experiments 
There are several strengths and limitations to the current study. A significant 
strength of the study is that it is ambitious in its aim to apply epigenetics in a 
clinically relevant manor. Several studies into epigenetics have focused on 
epigenome wide association studies (EWAS) in an attempt to find epigenetic links 
to disease processes (196-199). The most suitable epigenetic phenomena for EWAS 
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is DNA methylation due to the development of chips allowing interrogation of 
several thousand CpG sites. Whilst often successful, the clinical applications of such 
studies are limited as EWAS is a costly and time intensive technique. The next step 
in the clinical application of epigenetic data is to demonstrate that targeted 
epigenetic data can be associated with disease states. This study attempts to do just 
that by building on previous data acquired from EWAS studies to perform targeted 
methylation analysis and apply it to a common clinical scenario (CSA-AKI). By 
mapping just 71 probes instead of the 850,000 mapped in the EPIC methylation 
array (200) or the 450,000 mapped in the Illumina HumanMethylation450 BeadChip 
(201), such techniques may form the basis of targeted epigenetic tests for specific 
clinical conditions. A further strength of the current study is that it was sufficiently 
powered to detect a significant difference in pMA for the primary outcome of CSA-
AKI. It was not expected that there would be a sufficient number of endpoints to 
detect differences in methylation states between patients grouped by mortality at 
discharge or at 1-year follow-up. The study also employed a range of statistical 
methodology to evaluate associations between pMA and the defined endpoints 
including multivariate modelling with logistic regression and propensity matching.  
 
The current study has several limitations. Firstly, not all 71 of the aging signature 
CpG’s nor all 6 of the senescence signature CpG’s were successfully mapped. This 
was primarily due to a failure to design primers specific enough to amplify the CpG 
of interest. This is a limitation of determining methylation status via this method 
rather than using an epigenome wide array. A previous study by Weidner et al in 
which an epigenetic clock was developed to predict chronological age, also 
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encountered this problem in primer design when trying to perform targeted 
bisulphite pyrosequencing (167). After identifying 102 age-associated CpG sites 
based on DNA profiles from 4 studies using the Human-Methylation27 BeadChip 
platform, the authors attempted to pyrosequence the top 5 most associated sites 
in a second cohort but were only able to map 3 of the 5 due to failure in primer 
design for the other 2. As a result of this limitation, only 48 of the 71 CpG’s identified 
by Hannum et al were used to generate our model of methylation age. Despite this 
we were able to generate a model for pMA that correlated well with chronological 
age in the healthy controls (RMSE 6.89, R=0.75). Therefore, the loss of some of the 
original CpG’s described by Hannum might well not be a limitation but it is important 
to note that the final model used in our analysis was not the exact same signature 
as that described in this paper (76).  Secondly, as with the Telomere analysis in 
chapter 3, DNA methylation was performed on DNA extracted from peripheral 
blood leukocytes. It is not yet known whether DNA methylation age of easily 
accessible tissues such as blood or saliva can act as surrogate markers for 
inaccessible tissues such as the kidney (164). As such the aging or senescence 
signatures from peripheral blood might not be representative of those in the kidney 
that ultimately determine the propensity to develop CSA-AKI. However, we would 
defend the use of peripheral blood in this setting by contending that if a test is to 
be clinically relevant then it must be acceptable to the patient, and obtaining DNA 
from peripheral blood is much more feasible than obtaining renal tissue.  
 
A third limitation of the study is in the analysis of DNA methylation data for the 
senescence associated CpG’s. Of the 4 CpG’s successfully mapped, none correlated 
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with CSA-AKI on logistic regression analysis. In an attempt to convert the data to a 
binary output, the original plots from Koch’s paper have been used (77). This 
methodology is open to criticism as these plots were derived from fibroblasts and 
mesenchymal stem cells growing in vitro and therefore may not be applicable to 
methylation of DNA extracted from peripheral blood. As there is no possible way of 
measuring passage number or populations doubling time of leukocytes harvested 
in this manor there was no alternative way of converting the continuous 
methylation data to a binary output. Performing such a conversion seems logical as 
it is not the exact level of methylation that is critical to cellular function but rather 
whether or not the cell has been triggered to senescence. Because of the inability 
to validate this conversion against a defined marker of senescence, the association 
of CSA-AKI with hypo-methylated CpG sites correlating with KRTAP13-3 remains 
speculative.  
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CHAPTER 7: Telomerase Activity and outcome after cardiac 
surgery: Summary of failed optimisation experiments 
7.1 Introduction 
Prior to starting recruitment, attempts were made to optimise a protocol for 
measuring the activity of the enzyme Telomerase. Unfortunately, despite a lot of 
time and effort, we were unable to satisfy ourselves that any of the tests trialled 
were able to produce results with a level of reproducibility that could be depended 
on. However, the scientific processes that we undertook in trying to measure 
telomerase activity taught me many useful lessons and was one of the major 
learning experiences of my PhD. As such, we have outlined this process in this 
chapter.  
7.2 Isolation of Peripheral Blood Mononuclear Cells 
7.2.1 Harvest of Peripheral Blood Mononuclear Cells 
Telomerase activity was measured in Peripheral Blood Mononuclear Cells (PBMC). 
PBMC from healthy volunteers were harvested using the BD Vacutainer 
Mononuclear Cell Preparation Tube (CPT) (BD Biosciences, San Hose, CA). This 
system is based on the Ficoll density gradient separation method of PBMC isolation 
but is more time efficient as blood is not required to be layered onto the Ficoll 
manually. Comparative studies have shown that vacutainer CPT and Ficoll density 
gradient separation perform equivalently in terms of maintaining the quality and 
function of PBMC (203). PBMC were harvested in accordance with the 
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manufacturer’s instructions. In brief, blood is taken by standard venepuncture 
directly into a BD vacutainer CPT and stored upright at room temperature until 
processed (within 2 hours of collection). After remixing the blood by inverting 8-10 
times, the CPT’s were processed by centrifuging the CPT for 15 mins at 1800 RCF at 
room temperature. Centrifugation caused the blood to separate into constituent 
layers as shown in Figure 35. The Monocyte layer was seen as a whitish layer 
immediately below the plasma layer. This layer was aspirated off with a Pasteur 
pipette and transferred to a fresh 15ml conical Eppendorf tube together with 
Phosphate Buffered Saline (PBS) to a total volume of 15ml. The tube was inverted 
15 times to mix the cells before being centrifuged at 300 Relative Centrifugal Force 
(RCF) for 15 minutes. The supernatant was aspirated and the cell pellet resuspended 
in a further 10 mls of PBS. A further centrifugation step was performed at 300 RCF 
for 10 minutes. To reduce the degree of platelet contamination we found that a 
further centrifugation step at 100RCF for 10 minutes was required. The final cell 
pellet was diluted in 2mls of PBS. 
 
Figure 35: Figure demonstrating the separation of blood in a BD Vacutainer CPT 
tube after centrifugation.  
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7.2.2 Quantifying starting amount of PBMC 
Accurate comparative quantification of Telomerase activity (TA) is dependent on 
the same starting quantity of PBMC being used for each sample. Initial optimisation 
experiments were performed using a set number of cells in each reaction (2x105). 
Cell counts of each sample were determined manually using a haemocytometer. 
100µL of the final 2ml stock solution obtained from the PBMC harvest was taken 
and combined with an equal volume of Tryptan Blue. The Tryptan Blue helps to 
identify non-viable cells by staining them blue as it is able to permeate their cell 
membrane. 10µL of the mixed solution was loaded onto a disposable 
haemocytometer which was then visualised using the 10x objective of a standard 
light microscope. The cell count was obtained by counting the cell number in an 
area of 16 squares (Figure 36). In total 4 areas of 16 squares were counted per 
sample and the total cell count divided by 4 to give an average value across the 4 
areas. This figure was multiplied by 104 to give the cell count per ml of solution. 
Finally, this number was multiplied by two to adjust for the 1:2 dilution of the 
original stock PBMC when mixed with Tryptan Blue. Samples with high cell counts 
that made counting difficult were subjected to a further 2-4 fold dilution and 
recounted. 
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Figure 36: Method of cell counting using a haemocytometer. Number of cells in a 
peripheral 16-square area (shaded red) were counted. Cells were counted if they 
were within a square or on the right-hand or bottom boundary line. Image by 
Zephyris at the English language Wikipedia, CC BY-SA 3.0, 
[https://commons.wikimedia.org/w/index.php?curid=10553213] 
 
 
7.3 Measuring Telomerase activity: Validation experiments  
7.3.1 Telomerase activity: validation experiments 1 
TA was measured on a small number of healthy controls from volunteers within our 
research group (samples D, S, W and J) using the TeloTAGGG Telomerase PCR ELISA 
(Cat No. 11 854666910 Roche Lifesciences, Pentzberg, Germany). This product 
combines the Telomerase reverse amplification protocol (TRAP) assay first 
described by Kim et al (204) with an ELISA to detect the amplified product. The steps 
of this reaction are outlined below. 
• Step 1: During the TRAP reaction the native telomerase within the test 
sample is used to add Telomeric repeats (TTAGGG) to the end of a biotin 
labelled synthetic primer (P1-TS) 
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• Step 2: The elongation products are amplified by PCR using the primers P1-
TS and P2  
• Step 3: An aliquot of the PCR product is denatured and hybridised to a 
digoxigenin- (DIG) – labelled detection probe specific to the telomeric repeat 
sequence (P3). Next, the product is immobilised on a streptavidin coated 
microplate via the biotin labelled primer.  
• Step 4: The immobilised PCR product is detected using an anti-DIG antibody 
conjugated to horseradish peroxidase (anti-DIG-HRP). Finally, the addition 
of Tetramethylbenzidine (TMB) results in a coloured reaction product as it is 
metabolised by the peroxidase enzyme. The degree of reaction product is 
quantified using a microplate reader by measuring the absorbance at 450nm 
(with a reference wavelength of approximately 690nm). 
 
 
Unfortunately, difficulties were encountered with this assay in terms of its 
consistency and reproducibility. Initial validation runs were made in accordance 
with the manufacturer’s instructions. The results of these runs are summarised in 
Table 54. Detailed descriptions and results of each validation experiment are 
showed in Appendix M.  
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Run 1 Starting amount of PBMC = Large coefficients of variability for 
duplicate runes (up to 35%) 
Run2 Repeat of run 1: Run filed due to positive control falling below 
acceptable range. 
Run 3 Repeat of run 1: Inter-assay variability of 34.5%. samples also run with 
citrate CPT tubes rather than Heparin CPT tubes 
Run 4 Starting amount of PBMC = 1µg of protein as determined by BCA assay 
This run produced a much higher TA value for sample D than 
previously observed (TA = 0.49) but similar values of intra-assay 
variability with CV values of 20% 
Run 5 Repeat of Run 4: Inter-assay variability of 53.3% 
 
Table 54: Summary of TA experiments using TeloTAGGG Telomerase PCR ELISA kit.  
 
7.3.2 Conclusions from validation experiment 1  
 
1. The use of 2x105 PBMC as the reaction substrate produced high intra-assay and 
inter-assay variability (CV>20%) 
2. The use of 1µg Protein content derived from purified PBMC as the reaction 
substrate did not improve the reproducibility of the assay. 
3. The majority of the intra-assay variability comes from the PCR step 
4. The likely source of the observed inter-assay variability comes from differences 
in the starting amount of PBMC, either when using 2x105 cells of 1µg of protein. 
5. When using 1µg of protein, the difference in starting amount appears to arise 
prior to the BCA assay, i.e. during the extraction of purified PBMC from whole blood. 
6. Both Heparin and Citrate containing PBMC BD Vacutainer tubes have similar 
degrees of intra-assay variability. 
226  
7.3.3: Telomerase activity: Validation experiments 2 
In order to overcome the problems of reproducibility with the TeloTAGGG 
Telomerase PCR ELISA assay, the validation experiments were repeated using the 
TeloTAGGG Telomerase PCR ELISA Plus assay (Cat No. 12 013 789 001, Roche 
Lifesciences, Pentzberg, Germany). This assay is a modification on the protocol of 
the standard TeloTAGG Telomerase PCR ELISA assay to include a 216 base pair 
internal control that is amplified alongside the telomeric repeats of the TRAP 
reaction. Both the telomeric and internal control PCR products are then detected 
by ELISA using identical protocols. As such, the internal control should normalise the 
measured TA levels between samples, and correct for sample specific differences in 
PCR (for example; falsely low readings due to the presence of PCR inhibitors in 
samples). The TeloTAGG Telomerase PCR ELISA Plus assay also includes a Control 
Sample. This sample is run in every run and allows for standardisation of telomerase 
activity across samples and across runs. The below validation experiments were run 
for the same 3 samples as the initial validation experiments (D,S and W) and an 
additional sample (J). TA was measured with the TeloTAGG Telomerase PCR ELISA 
Plus as per the manufacturer’s instructions (205). A summary of the optimisation 
experiments performed is outlined in Table 55. 
 
All the of the values of Absorbance of Samples (AS) and Relative Telomerase Activity 
(RTA) for the two samples common to runs 6-12 are shown in Table 56 together 
with their coefficient of variance. Runs in which PCR amplification of the internal 
control appeared to be inhibited are excluded. High CV values are seen for both AS 
and RTA across both samples. If the RTA results from Run 12 are excluded on the 
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basis that the Internal Control may not have amplified correctly, the CV values for 
RTA for samples D and J improve to 35.6% and 73.21% respectively. Both of these 
results are no improvement on the results that we found with the standard 
TeloTAGGG PCR ELISA Protocol.  
 
Run 6 Internal control failed to amplify for 3 of the 4 samples 
Run 7 Repeat of Run 6.  
Run 8 Repeat of run 6 using lysate created from frozen PBMC rather than 
fresh. Again, internal controls for 3 of the 4 samples failed to amplify. 
Run 9 Repeat of run 6 with input amount of PBMC standardised by either cell 
count (2x105 cells) or BCA Assay (3ug Protein). Negative controls out of 
range so whole run invalid  
Run 10 Repeat of run 9 but with just 2 samples to reduce cost of materials for 
optimisation experiments 
Run 11 Repeat of Run 10.  
Run 12 Repeat of Run 10. Reduced absorbance seen in internal controls. 
 
Table 55: Summary of TA experiments using TeloTAGGG Telomerase PCR ELISA 
PLUS kit.  
 
 
 
 D J 
 AS RTA AS RTA 
Run 7 0.4027 12.482 0.2688 10.678 
Run 7 0.2853 9.3870 0.1927 8.1527 
Run 10 0.3623 12.821 0.0078 1.5714 
Run 10 0.3942 18.250 0.0904 2.3178 
Run 10 0.2025 6.6321 0.0526 0.4968 
Run 11 0.0848 7.29 0.12 10.63 
Run 11 0.109 10.72 0.0993 8.43 
Run 12 0.2389 60.5 0.1864 47.62 
Run 12 0.3276 95.4 0.1756 * 
Mean 0.267 25.94 0.133 11.24 
SD 0.118 30.94 0.081 15.26 
CV 44.00 119.3 60.75 135.8 
 
Table 56: Measures of reproducibility in AS and RTA for samples D and J 
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7.3.4 Conclusions from validation experiment 2  
 
1. The ELISA plus assay does not appear to improve the reproducibility of 
Telomerase activity quantification which remains poor.  
2. The amplification of the internal controls in this assay appear erratic and 
may represent the presence of PCR inhibitors in the samples. There were no 
clear differences in the handling of the samples which might have explained 
the discrepancies in internal control amplification.  
3. The repeated finding of valid positive and negative controls in the PCR rings 
suggest that the PCR reaction was running as it should in these samples.  
4. Freezing the lysate for later assaying risks increasing the variability in the 
input amounts of PBMC added to each TRAP reaction.    
 
Because we were not satisfied with the variability in TA quantification with both 
TeloTAGGG PCR ELISA assays, we abandoned their use and looked at alternative 
measures of TA. 
 
7.4 Measuring TERT expression 
7.4.1 Introduction 
The structure and function of Telomerase were described in section 1.4.2. 
Telomerase Reverse Transcriptase (TERT) is a DNA polymerase subunit of 
Telomerase which synthesises Telomeric DNA to the end of chromosomes to 
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maintain the length of the Telomere. Several studies have demonstrated that the 
expression of TERT correlates well with Telomerase Activity, so much so that some 
studies such as Janic et al, report measurement of Telomerase Activity where what 
they have in fact measured is TERT (rather than protein levels of Telomerase) (87). 
This study had also demonstrated that it was possible to measure TERT in RNA 
extracted from peripheral blood leukocytes of healthy middle-aged males. As such, 
we attempted to measure TERT expression in peripheral leukocytes as a surrogate 
marker of Telomerase Activity. 
 
7.4.2 Methodology 
Measuring gene expression requires quantification of mRNA. As such RNA was 
extracted and quality control performed as previously described in Sections 4.3.5 
and 4.3.6. mRNA was quantified by reverse transcription polymerase chain reaction 
(RT-qPCR). Extracted RNA was reverse transcribed to cDNA using the SuperScript 
VILO cDNA Synthesis Kit (Invitrogen, Life Technologies, Carlsbad CA, USA) in 
accordance with the manufacturer’s instruction (206). In brief, for each sample 4 μl 
Quantity 5X VILO Reaction Mix was combined with 2μl of 10X SuperScript Enzyme 
Mix together with up to 2.5μg of RNA made up to a total volume of 20μl with DEPC-
treated water (components mixed on ice). The components were gently mixed 
before being run in a PCR machine according to the following protocol: 10 minutes 
at 25°C (Primer Annealing); 60 minutes at 42°C (Reverse transcription step); 5 
minutes at 85°C (Inactivation of enzymes). The TaqMan assay was either carried out 
immediately or the generated cDNA was stored at -20°C for up to a week or -80°C 
for longer storage. The cDNA was not quantified with Spectrophotometry as it 
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contains lots of dNTP’s and residual RNA that can invalidate the result. Such a step 
is unnecessary if a standard amount of RNA is inputted into the Reverse 
Transcription step and the same protocol used for all cases. 
 
TERT expression was performed using purchased TaqMan® Gene Expression Assays 
and the TaqMan® Fast Advanced Master Mix in accordance with the manufacturer’s 
protocols(207). In brief, for each sample 10µl of TaqMan® Fast Advanced Master 
Mix (2X), 1µl of TaqMan®Assay (20X) and 7µl of Nuclease free water were combined 
with 2µl of cDNA template to give a total reaction volume of 20µl. The TaqMan 
Assay contain a mixture of PCR primers and TaqMan probes with an Applied 
Biosystems FAM or VIC dye label on the 5’ end and minor groove binder and a 
nonfluorescent quencher on the 3’ end (Thermofisher, Germany). Labelling the PCR 
products with different dyes allows the amplification of separate PCR products in 
the same reaction tube.  
 
Each reaction was run in a separate well of a 96-well plate and each sample was run 
in duplicate. qPCR was run according to the following conditions: 2 minutes at 50°C 
(UNG incubation); 2 minutes at 95°C (Polymerase activation); 40 cycles of 3 seconds 
at 95°C (denaturing) and 30 seconds at 60°C (anneal/extension step). PCR was run 
on a Corbett Research Rotorgene 6000 Thermocycler (Qiagen, Manchester, UK) and 
results interpreted with the use of the Rotor-gene Q series analysis software.  
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7.4.3 Results 
The fundamental problem that we encountered in measuring TERT expression was 
a failure to achieve amplification of TERT in any of the samples or positive controls 
that were tested. A summary of the optimisation experiments performed is given in 
Appendix M.  
 
Following these experiments, expert help was sought from the Genome Centre at 
Queen Mary University of London. Fresh RNA was extracted to be used in the 
optimization experiments and its quality checked with the use of an Agilent 2100 
Bioanalyzer (Agilent, Santa Clara, CA, USA). The resulting gel electrophoresis of 11 
samples tested showed good integrity (Figure 37) as did the individual 
electropherograms for each sample (Figure 38). Average RNA Integrity Number 
(RIN) for all samples was 8.7. RIN is a numerical measure of integrity, and is 
measured on a scale of 0-10 with 10 representing 100% intact RNA with no 
degradation. Our results showed a good level of integrity of extracted RNA. The 7 
samples with the best integrity were run for TERT expression using a different 
Thermocycler (Applied Biosystems 7900 HT fast RT PCR machine) in a 384 well plate, 
using the corresponding Mastermix and the TERT probe HS00972650_m1 (TERT 1). 
5-point standard curves were run for both a positive control consisting of XpressRef 
Total RNA as the sample with best yield and RIN (S1). Unfortunatly, this run again 
showed late amplification for TERT but no amplification for GAPDH.  
 
A further experiment was run on the Genome centre thermocycler which was a 
repeat of the previous experiments but with a differrent positive control. A human 
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breast adenocarcinoma cell line (MCF-7) was used, as in the study by Janic et al (87). 
This run showed some late and discordant amplifcation for both TERT and GAPDH 
in the samples, but suprisingly no TERT amplification was seen in the MCF7 positive 
control. As this cell line had previously been used as a positive control in TERT assays 
this lack of amplifcation was surprising and calls into question whether the late 
amplification seen in previous assays was truly due to amplification of TERT or the 
result of non-specific amplification. 
 
 
 
 
 
Figure 37: Results of gel electrophoresis of 11 samples extracted RNA plus 1 control 
sample (GC-Ctrl). The 2distinct bands represent the ribosomal subunits 28S and 18S. 
The lack of other bands seem demonstrates the absence of smaller fragments 
produced by degradation.  
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Figure 38: Electrogram for sample S1 (see Figure 37) Two peaks seen corresponding 
to the two ribosomal subunits and an early peak corresponding to the marker. 
 
7.4.4 Conclusions 
• There do not appear to be any issues with the quality or integrity of the 
extracted RNA using the PAXgene system. 
• The excellent amplification results for GAPDH across both samples and 
XpressRef Total RNA indicates that the reverse transcription reaction is 
working and that there is no significant PCR inhibition occurring.  
• The reason behind the inability to reliably amplify TERT is not clear, even in 
an MCF7 cell line positive control. Alterations in probes, cycling conditions, 
Mastermix components and concentration of input RNA all failed to correct 
the issue.  
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7.5 Overall Conclusion of Telomerase Experiments 
Following nearly 2 months of attempting to optimise both the TeloTAGG PCR-ELISA 
assays and the TERT PCR , a decision was taken to abandon further experiments. 
Part of the decision to do this lay in the preliminary results of the mTL analysis. We 
were primarily interested in measuring Telomerase to support our telomere length 
analysis. In the event of a significant association between mTL and CSA-AKI it would 
have been useful to demonstrate a complimentary association between Telomerase 
activity and CSA-AKI as telomerase acts to increase mTL. By this stage of my thesis, 
mTL had been measured for the majority of the study cohort and preliminary 
analysis had shown no significant association between mTL and CSA-AKI. As such, 
the decision was taken to abandon further work on Telomerase activity in order to 
dedicate more time to measuring DNA methylation signatures.  
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CHAPTER 8. Conclusions and Future Work 
8.1 Summary of Key Findings 
From the results of this study the following conclusions can be drawn: 
1. Mean Telomere length was not associated with either the primary outcome of 
CSA-AKI, or the secondary outcomes of in-hospital or 1-year mortality in the total 
population.  
 
2. The STELA analysis pilot study did not indicate any significant difference in mTL 
between patients with or without CSA-AKI. 
 
3. There was little correlation between values of mTL when measured with qPCR or 
STELA. 
 
4. Increasing pMA is significantly associated with the development of post-operative 
AKI on univariate analysis and its predictive ability is superior to that of 
chronological age. 
 
5. In South Asian patients, mTL is significantly associated with CSA-AKI on both 
univariate and multivariate analysis. 
 
6. In South Asian patients, pMA is significantly associated with CSA-AKI with a 
stronger association than that demonstrated in the total population.  
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7. We were able to use targeted bisulphite amplicon sequencing to determine the 
methylation status at specific CpG sites and correlate them with clinical outcomes.  
 
8.2 Clinical impact of these findings 
These results suggest that genetic and epigenetic markers of aging and senescence 
might be able to more accurately predict long-term outcome after cardiac surgery 
than chronological age. Such findings could have potential clinical impacts as many 
decisions in the field of cardiac surgery are determined by age and likely post-
operative mortality. The major risk calculators for predicting mortality after cardiac 
surgery incorporate the patient’s age as a major risk factor. These risk calculators, 
whilst shown to have good predictive ability in the majority of cardiac cases, are not 
universally applicable. It is possible that personalised measures of epigenetic age 
such as pMA might provide better predictive powers in such models than the use of 
chronological age. Further work is required to develop this concept and we are 
planning for further analysis of this cohort to determine if that is the case. It is likely 
that further follow up of the cohort out to five years will be required for these 
analyses as discussed below.  
 
In order for markers of epigenetic aging to be clinically useful, methods are needed 
to identify and map key CpG sites of interest without the need to sequence the 
entire methylome for each patient. In the current study we have used a previously 
validated methylation signature of aging to perform targeted bisulphite amplicon 
sequencing of individual CpG sites and correlate them with clinical outcome. As 
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such, we have proved in principal that such targeted sequencing is able to correlate 
with clinical endpoints even if the associations identified in the present study are 
not strong enough to evaluate risk on an individual level.  
 
Finally, the novel findings that mTL and pMA are significantly associated with CSA-
AKI in South Asian patients provides interesting avenues for investigation into 
biological aging and senescence in this subgroup.  
 
8.3 Potential future analyses 
The main finding of this study is that CSA-AKI is associated with an age-associated 
signature of methylation (pMA). This raises the possibility that this might also be 
the case for other post-operative outcomes. No further analyses are planned at the 
current time. However, such relationships might become apparent with further 
follow up of this cohort. This cohort will be followed up to 5 and 10 years for 
mortality and the development of chronic renal impairment. The rationale for this 
is supported by the trends in Delta-age for both in-hospital mortality observed in 
this study (0.51yrs Dead Vs 3.25yrs Alive) and 1-year mortality (1.63 years Dead Vs 
2.97yrs Alive). Both of these results indicate that pMA was higher with respect to 
chronological age in patients who died post-operatively, although neither reached 
statistical significance. The failure to reach statistical significance is likely to be due 
to a lack of power in the study to detect these rarer endpoints. With further follow 
up out to 5 years and beyond, increasing mortality might result in relationships with 
pMA, AMAR, or Delta-age becoming apparent and achieving significance.  
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Further follow up might also reveal a significant association between mTL and mid 
or late survival. Whist no statistical significance was seen in mTL at 1-year follow up, 
the trend was towards greater mortality in patients with reduced mTL, particularly 
in the South Asian subgroup. As such, significant differences might become 
apparent with increased duration of follow up due to an increased number of 
endpoints. 
 
During the ethical submission and informed consenting process for this study, 
consent was obtained for future contact with patients or their general practitioner 
to obtain a latest serum creatinine/eGFR result. This will allow the proportion of 
patients that progress to chronic renal impairment in the future to be determined. 
We therefore plan to correlate the development of CKD at 5 and 10 years follow up 
with the patient’s methylation data and mean telomere length.  
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Chief Investigator:       Professor Magdi Yaqoob 
 
This letter is to confirm that Queen Mary University of London is willing to act as Sponsor as defined in the Research 
Governance Framework for Health and Social Care 2005. 
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as stated in the sponsorship agreement have been met. 
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Study title: Telomere length and telomerase activity as a predictor of 
acute kidney injury following cardiac surgery 
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Amendment date: 29 March 2016 
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1. Addition of a blood test on day 3 or 4 post operatively. 
2. Removal of remove the tests for blood and urine at 4 hours from the protocol. 
3. Amended protocol that blood and urine for renal biomarker analysis will not be taken on every 
patient. 
 
The above amendment was reviewed by the Sub-Committee in correspondence. 
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable ethical opinion of the amendment on 
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The Sub-Committee identified no ethical issues. 
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The documents reviewed and approved at the meeting were: 
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1.5 (tracked) 29 March 2016 
 
 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the relevant NHS care 
organisation of this amendment and check whether it affects R&D approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees and complies fully with the Standard Operating Procedures for Research Ethics 
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days – see details at http://www.hra.nhs.uk/hra-training/ 
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London - Queen Square Research Ethics Committee 
Attendance at Sub-Committee of the REC meeting 
 
Committee Members: 
 
Name Profession Present Notes 
Dr Ciaran Scott Hill Neurosurgery Speciality 
Registrar 
Yes  
Dr Eamonn Walsh Lecturer Yes  
 
Also in attendance: 
 
Name Position (or reason for attending) 
Ms Rachel Heron REC Manager 
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Participation Information Sheet (PIS) 
 
 
Study Title: Telomere length and telomerase activity as a predictor 
of acute kidney injury following cardiac surgery 
 
 
Invitation to participate in the above study 
We would like to invite you to participate in a research study during your upcoming 
hospital stay. Before you decide, we would like to explain why the research is being 
done and what it would involve for you. Please take time to read the information in this 
sheet carefully and discuss it with family and friends if you wish. You will have the 
opportunity to go through the information sheet in detail with a member of the 
research team and ask questions prior to deciding whether to participate.  
 
 
What is the purpose of the study? 
Following cardiac surgery, a proportion of patients will develop acute kidney failure. This 
is usually temporary and treatment is focused on supporting the kidneys and allowing 
them time to recover. At present it is difficult to predict who might develop acute kidney 
failure post-operatively. Whilst those with pre-existing kidney problems are at higher 
risk, patients with normal pre-operative kidney function can also suffer this 
complication.  
 
The primary aim of this study will be to run DNA tests on blood samples to determine if 
we can identify patients at greater risk of developing acute kidney injury following 
cardiac surgery. As a secondary aim we are hoping to identify new tests for detecting 
kidney failure earlier than those currently in clinical use.. 
 
 
Why have I been invited to participate? 
All patients undergoing cardiac surgery in the Barts Heart Centre will be considered for 
inclusion in this trial. In addition. a smaller group of patients having thoracic surgery will 
also be invited to participate. This will provide a comparison of our findings in patients 
not having cardiac surgery. 
 
 
Do I have to take part? 
It is entirely up to you whether or not to take part. If you decide to take part you will be 
given this information sheet and a member of the research team will address any 
questions or concerns you may have. If you decide to participate you will be asked to 
sign a consent form. If you chose not to take part in the study, this decision will not 
affect in any way the normal care you are entitled to receive from your doctor. 
 
 
What will happen to me if I take part? 
This research project does not alter the normal hospital care that you will receive whist 
undergoing your surgery. If you decide to participate, you will have additional blood 
tests taken. These will be performed on the day of admission and on the third or fourth 
day after your operation. Wherever possible, the blood tests will be coordinated to 
coincide with those that would need to be taken as part of your routine care. We will 
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simply take a few more millilitres of blood to perform the additional research related 
tests. Where additional blood tests are required, we will try to use existing access points 
such as the central venous line (required for all cardiac surgical operations) to minimise 
the need for additional venepuncture (taking blood from vein with a needle).  
 
In addition, you will be asked to provide a urine sample pre-operatively. You may also 
be asked to provide a urine sample on the 1st post-operative day. Where possible, 
samples will be taken from a urinary catheter (a tube placed into the bladder routinely 
after all cardiac operations). If you are asked to provide urine sample on the 1st post-
operative day, you will have a further blood test on the 1st post-operative day also. This 
will be taken from a central venous line. These blood and urine samples are collected in 
a subgroup of patients (i.e. not all patients) to test for early biomarkers for post-
operative acute kidney injury. 
 
In addition, any waste tissue generated from your surgery may be sampled and stored 
for later analysis. We will only sample tissue that would otherwise be disposed of 
following your surgery and will not take any additional material for the purpose of this 
research study.  
 
Following cardiac surgery it is expected that you will be unconscious for a period. During 
this period we will continue to take samples at the time points outlined above. Following 
cardiac surgery, it is not uncommon that you may experience a period of temporary 
confusion. If this is the case, or if you are unable to consent to ongoing testing yourself 
for any reason once your anaesthetic has worn off, we will ask a person close to you to 
advise on whether you should remain in the study. If no such person is available we shall 
ask an impartial member of the medical team to offer this advice.  
 
 
What are the potential disadvantages and risks of taking part? 
The only disadvantage to participating in the study is the potential need for 1 or 2 
additional blood tests over and above that required for your routine care. The exact 
number will depend on how frequently the surgical team decides to test your blood for 
clinical reasons. You will also have the minor inconvenience of having to provide 
additional urine samples.  
 
No harm will come to you from participating in this study. Nor will the quality of your 
medical care be compromised in anyway. The amount of additional blood you will be 
required to give above that given for your routine care is not clinically significant. The 
genetic tests that will be performed will have no effect on your clinical care and all data 
will be anonymised. However, if at any point you do not feel that you are able to 
continue in the trial you are free to withdraw your consent at any time. 
 
 
What are the possible benefits of taking part? 
It is unlikely that taking part in this study will be of significant benefit to you. However, 
by participating in this research, you will help to increase our understanding in this area 
and hopefully improve our ability to more accurately predict acute kidney injury 
following cardiac surgery. 
 
  
What if there is a problem? 
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If you have concerns about any aspect of this study, you should ask to speak with 
a member of the research team who will do their best to answer your questions. If 
you are not satisfied by this and wish to complain formally, this can be done 
through the NHS Complaints Procedure or Private Institution. The contact details 
for the Patient Advice and Liaison Service (PALS) at St Bartholomew’s Hospital 
are: 
 
PALS Helpline: Open Monday to Friday, 9.30am – 4.30pm. 
Tel: 02035942040 
pals@bartshealth.nhs.uk 
 
  
 
Will my taking part in the study be kept confidential? 
Yes. We will follow standard ethical and legal guidelines for good clinical practice. Any 
personal identifiable data will be anonymised. All data will be kept on secure hospital 
databases.  
 
 
What will happen if I no longer want to participate in the study? 
You will be free to withdraw from participation in the study at anytime. You will not 
have to give any justification and your medical care will not be affected in anyway. 
 
 
What will happen to the results of the research study? 
We will aim to present the results of this study at conferences at a national or 
international level, and publish them in scientific journals. You will not be identifiable in 
any report/publication. It will be possible to view a copy of the published research upon 
request to the researcher.  
 
 
Who is organising the research? 
The study is part of the ongoing research programme in the Cardiothoracic Department 
at St Bartholomew’s Hospital and is organised by Queen Mary University of London. 
None of the researchers have any conflicts of interest to declare. 
 
 
Who has reviewed the study? 
All research in the NHS is reviewed at by an independent panel, called a Research Ethics 
Committee, to protect your safety, rights, wellbeing and dignity. This study has been 
reviewed and given favourable opinion by London - Queen Square Research Ethics 
Committee.  
 
What do I do now? 
If you would like any further information or have any questions, the members of the 
research team will be happy to help you. Please feel free to discuss this information with 
your family, friends or GP if you wish. If you decide to participate in the study you will 
be asked to sign a consent form. You will be given a copy of the consent form to keep.  
 
Contact Details 
Please direct all enquiries that you may have about this research study to: 
Mr Damian Balmforth 
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Honorary Specialist Registrar in Cardiothoracic Surgery 
The Barts Heart Centre 
St Bartholomew’s Hospital 
Email: damiancharles.balmforth@bartshealth.nhs.uk 
 
 
Thank you for taking time to read this information and for considering whether to 
participate in the study. Please ask a member of the research team if there is anything 
that is not clear.
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REC Reference Number: 
 
Patient Identification Number: 
 
PATIENT CONSENT FORM 
 
Study Title:  Telomere length and telomerase activity as a 
predictor of acute kidney injury following cardiac surgery 
 
 
Contact Details of Researcher:  
 
Mr Damian Balmforth 
Specialist Registrar in Cardiothoracic Surgery 
Queen Mary, University of London 
Tel: 
Email: hhx313@qmul.ac.uk  
 
 
1. I confirm that I have read and understood the patient information sheet 
dated 29/3/16 (Version 1.5) for the above study and have had the 
opportunity to consider the information, ask questions and have these 
answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without my medical care or legal rights being 
affected. 
 
 
3. I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals 
from Queen Mary University of London (QMUL) and Barts Health NHS 
Trust (BHNT) or from regulatory authorities involved in auditing the study. 
I give permission for these individuals to have access to my records.  
 
 
4. I understand that following my operation it is expected that I will lose 
capacity to consent to further tissue sample collection for a period. If this 
is the case, I consent for my blood and urine to be tested for research 
purposes at the times stipulated in the information sheet dated 8/9/15 
(Version 1.4). I understand that venepuncture will not be attempted if I 
am unable to give implied or explicit consent.  
 
 
Please 
initial box 
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5. Following analysis, I consent for my tissues to be placed in long-term 
storage for use in future research. 
 
 
6. I consent to being contacted in the future to enquire about my last known 
renal function test result and general health enquiries.  
 
 
7. I consent to being contacted in the future for other ethically approved 
related research projects. 
 
 
8. I consent for my GP to be contacted in the future to obtain my latest renal 
function result. 
 
 
9. I agree to take part in the above study. 
 
 
10. I would/would not like to be contacted with information regarding the 
future publication of this research.  
 
Contact email ………………….
 
 
  
 
 
 
 
 
_________________________                   _______________              _____________________ 
Name of Patient                                           Date                                    Signature  
 
 
 
 
 
 
_________________________                   _______________              _____________________ 
Name of person taking consent                   Date                                    Signature  
 
 
2 copies to be made once completed: 1 for patient; 1 for researcher’s records; and 
original to be retained in the hospital notes. 
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Appendix B: DNA Methylation Methodology 
 
Bisulphite conversion protocol 
Bisuphite conversion was performed with the EZ-96 DNA methylation kit (Zymo 
Research, Cambridge Bioscience, Cambridge UK). For each sample, 500ng of stock 
DNA was added to 5µL of M-Dilution buffer and made up to a final volume of 50µL 
with nuclease free water (NFW) in a 96 well plate. This solution was incubated at 37 
°Celsius for 15 minutes. 100µL of CT Conversion reagent was then added and the 
samples incubated for 15 hours (overnight) in the dark, before being cooled on ice. 
During this incubation the denaturation, sulphonation and deamination steps of the 
conversion took place. Samples were then transferred to the Zymo-Spin™ I-96 Plate 
(Cataloque number: 5004) containing 400 µl of M-Binding Buffer. The plate was 
centrifuged at full speed (>10,000 x g) for 30 seconds and the follow-through 
discarded. 100 µl of M-Wash Buffer was added to the spin columns and the plate 
centrifuged for a further 30 seconds. The plate was then incubated with 200 µl of M-
Desulphonation Buffer at room temperature for 15 minutes.  During this stage, 
Desulphonation occurred to convert Uracil-SO3- to Uracil. After incubation, two 
further washes with 200 µl of M-Wash Buffer were performed. The final Bisulphite-
converted DNA (BC-DNA) was eluted by adding 10 µl of M-Elution Buffer directly to 
the column matrix and centrifuging for 30 seconds at full speed.  
 
Typical yields of BC-DNA were approximately 50ng/µL in 20µl volume. This 
quantification was performed by Spectrophotometry (Nanodrop). Each sample was 
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diluted to a concentration of 50ng/ µL with TE buffer prior to proceeding to Bisulphite 
PCR.  
Bisulphite PCR 
Region specific PCR was performed with the Fluidigm 48:48 Access Array (Fluidigm, 
San Francisco, US). Before proceeding with the Bisulphite PCR, the Fluidigm Access 
Array was primed to ensure all of its channels were cleared. 0.7ml of Control Line 
Fluid were instilled into the ‘Accumulators’ of the array and 500µl of 1x Access Array 
Harvest Solution were loaded into the H1, H2, H3, and H4 wells of the Access Array 
(both solutions provided by Fluidigm). The array was then placed onto the Pre-PCR 
Fluidigm IFC Controller AX for priming. Once priming was complete, the Access array 
was prepared by loading the Primer solution into the Primer inlets and the Sample 
reaction mixtures into the Sample inlets.  
 
Primer Solution Preparation 
The designed primers were provided by Fluidigm in Singleplex form in 96 well plates. 
Each well contained a single primer pair at a concentration of 60µM. Stock multiplex 
primer mix was made by combining 2-4 primer pairs per well and diluting to a final 
concentration of 5µM. The final primer solution was made up according to Table 1 
by dilution of the stock Multiplex primer mix in a separate 96 well plate. 4µL of the 
final pooled primer solutions were added to the 48 primer inlets.  
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The exact sequences for CS1 and CS2 used in our primer set were 
ACACTGACGACATGGTTCTACA and TACGGTAGCAGAGACTTGGTCT respectively  
 
Component  Volume (µL) Final Concentration 
Stock Primer mix (5 µM): 
• CS1-Forward Primers 
• CS2-Reverse Primers 
 
2 per primer 
2 per primer 
 
1µM per primer 
1µM per primer 
20X Access Array Loading 
Buffer 
5 1X 
DNA suspension buffer Make up to 100 total  
 
Table 1: Composition of the primer dilution for one well of the stock Multiplex primer 
mix plate.  
 
Sample reaction mix preparation 
A PCR master mix was created for a total of 60 reactions by combining the 
components listed in Table 2. The function of Dimethyl Sulphoxide (DMSO) in the mix 
was to alter the structure of cytosine residues from 3 hydrogen bonds to 2 hydrogen 
bonds to facilitate the PCR.  
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Component  Volume per reaction 
(µL) 
Volume for 60 reactions 
10X FastStart High 
Fidelity Reaction Buffer 
without MgCl2 (Roche) 
0.5 30 
25mM MgCl2 (Roche) 0.9 54 
DMSO (Roche) 0.25 15 
10mM PCR Grade 
Nucleotide Mix (Roche) 
0.1 6 
5 U/µL FastStart High 
Fidelity Enzyme Blend 
(Roche) 
0.05 3 
20X Access Array Loading 
Reagent (Fluidigm) 
0.25 15 
PCR Certified Water 
(TEKnova) 
1.95 117 
Total 4 240 
 
 Table 2: Constituents of PCR mastermix for the 48:48 Access Array 
 
4µL of master mix was combined with 1µL of BS-DNA (50ng/µL) for each sample to 
give a total volume of 5µL of sample mix solution. This step was performed in a plane 
96-well plate. 4µL of the resulting sample mix solution was then loaded into each of 
the sample inlets of the 48.48 Access Array using a hand-held multichannel pipette. 
Once both the primer mix and sample mix solutions had been manually loaded, the 
Access Array was placed in the primed Pre-PCR IFC Controller AX for the samples and 
primers to be automatically combined (1.5 hours duration). The Array was then 
transferred to the Fluidigm FC1TM Cycler for target amplification by PCR.  
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Touch down polymerase chain reaction 
The cycling conditions for this PCR are given in Table 3.  
 
Step Temperature (°C) Step Duration  Number of cycles 
- 50 2 mins 1 
- 70 20 mins 1 
- 95 10 mins 1 
- 95 
- 60 
15 secs 
30 secs 
10 
- 72 1 min 1 
- 95 
- 80 
- 60 
15 secs 
30 secs 
30 secs 
2 
- 95 
- 60 
15 secs 
30 secs 
8  
- 72 1 min 1 
- 95 
- 80 
- 60 
15 secs 
30 secs 
30 secs 
5 
- 72 1 min 1 
- 72 3 min 1 
- 4 Hold  
  
Table 3. Thermocycling conditions for the 48:48 Access Array PCR 
 
The total duration of the PCR was 2 hours and 10 minutes, following which the PCR 
products were harvested. After removing residual fluid from the H1-4 wells of the 
48.48 Access Array, 600µL of Access Array Harvest Solution was instilled into the 
same wells. A further 2µl of Harvest Solution was added to each sample inlet and the 
Array placed into the Post-PCR IFC Controller AX. The harvesting script duration was 
1.5 hours and resulted in approximately 10µl of harvested PCR product solution being 
drawn back into each of the 96 sample inlets. These were then transferred to a 96 
well plate. Quality control was performed on a random selection of the harvested 
279  
PCR products using an Aligent 2200 TapeStation System and D1000 ScreenTape 
(Aligent technologies) to determine the quantity and integrity of the PCR product.  
Barcoding 
Barcoding was performed using the Access Array Barcode Library for Illumina 
Sequencers - 384 (Single Direction) (Fluidigm, PN 100-4876) with a different 10 base 
pair sequence used for each sample. Firstly, the harvested PCR products were diluted 
100-fold by adding 1µL of PCR product from each sample with 99µL of water in a 
fresh 96 well plate. For each sample, 1µL of diluted PCR product was combined with 
4µL of sample specific barcode and 15µL of master mix to give a final volume of 20uL 
per sample mix. The constituents of the mastermix are shown in Table 4. The final 
concentration of barcode primer mix was 400nM per well. Barcoding of the Access 
Array PCR product was performed with a further PCR, the conditions of which are 
given in Table 5.  
 
Component  Volume per reaction (µL) Volume for 60 
reactions 
10X FastStart High 
Fidelity Reaction Buffer 
without MgCl2 (Roche) 
2 120 
25mM MgCl2 (Roche) 3.6 216 
DMSO (Roche) 1  60 
10mM PCR Grade 
Nucleotide Mix (Roche) 
0.4 24 
5 U/µL FastStart High 
Fidelity Enzyme Blend 
(Roche) 
0.2 12 
PCR Certified Water 
(TEKnova) 
7.8 469 
Total 15 900 
 
Table 4: Sample pre- mix constituents for barcoding PCR 
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Step Temperature (°C) Step Duration  Cycles 
95 10 mins 1 
95 
60 
72 
15 s 
30 s 
1 min 
15 
72 3 mins 1 
 
  
Table5: Thermocycling conditions for Barcoding PCR. 
 
 
Finally, Quality Control was performed on the barcoded PCR products for the same 
samples that were tested after Bisulphite PCR using the Aligent 2200 TapeStation. 
Successful barcoding was indicated by a barcoded PCR product that was 59 base pairs 
larger than the original PCR product (Figure 1)  
 
 
Figure 1: Library quality control to check barcoded product using the Agilent 
Tapestation. A successful barcoding reaction will produce a product approximately 60 
base pairs longer than the original PCR product. 
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Amplicon Product (250bp) 
Barcoded Product (310bp) 
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Once the PCR products had been successfully barcoded they could then be pooled 
for sequencing using the Illumina MiSeq platform (Illumina, California, USA). Samples 
were pooled by combining 2µL of each barcoded product.  
Sequencing 
The final constructs produced after barcoding were sequenced using the Illumina 
MiSeq Sequencing system. Sequencing was performed using the ‘Sequencing by 
Synthesis’ (SBS) method in which the library fragments are amplified and read 
simultaneously. SBS is comprised of four main stages; library preparation, cluster 
generation, sequencing and data analysis. 
 
1. Library Preparation 
Pooled PCR products were cleaned using the Agencourt AMPure XP PCR Purification 
system (Beckman Coulter, Massachusetts, USA). This system uses magnetic bead 
technology to selectively bind PCR amplicons greater then 100bp, allowing smaller 
fragments as well as excess primers, nucleotides, salts and enzymes to be washed 
way. In brief, 12µl of pooled PCR products were added to 24 µl of Tris-EDTA (TE) 
Buffer and 36µl of AMPure XP magnetic beads. The beads covalently bond to 
fragments >100 base pairs and magnetically separated from the supernatant which 
is discarded. The beads were then washed with 70% ethanol and the purified PCR 
product eluted from the beads with TE buffer. Finally, the unbound beads were 
magnetically separated leaving only purified PCR product. The purified PCR product 
was run on the Aligent 2200 TapeStation to check that fragments <100 base pairs had 
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been removed and to check the concentration. This concentration was then diluted 
to a concentration of 4nM. 
 
5µl of pooled PCR product (sequencing library) at a concentration of 4nM was 
combined with 5µl of 0.2M Sodium hydroxide and incubated for 5 minutes to 
denature the DNA. 990 µl of pre-chilled MiSeq HTI buffer (Illumina) was then added 
to stop the denaturation process and produce a final concentration of 20pM. 120 µl 
of this solution was then added to a further 480 µl of HT1 buffer to produce a final 
running concentration of 5pM. 
 
To 600 µl of the 5pM library we added the Fluidigm custom sequencing primers, FL1 
and FL2. FL1 contains 50 µM of CS1 and CS2 primers and equimolar concentrations 
of indexing primers. FL2 contains 50 µM or CS1 reverse compliment and CS2 reverse 
compliment and equimolar concentrations of indexing primers.  
 
2. Cluster generation. 
The prepared library is loaded onto a Flow-cell (Illumina) consisting of a lawn of 
membrane bound oligonucleotide sequences. There are two types of oligonucleotide 
sequence, complimentary to either the P5 or P7 adaptors within the library. As such, 
the DNA fragment strands within the library bind to the oligonucleotide sequences 
on the Flow-cell lawn via one of their adaptors. Next, a DNA polymerase synthesises 
a strand complimentary to the hybridized fragment. The resulting double stranded 
structure is denatured and the original non-membrane bound fragment is washed 
away. The remaining fragment is then clonally amplified by bridge amplification. The 
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newly formed membrane bound strand loops over so that the adapter at its free end 
is able to bind to the second type of oligonucleotide on the flow cell membrane. 
Again, DNA polymerases generate the complimentary strand, forming a double 
stranded bridge. This double stranded bridge is denatured, resulting in two DNA 
fragments that are tethered to the Flow-cell. These fragments undergo separate 
bridge amplification so that the DNA fragment is amplified exponentially. This 
process occurs simultaneously for all DNA fragments within the library resulting in 
clusters of the same DNA fragment grouped together on the Flow cell surface. 
Following bridge amplification, the reverse strands are cleaved and washed away 
leaving only the forward strands. The 3’ ends of these strands are then blocked to 
prevent unwanted priming. These clusters are then sequenced simultaneously. 
 
3. Sequencing by synthesis 
Sequencing by synthesis (SBS) refers to a process whereby the sequence of a single-
stranded DNA fragment is determined as its complimentary chain is formed. It 
employs a technique termed cyclic reversible termination (CRT). In this process DNA 
polymerization is performed with reversible terminators. These are 
deoxynucleotides with an attached fluorophore and blocking group. After the binding 
of a sequence primer, a complimentary deoxynucleotide binds to the first nucleotide 
of the template strand. The attached blocking agent terminates further DNA 
synthesis and unbound nucleotides are washed away. The incorporated nucleotide 
is imaged and identified from the wavelength of fluorescent signal emitted. In this 
way the sequence is determined, one base at a time. With each cycle, the 3 
deoxynucleotides (Bisulphite converted DNA is a 3 base-pair code) compete with 
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each other for addition to the chain. Finally, the blocking group and fluorphore are 
then cleaved, and the process repeats with the addition of the next deoxynucleotide. 
Sequencing occurs for all DNA fragments within a cluster and for multiple clusters 
simultaneously. In ‘Read 1’ the sequences of the membrane bound forward 
fragments are determined by the synthesis of complimentary strands. This read 
product is then washed away and the barcode or ‘index’ read primer hybridizes to 
the template fragment. The index portion of the fragment is then read by the same 
CRT process (Index read). This allows the source of the DNA fragment to be 
determined. The index read product is removed and the original bound fragment is 
again used as a template to generate a complimentary reverse strand. This is done 
by removing the blocking cap of the 3’ end of the forward fragment, allowing the 3’ 
end to bridge to a complimentary oligonucleotide sequence on the flow-cell surface. 
The reverse strand is then produced by DNA polymerase and unlabeled nucleotides. 
The double stranded bridge is denatured and the bound forward strand is cleaved 
and washed away. Read 2 is now undertaken in which the reverse strand is 
sequenced by CRT.  
 
4.Data Analysis 
The sequencing process generates millions of reads in total representing all of the 
DNA fragments. Sequences within the pooled DNA library are separated into 
individual samples based on the unique sample specific barcodes attached to each 
fragment during preparation of the library. Within fragments from the sample, reads 
with similar base sequences are clustered and grouped by forward and reverse reads. 
Any discrepancies are resolved by comparison within these grouped reads. Finally, 
285  
the percentage of methylated cytosine residues is calculated for each CpG site for all 
fragments generated from a single sample. 
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Appendix C: Sample log of patients included in mTL and Methylation analyses 
 
 
 
Sample 
Number 
Appearance 
of Buffy 
Extraction 
vol 
Nanodrop 
performed  
DNA Conc 
(ng/µl) 
260/280 260/230 Amount 
needed for 
DNAm (ng) 
Volume needed 
for DNAm (µl) 
Number of 
20uL Aliquots 
Single 
band on 
gel 
1 1 1R 300 Yes 65.3 1.84 1.54 500 7.65696784 1 Yes 
2 2 1S 300 Yes 89.7 1.86 1.44 500 5.57413601 1 Yes 
3 3 1S 300 Yes 28.4 1.91 2.31 500 17.6056338 1 Yes 
4 4 1S 300 Yes 99.2 1.84 1.3 500 5.04032258 1 Yes 
5 5 1R 300 Yes 84.3 1.88 2.33 500 5.9311981 1 Yes 
6 6 1R 300 Yes 89.8 1.86 1.2 500 5.56792873 1 Yes 
7 7 1S 300 Yes 96.7 1.86 1.53 500 5.17063082 1 Yes 
8 8 0 300 Yes 94.2 1.9 2.11 500 5.30785563 1 Yes 
9 9 1R 300 Yes 116.1 1.86 1.75 500 4.30663221 1 Yes 
10 10 1R 300 Yes 19.9 1.94 0.7 500 25.1256281 2 x 
11 11 1S 300 Yes 38.1 1.88 1.9 500 13.1233596 1 Yes 
12 12 1R 300 Yes 64.6 1.87 2.16 500 7.73993808 1 Yes 
13 13 1S 300 Yes 93.9 1.89 2.4 500 5.32481363 1 Yes 
14 14 1R 300 Yes 32.7 1.94 2.45 500 15.2905199 2 Yes 
15 15 1R 300 Yes 101.9 1.9 2.37 500 4.90677134 1 Yes 
16 16 1R 300 Yes 85 1.89 2.36 500 5.88235294 1 Yes 
17 17 1R 300 Yes 71.7 1.85 0.21 500 6.9735007 1 Yes 
18 18 1R 300 Yes 57.9 1.87 1.65 500 8.63557858 1 Yes 
19 19 1R 300 Yes 105.8 1.9 2.04 500 4.72589792 1 Yes 
20 20 1R 300 Yes 35.9 1.89 2.07 500 13.9275766 1 Yes 
21 21 1R 300 Yes 74.2 1.88 2.24 500 6.73854447 1 Yes 
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22 22 1R 300 Yes 152.3 1.88 1.88 500 3.28299409 1 Yes 
23 23 2R 300 Yes 126.1 1.88 2.18 500 3.96510706 1 Yes 
24 24 1R 300 Yes 91 1.91 1.62 500 5.49450549 1 Yes 
25 25 2R 300 Yes 36.7 1.93 1.95 500 13.6239782 1 Yes 
26 26 2R 300 Yes 91.2 1.86 0.56 500 5.48245614 1 Yes 
27 27 1R 300 Yes 76.4 1.88 0.99 500 6.54450262 1 Yes 
28 28 2R 150 Yes 47 1.89 1.98 500 10.6382979 1 Yes 
29 29 2R 150 Yes 77 1.87 1.53 500 6.49350649 1 Yes 
30 30 3R 150 Yes 72.6 1.87 2.01 500 6.88705234 1 Yes 
31 31 3R 150 Yes 40.9 1.88 1.98 500 12.2249389 1 Yes 
32 32 3R 150 Yes 32.8 1.89 1.94 500 15.2439024 1 Yes 
33 33 2R 150 Yes 29.5 1.9 1.84 500 16.9491525 1 Yes 
34 35 3R 150 Yes 41.6 1.89 1.71 500 12.0192308 1 Yes 
35 36 2R 150 Yes 61.4 1.91 2.33 500 8.14332248 1 Yes 
36 37 2R 150 Yes 62.6 1.91 2.31 500 7.98722045 1 Yes 
37 38 2R 150 Yes 34.3 1.89 2.64 500 14.5772595 1 Yes 
38 39 2R 150 Yes 36.5 1.93 1.17 500 13.6986301 1 Yes 
39 40 2R 150 Yes 31.3 1.82 1.43 500 15.9744409 1 Yes 
40 41 1R 75 Yes 85 1.87 2.08 500 5.88235294 1 Yes 
41 42 1S 75 Yes 90.1 1.87 2.12 500 5.54938957 1 Yes 
42 43 2S 150 Yes 67.5 1.9 1.61 500 7.40740741 1 Yes 
43 44 1R 150 Yes 58.4 1.84 1.89 500 8.56164384 1 Yes 
44 45 2R 150 Yes 94.1 1.83 1.98 500 5.31349628 1 Yes 
45 46 2S 75 Yes 41.4 1.87 0.58 500 12.0772947 1 Yes 
46 47 2R 150 Yes 54.7 1.87 0.96 500 9.14076782 1 Yes 
47 48 2R 150 Yes 73.7 1.89 1.83 500 6.78426052 1 Yes 
48 49 2S 150 Yes 36.4 1.8 1.7 500 13.7362637 1 Yes 
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49 50 2S 150 Yes 16.2 1.9 1.34 500 30.8641975 2 Yes 
50 51 2S 150 Yes 41.4 1.83 1.45 500 12.0772947 1 Yes 
51 52 1S 75 Yes 45.4 1.86 1.45 500 11.0132159 1 Yes 
52 53 2S 75 Yes 79 1.89 1.98 500 6.32911392 1 Yes 
53 54 2S 150 Yes 76.3 1.87 1.89 500 6.55307995 1 Yes 
54 55 2S 75 Yes 60.2 1.87 1.65 500 8.30564784 1 Yes 
55 56 2S 150 Yes 40.5 1.83 1.44 500 12.345679 1 Yes 
56 57 1S 150 Yes 70 1.85 1.66 500 7.14285714 1 Yes 
57 58 2R 150 Yes 51.3 1.86 1.66 500 9.74658869 1 Yes 
58 59 2R 150 Yes 93.3 1.86 1.01 500 5.35905681 1 Yes 
59 60 2S 150 Yes 93.3 1.85 2.11 500 5.35905681 1 Yes 
60 61 2S 150 Yes 86.1 1.87 1.86 500 5.80720093 1 Yes 
61 62 2R 150 Yes 79.8 1.9 1.46 500 6.26566416 1 Yes 
62 63 2R 150 Yes 23.5 1.97 1.25 500 21.2765957 2 Yes 
63 64 2R 150 Yes 74.2 1.86 1.88 500 6.73854447 1 Yes 
64 65 2R 150 Yes 18.1 1.96 1.24 500 27.6243094 2 Yes 
65 66 2R 150 Yes 33.4 1.81 1.23 500 14.9700599 1 Yes 
66 67 2R 150 Yes 68.7 1.88 1.92 500 7.27802038 1 Yes 
67 68 2R 150 Yes 74.8 1.88 1.61 500 6.68449198 1 Yes 
68 69 2R 150 Yes 59 1.89 0.88 500 8.47457627 1 Yes 
69 70 2R 150 Yes 55.5 1.87 1.53 500 9.00900901 1 Yes 
70 71 2R 150 Yes 54.4 1.87 1.81 500 9.19117647 1 Yes 
71 72 1S 150 Yes 12.3 1.96 0.42 500 40.6504065 3 Yes 
72 73 1S 150 Yes 71.7 1.89 1.8 500 6.9735007 1 Yes 
73 74 1S1C 150 Yes 79 1.88 2.12 500 6.32911392 1 Yes 
74 75 2S 150 Yes 70.7 1.88 2.06 500 7.07213579 1 Yes 
75 76 2C 150 Yes 82.2 1.88 1.08 500 6.08272506 1 Yes 
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76 77 2S 150 Yes 33.1 1.87 0.95 500 15.1057402 1 Yes 
77 78 1S1C 150 Yes 26.2 1.44 0.66 500 19.0839695 2 Yes 
78 87 1R1S 300 Yes 90.9 1.83 2.09 500 5.50055006 1 Yes 
79 90 2R 300 Yes 82.7 1.84 1.98 500 6.04594921 1 Yes 
80 91 2S 300 Yes 44.2 1.83 0.47 500 11.3122172 1 Yes 
81 92 1S1C 300 Yes 51.3 1.8 0.56 500 9.74658869 1 Yes 
82 93 2S 300 Yes 36.2 1.85 0.72 500 13.8121547 1 Yes 
83 94 2C 300 Yes 38.6 1.81 1.66 500 12.9533679 1 Yes 
84 95 1S1C 300 Yes 83.9 1.85 2.09 500 5.95947557 1 Yes 
85 96 1S1C 300 Yes 37.6 1.8 1.71 500 13.2978723 1 Yes 
86 98 2C 300 Yes 37.3 1.95 1.8 500 13.4048257 1 x 
87 100 2S 300 Yes 79.9 1.83 2.02 500 6.25782228 1 Yes 
88 103 1S1C 300 Yes 11 1.89 0.54 500 45.4545455 3 Yes 
89 104 1S1C 300 Yes 36.7 1.79 1.4 500 13.6239782 1 Yes 
90 108 2C 300 Yes 12.7 1.7 1.13 500 39.3700787 3 x 
91 109 1S1C 300 Yes 21.2 1.82 1 500 23.5849057 1 Yes 
92 110 1S1C 300 Yes 14.8 1.81 1.11 500 33.7837838 2 Yes 
93 113 2C 300 Yes 16.4 2.05 1.34 500 30.4878049 2 x 
94 114 2C 300 Yes 16.1 1.73 1.19 500 31.0559006 2 Yes 
95 117 2R 300 Yes 78.8 1.83 1.74 500 6.34517766 1 Yes 
96 118 2R 300 Yes 87.1 1.81 2.01 500 5.74052813 1 Yes 
97 119 2R 300 Yes 59.5 1.82 1.6 500 8.40336134 1 Yes 
98 120 2R 300 Yes 53 1.84 1.21 500 9.43396226 1 Yes 
99 121 2R 300 Yes 43.3 1.84 1.92 500 11.5473441 1 Yes 
100 122 1S1C 300 Yes 39.9 1.78 1.83 500 12.5313283 1 Yes 
101 123 1S1C 300 Yes 48.4 1.82 1.86 500 10.3305785 1 Yes 
102 124 2S 300 Yes 68.1 1.82 1.88 500 7.34214391 1 Yes 
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103 125 2S 300 Yes 58.8 1.84 1.44 500 8.50340136 1 Yes 
104 126 2S 300 Yes 50.2 1.81 1.93 500 9.96015936 1 Yes 
105 127 1S1C 300 Yes 43 1.85 1.78 500 11.627907 1 Yes 
106 129 2R 300 Yes 30.3 1.86 1.44 500 16.5016502 2 Yes 
107 130 2R 300 Yes 38.6 1.86 1.55 500 12.9533679 1 Yes 
108 131 2R 300 Yes 13.7 1.99 0.69 500 36.4963504 1 Yes 
109 132 2R 300 Yes 74.7 1.85 1.32 500 6.69344043 1 Yes 
110 133 1S1C 300 Yes 35 1.89 1.98 500 14.2857143 1 Yes 
111 134 2R 300 Yes 23.1 1.88 1.12 500 21.6450216 2 Yes 
112 135 2R 300 Yes 27.8 1.91 1.5 500 17.9856115 2 Yes 
113 136 2R 300 Yes 37.2 1.86 0.63 500 13.4408602 1 Yes 
114 137 2S 300 Yes 38.7 1.89 1.71 500 12.9198966 1 Yes 
115 138 2S 300 Yes 46 1.84 1.46 500 10.8695652 1 Yes 
116 139 2R 300 Yes 17.1 1.85 1.08 500 29.2397661 2 Yes 
117 140 2R 300 Yes 10.7 1.84 0.85 500 46.728972 3 Yes 
118 141 2R 300 Yes 146.7 1.85 2.03 500 3.40831629 1 Yes 
119 142 2C 300 Yes 34.7 1.89 1.69 500 14.4092219 1 x 
120 143 2R 300 Yes 19.5 1.91 1.21 500 25.6410256 2 Yes 
121 144 2R 300 Yes 87.5 1.87 1.63 500 5.71428571 1 Yes 
122 145 2S 300 Yes 45.8 1.82 1.48 500 10.9170306 1 Yes 
123 146 2S 300 Yes 22.9 1.95 1.68 500 21.8340611 2 Yes 
124 147 2S 300 Yes 36.3 1.88 1.82 500 13.7741047 1 Yes 
125 148 1S1C 300 Yes 18.2 1.85 1.42 500 27.4725275 2 Yes 
126 150 2R 300 Yes 78 1.85 1.1 500 6.41025641 1 Yes 
127 151 2S 300 Yes 41.8 1.93 1.87 500 11.9617225 1 Yes 
128 152 2S 300 Yes 29.9 1.92 1.74 500 16.722408 2 Yes 
129 153 2S 300 Yes 41.5 1.85 1.74 500 12.0481928 1 Yes 
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130 154 1S 300 Yes 39.2 1.87 0.51 500 12.755102 1 Yes 
131 155 2S 300 Yes 48.3 1.89 1.67 500 10.3519669 1 Yes 
132 156 2S 300 Yes 12 1.88 1.12 500 41.6666667 3 Yes 
133 157 2S 300 Yes 37.6 1.94 2.2 500 13.2978723 1 Yes 
134 158 2R 300 Yes 57.6 1.81 2.13 500 8.68055556 1 Yes 
135 159 2S 300 Yes 72.6 1.88 2.09 500 6.88705234 1 Yes 
136 160 2C 300 Yes 67.5 1.91 2.14 500 7.40740741 1 x 
137 161 2R 300 Yes 39.3 1.9 1.69 500 12.7226463 1 Yes 
138 162 2R 300 Yes 72.7 1.89 1.94 500 6.87757909 1 Yes 
139 163 2R 300 Yes 83.2 1.87 2.18 500 6.00961538 1 Yes 
140 164 2R 300 Yes 63.4 1.86 1.6 500 7.88643533 1 Yes 
141 165 2R 300 Yes 68.1 1.87 0.96 500 7.34214391 1 Yes 
142 166 2R 300 Yes 109 1.86 2.15 500 4.58715596 1 Yes 
143 167 2R 300 Yes 101.2 1.88 1.93 500 4.94071146 1 Yes 
144 168 2R 300 Yes 65.1 1.89 2.05 500 7.68049155 1 Yes 
145 169 2R 300 Yes 48.9 1.9 1.76 500 10.2249489 1 Yes 
146 171 2R 300 Yes 87.7 1.92 1.32 500 5.70125428 1 Yes 
147 172 2R 300 Yes 67 1.9 2.05 500 7.46268657 1 Yes 
148 173 2R 300 Yes 96.8 1.87 1.34 500 5.16528926 1 Yes 
149 174 2R 300 Yes 80.2 1.89 1.7 500 6.23441397 1 Yes 
150 175 2R 300 Yes 63.4 1.87 1.66 500 7.88643533 1 Yes 
151 176 2R 300 Yes 84.9 1.88 1.72 500 5.88928151 1 Yes 
152 178 2R 300 Yes 103 1.77 1.01 500 4.85436893 1 Yes 
153 179 2R 300 Yes 116 1.89 1.26 500 4.31034483 1 Yes 
154 180 2S 300 Yes 104.4 1.87 0.73 500 4.78927203 1 Yes 
155 181 2R 300 Yes 78.6 1.88 2.27 500 6.36132316 1 Yes 
156 182 2R 300 Yes 73.5 1.89 2.38 500 6.80272109 1 Yes 
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157 183 2R 300 Yes 49.5 1.92 1.11 500 10.1010101 1 Yes 
158 184 2S 300 Yes 82.5 1.89 2.01 500 6.06060606 1 Yes 
159 185 2R 300 Yes 88.2 1.89 2.31 500 5.66893424 1 Yes 
160 186 2R 300 Yes 113.5 1.89 1.98 500 4.40528634 1 Yes 
161 187 2R 300 Yes 82.3 1.88 1.69 500 6.07533414 1 Yes 
162 188 2R 300 Yes 107.6 1.87 2.2 500 4.64684015 1 Yes 
163 189 2R 300 Yes 77 1.89 1.48 500 6.49350649 1 Yes 
164 190 2R 300 Yes 40.9 1.89 1.42 500 12.2249389 1 Yes 
165 191 2R 300 Yes 62.9 1.75 2.17 500 7.9491256 1 Yes 
166 192 2C 300 Yes 93.8 1.89 2.08 500 5.33049041 1 x 
167 193 2S 300 Yes 143.8 1.88 1.12 500 3.47705146 1 Yes 
168 194 2R 300 Yes 98 1.86 2.14 500 5.10204082 1 Yes 
169 195 2R 300 Yes 97.6 1.86 1.92 500 5.12295082 1 Yes 
170 196 2R 300 Yes 94.3 1.86 1.97 500 5.30222694 1 Yes 
171 197 2R 300 Yes 134.9 1.86 1.88 500 3.70644922 1 Yes 
172 198 2S 300 Yes 61.2 1.9 1.36 500 8.16993464 1 Yes 
173 200 2S 300 Yes 47.1 1.86 1.92 500 10.6157113 1 Yes 
174 201 2S 300 Yes 72.3 1.86 1.92 500 6.91562932 1 Yes 
175 202 2S 300 Yes 69.3 1.86 1.4 500 7.21500722 1 Yes 
176 203 R2 300 Yes 105.6 1.86 2.08 500 4.73484848 1 Yes 
177 204 C2 300 Yes 24.9 1.83 0.15 500 20.0803213 2 Yes 
178 205 R2 300 Yes 90.2 1.86 1.82 500 5.54323725 1 Yes 
179 206 R2 300 Yes 76.7 1.85 1.64 500 6.51890482 1 Yes 
180 207 R2 300 Yes 69.7 1.87 2.03 500 7.17360115 1 Yes 
181 208 R1S1 300 Yes 83.6 1.87 2 500 5.98086124 1 Yes 
182 209 2S 300 Yes 34.3 1.88 1.73 500 14.5772595 1 Yes 
183 210 2S 300 Yes 35.9 1.91 1.57 500 13.9275766 1 Yes 
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184 211 2S 300 Yes 38.8 1.91 1.7 500 12.8865979 1 Yes 
185 212 2S 300 Yes 42.8 1.85 1.84 500 11.682243 1 Yes 
186 213 2S 300 Yes 64.7 1.89 1.95 500 7.72797527 1 Yes 
187 214 2S 300 Yes 71.2 1.87 1.8 500 7.02247191 1 Yes 
188 215 R2 300 Yes 82 1.87 1.38 500 6.09756098 1 Yes 
189 216 2S 300 Yes 84.3 1.87 1.56 500 5.9311981 1 Yes 
190 217 2S 300 Yes 80 1.86 1.58 500 6.25 1 Yes 
191 218 2S 300 Yes 50.8 1.91 1.86 500 9.84251969 1 Yes 
192 219 2S 300 Yes 38.6 1.91 2 500 12.9533679 1 Yes 
193 220 2S 300 Yes 49.8 1.87 1.74 500 10.0401606 1 Yes 
194 221 2S 300 Yes 59.2 1.87 2.02 500 8.44594595 1 Yes 
195 222 2S 300 Yes 55.1 1.88 2.05 500 9.07441016 1 Yes 
196 223 2S 300 Yes 51.2 1.89 1.93 500 9.765625 1 Yes 
197 224 2S 300 Yes 76.2 1.88 2.03 500 6.56167979 1 Yes 
198 225 2S 300 Yes 85 1.84 1.86 500 5.88235294 1 Yes 
199 226 2S 300 Yes 94.7 1.86 2.04 500 5.27983105 1 Yes 
200 227 2S 300 Yes 99.5 1.87 2.04 500 5.02512563 1 Yes 
201 228 2S 300 Yes 26.9 1.94 1.54 500 18.5873606 2 Yes 
202 229 2S 300 Yes 60 1.88 1.8 500 8.33333333 1 Yes 
203 230 2S 300 Yes 91.2 1.86 2.02 500 5.48245614 1 x 
204 231 2S 300 Yes 97.7 1.85 1.55 500 5.11770727 1 x 
205 232 2S 300 Yes 78.1 1.87 1.99 500 6.40204866 1 x 
206 233 2S 300 Yes 86.3 1.85 1.88 500 5.79374276 1 x 
207 234 2S 300 Yes 76.6 1.85 1.88 500 6.52741514 1 x 
208 235 2S 300 Yes 78 1.86 1.95 500 6.41025641 1 x 
209 236 2S 300 Yes 110.4 1.86 1.56 500 4.52898551 1 x 
210 237 2S 300 Yes 99.4 1.86 1.56 500 5.03018109 1 x 
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211 238 2S 300 Yes 77.2 1.85 1.17 500 6.47668394 1 x 
212 239 2S 300 Yes 48.6 1.86 1.9 500 10.2880658 1 x 
213 240 2S 300 Yes 73.9 1.87 1.98 500 6.76589986 1 x 
214 241 2S 300 Yes 98.5 1.85 1.81 500 5.07614213 1 x 
215 242 2S 300 Yes 92.2 1.86 2.1 500 5.42299349 1 x 
216 243 2S 300 Yes 113.7 1.86 2.03 500 4.39753738 1 x 
217 244 2S 300 Yes 86 1.85 1.17 500 5.81395349 1 x 
218 245 2S 300 Yes 87 1.86 1.83 500 5.74712644 1 x 
219 246 2S 300 Yes 43 1.88 1.65 500 11.627907 1 x 
220 247 2S 300 Yes 39.4 1.84 1.25 500 12.6903553 1 x 
221 248 2S 300 Yes 126.2 1.86 1.38 500 3.96196513 1 x 
222 249 2S 300 Yes 95.7 1.87 1.79 500 5.2246604 1 x 
223 250 2S 300 Yes 68.8 1.88 1.85 500 7.26744186 1 x 
224 251 2S 300 Yes 48.4 1.87 1.78 500 10.3305785 1 x 
225 252 2S 300 Yes 76.4 1.86 0.69 500 6.54450262 1 x 
226 253 2S 300 Yes 71.8 1.87 1.97 500 6.9637883 1 x 
227 254 2S 300 Yes 83.2 1.85 1.71 500 6.00961538 1 x 
228 255 2S 300 Yes 117.9 1.89 2.02 500 4.2408821 1 x 
229 256 2S 300 Yes 118.5 1.89 0.87 500 4.21940928 1 x 
230 257 2S 300 Yes 99.2 1.91 1.23 500 5.04032258 1 x 
231 258 2S 300 Yes 113.7 1.89 2.1 500 4.39753738 1 x 
232 259 2S 300 Yes 94.4 1.82 1.79 500 5.29661017 1 x 
233 260 2S 300 Yes 116.5 1.59 0.89 500 4.29184549 1 x 
234 261 2S 300 Yes 109 1.83 1.91 500 4.58715596 1 x 
235 262 2S 300 Yes 119.5 1.87 1.48 500 4.18410042 1 x 
236 263 2S 300 Yes 120.9 1.86 1.72 500 4.1356493 1 x 
237 264 2S 300 Yes 140.7 1.87 1.21 500 3.55366027 1 x 
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238 265 2S 300 Yes 93.1 1.88 2.01 500 5.37056928 1 x 
239 266 2S 300 Yes 120.1 1.85 1.83 500 4.16319734 1 x 
240 267 2S 300 Yes 143.4 1.88 0.79 500 3.48675035 1 x 
241 268 2S 300 Yes 76.7 1.87 1.44 500 6.51890482 1 x 
242 269 2S 300 Yes 120.5 1.93 1.78 500 4.14937759 1 x 
243 270 2S 300 Yes 133 1.85 0.95 500 3.7593985 1 x 
244 271 2S 300 Yes 101.3 1.86 1.85 500 4.93583416 1 x 
245 272 2S 300 Yes 106.8 1.85 1.75 500 4.68164794 1 x 
246 273 2S 300 Yes 127.1 1.85 1.58 500 3.93391031 1 x 
247 274 2S 300 Yes 130.2 1.86 1.58 500 3.84024578 1 x 
248 275 2S 300 Yes 17 2.05 0.25 500 29.4117647 1 x 
249 276 2S 300 Yes 25.9 1.89 0.3 500 19.3050193 2 x 
250 277 2S 300 Yes 28 1.9 0.36 500 17.8571429 2 x 
251 278 2S 300 Yes 65.6 1.85 0.58 500 7.62195122 1 x 
252 279 2S 300 Yes 64 1.82 0.59 500 7.8125 1 x 
253 280 2S 300 Yes 38.1 1.82 0.59 500 13.1233596 1 x 
254 281 2S 300 Yes 40.4 1.81 1.56 500 12.3762376 1 x 
 
Key: Appearance: Format = Number of cryovials:Appearance e.g. 1R = 1 cryovial of red buffy.  2S = 2 cryovials of blood stained buffy  
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Appendix D: Summary of Raw Mean Telomere Length Data 
 
 
Study 
ID 
T/S  1 T/S 2 T/S  3 T/S Final Study 
ID 
T/S  1 T/S 2 T/S  3 T/S Final Study 
ID 
T/S  1 T/S 2 T/S  3 T/S Final 
1 0.7691 
  
0.7691181 31 0.77505 
  
0.775052 62 0.572797 
  
0.572797 
2 0.7353 0.7731 0.7775 0.777452 32 0.8176 
  
0.817601 63 0.843467 
  
0.843467 
3 0.755 
  
0.7550166 33 0.83377 
  
0.833773 64 0.876335 1.012587 
 
1.012587 
4 0.5314 
  
0.5313573 35 0.95093 
  
0.95093 65 0.545709 
  
0.545709 
5 0.4964 
  
0.4963898 36 0.84777 
  
0.847767 66 0.92244 
  
0.92244 
6 0.596 
  
0.5959936 37 1.21238 0.65946 0.60286 0.602862 67 0.53386 0.591867 
 
0.591867 
7 0.7534 
  
0.7533878 38 1.0206 
  
1.020601 68 0.525219 
  
0.525219 
8 0.6927 0.6465 
 
0.646453 39 0.8536 
  
0.853603 69 0.621405 0.569191 
 
0.569191 
9 0.6854 
  
0.6854182 40 0.55171 
  
0.551708 70 0.74712 
  
0.74712 
10 0.6608 0.4541 0.4926 0.4925825 41 0.94481 
  
0.944814 71 0.735724 0.5572 
 
0.5572 
11 0.5281 
  
0.5280941 42 2.65827 0.60166 
 
0.601658 72 0.805654 
  
0.805654 
12 0.7383 
  
0.7383283 43 0.83412 
  
0.834118 73 0.464579 0.692081 
 
0.692081 
13 0.6171 
  
0.6170906 44 0.90013 
  
0.900134 74 0.96183 0.814369 0.610074 0.610074 
14 0.6799 
  
0.6799047 45 2.20697 0.60463 
 
0.604626 75 0.558867 
  
0.558867 
15 0.6939 
  
0.6938865 46 0.8877 
  
0.887697 76 0.990751 
  
0.990751 
16 0.5953 
  
0.595271 47 0.93901 
  
0.939009 77 0.903326 
  
0.903326 
17 0.5241 
  
0.5240863 48 1.01484 
  
1.014844 78 0.831409 
  
0.831409 
18 0.6693 
  
0.6693325 49 5.08813 0.96225 
 
0.962251 87 0.541213 
  
0.541213 
19 0.6762 0.6493 
 
0.6492813 50 1.35521 1.0179 
 
1.017899 90 0.771617 
  
0.771617 
20 0.8847 
  
0.884704 51 4.02558 0.74267 0.6389 0.638898 91 0.558571 0.486162 0.471453 0.471453 
21 0.7532 
  
0.7531748 52 0.88504 
  
0.885039 92 0.556429 0.538087 
 
0.538087 
22 0.9372 
  
0.9371509 53 0.83957 
  
0.839568 93 0.618705 0.859502 
 
0.859502 
23 0.8881 
  
0.8880516 54 0.88377 
  
0.88377 94 0.620535 
  
0.620535 
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24 0.9879 
  
0.9878738 55 0.85145 
  
0.851446 95 0.583098 
  
0.583098 
Study 
ID 
T/S  1 T/S 2 T/S  3 T/S Final Study 
ID 
T/S  1 T/S 2 T/S  3 T/S Final Study 
ID 
T/S  1 T/S 2 T/S  3 T/S Final 
25 0.9195 
  
0.9194587 56 0.96062 
  
0.960616 96 0.487092 
  
0.487092 
26 0.9534 
  
0.9534402 57 5.06702 0.69446 0.6207 0.620699 98 1.084802 0.96483 
 
0.96483 
27 1.0182 
  
1.0182439 58 0.9173 
  
0.917295 100 0.755722 
  
0.755722 
28 0.7274 
  
0.7273931 59 0.58734 0.71574 
 
0.715742 103 0.870569 
  
0.870569 
29 0.6859 0.8436 
 
0.8436333 60 0.69213 
  
0.692129 104 0.68793 
  
0.68793 
30 0.8443 
  
0.8443377 61 0.84752 
  
0.847515 108 0.891704 
  
0.891704 
109 0.933 
  
0.9329684 144 0.56884 
  
0.568841 176 0.799795 
  
0.799795 
110 0.819 
  
0.8189537 145 0.39369 
  
0.393685 178 0.709387 0.595625 
 
0.595625 
113 0.9246 
  
0.9246041 146 0.5371 0.52133 
 
0.521331 179 0.989579 
  
0.989579 
114 0.938 
  
0.9380321 147 0.48966 
  
0.489664 180 0.975856 
  
0.975856 
117 0.8762 
  
0.8761916 148 0.85887 0.70357 
 
0.703573 181 0.591518 0.484642 
 
0.484642 
118 0.9648 
  
0.9647781 150 0.68832 
  
0.688322 182 0.829818 0.580417 
 
0.580417 
119 0.8489 
  
0.8488622 151 0.52327 
  
0.523268 183 0.859469 0.614647 
 
0.614647 
120 0.8038 
  
0.8037888 152 0.74808 
  
0.748082 184 0.653424 
  
0.653424 
121 0.8866 
  
0.8865818 153 0.81981 
  
0.819806 185 0.929291 
  
0.929291 
122 0.8257 
  
0.8257062 154 0.71099 
  
0.710991 186 0.888071 
  
0.888071 
123 1.0196 
  
1.0196224 155 0.65525 
  
0.655254 187 1.027417 
  
1.027417 
124 0.5435 
  
0.5434836 156 0.54753 
  
0.547532 188 0.904107 
  
0.904107 
125 0.928 
  
0.9279616 157 0.59265 
  
0.592645 189 0.865072 
  
0.865072 
126 0.5762 
  
0.5762443 158 0.82503 
  
0.82503 190 1.022295 
  
1.022295 
127 0.6042 
  
0.6042463 159 0.75849 
  
0.758493 191 0.695009 0.546966 
 
0.546966 
129 0.7965 
  
0.7964663 160 0.75785 
  
0.757853 192 0.646575 
  
0.646575 
130 0.9405 
  
0.9404829 161 0.8515 
  
0.851502 193 0.595057 
  
0.595057 
131 0.9765 
  
0.9764963 162 0.70676 
  
0.706758 194 0.96992 
  
0.96992 
132 0.6201 
  
0.6200614 163 0.78096 
  
0.780959 195 0.907453 
  
0.907453 
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133 0.6084 
  
0.6083699 164 0.73251 
  
0.732513 196 1.081752 
  
1.081752 
134 0.614 
  
0.614015 165 0.89135 
  
0.89135 197 0.619257 
  
0.619257 
135 0.588 
  
0.5880364 166 0.97347 
  
0.973469 198 0.768462 0.819108 
 
0.768462 
Study 
ID 
T/S  1 T/S 2 T/S  3 T/S Final Study 
ID 
T/S  1 T/S 2 T/S  3 T/S Final Study 
ID 
T/S  1 T/S 2 T/S  3 T/S Final 
136 0.6437 
  
0.6437223 167 0.79319 0.8802 
 
0.880203 200 0.559602 
  
0.559602 
137 0.6332 0.5247 
 
0.524704 168 0.8025 1.19741 0.78346 0.783458 201 0.637447 
  
0.637447 
138 0.5754 0.5811 
 
0.5811403 169 0.93537 
  
0.935372 202 0.723327 0.801839 
 
0.801839 
139 1.1509 
  
1.1508512 171 0.89661 
  
0.896613 203 0.584141 
  
0.584141 
140 0.8932 
  
0.8931637 172 0.86841 
  
0.868407 204 0.655748 
  
0.655748 
141 0.573 
  
0.5729943 173 0.76692 
  
0.766916 205 0.77831 0.805584 
 
0.805584 
142 0.7258 
  
0.7258374 174 0.89595 
  
0.895949 206 0.916677 
  
0.916677 
143 0.6015 0.6309 
 
0.6309174 175 0.77152 
  
0.771518 207 0.929516 
  
0.929516 
208 0.7509 0.8488 
 
0.8488464 238 0.588 
  
0.587996 268 2.168728 0.799132 
 
0.799132 
209 0.5776 
  
0.5776419 239 0.44473 
  
0.444728 269 0.705047 0.941194 
 
0.941194 
210 0.5954 
  
0.5953521 240 1.05692 
  
1.056923 270 0.19577 0.519971 
 
0.519971 
211 0.9256 
  
0.9255678 241 0.73184 
  
0.731837 271 0.552628 
  
0.552628 
212 0.6297 
  
0.629707 242 0.90851 
  
0.908506 272 0.557005 
  
0.557005 
213 0.7586 0.5802 
 
0.5802039 243 0.75732 
  
0.757324 273 0.575372 
  
0.575372 
214 0.6547 
  
0.6547161 244 0.66278 
  
0.662779 274 0.513386 
  
0.513386 
215 0.8577 
  
0.8577077 245 0.70833 0.56284 
 
0.562842 275 1.079305 0.837042 
 
0.837042 
216 1.1725 
  
1.1725016 246 0.65333 
  
0.65333 276 0.999177 
  
0.999177 
217 0.6584 
  
0.6583899 247 0.62025 
  
0.620253 277 0.924364 
  
0.924364 
218 0.5047 
  
0.5046734 248 0.83117 
  
0.831175 278 0.921899 0.73712 
 
0.73712 
219 0.9889 
  
0.9889018 249 0.60759 
  
0.607591 279 0.782866 
  
0.782866 
220 0.5443 
  
0.5443161 250 0.60771 
  
0.607706 280 0.961422 
  
0.961422 
221 0.7435 0.7923 
 
0.7922687 251 0.90143 
  
0.901434 281 0.886769 
  
0.886769 
222 1.0125 0.8676 
 
0.8676324 252 0.72831 0.82189 
 
0.821888   
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223 0.541 
  
0.5409983 253 0.75994 
  
0.75994   
    
224 0.5953 
  
0.5952591 254 0.85033 
  
0.850331   
    
225 0.7417 0.8655 
 
0.865525 255 0.58038 
  
0.580379   
    
226 0.9007 
  
0.9007206 256 0.5649 
  
0.564905   
    
227 0.738 0.8536 
 
0.853584 257 0.86641 
  
0.866412   
    
Study 
ID 
T/S  1 T/S 2 T/S  3 T/S Final Study 
ID 
T/S  1 T/S 2 T/S  3 T/S Final Study 
ID 
T/S  1 T/S 2 T/S  3 T/S Final 
228 0.6923 0.7541 
 
0.7540571 258 0.89701 
  
0.897008   
    
229 0.6196 
  
0.619586 259 0.69665 0.76769 
 
0.767695   
    
230 1.0062 
  
1.0062014 260 0.96706 
  
0.967065   
    
231 0.6151 
  
0.6150693 261 0.66882 0.54039 
 
0.540391   
    
232 0.6304 
  
0.6303584 262 0.62681 
  
0.626811   
    
233 0.5942 
  
0.59423 263 1.06672 0.89773 
 
0.897726   
    
234 0.5979 
  
0.5979346 264 0.5424 
  
0.542397   
    
235 0.5955 
  
0.5954693 265 0.89936 
  
0.899359   
    
236 0.6188 0.7447 
 
0.7447205 266 0.85785 
  
0.857855   
    
237 0.8373 
  
0.8372643 267 0.90342 0.93363 
 
0.933635   
    
 
 
Table 1: Summary of raw data for mTL measurement. Red values indicate a failed measurement where by the Intra-assay coefficient of variation for duplicate 
samples was >10%. Such failed measurements were repeated. T/S = Telomere/Standard Ratio. ‘T/S Final’ represents the final value of T/S ratio (also known as 
mean telomere length) used in subsequent analysis.  
 
 
 
 
 
 
 
300  
Run Tel R2 Tel Efficiency Std R2 Std 
Efficiency 
Std TS 
T/S  
Std A T/S  Std B T/S  Std C T/S  Std D T/S  
  
0-19 0.998 0.99 0.991 1.14 0.995208 1.076866 0.941808 0.920313 1.076531 
  
20-39 0.998 1.06 0.999 1.17 0.991289 1.022454 0.972661 1.024108 0.990489 
  
40-57 0.999 1.05 0.998 1.17 0.998978 0.990347 1.026843 0.980404 1.004031 
  
58-76 0.995 1.01 0.998 1.17 1.037844 0.977785 0.960402 0.986258 1.026444 
  
77-114 0.998 1.09 0.997 1.17 1.036938 0.954739 0.974334 1.046933 0.990229 
  
117-136 0.998 1.05 0.998 1.15 1.004375 0.983261 1.006525 1.020377 0.985939 
  
137-156 0.994 1.14 0.999 1.14 0.948342 1.069402 1.010353 0.990307 0.985487 
  
157-176 0.991 0.95 0.997 1.11 0.975089 1.038772 1.026315 0.936916 1.026725 
  
178-196 0.999 1.04 0.994 1.04 1.050179 0.953885 0.989916 0.966631 1.043233 
  
197-216 0.999 1.04 0.999 1.04 1.031062 0.987239 0.973101 0.971135 1.039576 
  
217-235 0.999 1.05 0.999 1.14 0.982381 1.0201 1.000259 1.010944 0.98682 
  
236-254 0.994 1.07 0.999 1.15 0.967439 1.090629 0.945079 0.985232 1.017872 
  
255-273 0.999 1.03 0.998 1.19 0.977376 1.046748 0.986409 0.982004 1.009081 
  
274-281 0.999 1.05 0.999 1.16 1.013186 0.998758 0.963761 1.025474 0.9999 
  
Repeat 1 0.997 1.12 0.999 1.2 0.967511 1.012821 1.031828 1.061084 0.945251 
  
Repeat 2 0.999 1.06 0.999 1.14 1.012162 1.002702 0.964848 1.015235 1.005894 
  
Repeat 3 0.998 1.06 0.998 1.14 1.009873 0.996318 1.022004 0.996458 0.992727 
  
Repeat 4 0.998 1.09 0.998 1.16 1.042169 0.961994 0.968281 1.017465 1.012438 
  
Repeat 5 0.999 1.08 0.999 1.15 1.006242 1.003559 0.980015 1.004836 1.005602 
  
Repeat 6 0.995 1.02 0.998 1.16 0.981617 1.056847 0.9646 0.980621 1.019055 
  
Average 0.997263 1.055789474 0.998158 1.144736842 1.001792 1.008861 0.987765 1.000127 1.004568 Average 1.000623           
CV 0.029097 
 
 
Table 2: Summary of the T/S ratio values for all of the standards in each run of the mTL and CSA-AKI experiment. All standards should have a value of 1 I 
measured with 100% accuracy. The Average overall inter-assay CV value of all of the standards in all of the runs was 2.91%.   
301  
 
Appendix E: Normality test results 
 
 
 Normally distributed Combined 
AKI No AKI 
Length of post-op stay Not normal Not normal Not normal 
Age Not normal Not normal Not normal 
BMI Normal Not normal Not normal 
Extubation day Not normal Not normal Not normal 
Vasopressor day Not normal Not normal Not normal 
Inotrope day Not normal Not normal Not normal 
1st Hb in ITU Normal Normal Normal 
UO 1st 12 hours Normal Not normal Not normal 
Pre WCC Normal Not normal Not normal 
Pre INR Not normal Not normal Not normal 
Pre APTT Not normal Not normal Not normal 
Pre CRP Not normal Not normal Not normal 
D1 CRP Not normal Not normal Not normal 
D2 CRP Normal Not normal Not normal 
D3 CRP Normal Normal Not normal 
Pre Hb Normal Not normal Not normal 
D1 Hb Normal  Not normal Not normal 
Hb Diff Normal Not normal Not normal 
Bypass time Not normal Not normal Not normal 
Xclamp time Not normal Not normal Not normal 
Euroscore 2 Not normal Not normal Not normal 
Log EuroSCORE Not normal Not normal Not normal 
T/S ratio Normal Not normal Not normal 
 
Table 1: Summary of Normality tests for continuous variables for 
population used in Telomere length experiment (N=254). Shapiro-Wilks 
normality tests were calculated for the dataset as a whole and 
separately for the two cohorts; AKI and No-AKI. 
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Table 2: Additional normality tests for the DNAm cohort. Shapiro-Wilks 
normality tests were calculated for the dataset as a whole and 
separately for the two cohorts; AKI and No-AKI. 
 Normally distributed Combined 
AKI No AKI 
Age Not normal Not normal Not normal 
Predicted age Normal Not normal Not normal 
AMAR Normal Not normal Not normal 
Delta Age Normal Not normal Not normal 
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Appendix F: Propensity matched analysis of mTL and CSA-AKI 
 
Pair Study 
No. 
PODDAYS AGE GENDER ETHNIC OP DM LVEF AF sCR-
PRE 
AKI BYPASS 
TIME 
EUSCORE BMI SCORE 
                
1 73 11.24 61 1 1 1 0 1 0 88 1 72 2 30.8113 0.06584381 
1 58 6.78 68 1 1 2 0 1 0 84 0 96 4 29.9836 0.06682701 
2 191 10.1 56 1 2 5 0 1 0 60 1 76 2 21.304 0.08283217 
2 193 10.31 73 2 1 6 0 1 0 47 0 141 9 25.7778 0.08250884 
3 147 6.29 56 1 1 5 0 1 0 44 1 89 2 30.0947 0.08667486 
3 253 6.99 55 1 1 1 0 1 0 82 0 99 2 29.8028 0.08645776 
4 202 8 79 2 1 2 0 1 0 83 1 105 7 33.3109 0.08726834 
4 184 6.21 76 1 1 5 0 1 0 83 0 62 6 26.6749 0.08728066 
5 197 6.06 78 1 1 1 0 1 0 84 1 80 4 26.8544 0.09473302 
5 241 5.38 57 2 1 1 0 3 0 54 0 71 2 26.8977 0.0942969 
6 234 6.34 69 1 1 2 0 1 1 82 1 80 4 32.6048 0.1021873 
6 248 6.22 35 1 6 5 0 1 0 72 0 127 5 22.2222 0.1009649 
7 21 9.17 71.8 1 2 1 0 1 0 94 1 90 3 27.7634 0.1121 
7 156 6.17 78 1 1 1 0 2 1 95 0 38 6 31.6032 0.1127396 
8 220 6.31 48 1 1 1 0 1 0 79 1 126 0 36.5714 0.1260039 
8 96 6.17 48 1 1 1 1 1 0 90 0 78 1 26.2917 0.1265762 
9 158 60.42 79 2 1 6 0 1 0 69 1 156 8 29.4078 0.1495878 
9 37 6.35 86.7 2 1 5 0 1 0 77 0 97 10 32.6531 0.1493701 
304  
10 242 9.25 22 2 1 8 0 1 0 74 1 151 3 19.6506 0.1589347 
10 100 4.42 61 1 1 1 1 2 0 74 0 68 1 37.2907 0.1584779 
11 125 7.33 48 1 3 5 0 1 1 104 1 74 2 26.8817 0.173779 
11 178 20.15 72 2 2 1 1 1 0 98 0 75 6 19.9219 0.1722029 
12 145 8.08 76 1 2 1 1 1 0 100 1 91 8 31.6406 0.1749929 
12 70 6.12 69 1 2 4 1 1 0 65 0 91 4 22.9854 0.1752035 
13 187 15.33 37 2 1 6 0 2 0 87 1 187 4 38.2934 0.1838453 
13 18 6.16 75 2 4 1 1 2 0 74 0 63 4 30.4076 0.1846173 
14 252 13.13 72 1 2 2 1 1 0 80 1 117 5 32.7449 0.1852779 
14 54 5.38 81 2 1 1 1 1 0 60 0 88 6 30.5469 0.1850721 
15 155 7.29 79 1 2 1 0 2 0 94 1 106 5 25.2174 0.1910897 
15 238 6.13 55 1 2 1 1 1 0 93 0 91 0 29.4029 0.1940985 
16 192 8.19 83 1 2 4 1 1 0 65 1 99 8 19.433 0.2014911 
16 110 6.38 67 2 1 1 0 1 1 53 0 151 3 164 0.2004985 
17 228 13.12 87 1 1 5 0 1 1 104 1 62 8 26.5338 0.2126732 
17 40 72.01 77.6 2 1 5 0 1 1 126 0 55 7 35.4917 0.2098464 
18 45 7.09 74.2 2 1 5 0 1 1 74 1 76 6 23.2434 0.2157771 
18 134 15.25 69 2 1 5 1 1 0 60 0 86 5 31.1634 0.2194067 
19 262 7.19 66 1 2 1 1 1 0 94 1 93 2 26.6436 0.2214391 
19 55 15.16 77 1 2 1 0 1 0 103 0 134 5 29.7143 0.2222452 
20 140 7.17 66 1 1 1 0 2 1 68 1 96 2 28.2828 0.2382479 
20 189 5.11 71 1 1 1 0 1 1 67 0 109 3 22.8571 0.236327 
21 168 9.15 66 1 6 1 1 1 0 98 1 97 2 27.1416 0.2395645 
305  
21 59 11.38 68 1 6 1 0 2 1 88 0 99 5 30.4705 0.2365149 
22 165 6.29 37 1 1 5 0 1 0 90 1 174 5 22.2041 0.24338 
22 103 7.41 63 1 1 6 0 1 1 60 0 170 6 26.7299 0.2406059 
23 257 7.12 64 1 2 1 0 1 1 108 1 100 2 25.9645 0.2476401 
23 175 4.99 53 1 1 1 0 2 0 98 0 137 0 27.4286 0.2528579 
24 274 8.13 83 1 1 1 0 1 1 112 1 90 5 31.25 0.2547375 
24 169 7 72 1 2 2 1 2 0 109 0 112 6 27.7551 0.2537259 
25 136 7.2 72 1 6 5 1 1 0 86 1 102 7 31.2213 0.2679744 
25 109 8.35 65 2 2 5 1 1 0 117 0 87 6 34.9277 0.2691322 
26 104 6 68 2 1 5 1 2 0 92 1 73 5 31.139 0.277572 
26 264 37.94 70 1 1 1 1 3 0 74 0 109 8 27.4286 0.281325 
27 94 6.29 61 1 2 1 1 1 0 130 1 103 2 24.977 0.2894116 
27 150 5.19 76 2 1 1 1 2 0 146 0 74 6 37.3333 0.2907817 
28 243 12.18 62 1 2 1 1 2 1 105 1 80 6 25.7117 0.3145462 
28 277 5.57 69 1 5 1 0 1 1 81 0 123 2 26.7299 0.3118661 
29 269 6.33 70 1 1 1 0 1 1 111 1 119 3 25.344 0.3379006 
29 131 5.21 81 2 1 5 1 1 0 90 0 112 10 30.8185 0.3353188 
30 171 6.38 49 1 1 1 1 3 1 82 1 90 3 38.4243 0.3496264 
30 114 10.08 62 1 1 6 0 2 1 98 0 185 10 30.6689 0.3413568 
31 196 22.33 74 1 6 1 1 2 0 74 1 121 4 26.7949 0.3605377 
31 142 6.35 51 1 1 5 1 2 1 63 0 87 3 31.4627 0.359803 
32 132 7.14 61 2 2 1 1 2 0 78 1 136 4 32.4444 0.3783121 
32 118 8.38 24 2 1 5 0 2 1 61 0 195 9 32.4219 0.371208 
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33 35 8.2 63.2 1 3 2 0 2 0 83 1 204 4 27.9904 0.3822599 
33 225 10.15 72 2 1 4 0 2 1 73 0 151 10 24.3418 0.3886476 
34 93 9.35 68 1 1 1 1 2 1 74 1 96 4 30.9917 0.390415 
34 6 12.17 77.7 1 1 1 1 1 0 101 0 130 4 31.7901 0.3921399 
35 46 68.92 79.7 1 1 1 1 2 1 66 1 87 4 32.9287 0.4041749 
35 255 5.9 67 1 2 1 1 1 0 116 0 129 2 25.4028 0.4037426 
36 117 8.29 63 1 1 5 0 1 1 66 1 140 3 26.0617 0.4083235 
36 216 16.23 79 1 1 3 0 1 1 77 0 127 9 25.7276 0.4108442 
37 129 26.25 77 1 1 1 1 2 1 94 1 80 4 22.3863 0.4284192 
37 173 8.29 68 2 1 5 0 1 0 85 0 171 5 30.4878 0.4129123 
38 31 27.29 68.6 2 1 2 0 1 1 43 1 203 5 34.7078 0.4426372 
38 41 17.32 72 1 1 6 0 2 1 77 0 177 6 24.6755 0.4187496 
39 146 9.23 41 2 1 5 0 1 0 57 1 225 4 32.05 0.4474889 
39 275 10 84 2 1 2 1 2 0 69 0 165 10 23.7812 0.419258 
40 198 34.35 63 2 2 5 1 1 1 123 1 93 7 27.1809 0.4576877 
40 63 11.36 29 1 1 5 1 1 0 60 0 190 3 23.2317 0.4224392 
41 265 17.08 81 1 1 5 1 1 0 197 1 95 9 29.7578 0.4596599 
41 270 7.42 83 1 2 2 1 1 1 75 0 136 7 31.2452 0.4252106 
42 261 6.31 82 1 1 2 0 1 1 141 1 163 7 36.3636 0.4652047 
42 176 5.01 64 1 1 1 1 1 1 83 0 109 1 26.4721 0.4361532 
43 113 6.36 63 1 1 6 0 2 0 98 1 241 7 34.5581 0.4661489 
43 205 7.1 79 1 1 5 0 1 1 98 0 129 6 32.7449 0.4482423 
44 11 8.42 77.8 2 1 5 0 1 1 64 1 153 8 30.0781 0.4746976 
307  
44 71 5.27 62 1 1 5 0 1 1 84 0 145 3 31.6735 0.4516594 
45 8 8.35 70.5 2 1 1 1 2 1 71 1 130 5 20.3428 0.5816468 
45 60 7.36 80 1 1 2 0 1 1 91 0 191 7 27.0416 0.4921081 
46 76 38.75 53 1 3 8 0 1 0 122 1 220 5 36.2902 0.5867481 
46 120 15.99 79 1 1 2 0 3 1 88 0 173 9 23.8624 0.5149401 
47 181 26.29 77 1 1 3 0 1 1 110 1 155 9 26.7698 0.5891558 
47 137 14.33 33 1 1 8 0 1 0 71 0 254 5 24.9308 0.5281161 
48 39 10.14 80.5 2 1 5 1 1 1 113 1 115 8 20.5761 0.6338254 
48 2 15.43 69.9 1 2 1 1 2 0 188 0 120 4 27.7671 0.5573435 
49 17 42.92 65.3 1 1 8 0 1 0 73 1 329 12 26.8274 0.8437236 
49 278 5.08 75 1 1 5 1 1 1 128 0 112 6 24.281 0.620265 
50 162 17 65 1 1 8 0 1 0 107 1 314 12 23.2203 0.8464461 
50 151 11.47 64 1 1 1 1 1 1 94 0 150 1 31.1419 0.633777 
51 163 68.33 79 2 1 8 0 1 1 53 1 301 10 29.6427 0.9185391 
51 244 15.23 78 1 2 1 0 1 1 144 0 187 4 22.0386 0.7250457 
 
 
Table 1: Summary of data used to develop Propensity score and matched cohorts. PODAYS = Number of post-operative days; Op = type of operation 
performed (e.g. CABG or valve); DM = Diabetes Mellitus; LVEF = Left Ventricular Ejection Fraction; sCr-PRE = Pre-operative serum creatinine; AKI = 
acute kidney injury; Bypass Time = total time spent on cardiopulmonary bypass; EUSCORE = Logistic EuroSCORE; BMI = Body Mass Index. 
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Appendix G: Raw data values for STELA Analysis 
 
Study 
ID 
Number of 
values 
Minimum 25% 
Percentile 
Median 75% 
Percentile 
Maximum Mean Std. 
Deviation 
Std. Error 
of Mean 
Lower 95% 
CI of mean 
Upper 95% 
CI of mean 
Sum 
58 52 0.529 3.586 6.421 9.165 15.6 6.62 3.454 0.479 5.658 7.582 344.2 
73 24 1.976 3.151 3.539 4.179 5.323 3.605 0.7798 0.1592 3.275 3.934 86.51 
193 10 2.918 3.126 4.687 5.93 8.511 4.899 1.81 0.5722 3.604 6.193 48.99 
191 33 1.209 4.048 5.89 6.811 8.687 5.303 2.023 0.3522 4.585 6.02 175 
253 41 1.257 3.761 4.858 6.174 8.641 4.959 1.743 0.2722 4.409 5.509 203.3 
147 21 1.847 5.123 6.594 7.424 12.34 6.311 2.115 0.4616 5.348 7.273 132.5 
241 37 1.505 3.679 5.341 6.894 11.36 5.445 2.207 0.3628 4.709 6.18 201.5 
197 48 1.466 3.371 4.284 5.952 8.714 4.644 1.621 0.2339 4.173 5.115 222.9 
248 36 2.732 5.011 6.402 7.852 10.43 6.497 2.063 0.3438 5.799 7.195 233.9 
234 32 0.204 3.174 4.408 5.907 8.927 4.701 2.107 0.3724 3.941 5.46 150.4 
100 54 2.376 3.409 4.811 6.861 9.965 5.247 2.112 0.2874 4.671 5.824 283.4 
242 53 1.371 3.517 5.104 6.354 10.09 5.075 1.976 0.2715 4.53 5.62 269 
184 40 1.932 3.198 4.421 5.607 10.27 4.734 2.007 0.3174 4.092 5.376 189.4 
202 30 2.378 3.696 4.429 5.516 6.566 4.555 1.119 0.2043 4.137 4.973 136.7 
71 30 3.009 4.208 5.595 6.943 10.69 5.808 1.951 0.3562 5.079 6.536 174.2 
11 34 1.405 2.864 3.538 4.508 5.855 3.693 1.116 0.1914 3.304 4.083 125.6 
2 19 1.016 3.733 4.664 7.361 10.53 5.037 2.386 0.5474 3.887 6.187 95.7 
39 47 1.747 3.707 5.207 6.693 14.17 5.708 2.67 0.3894 4.925 6.492 268.3 
134 115 1.805 3.767 4.902 6.027 9.789 4.975 1.565 0.1459 4.686 5.264 572.1 
45 71 2.004 3.8 5.22 7.148 15.27 5.837 2.596 0.3081 5.223 6.452 414.4 
244             
163 98 1.247 3.829 4.716 5.886 11.59 4.959 1.878 0.1897 4.583 5.336 486 
309  
103 67 1.079 3.205 4.37 5.503 13.69 4.589 2.265 0.2768 4.036 5.141 307.4 
175 56 0.886 3.098 4.26 5.854 9.16 4.479 1.918 0.2564 3.965 4.993 250.8 
165 83 1.588 4.529 5.902 7.985 15.79 6.375 2.758 0.3027 5.773 6.978 529.2 
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Appendix H: Qiagen experiment into mTL measurement and association with age 
. 
 
Reproduced with permission from Qiagen 
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Appendix I: CpG probes used in DNAm aging model 
 
 
 
 
450K ProbeID   
cg22512670 cg24079702 
cg01789150 cg26344233 
cg08169949 cg06907053 
cg25410668 cg22016779 
cg04400972 Cg20787219 
cg13898106 cg18448426 
cg25256723 cg08415592 
cg16054275 cg03607117 
cg22796704 cg05121480 
cg19935065 cg00481951 
cg23744638 cg00457403 
cg04940570 cg02650266 
cg11067179 cg08234504 
cg22213242 cg22736354 
cg06419846 cg26718511 
cg05496363 cg06493994 
cg09843573 cg05675331 
cg02046143 cg16806794 
cg03032497 cg08540945 
cg14692377 cg16219603 
cg06874016 cg16419235 
cg14556683 cg16072688 
cg02085953 cg11610346 
cg06639320  
cg22454769  
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Appendix J: DNA methylation senescence markers: beta values and coded data 
 
Study 
ID 
  
SELP 
  
CASP14 
  
CASR 
  
KRTAP13_3 
  
SELP 
Passage No. 
CASP 
Passage No. 
CASR 
Passage No. 
KRTAP13 
Passage No. 
Composite 
Passage No. 
5 10 15 5 10 15 5 10 15 5 10 15 5 10 15 
1 88.2883 82.6087 12.9181 81.9672 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 59.5420 75.0000 24.6879 71.4286 1 1 0 0 0 0 1 1 0 0 0 0 2 2 0 
3 42.3841 70.0000 31.3090 30.5709 1 1 1 0 0 0 1 1 1 1 1 1 3 3 3 
4 37.0909 91.6667 28.2716 87.8151 1 1 1 0 0 0 1 1 0 0 0 0 2 2 1 
5 86.4000 64.2857 22.4764 75.3769 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
6 70.9677 80.0000 17.9520 74.9077 1 0 0 0 0 0 1 0 0 0 0 0 2 0 0 
7 56.0000 60.0000 15.9292 80.8081 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 
8 74.9263 89.2857 24.8563 60.6965 0 0 0 0 0 0 1 1 0 1 0 0 2 1 0 
9 42.0195 87.3239 9.7525 86.4583 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 
10 84.6154 75.0000 24.5122 69.9605 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
11 57.1930 88.8889 20.6385 54.0107 1 1 0 0 0 0 1 0 0 1 1 0 3 2 0 
12 50.1873 81.8182 18.5539 83.7662 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
13 71.4286 55.5556 32.2745 71.3693 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
14 69.4656 72.2222 21.0775 84.7584 1 0 0 0 0 0 1 0 0 0 0 0 2 0 0 
15 70.1149 77.1429 19.2797 66.4234 1 0 0 0 0 0 1 0 0 0 0 0 2 0 0 
16 72.4566 82.6087 13.3261 91.1032 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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17 77.0950 85.7143 11.7647 87.4074 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
18 54.5741 85.4167 20.0201 47.3333 1 1 1 0 0 0 1 0 0 1 1 0 3 2 1 
19 75.5952 43.4783 20.1780 35.2542 0 0 0 1 0 0 1 0 0 1 1 1 3 1 1 
20 71.5789 53.8462 20.3065 85.9091 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
21 58.3942 81.8182 17.6172 72.3636 1 1 0 0 0 0 1 0 0 0 0 0 2 1 0 
22 60.9677 79.3103 22.6501 34.5455 1 1 0 0 0 0 1 0 0 1 1 1 3 2 1 
23 83.0588 94.4444 13.4454 57.3460 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 
24 35.8255 93.9394 25.4144 78.7097 1 1 1 0 0 0 1 1 0 0 0 0 2 2 1 
25 85.2713 68.2927 24.9400 85.5670 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
26 94.9555 60.0000 17.3913 74.4444 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
27 63.6628 53.8462 9.7649 70.8223 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
28 50.5848 66.6667 17.4283 65.3137 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
29 66.1184 37.5000 28.2609 86.1190 1 0 0 1 1 0 1 1 0 0 0 0 3 2 0 
30 58.6667 62.5000 15.4856 75.2212 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 
31 70.2174 55.0000 15.1461 49.3197 1 0 0 0 0 0 0 0 0 1 1 0 2 1 0 
32 41.4110 93.7500 21.6279 93.0514 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
33 67.5841 68.7500 24.1119 61.1111 1 0 0 0 0 0 1 1 0 1 0 0 3 1 0 
35 58.9251 65.5172 21.6073 57.4132 1 1 0 0 0 0 1 0 0 1 0 0 3 1 0 
36 79.4964 83.3333 7.7766 71.0526 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
37 65.6371 91.3043 22.2343 83.8951 1 0 0 0 0 0 1 0 0 0 0 0 2 0 0 
314  
38 77.6860 69.2308 27.5613 84.4371 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
39 50.1639 66.6667 31.6779 82.9630 1 1 1 0 0 0 1 1 1 0 0 0 2 2 2 
40 72.6073 71.8750 24.5192 70.7904 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
41 49.0463 60.0000 24.9677 75.7143 1 1 1 0 0 0 1 1 0 0 0 0 2 2 1 
42 75.0769 79.3103 32.4427 76.2918 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
43 51.1706 80.0000 18.5430 90.0568 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
44 65.3386 80.0000 47.8426 59.4737 1 0 0 0 0 0 1 1 1 1 0 0 3 1 1 
45 86.2295 65.3846 21.4470 73.0519 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
46 48.1343 81.2500 23.7515 87.2404 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
47 85.0000 72.0930 26.3499 36.7698 0 0 0 0 0 0 1 1 0 1 1 1 2 2 1 
48 63.0137 81.2500 29.5724 63.0037 1 0 0 0 0 0 1 1 0 1 0 0 3 1 0 
49 57.5843 77.2727 13.8232 55.4545 1 1 0 0 0 0 0 0 0 1 0 0 2 1 0 
50 84.2491 75.0000 39.6783 40.4332 0 0 0 0 0 0 1 1 1 1 1 1 2 2 2 
51 56.9930 45.0000 11.7073 73.4375 1 1 0 1 0 0 0 0 0 0 0 0 2 1 0 
52 74.9333 72.7273 28.2332 68.7285 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
53 40.5512 100.0000 18.8082 59.6026 1 1 1 0 0 0 1 0 0 1 0 0 3 1 1 
54 45.2282 100.0000 32.0755 81.1475 1 1 1 0 0 0 1 1 1 0 0 0 2 2 2 
55 85.0515 50.0000 5.8989 55.0926 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 
56 66.6667 100.0000 16.1220 69.9115 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
57 72.2449 33.3333 20.8437 92.5926 0 0 0 1 1 1 1 0 0 0 0 0 2 1 1 
315  
58 70.2509 41.1765 26.7267 55.5102 1 0 0 1 0 0 1 1 0 1 0 0 4 1 0 
59 84.4920 54.5455 10.0000 66.0819 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
60 88.4170 71.4286 22.6064 70.2128 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
61 51.5152 100.0000 24.4681 66.1130 1 1 1 0 0 0 1 1 0 0 0 0 2 2 1 
62 57.7143 50.0000 37.4286 87.4419 1 1 0 0 0 0 1 1 1 0 0 0 2 2 1 
63 88.5714 80.0000 21.7172 71.3636 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
64 92.6108 NA 17.9558 77.9762 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
65 71.1656 75.0000 30.9406 87.6667 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
66 71.2919 90.0000 17.2840 56.2738 0 0 0 0 0 0 1 0 0 1 0 0 2 0 0 
67 85.8896 66.6667 44.8505 79.9331 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
68 64.2857 100.0000 5.4348 75.5725 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
69 72.0000 40.0000 3.5047 75.9690 0 0 0 1 1 0 0 0 0 0 0 0 1 1 0 
70 58.6826 100.0000 39.2097 58.7234 1 1 0 0 0 0 1 1 1 1 0 0 3 2 1 
71 90.4255 100.0000 8.4433 77.9783 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
72 61.1940 25.0000 29.9401 56.2500 1 1 0 1 1 1 1 1 0 1 0 0 4 3 1 
73 23.3010 100.0000 3.5370 62.7551 1 1 1 0 0 0 0 0 0 1 0 0 2 1 1 
74 46.5306 72.7273 23.4637 89.2593 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
75 82.0513 100.0000 16.6667 56.8000 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 
76 81.5094 75.0000 32.1875 66.3462 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
77 74.0741 66.6667 23.4940 52.0161 0 0 0 0 0 0 1 0 0 1 1 0 2 1 0 
316  
78 49.7382 100.0000 39.8625 91.6667 1 1 1 0 0 0 1 1 1 0 0 0 2 2 2 
87 61.7021 100.0000 24.5614 62.3853 1 1 0 0 0 0 1 1 0 1 0 0 3 2 0 
90 55.5102 NA 41.7755 58.2569 1 1 0 0 0 0 1 1 1 1 0 0 3 2 1 
91 39.0681 41.6667 28.1095 97.5845 1 1 1 1 0 0 1 1 0 0 0 0 3 2 1 
92 53.9007 83.3333 13.5135 84.3602 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 
93 81.2903 66.6667 24.3827 46.1165 0 0 0 0 0 0 1 1 0 1 1 0 2 2 0 
94 57.2917 50.0000 19.6552 82.8571 1 1 0 0 0 0 1 0 0 0 0 0 2 1 0 
95 59.8870 11.1111 23.9264 68.0180 1 1 0 1 1 1 1 0 0 0 0 0 3 2 1 
96 88.7255 100.0000 34.7985 70.5882 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
98 70.1657 100.0000 12.4646 77.2894 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
100 50.0000 50.0000 21.0654 65.9389 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
103 77.6892 100.0000 42.7807 74.1803 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
104 75.2988 100.0000 17.0792 66.3830 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
108 67.0391 88.8889 10.0000 77.8210 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
109 66.6667 100.0000 29.4118 56.5421 1 0 0 0 0 0 1 1 0 1 0 0 3 1 0 
110 83.6735 100.0000 9.1873 84.7973 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
113 62.5806 100.0000 15.2727 72.9858 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 
114 64.8649 100.0000 26.5116 75.3012 1 0 0 0 0 0 1 1 0 0 0 0 2 1 0 
117 85.7143 0.0000 15.6069 61.3527 0 0 0 1 1 1 0 0 0 1 0 0 2 1 1 
118 60.7477 77.7778 16.7123 52.2388 1 1 0 0 0 0 0 0 0 1 1 0 2 2 0 
317  
119 76.9634 66.9903 15.3094 89.1608 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
120 68.6411 49.2308 26.1538 69.9115 1 0 0 0 0 0 1 1 0 0 0 0 2 1 0 
121 51.7007 74.3590 5.4487 81.9188 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 
122 76.3265 64.2857 34.1176 53.2468 0 0 0 0 0 0 1 1 1 1 1 0 2 2 1 
123 81.3008 77.5000 38.7812 89.2241 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
124 62.4561 85.7143 21.9298 53.9171 1 1 0 0 0 0 1 0 0 1 1 0 3 2 0 
125 42.2500 74.5763 44.6224 58.3596 1 1 1 0 0 0 1 1 1 1 0 0 3 2 2 
126 95.7020 80.0000 28.0423 81.4672 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
127 49.6732 81.8182 20.1863 76.7857 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
129 58.8235 84.6154 29.4294 76.5125 1 1 0 0 0 0 1 1 0 0 0 0 2 2 0 
130 90.4000 86.8852 17.7083 68.1159 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
131 63.8095 71.4286 20.4301 53.8136 1 0 0 0 0 0 1 0 0 1 1 0 3 1 0 
132 64.6209 85.7143 19.2802 55.7994 1 0 0 0 0 0 1 0 0 1 0 0 3 0 0 
133 79.8587 23.4375 35.9621 62.5954 0 0 0 1 1 1 1 1 1 1 0 0 3 2 2 
134 67.2269 59.1837 24.8538 58.9041 1 0 0 0 0 0 1 1 0 1 0 0 3 1 0 
135 46.6667 87.8049 43.4426 46.9880 1 1 1 0 0 0 1 1 1 1 1 0 3 3 2 
136 24.3446 77.7778 8.3333 74.4337 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 
137 65.9919 63.6364 15.4839 79.5539 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
138 71.0084 73.6842 17.8182 74.0947 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
139 65.0980 79.1667 16.9675 34.8837 1 0 0 0 0 0 0 0 0 1 1 1 2 1 1 
318  
140 70.4319 95.1220 17.7596 74.7082 1 0 0 0 0 0 1 0 0 0 0 0 2 0 0 
141 75.3333 60.0000 17.4377 76.2712 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
142 78.1350 81.2500 13.9818 57.2000 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 
143 67.0695 65.3846 22.7723 77.2989 1 0 0 0 0 0 1 0 0 0 0 0 2 0 0 
144 83.8150 27.2727 47.3193 69.1304 0 0 0 1 1 1 1 1 1 0 0 0 2 2 2 
145 69.5341 73.1707 19.5846 83.4615 1 0 0 0 0 0 1 0 0 0 0 0 2 0 0 
146 60.9756 50.0000 18.4466 89.6104 1 1 0 0 0 0 1 0 0 0 0 0 2 1 0 
147 64.9123 33.3333 15.2104 65.1741 1 0 0 1 1 1 0 0 0 0 0 0 2 1 1 
148 69.5652 56.2500 57.7406 62.6866 1 0 0 0 0 0 1 1 1 1 0 0 3 1 1 
150 56.5371 63.6364 33.5347 65.5797 1 1 0 0 0 0 1 1 1 0 0 0 2 2 1 
151 56.5625 68.8889 23.9875 64.6377 1 1 0 0 0 0 1 0 0 1 0 0 3 1 0 
152 68.0653 79.4118 24.1192 84.0000 1 0 0 0 0 0 1 1 0 0 0 0 2 1 0 
153 75.7669 89.7436 23.0198 58.4677 0 0 0 0 0 0 1 0 0 1 0 0 2 0 0 
154 67.5595 89.8305 27.2973 87.3077 1 0 0 0 0 0 1 1 0 0 0 0 2 1 0 
155 59.4262 64.2857 38.2671 57.9310 1 1 0 0 0 0 1 1 1 1 0 0 3 2 1 
156 62.4434 50.0000 45.1178 74.2105 1 1 0 0 0 0 1 1 1 0 0 0 2 2 1 
157 62.6959 72.4138 21.2465 92.4419 1 1 0 0 0 0 1 0 0 0 0 0 2 1 0 
158 30.6383 100.0000 37.1094 73.0000 1 1 1 0 0 0 1 1 1 0 0 0 2 2 2 
159 29.6758 40.5405 26.2530 46.1538 1 1 1 1 1 0 1 1 0 1 1 0 4 4 1 
160 65.0442 75.0000 20.3085 40.6091 1 0 0 0 0 0 1 0 0 1 1 1 3 1 1 
319  
161 69.8630 77.2152 20.1893 75.9162 1 0 0 0 0 0 1 0 0 0 0 0 2 0 0 
162 59.3137 77.5000 27.6119 91.5789 1 1 0 0 0 0 1 1 0 0 0 0 2 2 0 
163 52.7363 64.7059 47.9554 65.6805 1 1 1 0 0 0 1 1 1 0 0 0 2 2 2 
164 64.1350 0.0000 16.9492 81.1927 1 0 0 1 1 1 0 0 0 0 0 0 2 1 1 
165 72.3333 43.5897 28.3133 82.7381 0 0 0 1 0 0 1 1 0 0 0 0 2 1 0 
166 90.8257 45.9459 9.1216 86.4754 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 
167 62.7063 90.1961 3.4946 82.9268 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 
168 67.3653 63.2911 16.9014 59.1928 1 0 0 0 0 0 0 0 0 1 0 0 2 0 0 
169 84.9162 73.4266 18.4290 91.6667 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
171 46.4789 78.7879 19.1729 11.2903 1 1 1 0 0 0 1 0 0 1 1 1 3 2 2 
172 77.8169 64.2857 50.7331 90.9483 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
173 76.4151 62.5000 33.6735 46.9484 0 0 0 0 0 0 1 1 1 1 1 0 2 2 1 
174 50.8772 68.9655 29.8611 71.3080 1 1 1 0 0 0 1 1 0 0 0 0 2 2 1 
175 90.2913 60.9756 13.8462 75.6458 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
176 79.4702 35.8974 40.0662 64.8148 0 0 0 1 1 0 1 1 1 1 0 0 3 2 1 
178 66.5722 78.0488 27.7778 82.2314 1 0 0 0 0 0 1 1 0 0 0 0 2 1 0 
179 48.2353 82.1918 5.5703 94.0000 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 
180 42.3729 80.3279 14.4295 89.7196 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 
181 56.5217 90.6250 22.6190 43.4343 1 1 0 0 0 0 1 0 0 1 1 1 3 2 1 
182 55.2870 37.5000 25.2226 80.4255 1 1 0 1 1 0 1 1 0 0 0 0 3 3 0 
320  
183 72.2930 83.3333 27.4566 90.2778 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
184 61.2903 77.7778 10.5572 55.5970 1 1 0 0 0 0 0 0 0 1 0 0 2 1 0 
185 81.8182 90.0000 12.8205 53.8860 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 
186 72.5212 76.4706 17.9054 82.9670 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
187 55.0523 86.1538 12.8713 60.0000 1 1 0 0 0 0 0 0 0 1 0 0 2 1 0 
188 32.0132 87.0130 32.1799 82.2967 1 1 1 0 0 0 1 1 1 0 0 0 2 2 2 
189 84.8837 44.4444 12.5000 75.5725 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 
190 52.3659 80.8511 21.2418 72.5490 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
191 41.2844 57.4468 19.5187 53.1250 1 1 1 0 0 0 1 0 0 1 1 0 3 2 1 
192 73.1861 80.4878 13.2258 81.3131 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
193 93.6963 96.0000 14.4118 37.3333 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 
194 76.4557 88.3333 13.7313 84.4106 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
195 72.8261 80.0000 26.4624 55.0000 0 0 0 0 0 0 1 1 0 1 0 0 2 1 0 
196 55.0314 73.3333 12.8358 64.1026 1 1 0 0 0 0 0 0 0 1 0 0 2 1 0 
197 71.9008 80.7692 26.9531 77.0898 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
198 53.3632 31.5789 6.2731 87.5380 1 1 1 1 1 1 0 0 0 0 0 0 2 2 2 
200 50.3356 70.2128 30.3226 68.3616 1 1 1 0 0 0 1 1 0 0 0 0 2 2 1 
201 59.7173 85.7143 13.8408 85.7616 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 
202 65.2482 71.4286 35.7341 85.2459 1 0 0 0 0 0 1 1 1 0 0 0 2 1 1 
203 64.1161 66.6667 17.6282 79.8193 1 0 0 0 0 0 1 0 0 0 0 0 2 0 0 
321  
204 62.6214 67.3267 25.6198 71.7791 1 1 0 0 0 0 1 1 0 0 0 0 2 2 0 
205 50.1385 77.1429 26.3014 57.8512 1 1 1 0 0 0 1 1 0 1 0 0 3 2 1 
206 75.7098 80.0000 29.6296 83.9286 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
207 62.9032 83.3333 18.5759 88.3333 1 1 0 0 0 0 1 0 0 0 0 0 2 1 0 
208 74.8521 86.4865 13.5870 80.6061 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
209 78.7546 72.0000 40.2439 91.9003 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
210 56.2500 82.2222 30.8943 67.1554 1 1 0 0 0 0 1 1 0 0 0 0 2 2 0 
211 41.7840 50.0000 27.4286 82.6531 1 1 1 0 0 0 1 1 0 0 0 0 2 2 1 
212 41.6667 50.0000 30.5842 70.5686 1 1 1 0 0 0 1 1 0 0 0 0 2 2 1 
213 61.9048 55.5556 41.9142 67.9245 1 1 0 0 0 0 1 1 1 0 0 0 2 2 1 
214 54.9180 95.5556 53.0249 88.8889 1 1 1 0 0 0 1 1 1 0 0 0 2 2 2 
215 32.2709 88.8889 8.0128 84.9206 1 1 1 0 0 0 0 0 0 0 0 0 1 1 1 
216 60.0000 72.7273 24.0000 75.5656 1 1 0 0 0 0 1 0 0 0 0 0 2 1 0 
217 91.5385 64.2857 11.4583 84.4262 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
218 86.5828 82.1429 17.2577 41.1765 0 0 0 0 0 0 1 0 0 1 1 1 2 1 1 
219 80.1386 60.9524 10.1235 93.1880 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
220 73.7931 68.4211 20.0000 82.5203 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
221 53.5452 95.9459 18.4080 85.0427 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
222 62.3482 81.8182 12.4242 75.0000 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 
223 78.2427 22.8571 42.6966 69.2308 0 0 0 1 1 1 1 1 1 0 0 0 2 2 2 
322  
224 76.9231 51.6129 40.8935 66.6667 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
225 50.9434 85.7143 18.9873 46.4516 1 1 1 0 0 0 1 0 0 1 1 0 3 2 1 
226 82.3362 71.4286 11.9891 75.4098 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
227 60.9418 64.8148 6.2500 70.2265 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 
228 60.6272 78.1250 28.2443 58.1498 1 1 0 0 0 0 1 1 0 1 0 0 3 2 0 
229 51.9337 94.4444 25.5132 91.7582 1 1 1 0 0 0 1 1 0 0 0 0 2 2 1 
230 85.2590 57.5000 5.5556 52.9617 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 
231 72.1569 80.0000 18.0000 91.1111 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
232 49.5677 50.9091 9.0625 54.7120 1 1 1 0 0 0 0 0 0 1 1 0 2 2 1 
233 43.5556 81.8182 20.5656 76.9022 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
234 87.1345 47.6190 31.6384 89.4161 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
235 89.8010 82.6531 25.4808 66.6667 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
236 76.0116 56.9767 21.4815 70.1754 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
237 85.0980 92.1053 33.0544 85.6383 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
238 79.7665 88.8889 27.8884 57.9832 0 0 0 0 0 0 1 1 0 1 0 0 2 1 0 
239 55.7078 62.5000 32.9167 84.5890 1 1 0 0 0 0 1 1 1 0 0 0 2 2 1 
240 82.7815 54.2857 23.8390 75.6944 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 
241 71.3793 86.6667 27.8810 81.6860 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
242 75.7106 61.8182 25.4717 83.6120 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 
243 65.7576 80.7692 20.0000 64.1844 1 0 0 0 0 0 1 0 0 1 0 0 3 0 0 
323  
244 73.9496 88.1356 22.4490 46.2406 0 0 0 0 0 0 1 0 0 1 1 0 2 1 0 
245 71.6475 83.3333 24.6637 55.9028 0 0 0 0 0 0 1 1 0 1 0 0 2 1 0 
246 88.7097 77.7778 15.2672 91.0615 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
247 65.4008 84.6154 18.8596 67.0068 1 0 0 0 0 0 1 0 0 0 0 0 2 0 0 
248 63.0996 90.9091 12.1771 94.1176 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
249 47.3545 86.4865 24.1888 87.0130 1 1 1 0 0 0 1 1 0 0 0 0 2 2 1 
250 57.5540 50.0000 21.6216 79.8283 1 1 0 0 0 0 1 0 0 0 0 0 2 1 0 
251 83.4951 58.8235 18.1467 64.4068 0 0 0 0 0 0 1 0 0 1 0 0 2 0 0 
252 59.4366 85.5556 31.2500 43.4307 1 1 0 0 0 0 1 1 1 1 1 1 3 3 2 
253 65.0735 94.4444 15.6716 31.3846 1 0 0 0 0 0 0 0 0 1 1 1 2 1 1 
254 78.8194 91.4286 7.6923 67.5000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
255 84.1176 63.6364 43.6667 72.2222 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
256 63.0094 80.4878 18.7500 78.7500 1 0 0 0 0 0 1 0 0 0 0 0 2 0 0 
257 74.6429 62.7119 41.4179 82.8313 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
258 51.6035 85.7143 27.5204 62.3053 1 1 1 0 0 0 1 1 0 1 0 0 3 2 1 
259 58.8595 62.0370 48.1675 88.9590 1 1 0 0 0 0 1 1 1 0 0 0 2 2 1 
260 70.0000 50.0000 11.6732 79.0476 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
261 73.7410 62.5000 5.7348 69.8997 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
262 64.5161 76.4706 22.3629 87.6289 1 0 0 0 0 0 1 0 0 0 0 0 2 0 0 
263 51.2739 76.5957 17.0833 69.2098 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
324  
264 59.4156 90.4762 16.3043 83.1804 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 
265 48.4321 74.5098 19.8556 60.6870 1 1 1 0 0 0 1 0 0 1 0 0 3 1 1 
266 68.7285 58.8235 8.4942 96.0432 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
267 53.8983 60.5769 32.3077 79.8851 1 1 1 0 0 0 1 1 1 0 0 0 2 2 2 
268 80.4348 25.9259 32.8125 80.1587 0 0 0 1 1 1 1 1 1 0 0 0 2 2 2 
269 69.7674 64.7059 27.6018 59.0625 1 0 0 0 0 0 1 1 0 1 0 0 3 1 0 
270 70.8333 61.5385 9.1623 58.1081 1 0 0 0 0 0 0 0 0 1 0 0 2 0 0 
271 33.3333 76.6667 34.8730 77.2595 1 1 1 0 0 0 1 1 1 0 0 0 2 2 2 
272 61.9048 76.6667 22.4537 79.8780 1 1 0 0 0 0 1 0 0 0 0 0 2 1 0 
273 87.5000 33.3333 9.1644 63.4703 0 0 0 1 1 1 0 0 0 1 0 0 2 1 1 
274 82.2581 66.6667 42.6901 86.4151 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 
275 59.1837 58.3333 4.8276 74.9206 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 
276 51.0638 86.0000 18.6207 76.4350 1 1 1 0 0 0 1 0 0 0 0 0 2 1 1 
277 91.3043 88.8889 14.7392 78.0928 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
278 30.0000 38.8889 38.0734 69.4639 1 1 1 1 1 0 1 1 1 0 0 0 3 3 2 
279 32.0000 25.0000 28.7726 89.7163 1 1 1 1 1 1 1 1 0 0 0 0 3 3 2 
280 75.8621 60.0000 12.1693 67.9310 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
281 62.9630 78.9474 27.0886 64.5985 1 1 0 0 0 0 1 1 0 1 0 0 3 2 0 
 
Table 1: Raw data for the Methylation senescence arrays (beta values) together with the data coded into a binary senescent/non-senescent 
variable. The composite variable is the sum of the 4 individually coded variables.  
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Appendix K: Logistical regression of individual CpG sites 
and CSA-AKI.  
 
CpG BETA SE p-value MEAN SD 
cg20426994.130418314 0.440034 0.123791 0.000462 NA 27.23802 
cg07082267.85429007 0.006084 0.001775 0.000717 61.19293 14.65783 
cg04940570.12696785 0.01022 0.003095 0.00111 11.92806 8.412798 
cg25410668.28241509 -0.0256 0.008517 0.002932 3.06599 3.053487 
cg07927379.156433095 0.009404 0.003349 0.0054 16.50134 8.388309 
cg22016779.230452310 -0.00993 0.003662 0.007175 10.45489 7.450601 
cg14556683.15343076 0.0132 0.004919 0.007809 5.440351 5.383566 
cg06419846.66083692 0.01032 0.003958 0.009708 87.77388 6.661769 
cg02046143.133797845 0.044956 0.017999 0.013184 0.971557 1.456574 
cg07927379.156433107 0.012396 0.005093 0.015687 6.742099 5.238876 
cg20426994.130418334 0.006551 0.002701 0.01605 5.136551 9.780799 
cg07927379.156433032 0.013628 0.005624 0.016143 7.007173 4.748746 
cg22736354.18122787 0.009627 0.004058 0.018476 4.678866 6.43849 
cg21296230.33010576 -0.03286 0.013935 0.019183 2.106596 1.870578 
cg16419235.57360555 0.006217 0.002669 0.020707 16.58626 9.754482 
cg03032497.61108129 0.00972 0.004204 0.021633 10.28029 6.208008 
cg07553761.160168094 -0.00419 0.001822 0.022211 31.55684 14.68951 
cg16419235.57360787 0.01507 0.006617 0.023645 2.709226 3.942149 
cg16419235.57360585 0.007835 0.003454 0.024196 10.90825 7.561611 
cg03607117.53080379 0.027211 0.012096 0.025399 1.162378 2.187365 
cg07927379.156433089 0.007067 0.003177 0.02709 20.85563 9.03587 
cg04940570.12696803 0.011328 0.005095 0.027127 3.833572 5.149851 
cg04940570.12696790 0.009297 0.004196 0.02766 5.581383 6.282213 
cg21139312.55663255 -0.93101 0.372194 0.029433 NA 20.83531 
cg20426994.130418178 -0.00223 0.001032 0.031667 35.56238 25.58058 
ch.2.30415474F.30561912 0.011906 0.005544 0.032771 93.25296 4.744738 
cg04474832.52008445 0.862896 0.403454 0.033787 NA 5.979224 
cg03607117.53080360 -0.0079 0.003733 0.035486 8.601068 7.150859 
cg07927379.156433098 0.010125 0.004844 0.037661 8.207077 5.587723 
cg24079702.106015796 -0.00771 0.003715 0.039029 11.73526 7.04264 
cg04940570.12696797 0.006726 0.003301 0.042683 7.715209 8.04156 
cg09651136.72525221 0.009523 0.004706 0.044134 92.48852 5.603714 
cg23744638.10323908 -0.00316 0.001581 0.04652 72.74258 17.04779 
cg20426994.130418099 0.003427 0.001731 0.048907 28.28284 15.18891 
cg20426994.130418325 0.79323 0.401799 0.049634 NA 17.75618 
cg07927379.156433011 0.780782 0.402418 0.053564 NA 5.09947 
cg22454769.106015770 0.004837 0.002557 0.059784 33.06222 10.73505 
cg20426994.130418149 0.806874 0.437078 0.067755 NA 25.43262 
cg04940570.12696853 0.017774 0.009809 0.071243 1.139446 2.723113 
 
Table 1: Logistical regression analysis of individual CpG sites and CSA-AKI. Results 
of top 40 associated probes shown. Highlighted p-values = significant at <0.05. 
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Appendix L: Comparison between measures of DNAm age: 
Raw data  
 
Study 
ID 
Age 
Predicted 
Age (y) 
Delta 
Age 
AMAR 
Study 
ID 
Age 
Predicted 
Age (y) 
Delta 
Age 
AMAR 
1 54.0 45.9 8.146 0.849 52 52.0 49.9 2.134 0.959 
2 69.9 70.5 -0.551 1.008 53 66.0 63.3 2.700 0.959 
3 54.8 32.3 22.534 0.589 56 75.0 65.7 9.299 0.876 
4 70.9 70.9 0.001 1.000 57 59.0 45.5 13.496 0.771 
5 61.3 66.8 -5.504 1.090 58 68.0 63.0 4.952 0.927 
6 77.7 40.7 37.021 0.524 59 68.0 63.8 4.241 0.938 
7 45.6 57.9 -12.330 1.270 60 80.0 49.9 30.095 0.624 
8 70.5 49.8 20.694 0.707 62 59.0 51.3 7.721 0.869 
9 59.0 53.7 5.291 0.910 64 63.0 72.4 -9.440 1.150 
10 46.2 55.9 -9.713 1.210 65 71.0 59.6 11.421 0.839 
11 77.8 80.7 -2.855 1.037 66 68.0 60.6 7.382 0.891 
12 59.0 58.7 0.265 0.996 67 75.0 59.4 15.569 0.792 
13 54.4 47.5 6.863 0.874 69 81.0 88.3 -7.295 1.090 
14 54.1 52.8 1.296 0.976 70 69.0 70.7 -1.667 1.024 
15 60.3 57.9 2.419 0.960 72 80.0 68.2 11.798 0.853 
16 59.4 53.5 5.872 0.901 74 67.0 63.1 3.938 0.941 
17 65.3 53.0 12.338 0.811 75 77.0 84.2 -7.199 1.093 
18 75.0 73.0 1.962 0.974 76 53.0 61.4 -8.425 1.159 
19 62.9 58.6 4.260 0.932 77 35.0 29.3 5.681 0.838 
20 80.7 66.1 14.620 0.819 78 59.0 48.0 11.028 0.813 
21 71.8 84.9 -13.089 1.182 87 72.0 77.4 -5.411 1.075 
22 64.0 63.1 0.938 0.985 90 69.0 69.8 -0.774 1.011 
23 51.7 56.5 -4.777 1.092 91 69.0 43.2 25.836 0.626 
24 77.8 86.2 -8.396 1.108 93 68.0 67.6 0.433 0.994 
25 80.0 80.3 -0.336 1.004 95 56.0 69.3 -13.318 1.238 
26 42.7 38.4 4.335 0.899 96 48.0 46.1 1.909 0.960 
27 47.9 41.7 6.188 0.871 98 69.0 59.3 9.660 0.860 
28 69.0 65.1 3.916 0.943 100 61.0 49.4 11.607 0.810 
29 52.1 60.9 -8.765 1.168 103 63.0 52.5 10.504 0.833 
30 49.7 65.4 -15.719 1.316 104 68.0 63.3 4.733 0.930 
31 68.6 69.6 -1.013 1.015 108 22.0 16.8 5.232 0.762 
32 67.4 53.3 14.052 0.792 109 65.0 64.1 0.868 0.987 
35 63.2 52.0 11.184 0.823 110 67.0 65.4 1.557 0.977 
36 70.5 60.1 10.362 0.853 113 63.0 57.6 5.437 0.914 
37 86.7 51.2 35.548 0.590 118 24.0 33.2 -9.216 1.384 
38 30.4 25.1 5.329 0.825 119 58.0 54.9 3.070 0.947 
39 80.5 74.2 6.335 0.921 120 79.0 71.5 7.532 0.905 
40 77.6 68.4 9.156 0.882 121 69.0 55.8 13.234 0.808 
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41 72.0 61.5 10.484 0.854 122 78.0 88.3 -10.337 1.133 
42 76.2 64.7 11.490 0.849 123 60.0 51.2 8.825 0.853 
43 64.6 59.9 4.673 0.928 124 88.0 98.4 -10.400 1.118 
44 82.8 76.8 6.040 0.927 125 48.0 52.0 -4.007 1.083 
45 74.2 65.7 8.531 0.885 126 62.0 59.2 2.821 0.955 
46 79.7 75.0 4.693 0.941 127 82.0 52.7 29.324 0.642 
47 54.5 49.1 5.434 0.900 129 77.0 72.5 4.469 0.942 
48 68.1 56.7 11.350 0.833 130 49.0 49.6 -0.643 1.013 
49 68.0 63.4 4.617 0.932 131 81.0 71.4 9.581 0.882 
50 52.0 80.4 -28.366 1.546 132 61.0 65.8 -4.754 1.078 
51 58.0 61.8 -3.760 1.065 133 58.0 61.0 -3.021 1.052 
Study 
ID 
Age 
Predicted 
Age (y) 
Delta 
Age  
AMAR 
Study 
ID 
Age 
Predicted 
Age (y) 
Delta 
Age  
AMAR 
134 69.0 58.6 10.443 0.849 188 53.0 48.8 4.190 0.921 
135 60.0 63.2 -3.168 1.053 189 71.0 58.8 12.239 0.828 
136 72.0 79.2 -7.233 1.101 190 62.0 62.6 -0.561 1.009 
137 33.0 31.9 1.055 0.968 191 56.0 58.8 -2.792 1.050 
138 50.0 48.7 1.303 0.974 192 83.0 97.5 -14.548 1.175 
139 27.0 26.8 0.215 0.992 193 73.0 65.6 7.378 0.899 
140 66.0 50.5 15.546 0.764 194 63.0 68.5 -5.546 1.088 
141 75.0 98.3 -23.275 1.310 195 52.0 53.0 -0.996 1.019 
142 51.0 51.0 0.022 1.000 196 74.0 67.3 6.673 0.910 
143 83.0 75.6 7.370 0.911 197 78.0 74.7 3.265 0.958 
144 56.0 62.2 -6.209 1.111 198 63.0 63.4 -0.435 1.007 
145 76.0 78.0 -1.955 1.026 200 70.0 73.5 -3.481 1.050 
146 41.0 45.8 -4.822 1.118 201 34.0 27.1 6.902 0.797 
147 56.0 57.6 -1.554 1.028 202 79.0 76.6 2.414 0.969 
148 72.0 66.2 5.786 0.920 203 76.0 66.4 9.566 0.874 
150 76.0 63.0 12.979 0.829 204 53.0 52.8 0.186 0.996 
151 64.0 64.2 -0.190 1.003 205 79.0 73.4 5.628 0.929 
152 69.0 56.6 12.359 0.821 206 65.0 60.2 4.797 0.926 
153 62.0 62.8 -0.792 1.013 207 57.0 77.7 -20.660 1.362 
154 78.0 95.3 -17.334 1.222 208 47.0 53.6 -6.567 1.140 
155 79.0 51.2 27.778 0.648 209 63.0 53.7 9.283 0.853 
156 79.0 51.2 27.778 0.648 210 70.0 53.9 16.126 0.770 
157 68.0 60.1 7.864 0.884 211 60.0 62.8 -2.753 1.046 
158 79.0 69.7 9.329 0.882 212 55.0 72.1 -17.096 1.311 
159 82.0 76.0 5.971 0.927 213 68.0 46.5 21.539 0.683 
160 79.0 70.9 8.086 0.898 214 47.0 44.7 2.259 0.952 
161 80.0 71.3 8.682 0.892 215 67.0 59.8 7.219 0.892 
162 65.0 53.9 11.086 0.829 216 79.0 77.0 2.029 0.974 
163 79.0 88.7 -9.700 1.123 217 30.0 22.6 7.434 0.752 
164 72.0 71.8 0.152 0.998 218 76.0 79.7 -3.678 1.048 
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165 37.0 54.8 -17.777 1.481 219 26.0 33.8 -7.846 1.302 
166 50.0 55.5 -5.494 1.110 220 48.0 39.9 8.083 0.832 
167 68.0 54.8 13.222 0.806 221 54.0 55.6 -1.618 1.030 
168 66.0 64.6 1.414 0.979 222 47.0 63.6 -16.607 1.353 
169 72.0 63.0 9.025 0.875 223 79.0 81.0 -2.001 1.025 
171 49.0 51.0 -1.986 1.041 224 56.0 70.3 -14.346 1.256 
172 68.0 58.8 9.235 0.864 225 72.0 69.1 2.927 0.959 
173 68.0 58.5 9.486 0.861 226 52.0 41.7 10.347 0.801 
174 61.1 57.7 3.382 0.945 227 56.0 50.6 5.408 0.903 
175 53.0 47.7 5.312 0.900 228 87.0 77.5 9.492 0.891 
176 64.0 60.9 3.116 0.951 229 79.0 77.0 2.019 0.974 
178 72.0 71.5 0.505 0.993 230 17.0 11.3 5.738 0.662 
179 44.0 43.6 0.378 0.991 231 65.0 65.5 -0.496 1.008 
180 75.0 67.9 7.065 0.906 232 57.0 58.6 -1.599 1.028 
181 77.0 75.1 1.934 0.975 233 69.0 73.0 -4.035 1.058 
182 78.0 66.2 11.803 0.849 234 69.0 66.5 2.498 0.964 
183 85.0 74.9 10.131 0.881 235 56.0 41.2 14.819 0.735 
184 76.0 82.6 -6.592 1.087 236 64.0 58.2 5.779 0.910 
186 65.0 51.7 13.291 0.796 237 57.0 55.6 1.423 0.975 
187 37.0 42.4 -5.390 1.146 238 55.0 60.5 -5.476 1.100 
Study 
ID 
Age 
Predicted 
Age (y) 
Delta 
Age 
AMAR 
Study 
ID 
Age 
Predicted 
Age (y) 
Delta 
Age  
AMAR 
239 71.0 62.0 9.010 0.873 260 72.0 57.6 14.423 0.800 
240 35.0 24.9 10.121 0.711 261 82.0 92.6 -10.568 1.129 
241 57.0 55.4 1.575 0.972 263 51.0 40.4 10.582 0.793 
242 22.0 27.1 -5.059 1.230 264 70.0 81.3 -11.349 1.162 
243 62.0 60.1 1.896 0.969 265 81.0 62.7 18.302 0.774 
244 78.0 81.4 -3.354 1.043 266 67.0 53.6 13.430 0.800 
245 62.0 52.3 9.745 0.843 267 65.0 56.9 8.057 0.876 
246 50.0 69.5 -19.535 1.391 268 42.0 50.9 -8.857 1.211 
247 52.0 59.0 -7.026 1.135 269 70.0 64.8 5.193 0.926 
248 35.0 39.5 -4.461 1.128 270 83.0 77.3 5.654 0.932 
249 66.0 89.8 -23.814 1.361 271 81.0 63.5 17.547 0.783 
250 55.0 41.0 14.032 0.745 272 78.0 72.6 5.373 0.931 
251 57.0 43.7 13.336 0.766 273 76.0 51.9 24.099 0.683 
252 72.0 61.7 10.285 0.857 274 83.0 90.6 -7.555 1.091 
253 55.0 68.1 -13.091 1.238 275 84.0 64.0 19.959 0.762 
254 63.0 51.1 11.872 0.812 276 60.0 57.5 2.545 0.958 
255 67.0 67.3 -0.286 1.004 277 69.0 57.8 11.169 0.838 
256 79.0 79.1 -0.062 1.001 278 75.0 61.0 14.029 0.813 
257 64.0 66.4 -2.446 1.038 279 87.0 66.8 20.153 0.768 
258 57.0 56.4 0.603 0.989 280 59.0 47.9 11.067 0.812 
259 77.0 86.3 -9.260 1.120 281 78.0 77.9 0.078 0.999 
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Appendix M: Results of TA Validation Experiments  
 
Results of Validation Experiment 1: TeloTAGGG PCR ELISA Protocol 
Runs 1-3 were performed on cells derived from a single PBMC collection tube for 
each sample. 
 
Run 1: 
• Run with Heparin CPT tubes 
• Run with 2x105cell count 
 
Sample PCR 1 
 
PCR 2 
 
PCR 3 
 
Average CV Negative 
control 
Av -  
control 
TA 
+ve ? 
D 0.267 0.2248 0.0824* 0.2459 12.13498 0.1174 0.1285 No 
S 0.2246 0.1089 0.1745 0.169333 34.26542 0.0973 0.0720 No 
W 0.0969 0.0987 0.0762* 0.0978 1.301424 0.1181 -0.0203 No 
Positive 
control  
2.4889 
 
Table 1: Results of Run 1 TRAP Assay. *. Some degree of evaporation of PCR product 
so result excluded from analysis 
 
Run 2 
• Run with Heparin CPT tubes 
• Run with 2x105cell count 
Sample PCR 1 
 
PCR 2 
 
PCR 3 
 
Average CV Negative 
control 
Av -  
control 
TA 
+ve? 
D 0.0879 0.0904 0.0769 0.0851 8.442971 0.0521 0.0330 No 
S 0.0723 0.0702 0.0894 0.0773 13.62404 0.0806 -0.0033 No 
W 0.0723 0.0867 0.0783 0.0791 9.144446 0.0701 0.009 No 
Positive 
control 
0.5629 
  
Table 2: Results of Run 2 TRAP Assay. Run failed. Positive control below threshold.  
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Run 3:  
• Run with Citrate CPT tubes (except DH sample run in Heparin CPT for comparison) 
• Run with 2x105 cell count 
 PCR 1 PCR 2 Av. CV Negative 
control 
Av – 
control 
TA 
+ve?  Hyb a Hyb b Hyb a Hyb b 
D 0.1861 0.1871 0.1795 0.1622 0.1788 6.446 0.1055 0.073 No 
S 0.127 0.1272 0.1623 0.1503 0.1417 12.390 0.1221 0.020 No 
W 0.2532 0.2462 0.1617 0.1722 0.2083 23.066 0.1068 0.102 No 
DH 0.1625 0.1279 0.1485 0.1583 0.1493 10.332 0.1112 0.038 No 
P  3.1727 
 
Table 3: Results of Run 3 TRAP Assay. 
 
It was felt that the observed issues with repeatability were most likely due to 
variability in the starting amount of PBMC that was being included in each reaction. 
As such an alternative method of standardising input amount of PBMC was adopted. 
This involved lysing the pellet from 1ml of final PBMC solution and then performing 
a Bichinchoninic (BCA) assay to measure the protein concentration of the sample. 
Assuming a pure sample of PBMC with minimal platelet contamination, protein 
concentration should be proportional to total quantity of PBMC cell lysate. However, 
making this assumption is a potential source of error as levels of contamination may 
differ between samples thus altering the proportion of PBMC entering the TRAP 
assay. To help reduce protein contamination an additional washing step was included 
in the PBMC harvest (centrifuging at 100 RCF for 10 minutes).  
 
Run 4 was a repeat of run 3 but with 1µg of protein used as a starting amount for 
each sample (Table 4). This run produced a much higher TA value for sample D than 
previously observed (TA = 0.49) but similar values of intra-assay variability with CV 
values of 20%. As such this sample was run again in Run 5, using a second extracted 
PBMC pellet (Table 5). Repeat BCA assays were performed on pellets from 0.5mls 
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PBMC and 1ml PBMC for comparison (both derived from a single purification). This 
run produced similar TA values for sample D as runs 1 and 3 but greatly different 
from that of run 4 (0.493 Vs 0.223; inter-assay CV of 53.3%). There was relative 
consistency in TA activity across samples derived from 0.5mls and 1ml of PBMC (CV 
of 13.9 across 10 valid samples).   
 
 
Run 4:  
• Run with Citrate CPT tubes  
• Run with 1 ug Protein  
Sample PCR 1 PCR 2 Av. CV Negative 
control 
Av – 
control 
TA 
+ve?  Hyb a Hyb b Hyb a Hyb b 
D 0.6027 0.5346 0.4681 0.368 0.493 20.273 0.1023 0.391 Yes 
S 0.1234 0.0892 0.1376 0.1509 0.125 21.187 0.1232 0.002 No 
W 0.2512 0.2272 0.2799 0.2696 0.257 9.000 0.1081 0.149 No 
P 3.1727  
 
Table 4: Results of Run 4.  
 
Run 5:  
• Run with Citrate CPT tubes  
• Run with 1 ug Protein 
 PCR 1 PCR 2 PCR 3 Av CV -ve 
control 
Av – 
control 
TA 
+ve?  Hyb a Hyb b Hyb a Hyb b Hyb a Hyb b 
D1: 
0.5ml 
0.089
* 
0.099
* 
0.281 0.25 0.185 0.177 0.2
23 
22.
62 
0.0881 0.135 No 
D2: 
1ml 
0.220 0.219 0.198 0.220 0.210 0.225 0.2
15 
4.5
71 
0.0967 0.118 No 
P  2.826 
 
Table 5: Results of Run 5. *. Some degree of evaporation of PCR product so result 
excluded from analysis 
 
 
Results of Validation Experiment 2: TeloTAGGG PCR ELISA PLUS Protocol 
TA was measured with the TeloTAGG Telomerase PCR ELISA Plus as per the 
manufacturer’s instructions (205). For Run 6, the internal control failed to amplify for 
3 of the 4 samples (Table 6) 
 
332  
Sample AS AS-AS,0 AS,0 x2 Telomerase 
positive? 
AS-IS RTA high 
D1 0.0771 0.0394 0.0754 No 0.0300 72.5482 
D2 0.0812 0.0435 0.0754 No 0.0300 80.0977 
S1 0.1305 0.0952 0.0706 Yes 0.0358 146.8946 
S2 0.0998 0.0645 0.0706 No 0.0326 109.2934 
W1 0.1835 0.1463 0.0744 Yes 0.4596 17.5839 
W2 0.2005 0.1633 0.0744 Yes 0.4875 18.5039 
J1 0.1331 0.0955 0.0752 Yes 0.0822 64.1776 
J2 0.1288 0.0912 0.0752 Yes 0.0617 81.6510 
 
Table 6: Run 6. Note that the internal standards (IS) of samples D, S and J have not 
amplified resulting in spuriously high RTA readings.  
 
 
Sample AS AS-AS,0 AS,0 x2 Telomerase 
positive? 
AS-IS RTA high 
D1 0.4027 0.3678 0.0698 Y 1.0529 12.4824 
D2 0.2853 0.2504 0.0698 Y 0.9532 9.3870 
S1 0.1720 0.1306 0.0828 Y 0.9637 4.8426 
S2 0.1801 0.1387 0.0828 Y 1.3084 3.7880 
W1 0.2154 0.1743 0.0822 Y 1.5145 4.1125 
W2 0.2262 0.1851 0.0822 Y 1.4736 4.4885 
J1 0.2688 0.2278 0.0820 Y 0.7623 10.6783 
J2 0.1927 0.1517 0.0820 Y 0.6649 8.1527 
 
Table 7: Run 7. All internal controls produced higher readings than in the previous 
run. 
 
As such, Run 7 was repeated with all conditions the same except that the PMBC lysate 
was generated from stored lysate generated in Run 6 (Table 7). All of these lysates 
had been diluted to a concentration of 0.33µg/µl prior to freezing. On defrosting, 
repeat BCA assay run in triplicate showed that there was some variation in the 
concentration of the lysates on thawing (Table 8). This may be due to clumping of 
protein upon thawing and non-homogenous distribution throughout the lysate. 
Irrespective of the cause, it creates a potential source of error in achieving uniformity 
333  
in terms of PBMC added to the TRAP assay for each sample. 1µg of protein was added 
for each of the thawed samples and the TRAP reaction performed (Run 8, Table 9).  
 
Sample 1 2 3 Average (µg/ml) 
DF 493.437 289.767 275.004 352.736 
JF 331.862 314.973 466.048 370.961 
SF 461.088 236.497 562.379 419.988 
WF 320.673 293.105 239.29 284.356 
 
Table 8: BCA assay of thawed PBMC lysate. Lysate diluted to conc of 333 µg/ml prior 
to freezing 
 
 
Sample AS AS-AS,0 AS,0 x2 Telomerase 
positive? 
AS-IS RTA high 
DF1 0.0690 0.0286 0.0808 No 0.0352 29.0334 
DF2 0.1199 0.0795 0.0808 No 0.0359 79.1311 
SF1 0.1234 0.0811 0.0846 No 0.0381 76.0618 
SF2 0.1278 0.0855 0.0846 Yes 0.0373 81.9083 
WF1 0.1890 0.1454 0.0872 Yes 0.3478 14.9384 
WF2 0.2580 0.2144 0.0872 Yes 0.5642 13.5788 
JF1 0.1249 0.0832 0.0834 No 0.0596 49.8829 
JF2 0.1740 0.1323 0.0834 Yes 0.0629 75.1595 
 
Table 9: Run 8. As in run 6, the internal controls of samples D,S and J failed. 
 
A further repeat of this experiment (Run 9) was performed in which samples D, S, W 
and J were run in duplicate with freshly extracted PBMC. In this run, two methods 
were used to standardise the amount of input PBMC. Firstly, PBMC was extracted 
from whole blood and a volume of 200,000 cells was obtained for each using the 
haemocytometer. This was done in duplicate for each sample (e.g D1 and D2). The 
volumes of 200,000 cells was lysed and frozen at -80°C. After 24 hours, the lysate was 
defrosted and a BCA assay performed at 1:5 dilution of the stock lysate to determine 
protein concentration. The results of this BCA assay are shown in Table 10.  
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Sample Reading 1 Reading 2 Average reading 
D1 279.818 293.747 286.78 
D2 290.554 334.528 312.541 
S1 305.478 317.212 311.345 
S2 312.371 317.180 314.76 
W1 289.611 301.666 295.64 
W2 358.810 360.710 359.76 
J1 306.897 312.750 309.823 
J2 290.632 294.487 292.56 
 
Table 10: Results of BCA assay for samples in Run 9 
 
They show that the process of extracting approximately 200,000 cells has yielded 
approximately equal concentrations of protein across all 4 samples (approx. 
300µg/ml), with good consistency between samples drawn from the same individual 
(e.g. D1 and D2) and between individuals (e.g. D1 and W1). Because of the 
consistency of these results, we were satisfied that approximately equal quantities 
of PBMC were being added to the TRAP reaction between samples. For each sample, 
i.e. both D1 and D2, 3µl of the stock lysate was added to the TRAP reaction (i.e for 
D1: 3µl of (5x286.78)/1000 = 4.3 µg protein). In addition, one of the samples for each 
individual were normalised for protein content by correcting the volume added to 
the TRAP reaction to contain a total of 3µg of protein. As such, three runs per sample 
were performed. Unfortunately, the negative controls for this PCR fell outside the 
acceptable range rendering the whole run invalid (results not shown). The cause for 
this failure was not apparent.  
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Further repeats of the assay were performed with just two samples D and S, in order 
to reduce the number of kits required for the optimisation experiments (Table 11). 
The two samples were prepared as for the failed Run 9 with both samples being run 
in triplicate (2 standardised by input volume of stock lysate, and 1 standardised by 
input protein content). The results of this run are shown in Table 11. Results were 
relatively stable between the samples standardised by input volume (e.g. D1 and D2) 
most likely reflecting the previously proven similarities in quantity of PBMC inputted 
to the TRAP reaction. The samples standardised by protein content (D2P and J2P) 
showed reduced TA but this is expected given the reduced quantity of input PBMC 
by this method (1µg). 
 
Sample AS AS-AS,0 AS,0 x2 Telomerase 
positive? 
AS-IS RTA high 
D1 0.3623 0.321 0.0826 Yes 0.8951 12.8217 
D2 0.3942 0.3414 0.1056 Yes 0.6688 18.2508 
D2P 0.2025 0.1425 0.12 Yes 0.7682 6.6321 
J1 0.0078 0.0356 0.085 No 0.81 1.5714 
J2 0.0904 0.0515 0.0778 No 0.7944 2.3178 
J2P 0.0526 0.0128 0.0796 No 0.9212 0.4968 
Table 11: Results of Run 10 TeloTAGGG Telomerase PCR ELISA Plus assay. D1, D2, J1 
and J2 standardised by input volume of cell lysate (3 µl). D2P and J2P = extracts of D2 
and J2 standardised by input amount of protein (1 µg).  
 
A further 2 runs, Run 11 and 12, were performed for samples D and J in repeats of 
Run 10 but using 3ug of input PBMC (Tables 12 and 13). The results of both the 
absolute TA and the RTA differ between the 2 runs and between Run 10. Run 12 
resulted in significantly higher values of RTA due to the reduction in absorbance of 
the internal control again suggesting the possibility of PCR inhibition in these 
reactions.  
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Sample AS AS-AS,0 AS,0 x2 Telomerase 
positive 
AS-IS RTA High 
D1 0.0848 0.0559 0.0588 N 0.5045 7.29 
D2 0.109 0.0801 0.0588 Y 0.4918 10.72 
J1 0.12 0.0908 0.0584 Y 0.5619 10.63 
J2 0.0993 0.0701 0.0584 Y 0.547 8.43 
 
Table 12: Results of Run 11. TeloTAGGG Telomerase PCR ELISA Plus assay.  
 
 
 
 AS AS-AS,0 AS,0 x2 Telomerase 
positive 
AS-IS RTA High 
D1 0.2389 0.2078 0.062 Y 0.1041 60.5 
D2 0.3276 0.2965 0.0622 Y 0.0943 95.4 
J1 0.1864 0.1556 0.0616 Y 0.0991 47.62 
J2 0.1756 0.1448 0.0616 Y 0.0067* 655.5 
 
Table 13: Results of Run 12. TeloTAGGG Telomerase PCR ELISA Plus assay 
 
Measuring TERT expression - Results 
A fundamental problem that we encountered in measuring TERT expression was a 
failure to achieve amplification of TERT in any of the samples or positives controls 
that were tested. A summary of the initial 9 optimisation experiments performed is 
given in Table 14.  
 
 
Experiment Summary 
1 Conditions 
• TERT 1 Probe: HS0097265Qm_1 (recommended TERT TaqMan probe by 
Thermofisher) 
• GAPDH Probe: Hs02786624_g1 
 
• 6 samples (10ng RNA) 
• Positive control = Total RNA (XpressRef universal Total RNA – QIAGEN) 
• 1x No Reverse Transcription control (NRTC) 
• 1x Negative Control (NC) 
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• 3 point standard curve (SC) (10, 5, 2.5 ng RNA) 
 
Results 
• GAPDH: Amplification with CT values ~15. Standard Curve R=0.94 
 
• TERT: Late amplification. Poor concordance between duplicates. Standard 
Curve R= 0.61 
Samples amplifying earlier for TERT than Total RNA positive control 
• Poor concordance of duplicates: possible pipetting error 
• Samples not all falling within range of standard curve 
 
Recommendations 
• Increase pipetting volumes of RNA into mastermix by diluting cDNA and 
pipetting large volumes (reduce water content of mastermix to 
compensate) 
• Increase the number of points in the standard curve 
• Trial of using samples as positive control. It may be that PBMC RNA is more 
TERT positive than pooled RNA from several body tissues.  
• May need to increase the input amount of RNA/cDNA 
2 Conditions 
• Same probes as Expt 1 
• 2 samples 
• 2x NRTC and 2xNC  
• Sample X used as positive control – 5-point standard curve 
(10,5,2.5,1.25,0.625ng RNA) 
Results 
• GAPDH: Good amplification: CT value of top standard (TS) ~16. R = 0.995, 
Efficiency 1.05 
• TERT: Unreliable amplification. Poor standard curve and high CT values >30 
 
Recommendations 
• Need to increase in input amount of RNA/cDNA. Even GAPDH CT values too 
high for such a ubiquitous marker.  
• Need to increase range of standard curve 
 
3 Conditions 
• Probes as per previous. 
• 8 point standard curve only run (80, 40, 20, 10, 5, 2.5, 1.25, 0.625ng) 
 
Results 
• GAPDH amplification still excellent. Standard Curve: R = 0.999, Efficiency= 
0.93. But Ct values still high. 
• TERT: Late amplification with extremely poor standard curve and poor 
concordance between duplicates.  
 
Recommendations 
• The excellent GAPDH result indicates that the RNA extraction and reverse 
transcription steps are OK. Also linear standard curve for GAPDH suggests 
that PCR itself is working efficiently and not inhibited. 
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• Cause of poor TERT amplification could be a probe issue or that TERT is in 
very low abundance and thus difficult to amplify  
• Try alternate TERT TaqMan probes such as Hs00972656_m1 (same as used 
by Janic et al (87). 
• May need to increase input RNA further. Janic et al used 200ng RNA as 
their starting amount in their successful TERT TaqMan Assays(87).  
 
4 Conditions 
• TERT 2 probe = Hs00972656_m1 (same as used by Janic et al (87)). GAPDH 
probe as per previous. 
• Same 8-point Standard Curve as Experiment 3 (80, 40, 20, 10, 5, 2.5, 1.25, 
0.625ng). 
Results 
• GAPDH: Excellent amplification. Standard Curve: R = 0.998, Efficiency= 0.96 
• TERT: Ongoing Late and erratic amplification. Worse than previous probe. 
 
Recommendations 
• Increase input RNA 
• Use previous Probe (HS00972650_m1 – recommended by Thermofischer) 
5 Conditions 
• Two TERT probes used; TERT1 (HS00972650_m1) and new probe – TERT 3 
(Hs00972648_g1) 
• 7-point standard curve run: 400, 200, 100, 50, 25, 12.5, 6.25ng 
 
Results 
GAPDH: Excellent amplification. Standard Curve: R = 0.999, Efficiency = 
0.99. 
• TERT 1(HS00972650_m1): Standard curve looks better at these higher 
concentrations but still late amplification and poor concordance between 
duplicates. 
• TERT 3(Hs00972648_g1). Worse amplification that TERT 1 probes 
 
Recommendations 
• As neither changing probes or increasing RNA input amount have resulted 
in successful amplification, need to try other strategies. 
 
6 Conditions 
• An attempt was made to try different PCR conditions to try to prolong 
amplification in the hope of increasing TERT amplification. New PCR 
conditions were taken from the standard TaqMan® Gene Expression 
Assays protocol consisting of: 2 minutes at 50°C (UNG incubation); 10 
minutes at 95°C (Polymerase activation); 40 cycles of 15 seconds at 95°C 
(denaturing) and 60 seconds at 60°C (anneal/extension step). 
• TERT 1 probes and TERT 2 probe used. 
• 6-point standard curve (100, 50, 25, 12.5, 6.25, 3.125ng). 
 
Results 
GAPDH: Reasonable amplification. No reduction in CT threshold values. 
Standard Curve: R=0.998, Efficiency = 0.87 
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• TERT 1 and TERT 2: Inconsistent amplification with many samples not 
amplifying at all.  
 
Recommendations 
• No improvement in TERT amplification with amended PCR protocol. 
7 Conditions 
• As per experiment 6 but with a 20-second-long 95®C denaturing step. 
• Only TERT 1 probes used. 
• 5-point standard curve run (100,50,25,12.5,6.25ng). 
 
Results 
• Worsening of amplification for both TERT and GAPDH. 
 
Recommendations 
• Alter Mastermix in addition to altering PCR Protocol. 
8 Conditions 
• As per Experiment 6 but new Mastrermix (TaqMan® Gene Expression 
Mastermix) used. 
• Additional TERT reaction run with Qiagen TERT Assay (TERT 4) and the 
corresponding recommended mastermix (SYBRgreen ROX fast mastermix 
solution). 
Results 
• GAPDH: No amplification seen.  
• Both TERT runs (TERT 1 and TERT 4 Assays) gave unreliable and late 
amplification. 
Recommendations 
• Since neither changing the input amount of RNA or changing the probes, 
mastermix and PCR conditions have improved TERT amplification, suggest 
seeking expert help. 
 
 
Table 14: Summary of Optimisation Experiments for TERT measurement. 
 
 
 
 
